PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
2694528-8	1989	Clinically, the centrally active cholinesterase inhibitor physostigmine has been shown to give postoperative pain relief although of short duration.	Physostigmine	58-71	butyrylcholinesterase	Rattus norvegicus	33-47
2628016-1	1989	The study of cerebral blood flow was performed with the aid of hydrogen clearance technique and the cinema-television method in alteration of cholinergic transmission by means of phosphorus-organic inhibitors of cholinesterase and a cholinolytic agent in unanesthetized rats.	Phosphorus	179-189	butyrylcholinesterase	Rattus norvegicus	212-226
2619991-7	1989	Most of AchE activity (88%) (41% G4 and 59% G2 + G1) was detergent soluble; 42% of ChE activity (detected only as G2 + G1) was high-salt soluble, whereas remaining ChE activity was detergent soluble.	Salts	132-136	butyrylcholinesterase	Rattus norvegicus	83-86
2628016-6	1989	The findings suggest that atropine widely used in poisoning with various inhibitors of cholinesterase, does not normalize the tonus of cerebral vessels.	Atropine	26-34	butyrylcholinesterase	Rattus norvegicus	87-101
2612789-0	1989	The effect of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide on tissue cholinesterase and carboxylesterase activities of the rat.	2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide	14-64	butyrylcholinesterase	Rattus norvegicus	75-89
2612789-6	1989	At doses of CBDP below 1.0 mg/kg, plasma, RBC, and brain regional ChE activities were inhibited by less than 10%, whereas at doses above 2.0 mg/kg, ChE activities were inhibited substantially (up to 80% in plasma, up to 60% in RBC, and greater than 90% in brain regions).	2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide	12-16	butyrylcholinesterase	Rattus norvegicus	66-69
2612789-6	1989	At doses of CBDP below 1.0 mg/kg, plasma, RBC, and brain regional ChE activities were inhibited by less than 10%, whereas at doses above 2.0 mg/kg, ChE activities were inhibited substantially (up to 80% in plasma, up to 60% in RBC, and greater than 90% in brain regions).	2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide	12-16	butyrylcholinesterase	Rattus norvegicus	148-151
2620959-1	1989	Effect of injection in third ventricle of GABA, the GABA agonist muscimol, and the GABA antagonist picrotoxin on the activities of acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and monoamine oxidase (MAO) in serum and succinic dehydrogenase (SDH) in plasma has been studied.	Picrotoxin	99-109	butyrylcholinesterase	Rattus norvegicus	160-181
2620959-2	1989	Surprisingly, the AChE, BuChE, MAO and SDH enzymes activity were inhibited by GABA and muscimol, while they were enhanced by picrotoxin.	gamma-Aminobutyric Acid	78-82	butyrylcholinesterase	Rattus norvegicus	24-29
2620959-2	1989	Surprisingly, the AChE, BuChE, MAO and SDH enzymes activity were inhibited by GABA and muscimol, while they were enhanced by picrotoxin.	Muscimol	87-95	butyrylcholinesterase	Rattus norvegicus	24-29
2620959-2	1989	Surprisingly, the AChE, BuChE, MAO and SDH enzymes activity were inhibited by GABA and muscimol, while they were enhanced by picrotoxin.	Picrotoxin	125-135	butyrylcholinesterase	Rattus norvegicus	24-29
2804555-12	1989	In vitro THA was a potent non-competitive inhibitor of rat brain cholinesterase (IC50: 57 +/- 6 nM) and bovine erythrocyte acetylcholinesterase (IC50: 50 +/- 10 nM) but was a more potent inhibitor of horse serum butyrylcholinesterase (IC50: 7.2 +/- 1.4 nM).	Tacrine	9-12	butyrylcholinesterase	Rattus norvegicus	65-79
2610946-0	1989	Effects of diisopropylfluorophosphate on brain acetylcholinesterase, butyrylcholinesterase, and neurotoxic esterase in rats.	Isoflurophate	11-37	butyrylcholinesterase	Rattus norvegicus	69-115
2608162-0	1989	The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.	physostigmine heptyl	14-34	butyrylcholinesterase	Rattus norvegicus	42-56
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	physostigmine heptyl	0-20	butyrylcholinesterase	Rattus norvegicus	154-168
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	physostigmine heptyl	0-20	butyrylcholinesterase	Rattus norvegicus	170-173
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	physostigmine heptyl	22-32	butyrylcholinesterase	Rattus norvegicus	154-168
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	physostigmine heptyl	22-32	butyrylcholinesterase	Rattus norvegicus	170-173
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	Physostigmine	7-20	butyrylcholinesterase	Rattus norvegicus	154-168
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	Physostigmine	7-20	butyrylcholinesterase	Rattus norvegicus	170-173
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	Physostigmine	29-32	butyrylcholinesterase	Rattus norvegicus	154-168
2608162-1	1989	Heptyl-physostigmine (Heptyl-Phy; MF-201) is a new carbamate derivative of physostigmine (Phy) with greater lipophilicity and longer inhibitory action on cholinesterase (ChE) activity than the parent compound.	Physostigmine	29-32	butyrylcholinesterase	Rattus norvegicus	170-173
2804555-17	1989	It is concluded that THA is a reversible non-competitive inhibitor of cholinesterase with a long half life (compared with physostigmine).	Tacrine	21-24	butyrylcholinesterase	Rattus norvegicus	70-84
2756526-1	1989	The inhibition of cholinesterase (ChE) activity in the central nervous system of the rat by the potent organophosphorus compound soman was examined.	organophosphorus	103-119	butyrylcholinesterase	Rattus norvegicus	18-32
2760841-1	1989	Tetrahydroaminoacridine (THA) is known to be a potent centrally acting cholinesterase inhibitor.	Tacrine	0-23	butyrylcholinesterase	Rattus norvegicus	71-85
2760841-1	1989	Tetrahydroaminoacridine (THA) is known to be a potent centrally acting cholinesterase inhibitor.	Tacrine	25-28	butyrylcholinesterase	Rattus norvegicus	71-85
2756526-1	1989	The inhibition of cholinesterase (ChE) activity in the central nervous system of the rat by the potent organophosphorus compound soman was examined.	organophosphorus	103-119	butyrylcholinesterase	Rattus norvegicus	34-37
2749782-0	1989	Cresylbenzodioxaphosphorin oxide pretreatment alters soman-induced toxicity and inhibition of tissue cholinesterase activity of the rat.	cresylbenzodioxaphosphorin oxide	0-32	butyrylcholinesterase	Rattus norvegicus	101-115
2749782-5	1989	These data support the hypothesis that CBDP pretreatment effectively blocks tissue CaE sites which serve to detoxify soman, thus potentiating both the soman-induced inhibition of ChE in the CNS and the lethality of soman.	CBDP	39-43	butyrylcholinesterase	Rattus norvegicus	179-182
2725816-4	1989	DPPC-induced reductions in [3H]ACh levels were blocked by 100 microM eserine, a tertiary amine cholinesterase inhibitor, but not with 100 microM neostigmine, a quaternary ammonium inhibitor.	1,2-Dipalmitoylphosphatidylcholine	0-4	butyrylcholinesterase	Rattus norvegicus	95-109
2498396-3	1989	For evaluating skin penetration of physostigmine the decrease of whole blood cholinesterase was measured.	Physostigmine	35-48	butyrylcholinesterase	Rattus norvegicus	77-91
2498396-6	1989	Ultrasound treatment also significantly increased (P less than 0.05) the inhibition of cholinesterase during the first hour after application in both physostigmine treated rats and guinea pigs: while in control guinea pigs no significant inhibition of cholinesterase could be detected during the first 2 h after application of physostigmine, the ultrasound treated group showed a 15 +/- 5% (mean +/- SEM) decrease in blood cholinesterase 1 h after ultrasound application.	Physostigmine	150-163	butyrylcholinesterase	Rattus norvegicus	87-101
2498396-7	1989	For physostigmine-treated rats the level of cholinesterase inhibition 1 h after ultrasound application was 53 +/- 5% in the ultrasound-treated group and 35 +/- 5% in the controls.	Physostigmine	4-17	butyrylcholinesterase	Rattus norvegicus	44-58
2706318-1	1989	The distribution, metabolism, and pharmacokinetics of physostigmine (Phy) and the time course of butyrylcholinesterase (BuChE) in plasma and cholinesterase (ChE) activity in brain and muscle and their relationship to Phy concentration were described after oral administration of 3H-Phy (650 micrograms kg-1) to rats.	Tritium	279-281	butyrylcholinesterase	Rattus norvegicus	120-125
2725829-0	1989	Alterations in the distribution of cholinesterase molecular forms in maternal and fetal brain following diisopropyl fluorophosphate treatment of pregnant rats.	Isoflurophate	104-131	butyrylcholinesterase	Rattus norvegicus	35-49
2719724-0	1989	Degradation by rat tissues in vitro of organophosphorus esters which inhibit cholinesterase.	organophosphorus esters	39-62	butyrylcholinesterase	Rattus norvegicus	77-91
2725816-4	1989	DPPC-induced reductions in [3H]ACh levels were blocked by 100 microM eserine, a tertiary amine cholinesterase inhibitor, but not with 100 microM neostigmine, a quaternary ammonium inhibitor.	Tritium	28-30	butyrylcholinesterase	Rattus norvegicus	95-109
2725816-4	1989	DPPC-induced reductions in [3H]ACh levels were blocked by 100 microM eserine, a tertiary amine cholinesterase inhibitor, but not with 100 microM neostigmine, a quaternary ammonium inhibitor.	Acetylcholine	31-34	butyrylcholinesterase	Rattus norvegicus	95-109
2603459-2	1989	In rats liver homogenates ethynylestradiol, one of the active components of Microgynon, acted as an inducer of gamma-glutamyltransferase and alkaline phosphatase while leaving aspartate aminotransferase and alanine aminotransferase unaffected, but reduced the level of cholinesterase.	Ethinyl Estradiol	26-42	butyrylcholinesterase	Rattus norvegicus	269-283
2603737-1	1989	The newly synthetized cholinesterase inhibitor C-8 (a structural analogue of physostigmine) at a dose of 4 mg.kg-1 exerted no inhibitory effect on the spontaneous locomotor activity in 2-, 10- and 22-month old male Wistar rats.	1-octene	47-50	butyrylcholinesterase	Rattus norvegicus	22-36
2725439-0	1989	Protection afforded by clonidine from the acute and chronic behavioral toxicity produced by the cholinesterase inhibitor soman.	Clonidine	23-32	butyrylcholinesterase	Rattus norvegicus	96-110
2725439-2	1989	The effect of clonidine is so marked, that pretreatment reduces both the accumulation of brain acetylcholine, and the toxicity caused by cholinesterase inhibitors such as soman.	Clonidine	14-23	butyrylcholinesterase	Rattus norvegicus	137-151
2489432-10	1989	This suggests that exposure to chlorphenvinphos may result in some behavioral disturbances lasting longer than the ChE recovery.	Chlorfenvinphos	31-47	butyrylcholinesterase	Rattus norvegicus	115-118
2489433-6	1989	injection of a carbamate cholinesterase inhibitor, physostigmine, in a dose of 1.0 mg/kg resulted in a dramatic increase of the theta content in the hippocampal EEG, and in the total disappearance of the spontaneous seizures.	Physostigmine	51-64	butyrylcholinesterase	Rattus norvegicus	25-39
2489433-7	1989	Determination of cholinesterase activity in blood and in the brain in a separate group of subjects showed that after injection of physostigmine (1.0 mg/kg), the inhibition of this enzyme does not exceed the inhibition after injecting CVP in the doses used.	Physostigmine	130-143	butyrylcholinesterase	Rattus norvegicus	17-31
2730338-2	1989	In the present paper, using pyridostigmine, a cholinesterase inhibitor, the possible role of acetylcholine in the genesis of cardiomyopathy was investigated.	Pyridostigmine Bromide	28-42	butyrylcholinesterase	Rattus norvegicus	46-60
2730338-2	1989	In the present paper, using pyridostigmine, a cholinesterase inhibitor, the possible role of acetylcholine in the genesis of cardiomyopathy was investigated.	Acetylcholine	93-106	butyrylcholinesterase	Rattus norvegicus	46-60
2602408-1	1989	Despite a strong rationale for the use of cholinesterase (ChE) inhibitors and related drugs to augment cholinergic function as palliative treatment for Alzheimer dementia, this approach met with limited and variable success until the striking results recently reported with tacrine (THA).	Tacrine	274-281	butyrylcholinesterase	Rattus norvegicus	58-61
2602408-1	1989	Despite a strong rationale for the use of cholinesterase (ChE) inhibitors and related drugs to augment cholinergic function as palliative treatment for Alzheimer dementia, this approach met with limited and variable success until the striking results recently reported with tacrine (THA).	Tacrine	283-286	butyrylcholinesterase	Rattus norvegicus	58-61
2602408-6	1989	However, after in vivo THA, the inhibition of plasma ChE or brain AChE declined as a log function of tissue dilution.	Tacrine	23-26	butyrylcholinesterase	Rattus norvegicus	53-56
2602408-9	1989	Pons-medulla AChE was much less sensitive to the effects of THA than hippocampus, cortex, cerebellum or plasma ChE, particularly at doses of 2.5 mg/kg or less.	Tacrine	60-63	butyrylcholinesterase	Rattus norvegicus	14-17
20702305-1	1989	The inhibition of rat plasma cholinesterase was used to screen the toxicity of carbamate pesticides in vitro.	Carbamates	79-88	butyrylcholinesterase	Rattus norvegicus	29-43
20702305-2	1989	All three carbamates studied-aldicarb, carbofuran and oxamyl-inhibited the rat cholinesterase in a dose-dependent manner, as determined by the Ellman technique.	Carbamates	10-20	butyrylcholinesterase	Rattus norvegicus	79-93
20702305-2	1989	All three carbamates studied-aldicarb, carbofuran and oxamyl-inhibited the rat cholinesterase in a dose-dependent manner, as determined by the Ellman technique.	Aldicarb	29-37	butyrylcholinesterase	Rattus norvegicus	79-93
20702305-2	1989	All three carbamates studied-aldicarb, carbofuran and oxamyl-inhibited the rat cholinesterase in a dose-dependent manner, as determined by the Ellman technique.	Carbofuran	39-49	butyrylcholinesterase	Rattus norvegicus	79-93
20702305-2	1989	All three carbamates studied-aldicarb, carbofuran and oxamyl-inhibited the rat cholinesterase in a dose-dependent manner, as determined by the Ellman technique.	oxamyl	54-60	butyrylcholinesterase	Rattus norvegicus	79-93
20702305-4	1989	In the interaction study, based on the data for the mixture of all three carbamates, and for the individual carbamates, cholinesterase inhibition by aldicarb was found to be potentiated by carbofuran and oxamyl.	Carbamates	108-118	butyrylcholinesterase	Rattus norvegicus	120-134
20702305-4	1989	In the interaction study, based on the data for the mixture of all three carbamates, and for the individual carbamates, cholinesterase inhibition by aldicarb was found to be potentiated by carbofuran and oxamyl.	Aldicarb	149-157	butyrylcholinesterase	Rattus norvegicus	120-134
20702305-4	1989	In the interaction study, based on the data for the mixture of all three carbamates, and for the individual carbamates, cholinesterase inhibition by aldicarb was found to be potentiated by carbofuran and oxamyl.	Carbofuran	189-199	butyrylcholinesterase	Rattus norvegicus	120-134
20702305-4	1989	In the interaction study, based on the data for the mixture of all three carbamates, and for the individual carbamates, cholinesterase inhibition by aldicarb was found to be potentiated by carbofuran and oxamyl.	oxamyl	204-210	butyrylcholinesterase	Rattus norvegicus	120-134
20702305-5	1989	The effects of carbofuran were also potentiated by aldicarb and oxamyl but the presence of carbofuran and aldicarb was found to reduce cholinesterase inhibition by oxamyl.	Carbofuran	91-101	butyrylcholinesterase	Rattus norvegicus	135-149
3225383-2	1988	The magnitude of the pressor response to the cholinesterase inhibitor, neostigmine, was greatest when the site of injection was restricted to the thoracic level.	Neostigmine	71-82	butyrylcholinesterase	Rattus norvegicus	45-59
20702305-5	1989	The effects of carbofuran were also potentiated by aldicarb and oxamyl but the presence of carbofuran and aldicarb was found to reduce cholinesterase inhibition by oxamyl.	Aldicarb	106-114	butyrylcholinesterase	Rattus norvegicus	135-149
20702305-5	1989	The effects of carbofuran were also potentiated by aldicarb and oxamyl but the presence of carbofuran and aldicarb was found to reduce cholinesterase inhibition by oxamyl.	oxamyl	164-170	butyrylcholinesterase	Rattus norvegicus	135-149
20702308-0	1989	The acute and subchronic effects of organophosphorus and carbamate pesticides on cholinesterase activity in aggregate cultures of neural cells from the foetal rat brain.	organophosphorus	36-52	butyrylcholinesterase	Rattus norvegicus	81-95
20702308-0	1989	The acute and subchronic effects of organophosphorus and carbamate pesticides on cholinesterase activity in aggregate cultures of neural cells from the foetal rat brain.	Carbamates	57-66	butyrylcholinesterase	Rattus norvegicus	81-95
20702308-4	1989	When the cholinesterase IC(50) values for malaoxon, fenitrothion, carbaryl and carbofuran, determined on culture day 17, were plotted against the previously published median lethal dose (oral LD(50)s) of the same compounds in rats and mice, there was a good linear relationship between IC(50) and LD(50) values.	malaoxon	42-50	butyrylcholinesterase	Rattus norvegicus	9-23
20702308-4	1989	When the cholinesterase IC(50) values for malaoxon, fenitrothion, carbaryl and carbofuran, determined on culture day 17, were plotted against the previously published median lethal dose (oral LD(50)s) of the same compounds in rats and mice, there was a good linear relationship between IC(50) and LD(50) values.	Carbaryl	66-74	butyrylcholinesterase	Rattus norvegicus	9-23
20702308-4	1989	When the cholinesterase IC(50) values for malaoxon, fenitrothion, carbaryl and carbofuran, determined on culture day 17, were plotted against the previously published median lethal dose (oral LD(50)s) of the same compounds in rats and mice, there was a good linear relationship between IC(50) and LD(50) values.	Carbofuran	79-89	butyrylcholinesterase	Rattus norvegicus	9-23
20702309-0	1989	Cholinesterase inhibition by organophosphorus and carbamate pesticides in aggregate cultures of neural cells from the foetal rat brain: The effects of metabolic activation and pesticide mixtures.	organophosphorus	29-45	butyrylcholinesterase	Rattus norvegicus	0-14
20702309-0	1989	Cholinesterase inhibition by organophosphorus and carbamate pesticides in aggregate cultures of neural cells from the foetal rat brain: The effects of metabolic activation and pesticide mixtures.	Carbamates	50-59	butyrylcholinesterase	Rattus norvegicus	0-14
20702309-2	1989	Studies of the effects of pesticide mixtures on the cholinesterase activity of cultures demonstrated that a hepatic microsomal fraction (S-9) played a major role in the nature of the interaction between combinations of malathion and fenitrothion or carbofuran.	Malathion	219-228	butyrylcholinesterase	Rattus norvegicus	52-66
20702309-3	1989	In the absence of S-9, malathion potentiated the anti-cholinesterase effect of fenitrothion, while neither synergistic nor antagonistic interactions occurred with mixtures of carbofuran and malathion.	Malathion	23-32	butyrylcholinesterase	Rattus norvegicus	54-68
20702309-3	1989	In the absence of S-9, malathion potentiated the anti-cholinesterase effect of fenitrothion, while neither synergistic nor antagonistic interactions occurred with mixtures of carbofuran and malathion.	Fenitrothion	79-91	butyrylcholinesterase	Rattus norvegicus	54-68
3250156-7	1988	These results suggest that differential pathways are involved in dopaminergic-cholinergic neuronal interaction, and that with increasing age, cholinergic neurons activated by cholinesterase inhibition (endogenous acetylcholine) were not affected but those by a direct acetylcholine agonist (muscarinic M-1 receptor agonist) were diminished.	Acetylcholine	213-226	butyrylcholinesterase	Rattus norvegicus	175-189
3438612-0	1987	[The inhaled effects of fenitrothion powder on blood cholinesterase in rats].	Fenitrothion	24-36	butyrylcholinesterase	Rattus norvegicus	53-67
2903757-5	1988	The cholinesterase activity in rat diaphragm homogenates was inhibited by hexamethonium.	Hexamethonium	74-87	butyrylcholinesterase	Rattus norvegicus	4-18
3245732-0	1988	Action of diisopropylfluorophosphate and of diacetylmonoxime on acetylcholine levels and on cholinesterase activity in the central nervous system.	Isoflurophate	10-36	butyrylcholinesterase	Rattus norvegicus	92-106
3245732-0	1988	Action of diisopropylfluorophosphate and of diacetylmonoxime on acetylcholine levels and on cholinesterase activity in the central nervous system.	diacetylmonoxime	44-60	butyrylcholinesterase	Rattus norvegicus	92-106
3245740-6	1988	In rat fundus homogenates, metoclopramide and ranitidine showed a significant cholinesterase inhibition.	Metoclopramide	27-41	butyrylcholinesterase	Rattus norvegicus	78-92
3245740-6	1988	In rat fundus homogenates, metoclopramide and ranitidine showed a significant cholinesterase inhibition.	Ranitidine	46-56	butyrylcholinesterase	Rattus norvegicus	78-92
2846316-1	1988	The specific binding of [3H]clonidine to alpha 2-adrenoceptors on neural membranes isolated from various brain areas was determined with rats treated for 7-14 days with the cholinesterase inhibitors neostigmine, triorthocresyl phosphate (TOCP), diisopropylfluorophosphate (DFP) and paraoxon, or with vehicle.	Clonidine	24-37	butyrylcholinesterase	Rattus norvegicus	173-187
3361925-10	1988	Methacholine, which is more resistant to cholinesterase, was more potent than Ach in blood-perfused tail arteries.	Methacholine Chloride	0-12	butyrylcholinesterase	Rattus norvegicus	41-55
3361925-12	1988	It is concluded that Ach can produce an endothelium-dependent dilatation in a vessel perfused with whole blood, although Ach in blood is susceptible to inactivation by cholinesterase.	Acetylcholine	121-124	butyrylcholinesterase	Rattus norvegicus	168-182
3368670-0	1988	[Effects of repeated inhalation-exposure to fenitrothion powder on blood cholinesterase activity in rats].	Fenitrothion	44-56	butyrylcholinesterase	Rattus norvegicus	73-87
3149406-0	1988	[Changes in the hexobarbital sleep and serum cholinesterase activity of rats treated with carbaryl].	Carbaryl	90-98	butyrylcholinesterase	Rattus norvegicus	45-59
3149406-1	1988	Studies are carried out on the changes during the hexobarbital sleep and the cholinesterase activity in male rats subject to multiple oral introduction of carbaryl in relative low doses (40 mg/kg daily).	Carbaryl	155-163	butyrylcholinesterase	Rattus norvegicus	77-91
2831477-3	1987	In the present study, monoiodo-NT-labeled binding sites are shown by combined autoradiography and cholinesterase histochemistry to be selectively associated with cholinergic nerve cell bodies in the diagonal band and substantia innominata of the rat basal forebrain.	monoiodo-nt	22-33	butyrylcholinesterase	Rattus norvegicus	98-112
3188010-1	1988	The organophosphate cholinesterase inhibitor soman produced a dramatic increase in arterial blood pressure of up to 60 mm Hg in the unanesthetized rat with variable changes in heart rate.	Soman	45-50	butyrylcholinesterase	Rattus norvegicus	20-34
3245740-7	1988	These results seem to cast a doubt on the generally held ACh release hypothesis for the action mechanism of metoclopramide on one hand, and suggest, on the other hand, that cholinesterase inhibition contributes to some extent to the gastrokinetic effects of metoclopramide and ranitidine.	Metoclopramide	258-272	butyrylcholinesterase	Rattus norvegicus	173-187
3245740-7	1988	These results seem to cast a doubt on the generally held ACh release hypothesis for the action mechanism of metoclopramide on one hand, and suggest, on the other hand, that cholinesterase inhibition contributes to some extent to the gastrokinetic effects of metoclopramide and ranitidine.	Ranitidine	277-287	butyrylcholinesterase	Rattus norvegicus	173-187
3421780-0	1988	Interaction of 2,4-diaminopyridine with cholinesterase inhibitors.	2,4-diaminopyridine	15-34	butyrylcholinesterase	Rattus norvegicus	40-54
3340327-1	1988	Spontaneous release of acetylcholine (ACh) from rat basal forebrain slices in the presence of cholinesterase inhibitor was directly determined using a specific radioimmunoassay for ACh.	Acetylcholine	23-36	butyrylcholinesterase	Rattus norvegicus	94-108
3340327-1	1988	Spontaneous release of acetylcholine (ACh) from rat basal forebrain slices in the presence of cholinesterase inhibitor was directly determined using a specific radioimmunoassay for ACh.	Acetylcholine	38-41	butyrylcholinesterase	Rattus norvegicus	94-108
3340327-1	1988	Spontaneous release of acetylcholine (ACh) from rat basal forebrain slices in the presence of cholinesterase inhibitor was directly determined using a specific radioimmunoassay for ACh.	Acetylcholine	181-184	butyrylcholinesterase	Rattus norvegicus	94-108
3242452-1	1988	Recently, the question was raised as to why iso-OMPA, generally known as a selective irreversible inhibitor of butyrylcholinesterase (BuChE), potentiates soman toxicity in rats but not in mice.	Tetraisopropylpyrophosphamide	44-52	butyrylcholinesterase	Rattus norvegicus	111-132
3242452-1	1988	Recently, the question was raised as to why iso-OMPA, generally known as a selective irreversible inhibitor of butyrylcholinesterase (BuChE), potentiates soman toxicity in rats but not in mice.	Tetraisopropylpyrophosphamide	44-52	butyrylcholinesterase	Rattus norvegicus	134-139
3242452-5	1988	The two doses were selected in such a way that both were high enough to inhibit more than 90% of plasma BuChE activity; plasma CarbE activity, however, was only slightly inhibited by the lower and substantially by the higher dose of iso-OMPA.	Tetraisopropylpyrophosphamide	233-241	butyrylcholinesterase	Rattus norvegicus	104-109
3672530-9	1987	With regard to their diagnostic value, the results of the reported study may be summarized as follows (beginning with the most sensitive parameter): plasma cholinesterase activity depression greater than or equal to acetylcholine-induced bronchoconstriction greater than or equal to cholinergic symptoms greater than erythrocyte cholinesterase activity depression greater than pulmonary resistance without acetylcholine provocation.	Acetylcholine	216-229	butyrylcholinesterase	Rattus norvegicus	329-343
3436439-3	1987	The introduction of zyxorin into a complex therapy with specific agents (atropine, reactivators of cholinesterase) potentiates their antidotic effect at poisoning with DDVP.	flumecinol	20-27	butyrylcholinesterase	Rattus norvegicus	99-113
3672530-9	1987	With regard to their diagnostic value, the results of the reported study may be summarized as follows (beginning with the most sensitive parameter): plasma cholinesterase activity depression greater than or equal to acetylcholine-induced bronchoconstriction greater than or equal to cholinergic symptoms greater than erythrocyte cholinesterase activity depression greater than pulmonary resistance without acetylcholine provocation.	Acetylcholine	406-419	butyrylcholinesterase	Rattus norvegicus	156-170
3691642-3	1987	administration of the cholinomimetics oxotremorine and arecoline and the cholinesterase blocker physostigmine evoked theta wave activity in the hippocampus, which was blocked by scopolamine.	Physostigmine	96-109	butyrylcholinesterase	Rattus norvegicus	73-87
3691642-3	1987	administration of the cholinomimetics oxotremorine and arecoline and the cholinesterase blocker physostigmine evoked theta wave activity in the hippocampus, which was blocked by scopolamine.	Scopolamine	178-189	butyrylcholinesterase	Rattus norvegicus	73-87
2822903-8	1987	The cholinesterase inhibitor physostigmine (50 microM) enhanced the response produced by elevated K+ at 14, 21 and 40 days but had no effect at 2 or 7 days.	Physostigmine	29-42	butyrylcholinesterase	Rattus norvegicus	4-18
3653335-0	1987	Trophic control of cholinesterase activity in a testosterone-dependent muscle of the rat.	Testosterone	48-60	butyrylcholinesterase	Rattus norvegicus	19-33
3682413-3	1987	Physostigmine, a cholinesterase inhibitor, antagonized these changes at the doses of 0.03 to 0.1 mg/kg.	Physostigmine	0-13	butyrylcholinesterase	Rattus norvegicus	17-31
2890115-2	1987	In the presence of the cholinesterase inhibitor physostigmine, acetylcholine significantly (p less than 0.05-p less than 0.01) stimulated inositol phosphate formation in a concentration-related fashion: carbachol, but not oxotremorine, produced similar effects.	Physostigmine	48-61	butyrylcholinesterase	Rattus norvegicus	23-37
2890115-2	1987	In the presence of the cholinesterase inhibitor physostigmine, acetylcholine significantly (p less than 0.05-p less than 0.01) stimulated inositol phosphate formation in a concentration-related fashion: carbachol, but not oxotremorine, produced similar effects.	Acetylcholine	63-76	butyrylcholinesterase	Rattus norvegicus	23-37
2890115-2	1987	In the presence of the cholinesterase inhibitor physostigmine, acetylcholine significantly (p less than 0.05-p less than 0.01) stimulated inositol phosphate formation in a concentration-related fashion: carbachol, but not oxotremorine, produced similar effects.	Inositol Phosphates	138-156	butyrylcholinesterase	Rattus norvegicus	23-37
2890115-2	1987	In the presence of the cholinesterase inhibitor physostigmine, acetylcholine significantly (p less than 0.05-p less than 0.01) stimulated inositol phosphate formation in a concentration-related fashion: carbachol, but not oxotremorine, produced similar effects.	Carbachol	203-212	butyrylcholinesterase	Rattus norvegicus	23-37
3608937-6	1987	Similar changes occurred in rats exposed to 10 mg of acephate/kg.day; however, plasma cholinesterase and RBC acetylcholinesterase activities were inhibited.	acephate	53-61	butyrylcholinesterase	Rattus norvegicus	86-100
2888515-1	1987	Ibotenic acid injections into the nucleus basalis (Ch4) resulted in a near-total loss of cortical cholinesterase fibers.	Ibotenic Acid	0-13	butyrylcholinesterase	Rattus norvegicus	98-112
3675088-6	1987	PAM-2 concentrations, continuously maintained in plasma, were distinctly better in protecting and reactivating peripheral cholinesterase activity than corresponding HI-6 concentrations in the case of quinalphos poisoning.	pam-2	0-5	butyrylcholinesterase	Rattus norvegicus	122-136
3629591-8	1987	It is concluded that the cycloheximide pretreatment potentiates DFP toxicity by a mechanism that is related to inhibition of the synthesis of proteins such as AChE, BuChE, and CarbE.	Cycloheximide	25-38	butyrylcholinesterase	Rattus norvegicus	165-170
3659063-1	1987	The organophosphorus compound soman irreversibly inhibits cholinesterase in both the central and peripheral nervous systems.	organophosphorus	4-20	butyrylcholinesterase	Rattus norvegicus	58-72
3630858-0	1987	Effects of ranitidine on the enzyme cholinesterase and the rat anococcygeus muscle.	Ranitidine	11-21	butyrylcholinesterase	Rattus norvegicus	36-50
3582544-0	1987	Trophic control of cholinesterase activity in a testosterone-dependent muscle of the rat: effects of castration and denervation.	Testosterone	48-60	butyrylcholinesterase	Rattus norvegicus	19-33
2444183-1	1987	In rats the effect of inhibition of the brain cholinesterase activity on the pressor and heart rate responses to 5-hydroxytryptamine (5-HT), administered into the lateral cerebral ventricle (l.c.v.)	Serotonin	113-132	butyrylcholinesterase	Rattus norvegicus	46-60
2444183-4	1987	The type of the cardiovascular response to ACh (5 micrograms l.c.v., 20 min after the second administration of 5-HT) indicates that the modification of the cardiovascular response to 5-HT was accompanied by inhibition of the brain cholinesterase activity.	Acetylcholine	43-46	butyrylcholinesterase	Rattus norvegicus	231-245
3573978-5	1987	Bis(trichloromethyl) sulfone produced in vitro inhibition of rat plasma cholinesterase and brain acetylcholinesterase.	bis(trichloromethyl)sulfone	0-28	butyrylcholinesterase	Rattus norvegicus	72-86
3308498-1	1987	We traced the origin and path of autonomic nerves to the rat eye using, as an aid to dissection, a modified thiocholine method for the histochemical demonstration of cholinesterase.	Thiocholine	108-119	butyrylcholinesterase	Rattus norvegicus	166-180
3601008-3	1987	of physostigmine are compared and the effect of two drugs producing inhibition of cholinesterase, physostigmine and metrifonate, on the activity of cholinesterase in the brain of the rat and on levels of acetylcholine (ACh) and choline (Ch).	Physostigmine	98-111	butyrylcholinesterase	Rattus norvegicus	82-96
3601008-3	1987	of physostigmine are compared and the effect of two drugs producing inhibition of cholinesterase, physostigmine and metrifonate, on the activity of cholinesterase in the brain of the rat and on levels of acetylcholine (ACh) and choline (Ch).	Physostigmine	98-111	butyrylcholinesterase	Rattus norvegicus	148-162
3601008-3	1987	of physostigmine are compared and the effect of two drugs producing inhibition of cholinesterase, physostigmine and metrifonate, on the activity of cholinesterase in the brain of the rat and on levels of acetylcholine (ACh) and choline (Ch).	Trichlorfon	116-127	butyrylcholinesterase	Rattus norvegicus	148-162
3037420-5	1987	However, in the presence of the cholinesterase inhibitor physostigmine, the responses to these stimuli were greatly enhanced and this could be blocked by atropine.	Physostigmine	57-70	butyrylcholinesterase	Rattus norvegicus	32-46
3037420-5	1987	However, in the presence of the cholinesterase inhibitor physostigmine, the responses to these stimuli were greatly enhanced and this could be blocked by atropine.	Atropine	154-162	butyrylcholinesterase	Rattus norvegicus	32-46
3573978-8	1987	In summary, bis(trichloromethyl) sulfone produced in vitro cholinesterase inhibition not demonstrated in vivo.	bis(trichloromethyl)sulfone	12-40	butyrylcholinesterase	Rattus norvegicus	59-73
3590218-2	1987	Oral administration of FTH (260 mg/kg) markedly inactivated cholinesterase (ChE) and carboxylesterase and elevated the activities of acid phosphatase, alanine aminotransferase and aspartate aminotransferase in different tissues 3 h after dosing.	Fenitrothion	23-26	butyrylcholinesterase	Rattus norvegicus	60-74
3590218-2	1987	Oral administration of FTH (260 mg/kg) markedly inactivated cholinesterase (ChE) and carboxylesterase and elevated the activities of acid phosphatase, alanine aminotransferase and aspartate aminotransferase in different tissues 3 h after dosing.	Fenitrothion	23-26	butyrylcholinesterase	Rattus norvegicus	76-79
3498823-20	1987	From hemidiaphragms with active cholinesterase about 120 pmol ACh was lost after prolonged nerve stimulation or incubation with 50 mM-KCl in the presence of hemicholinium-3, and about 35 pmol remained in the tissue.	Hemicholinium 3	157-172	butyrylcholinesterase	Rattus norvegicus	32-46
3498823-20	1987	From hemidiaphragms with active cholinesterase about 120 pmol ACh was lost after prolonged nerve stimulation or incubation with 50 mM-KCl in the presence of hemicholinium-3, and about 35 pmol remained in the tissue.	Acetylcholine	62-65	butyrylcholinesterase	Rattus norvegicus	32-46
3566805-10	1987	The different effects of cholinesterase inhibitors are probably linked to the synthesis and release mechanism of ACh rather than to the choline uptake mechanism.	Acetylcholine	113-116	butyrylcholinesterase	Rattus norvegicus	25-39
3819725-1	1987	The main objective of this study was to determine whether the excitotoxic cholinesterase inhibitor soman increases the catabolism of phospholipids in rat brain.	Phospholipids	133-146	butyrylcholinesterase	Rattus norvegicus	74-88
3564014-16	1987	A significant amount of soman binds to non-AChE enzymes with serine sites such as BuChE and carboxylesterases.	Serine	61-67	butyrylcholinesterase	Rattus norvegicus	82-87
3807893-5	1987	Treatment of rats with nicotine for 10 days increased the density of binding sites for both ligands, and treatment with the cholinesterase inhibitor soman for 9 days decreased the density of binding sites for both ligands.	Soman	149-154	butyrylcholinesterase	Rattus norvegicus	124-138
2883282-4	1987	Neither of these effects was seen in tissues which had been pretreated with the cholinesterase inhibitor BW284C51 (0.2 microM) though tetraethylammonium iodide (40 microM) was still able to enhance the responses to stimulation.	Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide	105-113	butyrylcholinesterase	Rattus norvegicus	80-94
2883282-7	1987	It is concluded that the cholinergic action of meptazinol in these tissues is due to an indirect effect, probably involving inhibition of cholinesterase and that no evidence was seen of any ability to increase the release of acetylcholine itself.	Meptazinol	47-57	butyrylcholinesterase	Rattus norvegicus	138-152
3675562-1	1987	Changes in plasma cholinesterase (ChE) activity after administration of glucocorticoids (prednisone, methyl-prednisolone and dexamethasone) were studied in male and female rats.	Prednisone	89-99	butyrylcholinesterase	Rattus norvegicus	18-32
3575348-6	1987	In addition, at the anti-aggressive doses, (+/-)propranolol (10 mg/kg) and UM-272 (10 mg/kg), significantly inhibited brain cholinesterase enzyme activity when compared to saline controls.	Propranolol	48-59	butyrylcholinesterase	Rattus norvegicus	124-138
3575348-6	1987	In addition, at the anti-aggressive doses, (+/-)propranolol (10 mg/kg) and UM-272 (10 mg/kg), significantly inhibited brain cholinesterase enzyme activity when compared to saline controls.	pranolium	75-81	butyrylcholinesterase	Rattus norvegicus	124-138
3575348-6	1987	In addition, at the anti-aggressive doses, (+/-)propranolol (10 mg/kg) and UM-272 (10 mg/kg), significantly inhibited brain cholinesterase enzyme activity when compared to saline controls.	Sodium Chloride	172-178	butyrylcholinesterase	Rattus norvegicus	124-138
3575359-4	1987	Mecamylamine pretreatment also reduced lordotic behavior induced by bilateral intracerebroventricular (ICV) injection of the cholinesterase inhibitor, eserine (5 micrograms/cannula).	Mecamylamine	0-12	butyrylcholinesterase	Rattus norvegicus	125-139
3575359-4	1987	Mecamylamine pretreatment also reduced lordotic behavior induced by bilateral intracerebroventricular (ICV) injection of the cholinesterase inhibitor, eserine (5 micrograms/cannula).	Physostigmine	151-158	butyrylcholinesterase	Rattus norvegicus	125-139
3128047-2	1987	After incubation of the muscle tissue in a medium containing butyrylthiocholine bromide as substrate and BW284c51 as the specific inhibitor of acetylcholinesterase, a distinct electron-dense precipitate corresponding to non-specific cholinesterase activity was found along the whole length of muscle spindles.	Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide	105-113	butyrylcholinesterase	Rattus norvegicus	149-163
3675562-1	1987	Changes in plasma cholinesterase (ChE) activity after administration of glucocorticoids (prednisone, methyl-prednisolone and dexamethasone) were studied in male and female rats.	Prednisone	89-99	butyrylcholinesterase	Rattus norvegicus	34-37
3675562-1	1987	Changes in plasma cholinesterase (ChE) activity after administration of glucocorticoids (prednisone, methyl-prednisolone and dexamethasone) were studied in male and female rats.	Methylprednisolone	101-120	butyrylcholinesterase	Rattus norvegicus	18-32
3675562-1	1987	Changes in plasma cholinesterase (ChE) activity after administration of glucocorticoids (prednisone, methyl-prednisolone and dexamethasone) were studied in male and female rats.	Methylprednisolone	101-120	butyrylcholinesterase	Rattus norvegicus	34-37
3675562-1	1987	Changes in plasma cholinesterase (ChE) activity after administration of glucocorticoids (prednisone, methyl-prednisolone and dexamethasone) were studied in male and female rats.	Dexamethasone	125-138	butyrylcholinesterase	Rattus norvegicus	18-32
3675562-1	1987	Changes in plasma cholinesterase (ChE) activity after administration of glucocorticoids (prednisone, methyl-prednisolone and dexamethasone) were studied in male and female rats.	Dexamethasone	125-138	butyrylcholinesterase	Rattus norvegicus	34-37
3675562-4	1987	The inhibitory effect of dexamethasone on ChE synthesis was significantly greater than the effect of equivalent antiinflammatory doses of the other two glucocorticoids investigated.	Dexamethasone	25-38	butyrylcholinesterase	Rattus norvegicus	42-45
3028835-4	1986	Results in this communication identify several quaternary amines which are equipotent with physostigmine for inhibition of cholinesterase.	quaternary amines	47-64	butyrylcholinesterase	Rattus norvegicus	123-137
3666870-4	1987	Dichlorvos produced abnormalities in ECG, decrease in heart rate, cardiac arrest and inhibition of cholinesterase activity.	Dichlorvos	0-10	butyrylcholinesterase	Rattus norvegicus	99-113
3666870-5	1987	It is suggested that cardiotoxic effect of DDVP may be mediated by the accumulated acetylcholine as a result of cholinesterase inhibition.	Acetylcholine	83-96	butyrylcholinesterase	Rattus norvegicus	112-126
3588658-4	1987	All three cholinesterase inhibitors caused an initial rise in corticosterone; DFP decreased growth hormone; physostigmine reduced prolactin.	Corticosterone	62-76	butyrylcholinesterase	Rattus norvegicus	10-24
3588658-4	1987	All three cholinesterase inhibitors caused an initial rise in corticosterone; DFP decreased growth hormone; physostigmine reduced prolactin.	Physostigmine	108-121	butyrylcholinesterase	Rattus norvegicus	10-24
3586068-2	1987	Echothiophate iodide (ECHO), a water-soluble cholinesterase inhibitor, was applied to muscles in situ to eliminate extracellular and/or extracellularly oriented enzyme.	Echothiophate Iodide	0-20	butyrylcholinesterase	Rattus norvegicus	45-59
3028835-4	1986	Results in this communication identify several quaternary amines which are equipotent with physostigmine for inhibition of cholinesterase.	Physostigmine	91-104	butyrylcholinesterase	Rattus norvegicus	123-137
3798464-1	1986	Acephate pre-exposure provided protection against the inhibition of RBC and brain acetylcholinesterase (AChE), and plasma cholinesterase (ChE) activities in rats exposed to both acephate and methamidophos.	acephate	0-8	butyrylcholinesterase	Rattus norvegicus	88-102
3798464-1	1986	Acephate pre-exposure provided protection against the inhibition of RBC and brain acetylcholinesterase (AChE), and plasma cholinesterase (ChE) activities in rats exposed to both acephate and methamidophos.	acephate	0-8	butyrylcholinesterase	Rattus norvegicus	105-108
3786359-3	1986	Consumption of pyridostigmine for 7 days (n = 34, 6.6 mg/day) resulted in a 23% (p less than 0.001) reduction of circulating cholinesterase when compared with a control group (n = 31) while ingestion for 14 days (n = 35, 8.9 mg/day) elicited a 39% (p less than 0.001) inhibition of circulating cholinesterase when compared to a second control group (n = 33).	Pyridostigmine Bromide	15-29	butyrylcholinesterase	Rattus norvegicus	125-139
3798464-1	1986	Acephate pre-exposure provided protection against the inhibition of RBC and brain acetylcholinesterase (AChE), and plasma cholinesterase (ChE) activities in rats exposed to both acephate and methamidophos.	methamidophos	191-204	butyrylcholinesterase	Rattus norvegicus	88-102
3798464-1	1986	Acephate pre-exposure provided protection against the inhibition of RBC and brain acetylcholinesterase (AChE), and plasma cholinesterase (ChE) activities in rats exposed to both acephate and methamidophos.	methamidophos	191-204	butyrylcholinesterase	Rattus norvegicus	105-108
2879019-0	1986	Tissue cholinesterase inhibition by propranolol and related drugs.	Propranolol	36-47	butyrylcholinesterase	Rattus norvegicus	7-21
2879019-1	1986	The effect of (+/-)-propranolol and some related drugs have been investigated on the cholinesterase (ChE) enzyme activity of heart and brain tissues of the rat.	Propranolol	14-31	butyrylcholinesterase	Rattus norvegicus	85-99
2879019-1	1986	The effect of (+/-)-propranolol and some related drugs have been investigated on the cholinesterase (ChE) enzyme activity of heart and brain tissues of the rat.	Propranolol	14-31	butyrylcholinesterase	Rattus norvegicus	101-104
2879019-3	1986	In-vitro, (+/-)-, (+)- and (-)-propranolol, as well as its quaternary analogue, UM-272, all significantly inhibited heart and brain ChE.	(+/-)-, (+)- and (-)-propranolol	10-42	butyrylcholinesterase	Rattus norvegicus	132-135
2879019-3	1986	In-vitro, (+/-)-, (+)- and (-)-propranolol, as well as its quaternary analogue, UM-272, all significantly inhibited heart and brain ChE.	pranolium	80-86	butyrylcholinesterase	Rattus norvegicus	132-135
2879019-5	1986	In-vivo, (+/-)-propranolol (30 mumol kg-1) significantly inhibited brain ChE activity in rats when compared with saline controls.	Propranolol	9-26	butyrylcholinesterase	Rattus norvegicus	73-76
2879019-6	1986	It is inferred that propranolol inhibits brain and heart ChE enzyme in a non-stereoselective manner and that this cholinomimetic action could be involved in the mediation of some of its therapeutic effects.	Propranolol	20-31	butyrylcholinesterase	Rattus norvegicus	57-60
3786359-3	1986	Consumption of pyridostigmine for 7 days (n = 34, 6.6 mg/day) resulted in a 23% (p less than 0.001) reduction of circulating cholinesterase when compared with a control group (n = 31) while ingestion for 14 days (n = 35, 8.9 mg/day) elicited a 39% (p less than 0.001) inhibition of circulating cholinesterase when compared to a second control group (n = 33).	Pyridostigmine Bromide	15-29	butyrylcholinesterase	Rattus norvegicus	294-308
3786359-7	1986	These data indicate that oral dosages of pyridostigmine can probably be titrated to levels of cholinesterase inhibition which are efficacious in prophylaxis against organophosphate toxicity without significant effects on selected physiologic and metabolic processes.	Pyridostigmine Bromide	41-55	butyrylcholinesterase	Rattus norvegicus	94-108
3786359-7	1986	These data indicate that oral dosages of pyridostigmine can probably be titrated to levels of cholinesterase inhibition which are efficacious in prophylaxis against organophosphate toxicity without significant effects on selected physiologic and metabolic processes.	Organophosphates	165-180	butyrylcholinesterase	Rattus norvegicus	94-108
3761745-1	1986	Diethyxime, a non-quaternary cholinesterase reactivator was evaluated for its antidotal efficacy against organophosphorus intoxication in rats using the protection index, cholinesterase reactivation and neuromuscular function as the experimental protocol.	diethyxime	0-10	butyrylcholinesterase	Rattus norvegicus	29-43
2876643-6	1986	Injection of neostigmine (5 X 10(-8) mol), an inhibitor of cholinesterase, into the ventricle resulted in the increase of not only glucose, but also glucagon, epinephrine, and norepinephrine in the hepatic venous plasma.	Neostigmine	13-24	butyrylcholinesterase	Rattus norvegicus	59-73
2876643-6	1986	Injection of neostigmine (5 X 10(-8) mol), an inhibitor of cholinesterase, into the ventricle resulted in the increase of not only glucose, but also glucagon, epinephrine, and norepinephrine in the hepatic venous plasma.	Glucose	131-138	butyrylcholinesterase	Rattus norvegicus	59-73
2876643-6	1986	Injection of neostigmine (5 X 10(-8) mol), an inhibitor of cholinesterase, into the ventricle resulted in the increase of not only glucose, but also glucagon, epinephrine, and norepinephrine in the hepatic venous plasma.	Glucagon	149-157	butyrylcholinesterase	Rattus norvegicus	59-73
2876643-6	1986	Injection of neostigmine (5 X 10(-8) mol), an inhibitor of cholinesterase, into the ventricle resulted in the increase of not only glucose, but also glucagon, epinephrine, and norepinephrine in the hepatic venous plasma.	Norepinephrine	176-190	butyrylcholinesterase	Rattus norvegicus	59-73
3753519-2	1986	The role of cholinergic and non-cholinergic mechanisms in mediating organophosphate cholinesterase (ChE) inhibitor-induced elevations in choline levels in brain was investigated.	Choline	12-19	butyrylcholinesterase	Rattus norvegicus	100-103
3732661-3	1986	Rats fed a diet containing oxamyl at 500 ppm showed clinical signs of cholinesterase inhibition and body weight loss within 2 days.	oxamyl	27-33	butyrylcholinesterase	Rattus norvegicus	70-84
3761745-1	1986	Diethyxime, a non-quaternary cholinesterase reactivator was evaluated for its antidotal efficacy against organophosphorus intoxication in rats using the protection index, cholinesterase reactivation and neuromuscular function as the experimental protocol.	diethyxime	0-10	butyrylcholinesterase	Rattus norvegicus	171-185
3726876-1	1986	Methylphosphonic difluoride (difluoro) and its hydrolysis products, methylphosphonofluoridate (MF) and fluoride, were examined for cholinesterase-inhibiting ability in rats and guinea pigs by both inhalation and intraperitoneal exposure routes.	methylphosphonic difluoride	0-27	butyrylcholinesterase	Rattus norvegicus	131-145
3748273-0	1986	Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat.	Physostigmine	27-40	butyrylcholinesterase	Rattus norvegicus	58-72
3748273-11	1986	There was a relationship between ChE activity, Phy concentration and ACh levels in all areas examined with exception of the medulla oblongata (MO).	Acetylcholine	69-72	butyrylcholinesterase	Rattus norvegicus	33-36
3712275-1	1986	The chronic effects of sublethal injections of the cholinesterase inhibitor, paraoxon, on transmitter release were examined in the rat.	Paraoxon	77-85	butyrylcholinesterase	Rattus norvegicus	51-65
3726876-1	1986	Methylphosphonic difluoride (difluoro) and its hydrolysis products, methylphosphonofluoridate (MF) and fluoride, were examined for cholinesterase-inhibiting ability in rats and guinea pigs by both inhalation and intraperitoneal exposure routes.	methionylphenylalanine	95-97	butyrylcholinesterase	Rattus norvegicus	131-145
3718528-1	1986	The in vitro exposure of rat bronchial smooth muscle to the cholinesterase inhibitor soman (O-[1,2,2-trimethylpropyl]-methyl-phosphonofluoridate) potentiated the rapid and concentration dependent increase in the contraction induced by acetylcholine (ACh).	o-[1,2,2-trimethylpropyl]-methyl-phosphonofluoridate	92-144	butyrylcholinesterase	Rattus norvegicus	60-74
3718528-1	1986	The in vitro exposure of rat bronchial smooth muscle to the cholinesterase inhibitor soman (O-[1,2,2-trimethylpropyl]-methyl-phosphonofluoridate) potentiated the rapid and concentration dependent increase in the contraction induced by acetylcholine (ACh).	Acetylcholine	235-248	butyrylcholinesterase	Rattus norvegicus	60-74
3718528-1	1986	The in vitro exposure of rat bronchial smooth muscle to the cholinesterase inhibitor soman (O-[1,2,2-trimethylpropyl]-methyl-phosphonofluoridate) potentiated the rapid and concentration dependent increase in the contraction induced by acetylcholine (ACh).	Acetylcholine	250-253	butyrylcholinesterase	Rattus norvegicus	60-74
3961810-8	1986	Serum cholinesterase, sampled 48 hr after the second TPP exposure was depressed by 33%.	triphenyl phosphite	53-56	butyrylcholinesterase	Rattus norvegicus	6-20
3095801-2	1986	DS, 600 mg/kg, administered by gavage for 3 days caused an increase in asparagine aminotransferase (AspAT) and alkaline phosphatase (AP) and a decrease in cholinesterase (ChE) activity in the serum and decrease in AspAT and ChE activity in the liver.	Disulfiram	0-2	butyrylcholinesterase	Rattus norvegicus	155-169
3095801-2	1986	DS, 600 mg/kg, administered by gavage for 3 days caused an increase in asparagine aminotransferase (AspAT) and alkaline phosphatase (AP) and a decrease in cholinesterase (ChE) activity in the serum and decrease in AspAT and ChE activity in the liver.	Disulfiram	0-2	butyrylcholinesterase	Rattus norvegicus	171-174
3095801-2	1986	DS, 600 mg/kg, administered by gavage for 3 days caused an increase in asparagine aminotransferase (AspAT) and alkaline phosphatase (AP) and a decrease in cholinesterase (ChE) activity in the serum and decrease in AspAT and ChE activity in the liver.	Disulfiram	0-2	butyrylcholinesterase	Rattus norvegicus	224-227
3699340-4	1986	Physostigmine caused only slight inhibition of cholinesterase in blood and skeletal muscle.	Physostigmine	0-13	butyrylcholinesterase	Rattus norvegicus	47-61
3699340-5	1986	Cholinesterase activity in blood and muscle of rats pretreated with physostigmine before sarin administration was significantly higher than in tissues from rats injected with sarin alone.	Physostigmine	68-81	butyrylcholinesterase	Rattus norvegicus	0-14
3699340-8	1986	Effective protection against lethality by physostigmine could be related to protection of cerebral cholinesterase since inhibition of this enzyme by sarin was lowered significantly after pretreatment with physostigmine.	Physostigmine	42-55	butyrylcholinesterase	Rattus norvegicus	99-113
3699340-8	1986	Effective protection against lethality by physostigmine could be related to protection of cerebral cholinesterase since inhibition of this enzyme by sarin was lowered significantly after pretreatment with physostigmine.	Physostigmine	205-218	butyrylcholinesterase	Rattus norvegicus	99-113
3714119-1	1986	Pyridostigmine bromide, a quaternary carbamate, is widely used in treatment of myasthenia gravis and has been suggested for use in prophylaxis against intoxication with irreversible cholinesterase inhibitors.	Pyridostigmine Bromide	0-22	butyrylcholinesterase	Rattus norvegicus	182-196
3714119-1	1986	Pyridostigmine bromide, a quaternary carbamate, is widely used in treatment of myasthenia gravis and has been suggested for use in prophylaxis against intoxication with irreversible cholinesterase inhibitors.	quaternary	26-36	butyrylcholinesterase	Rattus norvegicus	182-196
3714119-1	1986	Pyridostigmine bromide, a quaternary carbamate, is widely used in treatment of myasthenia gravis and has been suggested for use in prophylaxis against intoxication with irreversible cholinesterase inhibitors.	Carbamates	37-46	butyrylcholinesterase	Rattus norvegicus	182-196
2867830-1	1986	Coated vesicles isolated from rat liver perfused with diisopropylfluorophosphate (DFP) to inactivate endogenous cholinesterase contained newly synthesized secretory cholinesterase after a 30 min recovery.	Isoflurophate	54-80	butyrylcholinesterase	Rattus norvegicus	112-126
3948777-3	1986	Adult male rats treated neonatally with monosodium L-glutamate to induce arcuate nucleus lesions of the hypothalamus have higher serum cholinesterase activities and decreased serum GH concentrations.	Sodium Glutamate	40-62	butyrylcholinesterase	Rattus norvegicus	135-149
3703907-4	1986	Cholinesterase activity was inhibited in a dose-dependent manner in brain and plasma after administration of the organophosphates and CTA was correlated with the degree of plasma cholinesterase inhibition.	Organophosphates	113-129	butyrylcholinesterase	Rattus norvegicus	0-14
3703907-4	1986	Cholinesterase activity was inhibited in a dose-dependent manner in brain and plasma after administration of the organophosphates and CTA was correlated with the degree of plasma cholinesterase inhibition.	Organophosphates	113-129	butyrylcholinesterase	Rattus norvegicus	179-193
3703907-5	1986	CTA appears to be a sensitive indicator of neurobehavioral effects of mild exposure to organophosphates which causes only 30-40% inhibition of plasma cholinesterase.	Organophosphates	87-103	butyrylcholinesterase	Rattus norvegicus	150-164
2820334-4	1986	Furthermore, the activities of cholinesterase and alpha-amylase also varied depending on the vitamin D2 doses administered.	Ergocalciferols	93-103	butyrylcholinesterase	Rattus norvegicus	31-45
2867830-1	1986	Coated vesicles isolated from rat liver perfused with diisopropylfluorophosphate (DFP) to inactivate endogenous cholinesterase contained newly synthesized secretory cholinesterase after a 30 min recovery.	Isoflurophate	54-80	butyrylcholinesterase	Rattus norvegicus	165-179
2867830-1	1986	Coated vesicles isolated from rat liver perfused with diisopropylfluorophosphate (DFP) to inactivate endogenous cholinesterase contained newly synthesized secretory cholinesterase after a 30 min recovery.	Isoflurophate	82-85	butyrylcholinesterase	Rattus norvegicus	112-126
2867830-1	1986	Coated vesicles isolated from rat liver perfused with diisopropylfluorophosphate (DFP) to inactivate endogenous cholinesterase contained newly synthesized secretory cholinesterase after a 30 min recovery.	Isoflurophate	82-85	butyrylcholinesterase	Rattus norvegicus	165-179
2879704-1	1986	The present investigation revealed the effect of the organochlorine insecticide dieldrin at the dose level 0.25 LD50 at different time intervals on the concentration of 11 rat brain amino acids, on the activities of glutamic oxyacetic transaminase (GOT), glutamic pyruvic transaminase (GpT) and cholinesterase.	Dieldrin	80-88	butyrylcholinesterase	Rattus norvegicus	295-309
3631954-0	1986	[Organophosphorus compounds as tools for the pharmaco-histochemical study of cholinesterase in the rat striatum].	organophosphorus	1-17	butyrylcholinesterase	Rattus norvegicus	77-91
3517501-2	1986	Exposure of neonatal rats to antioestrogen (tamoxifen or CI-628) resulted in increased serum cholinesterase in adult females only and no effect on hepatic histidase and monoamine oxidase in both sexes.	Tamoxifen	44-53	butyrylcholinesterase	Rattus norvegicus	93-107
3517501-2	1986	Exposure of neonatal rats to antioestrogen (tamoxifen or CI-628) resulted in increased serum cholinesterase in adult females only and no effect on hepatic histidase and monoamine oxidase in both sexes.	Nitromifene	57-63	butyrylcholinesterase	Rattus norvegicus	93-107
3821694-7	1986	These results indicate that escape of gastric submucosal arterioles from acetylcholine-induced dilatation is mediated by endogenous cholinesterase (catabolism of acetylcholine by endogenous cholinesterase), and basal arteriolar diameter may be determined, in part, by endogenous acetylcholine, this effect being modulated by endogenous cholinesterase.	Acetylcholine	73-86	butyrylcholinesterase	Rattus norvegicus	132-146
2872013-3	1986	Ethopropazine totally depressed the pseudo ChE activity from horse serum at a concentration of 5 X 10(-5) M. The true ChE was not inhibited at this concentration.	profenamine	0-13	butyrylcholinesterase	Rattus norvegicus	43-46
2872013-4	1986	For true ChE from bovine erythrocytes and pseudo ChE from horse serum BW 284C51 and ethopropazine therefore certainly have a potential as selective ChE inhibitors.	profenamine	84-97	butyrylcholinesterase	Rattus norvegicus	9-12
2872013-4	1986	For true ChE from bovine erythrocytes and pseudo ChE from horse serum BW 284C51 and ethopropazine therefore certainly have a potential as selective ChE inhibitors.	profenamine	84-97	butyrylcholinesterase	Rattus norvegicus	49-52
2872013-4	1986	For true ChE from bovine erythrocytes and pseudo ChE from horse serum BW 284C51 and ethopropazine therefore certainly have a potential as selective ChE inhibitors.	profenamine	84-97	butyrylcholinesterase	Rattus norvegicus	49-52
2872013-5	1986	Ethopropazine at a concentration of 5 X 10(-6) M completely inhibited the pseudo ChE activity in rat plasma and cortex without affecting true ChE activity.	profenamine	0-13	butyrylcholinesterase	Rattus norvegicus	81-84
3821694-7	1986	These results indicate that escape of gastric submucosal arterioles from acetylcholine-induced dilatation is mediated by endogenous cholinesterase (catabolism of acetylcholine by endogenous cholinesterase), and basal arteriolar diameter may be determined, in part, by endogenous acetylcholine, this effect being modulated by endogenous cholinesterase.	Acetylcholine	73-86	butyrylcholinesterase	Rattus norvegicus	190-204
3821694-7	1986	These results indicate that escape of gastric submucosal arterioles from acetylcholine-induced dilatation is mediated by endogenous cholinesterase (catabolism of acetylcholine by endogenous cholinesterase), and basal arteriolar diameter may be determined, in part, by endogenous acetylcholine, this effect being modulated by endogenous cholinesterase.	Acetylcholine	73-86	butyrylcholinesterase	Rattus norvegicus	190-204
3821694-7	1986	These results indicate that escape of gastric submucosal arterioles from acetylcholine-induced dilatation is mediated by endogenous cholinesterase (catabolism of acetylcholine by endogenous cholinesterase), and basal arteriolar diameter may be determined, in part, by endogenous acetylcholine, this effect being modulated by endogenous cholinesterase.	Acetylcholine	162-175	butyrylcholinesterase	Rattus norvegicus	132-146
3821694-7	1986	These results indicate that escape of gastric submucosal arterioles from acetylcholine-induced dilatation is mediated by endogenous cholinesterase (catabolism of acetylcholine by endogenous cholinesterase), and basal arteriolar diameter may be determined, in part, by endogenous acetylcholine, this effect being modulated by endogenous cholinesterase.	Acetylcholine	162-175	butyrylcholinesterase	Rattus norvegicus	132-146
4049426-0	1985	Depression of serum cholinesterase activity by cadmium.	Cadmium	47-54	butyrylcholinesterase	Rattus norvegicus	20-34
2996577-4	1985	These effects were similar to those obtained with neostigmine and it was demonstrated that meptazinol had significant anti-cholinesterase activity in the concentrations used.	Meptazinol	91-101	butyrylcholinesterase	Rattus norvegicus	123-137
2996577-5	1985	Inhibition of cholinesterase with ecothiopate revealed a neuromuscular blocking activity of meptazinol in concentrations as low as 0.25 micrograms ml-1.	Echothiophate	34-45	butyrylcholinesterase	Rattus norvegicus	14-28
2996577-5	1985	Inhibition of cholinesterase with ecothiopate revealed a neuromuscular blocking activity of meptazinol in concentrations as low as 0.25 micrograms ml-1.	Meptazinol	92-102	butyrylcholinesterase	Rattus norvegicus	14-28
4060172-6	1985	It was indicated that the ChE inhibition by diazinon exposure is greater in the plasma than in the erythrocytes for male mice, while its inhibition is greater in the erythrocytes for male rats.	Diazinon	44-52	butyrylcholinesterase	Rattus norvegicus	26-29
3860856-0	1985	Glycyl-L-glutamine, a precursor, and glycyl-L-glutamic acid, a neurotrophic factor for maintenance of acetylcholinesterase and butyrylcholinesterase in the preganglionically denervated superior cervical ganglion of the cat in vivo.	glycylglutamine	0-18	butyrylcholinesterase	Rattus norvegicus	127-148
3860856-0	1985	Glycyl-L-glutamine, a precursor, and glycyl-L-glutamic acid, a neurotrophic factor for maintenance of acetylcholinesterase and butyrylcholinesterase in the preganglionically denervated superior cervical ganglion of the cat in vivo.	N-glycylglutamic acid	37-59	butyrylcholinesterase	Rattus norvegicus	127-148
3860856-5	1985	Since Gly-Gln meets the criteria established for the neurotrophic factor (NF) in extracts of central nervous system/sciatic nerves that maintains AcChoEase and butyrylcholinesterase (BtChoEase) in the denervated cat superior cervical ganglion (SCG) in vivo, it was tested by the latter procedure.	glycylglutamine	6-13	butyrylcholinesterase	Rattus norvegicus	160-181
4092896-3	1985	The in vitro kinetics of the reaction of O,S,S-trimethyl phosphorodithioate or O,O,S-triethyl phosphorothioate with plasma cholinesterase and carboxylesterase and brain acetylcholinesterase have been determined.	O,S,S-trimethyl phosphorodithioate	41-75	butyrylcholinesterase	Rattus norvegicus	123-137
4092896-3	1985	The in vitro kinetics of the reaction of O,S,S-trimethyl phosphorodithioate or O,O,S-triethyl phosphorothioate with plasma cholinesterase and carboxylesterase and brain acetylcholinesterase have been determined.	O,O,S-triethyl phosphorothioate	79-110	butyrylcholinesterase	Rattus norvegicus	123-137
2869436-8	1985	The H2-antagonist ranitidine, however, proved a good antagonist of responses to histamine and the H1- and H2-agonists, despite an unrelated excitatory action which may be linked to inhibition of cholinesterase.	Ranitidine	18-28	butyrylcholinesterase	Rattus norvegicus	195-209
3008131-5	1985	In acute poisoning with parathion-methyl it was observed that ChE and paraoxonase activities were inhibited, while beta-gluc activity was enhanced in the serum.	Parathion	24-33	butyrylcholinesterase	Rattus norvegicus	62-65
3008132-4	1985	Parathion-methyl inhibited ChE and paraoxonase activities and an increased beta-gluc activity in the serum.	Methyl Parathion	0-16	butyrylcholinesterase	Rattus norvegicus	27-30
4009168-2	1985	After 10 days of treatment with the cholinesterase inhibitor diisopropyl fluorophosphate, [3H]ACh binding in the cortex, thalamus, striatum, and hypothalamus was decreased.	Isoflurophate	61-88	butyrylcholinesterase	Rattus norvegicus	36-50
4009168-2	1985	After 10 days of treatment with the cholinesterase inhibitor diisopropyl fluorophosphate, [3H]ACh binding in the cortex, thalamus, striatum, and hypothalamus was decreased.	Tritium	91-93	butyrylcholinesterase	Rattus norvegicus	36-50
4009168-2	1985	After 10 days of treatment with the cholinesterase inhibitor diisopropyl fluorophosphate, [3H]ACh binding in the cortex, thalamus, striatum, and hypothalamus was decreased.	Acetylcholine	94-97	butyrylcholinesterase	Rattus norvegicus	36-50
4059650-4	1985	ChE activity in the end plate region of the diaphragm was progressively inhibited by both doses of paraoxon throughout the 60 day period.	Paraoxon	99-107	butyrylcholinesterase	Rattus norvegicus	0-3
4059650-8	1985	Results indicate that prolonged exposure to low doses of organophosphate ChE inhibitors leads to necrosis of skeletal muscle fibers and may be observed without other overt signs of organophosphate toxicity.	Organophosphates	57-72	butyrylcholinesterase	Rattus norvegicus	73-76
4059650-8	1985	Results indicate that prolonged exposure to low doses of organophosphate ChE inhibitors leads to necrosis of skeletal muscle fibers and may be observed without other overt signs of organophosphate toxicity.	Organophosphates	181-196	butyrylcholinesterase	Rattus norvegicus	73-76
3860856-5	1985	Since Gly-Gln meets the criteria established for the neurotrophic factor (NF) in extracts of central nervous system/sciatic nerves that maintains AcChoEase and butyrylcholinesterase (BtChoEase) in the denervated cat superior cervical ganglion (SCG) in vivo, it was tested by the latter procedure.	glycylglutamine	6-13	butyrylcholinesterase	Rattus norvegicus	183-192
4049426-5	1985	Cholinesterase (CHE; EC 3.1.1.8) activity in serum was found to decrease with time after the administration of a single injection of cadmium chloride and, in all experimental groups, was significantly lower than the control values on day 2 after the injection.	Cadmium Chloride	133-149	butyrylcholinesterase	Rattus norvegicus	0-14
4049426-5	1985	Cholinesterase (CHE; EC 3.1.1.8) activity in serum was found to decrease with time after the administration of a single injection of cadmium chloride and, in all experimental groups, was significantly lower than the control values on day 2 after the injection.	Cadmium Chloride	133-149	butyrylcholinesterase	Rattus norvegicus	16-19
4049426-9	1985	The results indicate that CHE activity in serum is a sensitive biological indicator for cadmium toxicity.	Cadmium	88-95	butyrylcholinesterase	Rattus norvegicus	26-29
3992605-0	1985	Diazinon concentrations and blood cholinesterase activities in rats exposed to diazinon.	Diazinon	79-87	butyrylcholinesterase	Rattus norvegicus	34-48
4000406-8	1985	Physostigmine, an anti-cholinesterase lacking agonistic action, decreased the uptake of Ch to 73% of control at 1 mM.	Physostigmine	0-13	butyrylcholinesterase	Rattus norvegicus	23-37
6713203-5	1984	Atropine (1-100 microM) increased endogenous ACh release by 32-91% and effective doses were 10-fold lower in the presence of a cholinesterase inhibitor.	Atropine	0-8	butyrylcholinesterase	Rattus norvegicus	127-141
3838196-1	1985	7-(Methylethoxyphosphinyloxy)-1-methyl quinolinium iodide (MEPQ), a new quaternary anti-cholinesterase (anti-ChE) compound was prepared and evaluated as a potential probe for assessing changes in the blood-brain barrier (B-BB) permeability.	7-((methylethoxyphosphinyl)oxy)-1-methylquinolinium	0-57	butyrylcholinesterase	Rattus norvegicus	88-102
3838196-1	1985	7-(Methylethoxyphosphinyloxy)-1-methyl quinolinium iodide (MEPQ), a new quaternary anti-cholinesterase (anti-ChE) compound was prepared and evaluated as a potential probe for assessing changes in the blood-brain barrier (B-BB) permeability.	7-((methylethoxyphosphinyl)oxy)-1-methylquinolinium	59-63	butyrylcholinesterase	Rattus norvegicus	88-102
3838196-2	1985	MEPQ was found to be 170 times more potent in its cholinesterase inhibitory activity than phospholine iodide, a previously reported anti-ChE probe in B-BB research.	7-((methylethoxyphosphinyl)oxy)-1-methylquinolinium	0-4	butyrylcholinesterase	Rattus norvegicus	50-64
6502210-5	1984	The alkaloid nicotinic agonists, cytisine and lobeline, were potent inhibitors of binding, while acetylcholine in the presence of the cholinesterase inhibitor di-isopropylfluorophosphate was equipotent with (+)-nicotine.	Lobeline	46-54	butyrylcholinesterase	Rattus norvegicus	134-148
6502210-5	1984	The alkaloid nicotinic agonists, cytisine and lobeline, were potent inhibitors of binding, while acetylcholine in the presence of the cholinesterase inhibitor di-isopropylfluorophosphate was equipotent with (+)-nicotine.	Acetylcholine	97-110	butyrylcholinesterase	Rattus norvegicus	134-148
6502210-5	1984	The alkaloid nicotinic agonists, cytisine and lobeline, were potent inhibitors of binding, while acetylcholine in the presence of the cholinesterase inhibitor di-isopropylfluorophosphate was equipotent with (+)-nicotine.	Isoflurophate	159-186	butyrylcholinesterase	Rattus norvegicus	134-148
6083633-4	1984	HI-6 produced appreciable plasma ChE reactivation but brain AChE activity was not significantly altered.	asoxime chloride	0-4	butyrylcholinesterase	Rattus norvegicus	33-36
6524963-10	1984	For the HPD, spontaneous regeneration of ChE diminished in RBCs in parathion-intoxicated rats and in plasma and RBCs of dichlorvos-intoxicated rats.	Parathion	67-76	butyrylcholinesterase	Rattus norvegicus	41-44
6500669-13	1984	Central injection of echothiophate (a long-acting cholinesterase inhibitor) to potentiate brain cholinergic activity resulted in a sustained hypertensive response (greater than 40 mm Hg) in SHR for at least 150 minutes.	Echothiophate	21-34	butyrylcholinesterase	Rattus norvegicus	50-64
6331583-8	1984	After chromatography on Sepharose 6B-100 columns, 3 forms (a, c, d) of cholinesterase activity could be separated from homogenates of single ganglia.	Sepharose	24-33	butyrylcholinesterase	Rattus norvegicus	71-85
6733361-0	1984	Interactions of cholinesterase inhibitors and glucocorticoids with ketamine and pentobarbitone-induced general anaesthesia in the rat: possible effects on central cholinergic activity.	Ketamine	67-75	butyrylcholinesterase	Rattus norvegicus	16-30
6733361-0	1984	Interactions of cholinesterase inhibitors and glucocorticoids with ketamine and pentobarbitone-induced general anaesthesia in the rat: possible effects on central cholinergic activity.	Pentobarbital	80-94	butyrylcholinesterase	Rattus norvegicus	16-30
6733361-1	1984	Doses of 100, 150 and 200 micrograms kg-1 of the cholinesterase inhibitor neostigmine reverse the anaesthetic action of ketamine.	Neostigmine	74-85	butyrylcholinesterase	Rattus norvegicus	49-63
6733361-1	1984	Doses of 100, 150 and 200 micrograms kg-1 of the cholinesterase inhibitor neostigmine reverse the anaesthetic action of ketamine.	Ketamine	120-128	butyrylcholinesterase	Rattus norvegicus	49-63
6733361-3	1984	The duration of anaesthesia induced by pentobarbitone is reversed by the cholinesterase inhibitor in doses of 150, 200 and 250 micrograms kg-1.	Pentobarbital	39-53	butyrylcholinesterase	Rattus norvegicus	73-87
6740698-4	1984	In this study an irreversible cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in doses of 1-4 mg/kg, was tested on renal function.	Isoflurophate	56-82	butyrylcholinesterase	Rattus norvegicus	30-44
6740698-4	1984	In this study an irreversible cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in doses of 1-4 mg/kg, was tested on renal function.	Isoflurophate	84-87	butyrylcholinesterase	Rattus norvegicus	30-44
6326923-3	1984	Compared to physostigmine, the analogues were weak inhibitors of cholinesterase enzymes.	Physostigmine	12-25	butyrylcholinesterase	Rattus norvegicus	65-79
6725066-6	1984	We concluded that pyridostigmine-induced cholinesterase inhibition had a variety of debilitating effects during work in the heat.	Pyridostigmine Bromide	18-32	butyrylcholinesterase	Rattus norvegicus	41-55
3989221-6	1985	The cholinesterase-inhibiting properties of acephate and methamidophos were compared in vitro to that of paraoxon, a known strong anticholinesterase.	acephate	44-52	butyrylcholinesterase	Rattus norvegicus	4-18
3989221-6	1985	The cholinesterase-inhibiting properties of acephate and methamidophos were compared in vitro to that of paraoxon, a known strong anticholinesterase.	methamidophos	57-70	butyrylcholinesterase	Rattus norvegicus	4-18
3989221-9	1985	Trout brain cholinesterase was the exception; it was as sensitive to paraoxon as it was to methamidophos.	Paraoxon	69-77	butyrylcholinesterase	Rattus norvegicus	12-26
3989221-9	1985	Trout brain cholinesterase was the exception; it was as sensitive to paraoxon as it was to methamidophos.	methamidophos	91-104	butyrylcholinesterase	Rattus norvegicus	12-26
2857526-5	1985	The cholinesterase inhibitor neostigmine also decreases K+-stimulated [3H]acetylcholine overflow, whereas the muscarinic antagonist atropine enhances the overflow of [3H]acetylcholine.	Neostigmine	29-40	butyrylcholinesterase	Rattus norvegicus	4-18
2857526-5	1985	The cholinesterase inhibitor neostigmine also decreases K+-stimulated [3H]acetylcholine overflow, whereas the muscarinic antagonist atropine enhances the overflow of [3H]acetylcholine.	Acetylcholine	70-87	butyrylcholinesterase	Rattus norvegicus	4-18
2858527-3	1985	BW 62c47 and iso-OMPA respectively produced a 48, 50 and 68% inhibition of cholinesterase activity in homogenates of anococcygeus muscle.	Tetraisopropylpyrophosphamide	13-21	butyrylcholinesterase	Rattus norvegicus	75-89
2858527-4	1985	The ED50 for cholinesterase inhibition by neostigmine (1.4 X 10(-5) M) is approximately 15 fold greater than the ED50 for the augmentation of the response to field stimulation (9.5 X 10(-7) M).	Neostigmine	42-53	butyrylcholinesterase	Rattus norvegicus	13-27
6532516-9	1984	Cholinesterase histochemistry in alternate sections revealed staining of motoneurons and their dendrites, and confirmed the location of the catecholamine varicosities within the motoneuron dendrite bundles.	Catecholamines	140-153	butyrylcholinesterase	Rattus norvegicus	0-14
6533340-0	1984	[Effects of organophosphorus compounds and PAM on cholinesterase activity in rat tissues].	organophosphorus	12-28	butyrylcholinesterase	Rattus norvegicus	50-64
6504953-1	1984	This paper reports the use of an RF capacitance field transducer and spectral analysis to examine the effects of the cholinesterase inhibitor physostigmine on the behavior of unrestrained rats.	Physostigmine	142-155	butyrylcholinesterase	Rattus norvegicus	117-131
6148115-4	1984	The cholinesterase in the ganglia was reduced by guanethidine treatment, but such ganglia retained their ability to accumulate surplus acetylcholine when they were incubated with physostigmine.	Guanethidine	49-61	butyrylcholinesterase	Rattus norvegicus	4-18
6381661-1	1984	[3H]Quinuclidinyl benzilate binding to rat brain muscarinic receptors decreased after repeated exposure to soman, a potent organophosphorus cholinesterase inhibitor.	[3h]quinuclidinyl benzilate	0-27	butyrylcholinesterase	Rattus norvegicus	140-154
6203358-2	1984	In the presence of cholinesterase inhibitors, supramaximal field stimulation (10 Hz) resulted in twitch responses accompanied by an increased release of acetylcholine.	Acetylcholine	153-166	butyrylcholinesterase	Rattus norvegicus	19-33
6491879-0	1984	[Effect of serum cholinesterase activity on muscle relaxation by succinylcholine in rats].	Succinylcholine	65-80	butyrylcholinesterase	Rattus norvegicus	17-31
6483827-0	1984	[Dynamics of cholinesterase inhibition in methylparathion poisoning].	Methyl Parathion	42-57	butyrylcholinesterase	Rattus norvegicus	13-27
6609006-4	1984	ChE activity and [3H]QNB binding were significantly decreased in the pancreas from disulfoton-treated rats.	Disulfoton	83-93	butyrylcholinesterase	Rattus norvegicus	0-3
6704181-1	1984	The effect of chronic administration of diisopropylphosphorofluoridate (DFP) on the levels and forms of plasma cholinesterase (ChE), were studied in male Wistar albino rats sacrificed at different time intervals after various schedules of treatment.	Isoflurophate	40-70	butyrylcholinesterase	Rattus norvegicus	111-125
6704181-1	1984	The effect of chronic administration of diisopropylphosphorofluoridate (DFP) on the levels and forms of plasma cholinesterase (ChE), were studied in male Wistar albino rats sacrificed at different time intervals after various schedules of treatment.	Isoflurophate	40-70	butyrylcholinesterase	Rattus norvegicus	127-130
6704181-1	1984	The effect of chronic administration of diisopropylphosphorofluoridate (DFP) on the levels and forms of plasma cholinesterase (ChE), were studied in male Wistar albino rats sacrificed at different time intervals after various schedules of treatment.	Isoflurophate	72-75	butyrylcholinesterase	Rattus norvegicus	111-125
6704181-1	1984	The effect of chronic administration of diisopropylphosphorofluoridate (DFP) on the levels and forms of plasma cholinesterase (ChE), were studied in male Wistar albino rats sacrificed at different time intervals after various schedules of treatment.	Isoflurophate	72-75	butyrylcholinesterase	Rattus norvegicus	127-130
6483827-1	1984	The inhibition of cholinesterase (ChEA) and acetylcholinesterase activity (AcChEA) in blood and brain of albino rats was followed up after repeated exposure to methylparathion (MP).	Methyl Parathion	160-175	butyrylcholinesterase	Rattus norvegicus	18-32
6662228-5	1983	Histochemical analysis revealed a product of response to cholinesterase which is the index of formation of the acetylcholine hydrolysis system in the culture"s I type neurons.	Acetylcholine	111-124	butyrylcholinesterase	Rattus norvegicus	57-71
6333719-3	1984	Iso-OMPA and BW-284 C 51 were used as inhibitors for nonspecific cholinesterase (nsChE) and acetylcholinesterase (AChE), respectively.	Tetraisopropylpyrophosphamide	0-8	butyrylcholinesterase	Rattus norvegicus	65-79
6695398-1	1984	The acute toxicity of quinuronium was investigated by measurements of lethal doses (LD50) in mice and rats, cholinesterase activity in vivo in whole blood, and protection from anticholinesterase activity by atropinisation in sheep and rabbits.	Quinuronium	22-33	butyrylcholinesterase	Rattus norvegicus	108-122
6667067-0	1983	Study of the analgesic effects of galanthamine, a cholinesterase inhibitor.	Galantamine	34-46	butyrylcholinesterase	Rattus norvegicus	50-64
6657721-1	1983	To determine the effects of low-dosage organophosphate administration on exercise in a hot environment, malathion (7.5 mg/day, 4 days) was administered IP to rats, and effected a 35% (p less than 0.01) reduction in plasma cholinesterase levels.	Malathion	104-113	butyrylcholinesterase	Rattus norvegicus	222-236
6639738-1	1983	Awake, unrestrained rats received direct bilateral infusions of the cholinesterase inhibitor, echothiophate, into the dentate gyrus during a 40-min experimental session in a holeboard/activity chamber.	Echothiophate	94-107	butyrylcholinesterase	Rattus norvegicus	68-82
6639738-2	1983	Additional animals were similarly tested during intrahippocampal infusions of a novel cholinesterase inhibitor, NBD-AP-MPF.	5-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)pentyl methylphosphonofluoridate	112-122	butyrylcholinesterase	Rattus norvegicus	86-100
6194444-8	1983	It is postulated that effects of soman and antidotes on neuronal RNA metabolism may signify alterations in acetylcholine (ACh) sensitivity and that pharmacologic manipulation of ACh responsiveness during organophosphate cholinesterase poisoning may be a mechanism for additional therapeutic intervention.	Acetylcholine	178-181	butyrylcholinesterase	Rattus norvegicus	220-234
6887013-2	1983	In the heart, the phospholipase A2 inhibitor mepacrine (10(-4) M) reduced the choline efflux (1.1 nmol g-1 min-1) by 51 +/- 5% (N = 3), whereas several cholinesterase inhibitors (physostigmine, neostigmine and diisopropylfluorophosphate) and muscarinic agonists (acetylcholine, oxotremorine and bethanechol) caused an increase.	Quinacrine	45-54	butyrylcholinesterase	Rattus norvegicus	152-166
6873393-1	1983	Chronic experiments in dogs with isolated loop of the small intestine and acute experiments in rats revealed specific interrelationships between the gastrin and the cholinergic activity: pentagastrin potentiated its effects by activation of cholinergic processes in the intestinal mucosa (increasing the acetylcholin content and the cholinesterase activity).	Pentagastrin	187-199	butyrylcholinesterase	Rattus norvegicus	333-347
6408651-7	1983	Maximum effects of propoxur and carbaryl on blood and brain cholinesterase and motor activity were seen within 15 min.	Propoxur	19-27	butyrylcholinesterase	Rattus norvegicus	60-74
6860351-0	1983	Cholinesterase and carboxylesterase activities in soman poisoned rats treated with bispyridinium mono-oximes HI-6 and HS-6.	bispyridinium mono-oximes	83-108	butyrylcholinesterase	Rattus norvegicus	0-14
6860351-0	1983	Cholinesterase and carboxylesterase activities in soman poisoned rats treated with bispyridinium mono-oximes HI-6 and HS-6.	asoxime chloride	109-113	butyrylcholinesterase	Rattus norvegicus	0-14
6860351-0	1983	Cholinesterase and carboxylesterase activities in soman poisoned rats treated with bispyridinium mono-oximes HI-6 and HS-6.	HS 6	118-122	butyrylcholinesterase	Rattus norvegicus	0-14
6828889-3	1983	After 10 days of exposure to the cholinesterase inhibitor diisopropyl fluorophosphate, binding of tritiated acetylcholine in the cerebral cortex was decreased.	Isoflurophate	58-85	butyrylcholinesterase	Rattus norvegicus	33-47
6828889-3	1983	After 10 days of exposure to the cholinesterase inhibitor diisopropyl fluorophosphate, binding of tritiated acetylcholine in the cerebral cortex was decreased.	tritiated acetylcholine	98-121	butyrylcholinesterase	Rattus norvegicus	33-47
6411799-3	1983	The 14C radioactivity in the blood and, in parallel, cholinesterase inhibition were maintained at a higher level in animals with an altered hepatic function.	Carbon-14	4-7	butyrylcholinesterase	Rattus norvegicus	53-67
6411799-5	1983	In all cases, tranylcypromine had a greater effect on blood kinetics, cholinesterase inhibition and LD50 than did 70% hepatectomy.	Tranylcypromine	14-29	butyrylcholinesterase	Rattus norvegicus	70-84
6726618-5	1984	In rabbits as well as rats, the considerable reactivations of inactivated AChEs in RBC and brain and inactivated ChE in plasma were observed by the single treatment with 2-PAM in fenitrothion poisoning.	Fenitrothion	179-191	butyrylcholinesterase	Rattus norvegicus	75-78
6620420-2	1983	Pretreatment with CAP also decreased the extent and duration of MTH-induced inhibition of cholinesterase (ChE).	Malathion	64-67	butyrylcholinesterase	Rattus norvegicus	90-104
6620420-2	1983	Pretreatment with CAP also decreased the extent and duration of MTH-induced inhibition of cholinesterase (ChE).	Malathion	64-67	butyrylcholinesterase	Rattus norvegicus	106-109
6408651-7	1983	Maximum effects of propoxur and carbaryl on blood and brain cholinesterase and motor activity were seen within 15 min.	Carbaryl	32-40	butyrylcholinesterase	Rattus norvegicus	60-74
6408651-8	1983	Maze activity had returned to control levels within 30 and 60 min whereas cholinesterase levels remained depressed for 120 and 240 min for propoxur and carbaryl, respectively.	Propoxur	139-147	butyrylcholinesterase	Rattus norvegicus	74-88
6408651-8	1983	Maze activity had returned to control levels within 30 and 60 min whereas cholinesterase levels remained depressed for 120 and 240 min for propoxur and carbaryl, respectively.	Carbaryl	152-160	butyrylcholinesterase	Rattus norvegicus	74-88
7150808-0	1982	Cholinesterase activity in rats treated with propoxur.	Propoxur	45-53	butyrylcholinesterase	Rattus norvegicus	0-14
6628257-0	1983	Reactivation of VX-inhibited cholinesterase by 2-PAM and HS-6 in rats.	HS 6	57-61	butyrylcholinesterase	Rattus norvegicus	29-43
6628257-3	1983	Both 2-PAM C1 and HS-6 markedly reactivated VX-inhibited blood and diaphragm ChE.	HS 6	18-22	butyrylcholinesterase	Rattus norvegicus	77-80
6315088-1	1983	Presynaptic effect of compound application of the cholinesterase (ChE) inhibitors of the reversible (galanthamine) and the irreversible (armin) after galanthamine pretreatment has been studied on the neuromuscular transmission at the rat diaphragm.	Galantamine	101-113	butyrylcholinesterase	Rattus norvegicus	50-64
6315088-1	1983	Presynaptic effect of compound application of the cholinesterase (ChE) inhibitors of the reversible (galanthamine) and the irreversible (armin) after galanthamine pretreatment has been studied on the neuromuscular transmission at the rat diaphragm.	Galantamine	101-113	butyrylcholinesterase	Rattus norvegicus	66-69
6315088-1	1983	Presynaptic effect of compound application of the cholinesterase (ChE) inhibitors of the reversible (galanthamine) and the irreversible (armin) after galanthamine pretreatment has been studied on the neuromuscular transmission at the rat diaphragm.	Galantamine	150-162	butyrylcholinesterase	Rattus norvegicus	50-64
6315088-1	1983	Presynaptic effect of compound application of the cholinesterase (ChE) inhibitors of the reversible (galanthamine) and the irreversible (armin) after galanthamine pretreatment has been studied on the neuromuscular transmission at the rat diaphragm.	Galantamine	150-162	butyrylcholinesterase	Rattus norvegicus	66-69
6138014-2	1983	60 min before sacrifice) did not modify cholinesterase (ChE) activity, but considerably enhanced the inhibition of total ChE induced by physostigmine (PhS, 0.5 mg/kg i.p.	Physostigmine	136-149	butyrylcholinesterase	Rattus norvegicus	121-124
6138014-2	1983	60 min before sacrifice) did not modify cholinesterase (ChE) activity, but considerably enhanced the inhibition of total ChE induced by physostigmine (PhS, 0.5 mg/kg i.p.	Physostigmine	151-154	butyrylcholinesterase	Rattus norvegicus	121-124
6138014-5	1983	The enhanced inhibition of total ChE due to CPZ depended in most peripheral organs on the effect on pseudoChE (as measured by a spectrophotometric method), except in the case of skeletal muscle in which potentiation of PhS effect was observed on true acetylcholinesterase (AcChE).	Chlorpromazine	44-47	butyrylcholinesterase	Rattus norvegicus	33-36
6628257-5	1983	The effectiveness of these oximes in restoration of VX-inactivated ChE in vivo offers an explanation as to why conventional atropine/oxime therapy is so effective against VX intoxication.	Oximes	27-33	butyrylcholinesterase	Rattus norvegicus	67-70
6628257-5	1983	The effectiveness of these oximes in restoration of VX-inactivated ChE in vivo offers an explanation as to why conventional atropine/oxime therapy is so effective against VX intoxication.	Atropine	124-132	butyrylcholinesterase	Rattus norvegicus	67-70
6628257-5	1983	The effectiveness of these oximes in restoration of VX-inactivated ChE in vivo offers an explanation as to why conventional atropine/oxime therapy is so effective against VX intoxication.	Oximes	27-32	butyrylcholinesterase	Rattus norvegicus	67-70
7105011-0	1982	Histochemical and cytochemical study of butyrylcholinesterase activity in rat hepatocellular carcinomas induced by 3"-methyl-4-dimethylaminoazobenzene.	Methyldimethylaminoazobenzene	115-150	butyrylcholinesterase	Rattus norvegicus	40-61
6761901-0	1982	The influence of obidoxime, diacetylmonoxime, pralidoxime, and two less hydrophilic derivatives of pralidoxime upon the cholinesterase inhibition and the pressor effect by paraoxon in the rat.	pralidoxime	99-110	butyrylcholinesterase	Rattus norvegicus	120-134
7105011-1	1982	The activity of butyrylcholinesterase (BCHE), a liver fetal isozyme (Zone L-V) of a nonspecific esterase, was studied histochemically and cytochemically in rat hepatocellular carcinomas induced by 3"-methyl-4-dimethylaminoazobenzene (3"-Me-DAB).	Methyldimethylaminoazobenzene	197-232	butyrylcholinesterase	Rattus norvegicus	16-37
7105011-1	1982	The activity of butyrylcholinesterase (BCHE), a liver fetal isozyme (Zone L-V) of a nonspecific esterase, was studied histochemically and cytochemically in rat hepatocellular carcinomas induced by 3"-methyl-4-dimethylaminoazobenzene (3"-Me-DAB).	Methyldimethylaminoazobenzene	197-232	butyrylcholinesterase	Rattus norvegicus	39-43
7105011-1	1982	The activity of butyrylcholinesterase (BCHE), a liver fetal isozyme (Zone L-V) of a nonspecific esterase, was studied histochemically and cytochemically in rat hepatocellular carcinomas induced by 3"-methyl-4-dimethylaminoazobenzene (3"-Me-DAB).	Methyldimethylaminoazobenzene	234-243	butyrylcholinesterase	Rattus norvegicus	16-37
7105011-1	1982	The activity of butyrylcholinesterase (BCHE), a liver fetal isozyme (Zone L-V) of a nonspecific esterase, was studied histochemically and cytochemically in rat hepatocellular carcinomas induced by 3"-methyl-4-dimethylaminoazobenzene (3"-Me-DAB).	Methyldimethylaminoazobenzene	234-243	butyrylcholinesterase	Rattus norvegicus	39-43
7105011-4	1982	3"-Me-DAB induced poorly differentiated hepatocellular carcinomas showing an intense BCHE activity, especially in areas consisting of small tumoral cells proliferating in a sheet-like pattern.	Methyldimethylaminoazobenzene	0-9	butyrylcholinesterase	Rattus norvegicus	85-89
7105011-8	1982	Thus, in confirmation of a previous report, BCHE appears to be a positive marker of poorly differentiated hepatocellular carcinomas induced by 3"-Me-DAB.	Methyldimethylaminoazobenzene	143-152	butyrylcholinesterase	Rattus norvegicus	44-48
7105011-10	1982	The significance of the appearance of BCHE activity in hepatocellular carcinomas induced by 3"-Me-DAB is discussed.	Methyldimethylaminoazobenzene	92-101	butyrylcholinesterase	Rattus norvegicus	38-42
7128789-1	1982	Unlike dipyroxime (10 mg/kg), a new cholinesterase reactivator diethyxime (20 mg/kg) exerts a therapeutic action in acute poisoning of rats with carbamine pesticides (carbofuran, elocron, pirimor, croneton).	diethyxime	63-73	butyrylcholinesterase	Rattus norvegicus	36-50
7128789-1	1982	Unlike dipyroxime (10 mg/kg), a new cholinesterase reactivator diethyxime (20 mg/kg) exerts a therapeutic action in acute poisoning of rats with carbamine pesticides (carbofuran, elocron, pirimor, croneton).	Carbaryl	145-154	butyrylcholinesterase	Rattus norvegicus	36-50
7128789-1	1982	Unlike dipyroxime (10 mg/kg), a new cholinesterase reactivator diethyxime (20 mg/kg) exerts a therapeutic action in acute poisoning of rats with carbamine pesticides (carbofuran, elocron, pirimor, croneton).	dioxacarb	179-186	butyrylcholinesterase	Rattus norvegicus	36-50
7128789-1	1982	Unlike dipyroxime (10 mg/kg), a new cholinesterase reactivator diethyxime (20 mg/kg) exerts a therapeutic action in acute poisoning of rats with carbamine pesticides (carbofuran, elocron, pirimor, croneton).	pirimicarb	188-195	butyrylcholinesterase	Rattus norvegicus	36-50
7128789-1	1982	Unlike dipyroxime (10 mg/kg), a new cholinesterase reactivator diethyxime (20 mg/kg) exerts a therapeutic action in acute poisoning of rats with carbamine pesticides (carbofuran, elocron, pirimor, croneton).	croneton	197-205	butyrylcholinesterase	Rattus norvegicus	36-50
7128789-4	1982	The mechanism of the therapeutic action of diethyxime is determined by its capacity to recover cholinesterase activity both in the peripheral and central nervous systems, as well as to normalize neuromuscular transmission.	diethyxime	43-53	butyrylcholinesterase	Rattus norvegicus	95-109
7070215-3	1982	Neostigmine (1 microgram) and physostigmine (15 microgram) caused nearly maximal and approximately equal degrees of cholinesterase inhibition in several brain regions.	Neostigmine	0-11	butyrylcholinesterase	Rattus norvegicus	116-130
6178187-1	1982	The organophosphate insecticide, leptophos, inhibited rat liver isocarboxazid amidase (ISOCase) activity to 20% of control at 5.0 mg/kg l h after administration, but at this dose brain cholinesterase (ChE) activity was not affected.	Organophosphates	4-19	butyrylcholinesterase	Rattus norvegicus	201-204
6178187-1	1982	The organophosphate insecticide, leptophos, inhibited rat liver isocarboxazid amidase (ISOCase) activity to 20% of control at 5.0 mg/kg l h after administration, but at this dose brain cholinesterase (ChE) activity was not affected.	Leptophos	33-42	butyrylcholinesterase	Rattus norvegicus	185-199
6178187-1	1982	The organophosphate insecticide, leptophos, inhibited rat liver isocarboxazid amidase (ISOCase) activity to 20% of control at 5.0 mg/kg l h after administration, but at this dose brain cholinesterase (ChE) activity was not affected.	Leptophos	33-42	butyrylcholinesterase	Rattus norvegicus	201-204
6178187-3	1982	With repeated administration of leptophos at a dose of 1 mg/kg for 10 days, ISOCase activity decreased to 34% of control on day 1 and the inhibition increased to 85% on day 10 without inhibition of brain ChE activity.	Leptophos	32-41	butyrylcholinesterase	Rattus norvegicus	204-207
6178187-5	1982	Pretreatment with carboxylesterase inhibitors, triorthocresylphosphate (TOCP) and bis-p-nitrophenylphosphate (BNPP), potentiated the inhibition of brain ChE by leptophos, suggesting that ISOCase might take a role in leptophos detoxification.	tri-o-cresyl phosphate	47-70	butyrylcholinesterase	Rattus norvegicus	153-156
6178187-5	1982	Pretreatment with carboxylesterase inhibitors, triorthocresylphosphate (TOCP) and bis-p-nitrophenylphosphate (BNPP), potentiated the inhibition of brain ChE by leptophos, suggesting that ISOCase might take a role in leptophos detoxification.	tri-o-cresyl phosphate	72-76	butyrylcholinesterase	Rattus norvegicus	153-156
6178187-5	1982	Pretreatment with carboxylesterase inhibitors, triorthocresylphosphate (TOCP) and bis-p-nitrophenylphosphate (BNPP), potentiated the inhibition of brain ChE by leptophos, suggesting that ISOCase might take a role in leptophos detoxification.	bis(4-nitrophenyl)phosphate	82-108	butyrylcholinesterase	Rattus norvegicus	153-156
6178187-5	1982	Pretreatment with carboxylesterase inhibitors, triorthocresylphosphate (TOCP) and bis-p-nitrophenylphosphate (BNPP), potentiated the inhibition of brain ChE by leptophos, suggesting that ISOCase might take a role in leptophos detoxification.	bis(4-nitrophenyl)phosphate	110-114	butyrylcholinesterase	Rattus norvegicus	153-156
6178187-5	1982	Pretreatment with carboxylesterase inhibitors, triorthocresylphosphate (TOCP) and bis-p-nitrophenylphosphate (BNPP), potentiated the inhibition of brain ChE by leptophos, suggesting that ISOCase might take a role in leptophos detoxification.	Leptophos	160-169	butyrylcholinesterase	Rattus norvegicus	153-156
6178187-5	1982	Pretreatment with carboxylesterase inhibitors, triorthocresylphosphate (TOCP) and bis-p-nitrophenylphosphate (BNPP), potentiated the inhibition of brain ChE by leptophos, suggesting that ISOCase might take a role in leptophos detoxification.	Leptophos	216-225	butyrylcholinesterase	Rattus norvegicus	153-156
7097482-0	1982	Spontaneous reactivation of fenitro-oxon-inhibited plasma cholinesterase in various mammals.	fenitrooxone	28-40	butyrylcholinesterase	Rattus norvegicus	58-72
7097482-1	1982	It was investigated as to whether a spontaneous reactivation was also observed in fenitro-oxon-inhibited plasma cholinesterase (ChE) of human and several animals, such as mice, guinea pigs and rabbits, as previously reported in rat plasma ChE.	fenitrooxone	82-94	butyrylcholinesterase	Rattus norvegicus	239-242
7097482-4	1982	These results suggest that the spontaneous reactivation takes place in plasma pseudo ChE of various animals after inhibition with fenitro-oxon.	fenitrooxone	130-142	butyrylcholinesterase	Rattus norvegicus	85-88
7070215-3	1982	Neostigmine (1 microgram) and physostigmine (15 microgram) caused nearly maximal and approximately equal degrees of cholinesterase inhibition in several brain regions.	Physostigmine	30-43	butyrylcholinesterase	Rattus norvegicus	116-130
7070215-4	1982	The recovery of the cardiovascular parameters and of brain cholinesterase activity was significantly faster following physostigmine compared to neostigmine.	Physostigmine	118-131	butyrylcholinesterase	Rattus norvegicus	59-73
7070215-4	1982	The recovery of the cardiovascular parameters and of brain cholinesterase activity was significantly faster following physostigmine compared to neostigmine.	Neostigmine	144-155	butyrylcholinesterase	Rattus norvegicus	59-73
6182711-0	1982	Effect of dextran gelatin on cholinesterase of rats.	Dextrans	10-17	butyrylcholinesterase	Rattus norvegicus	29-43
6182711-4	1982	In case of dextran and gelatin, a significant increase in ChE activity in blood serum and the tested organs was observed at different time intervals after infusion.	Dextrans	11-18	butyrylcholinesterase	Rattus norvegicus	58-61
7124253-0	1982	Effect of dietary trans fatty acids on cholinesterase and monoamine oxidase activities in different organs of rats.	Trans Fatty Acids	18-35	butyrylcholinesterase	Rattus norvegicus	39-53
7124253-1	1982	The effect of trans fatty acids and essential fatty acid deficiency upon the activities of cholinesterase and monoamine oxidase in livers, hearts, brains and lungs of rats was studied.	Trans Fatty Acids	14-31	butyrylcholinesterase	Rattus norvegicus	91-105
7124253-4	1982	In the group of rats fed HCNO the activities of cholinesterase and monoamine oxidase in their livers, hearts, brains and lungs were not significantly different from those of the control group fed CO.	Fulminic acid	25-29	butyrylcholinesterase	Rattus norvegicus	48-62
7059232-0	1982	Effect of phenobarbitol pretreatment on regeneration of plasma cholinesterase activity inhibited by parathion or dichlorovos.	Phenobarbital	10-23	butyrylcholinesterase	Rattus norvegicus	63-77
7097808-1	1982	The effects of fenitrothion and methylparathion on the activities of cholinesterase and hepatic microsomal monooxygenases were investigated and compared following a single or repeated oral administration of an equimolar and low dose of the insecticides.	Fenitrothion	15-27	butyrylcholinesterase	Rattus norvegicus	69-83
7097808-1	1982	The effects of fenitrothion and methylparathion on the activities of cholinesterase and hepatic microsomal monooxygenases were investigated and compared following a single or repeated oral administration of an equimolar and low dose of the insecticides.	Methyl Parathion	32-47	butyrylcholinesterase	Rattus norvegicus	69-83
7059232-0	1982	Effect of phenobarbitol pretreatment on regeneration of plasma cholinesterase activity inhibited by parathion or dichlorovos.	Parathion	100-109	butyrylcholinesterase	Rattus norvegicus	63-77
7059232-0	1982	Effect of phenobarbitol pretreatment on regeneration of plasma cholinesterase activity inhibited by parathion or dichlorovos.	Dichlorvos	113-124	butyrylcholinesterase	Rattus norvegicus	63-77
7059232-1	1982	Rats were pretreated with phenobarbitol [PB (75 mg/kg, IP)] for 3 days and subsequently injected with parathion, an organophosphorous insecticide, which requires microsomal activation for its anticholinesterase effect or with dichlorovos, a cholinesterase (ChE) inhibitor as such.	Phenobarbital	26-39	butyrylcholinesterase	Rattus norvegicus	196-210
7059232-1	1982	Rats were pretreated with phenobarbitol [PB (75 mg/kg, IP)] for 3 days and subsequently injected with parathion, an organophosphorous insecticide, which requires microsomal activation for its anticholinesterase effect or with dichlorovos, a cholinesterase (ChE) inhibitor as such.	Parathion	102-111	butyrylcholinesterase	Rattus norvegicus	196-210
7059232-1	1982	Rats were pretreated with phenobarbitol [PB (75 mg/kg, IP)] for 3 days and subsequently injected with parathion, an organophosphorous insecticide, which requires microsomal activation for its anticholinesterase effect or with dichlorovos, a cholinesterase (ChE) inhibitor as such.	Parathion	102-111	butyrylcholinesterase	Rattus norvegicus	257-260
7059232-6	1982	A lower dose of dichlorovs (20 mg/kg) resulted in plasma ChE activity which was 48, 82, 90, and 97% of initial levels in PB-untreated rats, and 60, 100, 100, and 130% in PB-pretreated rats at 2 hr, 1, 3, and 5 day"s, respectively.	dichlorovs	16-26	butyrylcholinesterase	Rattus norvegicus	57-60
7059232-8	1982	Phenobarbital caused accelerated in vitro ChE regeneration in the case of dichlorovos-inhibited enzyme in the plasma, but not in the case of parathion-inhibited enzyme.	Phenobarbital	0-13	butyrylcholinesterase	Rattus norvegicus	42-45
7059232-8	1982	Phenobarbital caused accelerated in vitro ChE regeneration in the case of dichlorovos-inhibited enzyme in the plasma, but not in the case of parathion-inhibited enzyme.	Dichlorvos	74-85	butyrylcholinesterase	Rattus norvegicus	42-45
7029339-2	1981	injection of 1.82 mg/kg of the irreversible cholinesterase inhibitor organophosphate, diisopropylfluorophosphate (DFP).	Organophosphates	69-84	butyrylcholinesterase	Rattus norvegicus	44-58
7056378-1	1982	It has been shown in rat experiments that armin in doses that inhibit blood cholinesterase by 50 and more per cent lowers the content of nicotinamide coenzymes in the myocardium and liver of the animals, primarily at the expense of the diminution of the oxidized forms.	Niacinamide	137-149	butyrylcholinesterase	Rattus norvegicus	76-90
7056378-3	1982	Dipyroxime prevents changes induced by armin, which is accompanied by partial reactivation of cholinesterase.	Trimedoxime	0-10	butyrylcholinesterase	Rattus norvegicus	94-108
6217470-2	1982	AChE accounted for only 12% and BuChE for 88% of the total ability of atrial homogenates to hydrolyse acetylcholine.	Acetylcholine	102-115	butyrylcholinesterase	Rattus norvegicus	32-37
6217470-3	1982	The concentration of exogenous ACh needed to reduce the spontaneous frequency of contractions of the isolated right atrium by 30, 60, or 90/min fell by 78%, 79% and 84% respectively after BW 284 C51 inhibition of AChE and by 95%, 94% and 94% after simultaneous inhibition of AChE and BuChE.	Acetylcholine	31-34	butyrylcholinesterase	Rattus norvegicus	284-289
6273940-6	1981	This THC effect was slightly increased by physostigmine, a cholinesterase inhibitor, relatively unaffected by scopolamine, a muscarinic antagonist, and almost completely blocked by ethopropazine, an anticholinergic antiparkinson drug.	Dronabinol	5-8	butyrylcholinesterase	Rattus norvegicus	59-73
6273940-6	1981	This THC effect was slightly increased by physostigmine, a cholinesterase inhibitor, relatively unaffected by scopolamine, a muscarinic antagonist, and almost completely blocked by ethopropazine, an anticholinergic antiparkinson drug.	Physostigmine	42-55	butyrylcholinesterase	Rattus norvegicus	59-73
7029339-2	1981	injection of 1.82 mg/kg of the irreversible cholinesterase inhibitor organophosphate, diisopropylfluorophosphate (DFP).	Isoflurophate	86-112	butyrylcholinesterase	Rattus norvegicus	44-58
7029339-2	1981	injection of 1.82 mg/kg of the irreversible cholinesterase inhibitor organophosphate, diisopropylfluorophosphate (DFP).	Isoflurophate	114-117	butyrylcholinesterase	Rattus norvegicus	44-58
7299616-0	1981	Difference in fenitrothion-inhibited rat plasma cholinesterase activities determined by delta pH-method and DTNB-method, due to spontaneous reactivation.	Fenitrothion	14-26	butyrylcholinesterase	Rattus norvegicus	48-62
7299616-1	1981	Rat cholinesterase (ChE) activities were measured by DTNB-method after an oral administration of fenitrothion, and the following facts were observed.	Dithionitrobenzoic Acid	53-57	butyrylcholinesterase	Rattus norvegicus	20-23
7299616-1	1981	Rat cholinesterase (ChE) activities were measured by DTNB-method after an oral administration of fenitrothion, and the following facts were observed.	Fenitrothion	97-109	butyrylcholinesterase	Rattus norvegicus	4-18
7299616-1	1981	Rat cholinesterase (ChE) activities were measured by DTNB-method after an oral administration of fenitrothion, and the following facts were observed.	Fenitrothion	97-109	butyrylcholinesterase	Rattus norvegicus	20-23
7299616-3	1981	In vitro, the spontaneous reactivation was also observed in rat plasma ChE inhibited by oxon-type of fenitrothion.	Fenitrothion	101-113	butyrylcholinesterase	Rattus norvegicus	71-74
6787736-0	1981	Carbaryl residues in tissues and cholinesterase activities in brain and blood of rats receiving carbaryl.	Carbaryl	96-104	butyrylcholinesterase	Rattus norvegicus	33-47
6135639-6	1981	C6 (117 microM) and to a lesser degree atropine (30-60 microM) also improve ganglionic transmission and the metabolic response in cholinesterase poisoning.	Atropine	39-47	butyrylcholinesterase	Rattus norvegicus	130-144
6260515-4	1981	It is concluded that, in contrast to other aminopyridines, 4M2AP facilitates neuromuscular transmission by inhibition of cholinesterase rather than augmenting release of acetylcholine and depresses rather than enhances muscles contractility.	2-amino-4-picoline	59-64	butyrylcholinesterase	Rattus norvegicus	121-135
7245224-5	1981	The combined treatment with molybdenum and copper exhibited reversible enzyme changes, however, cholinesterase activity remained inhibited.	Molybdenum	28-38	butyrylcholinesterase	Rattus norvegicus	96-110
7288900-8	1981	Rat serum carboxylesterase and cholinesterase were inhibited for prolonged periods after a single oral dose of O,O,S-trimethyl phosphorothioate, but the duration of inhibition was significantly less when the toxicant contained 1% O,O,O-trimethyl isomer.	O,O,S-trimethyl phosphorothioate	111-143	butyrylcholinesterase	Rattus norvegicus	31-45
7288900-8	1981	Rat serum carboxylesterase and cholinesterase were inhibited for prolonged periods after a single oral dose of O,O,S-trimethyl phosphorothioate, but the duration of inhibition was significantly less when the toxicant contained 1% O,O,O-trimethyl isomer.	o,o,o-trimethyl isomer	230-252	butyrylcholinesterase	Rattus norvegicus	31-45
7414624-1	1980	Toxicity of tri-n-butyl phosphate (TBP) was investigated in male rats with special reference to body and organ weights, serum components and cholinesterase (ChE) activity.	tributyl phosphate	35-38	butyrylcholinesterase	Rattus norvegicus	141-155
6785572-0	1981	Acetylcholinesterase from rat red cells and cholinesterase of Pseudomonas aeruginosa: different types of inhibition by atropine.	Atropine	119-127	butyrylcholinesterase	Rattus norvegicus	6-20
6785572-1	1981	The inhibition by atropine of cholinesterase from Pseudomonas aeruginosa has been studied in parallel with the membrane bound acetylcholinesterase from rat red cells.	Atropine	18-26	butyrylcholinesterase	Rattus norvegicus	30-44
6785572-2	1981	Acetylcholinesterase of rat red cells, like other animal cholinesterases, was competitively inhibited while the cholinesterase from Pseudomonas aeruginosa was partially non competitively inhibited by atropine.	Atropine	200-208	butyrylcholinesterase	Rattus norvegicus	6-20
7344408-8	1981	The toxicological profile of trichlorfon in the chronic toxicity study consists, on the one hand, in a depression of cholinesterase activity whereby the different animal species differed in their sensitivity.	Trichlorfon	29-40	butyrylcholinesterase	Rattus norvegicus	117-131
7204881-5	1981	However, parathion inhibited ChE much less than diazinon, and slight recovery of both enzymes was evident in the parathion-treated groups.	Parathion	9-18	butyrylcholinesterase	Rattus norvegicus	29-32
6459593-3	1981	If cholinesterase activity was inhibited with physostigmine, the differences between the various age groups were obliterated.	Physostigmine	46-59	butyrylcholinesterase	Rattus norvegicus	3-17
6459593-4	1981	It is thus evident that the actual acetylcholine sensitivity of the sinoatrial node tissue does alter during postnatal life, but that growing cholinesterase activity reduces the amount of acetylcholine diffusing from the medium into the acetylcholine receptor zone.	Acetylcholine	188-201	butyrylcholinesterase	Rattus norvegicus	142-156
7469957-0	1980	Effect of palmitic acid on regeneration of dichlorovos-inhibited plasma cholinesterase activity in vitro.	Palmitic Acid	10-23	butyrylcholinesterase	Rattus norvegicus	72-86
7469957-0	1980	Effect of palmitic acid on regeneration of dichlorovos-inhibited plasma cholinesterase activity in vitro.	Dichlorvos	43-54	butyrylcholinesterase	Rattus norvegicus	72-86
7469957-3	1980	The spontaneous regeneration of dichlorovos-inhibited plasma cholinesterase activity in vivo was faster in the HFD rats compared to the other three dietary groups.	Dichlorvos	32-43	butyrylcholinesterase	Rattus norvegicus	61-75
7469957-4	1980	Adding palmitic acid (PA) in vitro to the plasma system, at PA/albumin molar ratios in the range 0.53:2.83, accelerated spontaneous regeneration of dichlorovos-inhibited plasma cholinesterase activity significantly during 2-24 h periods.	Palmitic Acid	7-20	butyrylcholinesterase	Rattus norvegicus	177-191
7469957-4	1980	Adding palmitic acid (PA) in vitro to the plasma system, at PA/albumin molar ratios in the range 0.53:2.83, accelerated spontaneous regeneration of dichlorovos-inhibited plasma cholinesterase activity significantly during 2-24 h periods.	Palmitic Acid	22-24	butyrylcholinesterase	Rattus norvegicus	177-191
7469957-4	1980	Adding palmitic acid (PA) in vitro to the plasma system, at PA/albumin molar ratios in the range 0.53:2.83, accelerated spontaneous regeneration of dichlorovos-inhibited plasma cholinesterase activity significantly during 2-24 h periods.	Dichlorvos	148-159	butyrylcholinesterase	Rattus norvegicus	177-191
6156333-1	1980	Intravenous injection of the cholinesterase inhibitor physostigimine evoked a hypertensive response in the unanesthetized 12- to 14-week-old spontaneously hypertensive rat (SHR).	physostigimine	54-68	butyrylcholinesterase	Rattus norvegicus	29-43
6662350-1	1983	Sumithion is the most active cholinesterase inhibitor.	Fenitrothion	0-9	butyrylcholinesterase	Rattus norvegicus	29-43
6662350-2	1983	The cholinesterase inhibiting action of the organophosphates (OPs) is better compensated by vitamin E in normal animals, but by vitamin A in vitamin A-deficient animals.	Organophosphates	44-60	butyrylcholinesterase	Rattus norvegicus	4-18
7414624-1	1980	Toxicity of tri-n-butyl phosphate (TBP) was investigated in male rats with special reference to body and organ weights, serum components and cholinesterase (ChE) activity.	tributyl phosphate	35-38	butyrylcholinesterase	Rattus norvegicus	157-160
6662350-2	1983	The cholinesterase inhibiting action of the organophosphates (OPs) is better compensated by vitamin E in normal animals, but by vitamin A in vitamin A-deficient animals.	Vitamin E	92-101	butyrylcholinesterase	Rattus norvegicus	4-18
6662350-2	1983	The cholinesterase inhibiting action of the organophosphates (OPs) is better compensated by vitamin E in normal animals, but by vitamin A in vitamin A-deficient animals.	Vitamin A	128-137	butyrylcholinesterase	Rattus norvegicus	4-18
6662350-2	1983	The cholinesterase inhibiting action of the organophosphates (OPs) is better compensated by vitamin E in normal animals, but by vitamin A in vitamin A-deficient animals.	Vitamin A	141-150	butyrylcholinesterase	Rattus norvegicus	4-18
6108039-9	1980	The unspecific cholinesterase, localized in the hippocampal region within vessel and capillary walls, exists in an electrophoretic mobile, formalin-sensitive form.	Formaldehyde	139-147	butyrylcholinesterase	Rattus norvegicus	15-29
7446142-1	1980	Gamma-aminobutyric acid (GABA) injected into the lateral ventricles of rat bran in a dose of 600 microgram raised the level and increased the synthesis of acetylcholine (ACh) raising also the activity of choline acetyltransferase (ChAc) but had no effect on the activity of cholinesterase (AChE) in rat striatum.	gamma-Aminobutyric Acid	0-23	butyrylcholinesterase	Rattus norvegicus	274-288
7446142-1	1980	Gamma-aminobutyric acid (GABA) injected into the lateral ventricles of rat bran in a dose of 600 microgram raised the level and increased the synthesis of acetylcholine (ACh) raising also the activity of choline acetyltransferase (ChAc) but had no effect on the activity of cholinesterase (AChE) in rat striatum.	gamma-Aminobutyric Acid	25-29	butyrylcholinesterase	Rattus norvegicus	274-288
7399597-0	1980	Effect of methyl demeton on vital organs & cholinesterase in male rats.	methyl demeton	10-24	butyrylcholinesterase	Rattus norvegicus	47-61
7469478-7	1980	Feeding trials up to 90 days revealed that rats were highly sensitive to diazinon after 31 to 35 days exposure, as judged by reduction of plasma and erythrocyte cholinesterase activities.	Diazinon	73-81	butyrylcholinesterase	Rattus norvegicus	161-175
7469478-9	1980	For all feeding trials, plasma cholinesterase was a more sensitive indicator of diazinon toxicity compared to erythrocyte or brain acetylcholinesterase.	Diazinon	80-88	butyrylcholinesterase	Rattus norvegicus	31-45
443426-7	1979	In contrast, physostigmine, the cholinesterase inhibitor, caused displacement of the curve to the left.	Physostigmine	13-26	butyrylcholinesterase	Rattus norvegicus	32-46
6771826-2	1980	A cholinesterase inhibitor, physostigmine, was administered in conjunction with imipramine to determine if these effects of imipramine were cholinergically medicated.	Physostigmine	28-41	butyrylcholinesterase	Rattus norvegicus	2-16
6904065-6	1980	However, a similar synergism of lethality caused by neostigmine methylsulfate (0.3 mg/kg, s.c.) after treatment with lithium, which could be eliminated by methylatropine or glycopyrrolate, indicates that lithium may also produce lethal synergism of a cholinesterase (ChE) inhibitor that does not act centrally.	Neostigmine	52-77	butyrylcholinesterase	Rattus norvegicus	251-265
6904065-6	1980	However, a similar synergism of lethality caused by neostigmine methylsulfate (0.3 mg/kg, s.c.) after treatment with lithium, which could be eliminated by methylatropine or glycopyrrolate, indicates that lithium may also produce lethal synergism of a cholinesterase (ChE) inhibitor that does not act centrally.	Neostigmine	52-77	butyrylcholinesterase	Rattus norvegicus	267-270
6904065-6	1980	However, a similar synergism of lethality caused by neostigmine methylsulfate (0.3 mg/kg, s.c.) after treatment with lithium, which could be eliminated by methylatropine or glycopyrrolate, indicates that lithium may also produce lethal synergism of a cholinesterase (ChE) inhibitor that does not act centrally.	Lithium	117-124	butyrylcholinesterase	Rattus norvegicus	251-265
6904065-6	1980	However, a similar synergism of lethality caused by neostigmine methylsulfate (0.3 mg/kg, s.c.) after treatment with lithium, which could be eliminated by methylatropine or glycopyrrolate, indicates that lithium may also produce lethal synergism of a cholinesterase (ChE) inhibitor that does not act centrally.	Lithium	117-124	butyrylcholinesterase	Rattus norvegicus	267-270
6904065-8	1980	These findings support the hypothesis that lithium causes the toxic synergism via a reduction of adrenergic activity, leading to an imbalance between adrenergic and cholinergic influences and a consequent failure to tolerate the effects of the ChE inhibitors.	Lithium	43-50	butyrylcholinesterase	Rattus norvegicus	244-247
95070-6	1979	injections of Dursban in a dose of half the LD 50 resulted in a significant increase in serum GOT, GPT and alkaline phosphatase activity and a decrease of cholinesterase.	Chlorpyrifos	14-21	butyrylcholinesterase	Rattus norvegicus	155-169
516533-1	1979	After intraperitoneal administration of acrylonitrile into rats, fructose monophosphate aldolase was found in blood serum, activity of butyryl cholinesterase was inhibited but activity of alkaline phosphatase was unaltered in rat blood serum; these data demonstrate the necro-bystrophic type impairment.	Acrylonitrile	40-53	butyrylcholinesterase	Rattus norvegicus	143-157
575645-0	1979	Morphine-induced catalepsy in the rat: effect on striatal acetylcholine & cholinesterase.	Morphine	0-8	butyrylcholinesterase	Rattus norvegicus	78-92
575645-0	1979	Morphine-induced catalepsy in the rat: effect on striatal acetylcholine & cholinesterase.	Acetylcholine	58-71	butyrylcholinesterase	Rattus norvegicus	78-92
92820-6	1979	If administration of the same ABATE dose was distributed over 6 days (167 mg/kg/day), cholinesterase and motor activity depression was still evident but conditioned avoidance performance was unimpaired.	Temefos	30-35	butyrylcholinesterase	Rattus norvegicus	86-100
465377-2	1979	The results show that, in the male rat, TCP given intraperitoneally induces an increase in liver microsomal ARE AND NADPH2-oxidase and a decrease in ALI and cholinesterase; no activation of ARE and NADPH2-oxidase is observed in female rats.	Tritolyl Phosphates	40-43	butyrylcholinesterase	Rattus norvegicus	157-171
554652-3	1979	It is concluded that the synergism eserine-acetylcholine is a synergism with potentiation and the acetylcholine introduced in the Krebs solution interacts with receptors different from those activated by the acetylcholine which accumulates when cholinesterase is inhibited by eserine.	Acetylcholine	43-56	butyrylcholinesterase	Rattus norvegicus	245-259
554652-3	1979	It is concluded that the synergism eserine-acetylcholine is a synergism with potentiation and the acetylcholine introduced in the Krebs solution interacts with receptors different from those activated by the acetylcholine which accumulates when cholinesterase is inhibited by eserine.	Acetylcholine	98-111	butyrylcholinesterase	Rattus norvegicus	245-259
489075-0	1979	Duration of phosphamidon-induced changes in cholinesterase activity in different organs of rats.	Phosphamidon	12-24	butyrylcholinesterase	Rattus norvegicus	44-58
554652-3	1979	It is concluded that the synergism eserine-acetylcholine is a synergism with potentiation and the acetylcholine introduced in the Krebs solution interacts with receptors different from those activated by the acetylcholine which accumulates when cholinesterase is inhibited by eserine.	krebs	130-135	butyrylcholinesterase	Rattus norvegicus	245-259
554652-3	1979	It is concluded that the synergism eserine-acetylcholine is a synergism with potentiation and the acetylcholine introduced in the Krebs solution interacts with receptors different from those activated by the acetylcholine which accumulates when cholinesterase is inhibited by eserine.	Acetylcholine	98-111	butyrylcholinesterase	Rattus norvegicus	245-259
456553-0	1979	Decay of bile flow and serum cholinesterase activity in parathion-intoxicated rats.	Parathion	56-65	butyrylcholinesterase	Rattus norvegicus	29-43
112721-1	1979	The time dependence of the level of blood cholinesterase was determined in rats with the reticulo-endothelial system (RES) inhibited with colloidal carbon and in control rats after i.v.	Carbon	148-154	butyrylcholinesterase	Rattus norvegicus	42-56
446625-3	1979	Cholesterol ester synthesis in these cultures was inhibited by neostigmine, a cholinesterase inhibitor.	Cholesterol Esters	0-17	butyrylcholinesterase	Rattus norvegicus	78-92
446625-3	1979	Cholesterol ester synthesis in these cultures was inhibited by neostigmine, a cholinesterase inhibitor.	Neostigmine	63-74	butyrylcholinesterase	Rattus norvegicus	78-92
88516-2	1979	It has been proposed that the influence of innervation on the cholinesterase activity (ChE) of skeletal muscle and on end-plate ChE in particular is mediated by trophic substance(s) moved by axonal transport and released from nerve.	che	87-90	butyrylcholinesterase	Rattus norvegicus	62-76
112721-4	1979	Carbaryl rapidly inhibits cholinesterase; the time of "reactivation" of this enzyme increases with the administered dose.	Carbaryl	0-8	butyrylcholinesterase	Rattus norvegicus	26-40
112721-5	1979	However, when the RES is inhibited with colloidal carbon, "reactivation" of cholinesterase is significantly slowed down, to a varying degree, depending on the dose of carbaryl.	Carbon	50-56	butyrylcholinesterase	Rattus norvegicus	76-90
112721-5	1979	However, when the RES is inhibited with colloidal carbon, "reactivation" of cholinesterase is significantly slowed down, to a varying degree, depending on the dose of carbaryl.	Carbaryl	167-175	butyrylcholinesterase	Rattus norvegicus	76-90
421888-0	1979	[Age and the effect of proserine on the contractile response of the rectum and inhibition of its cholinesterase in rats].	Neostigmine	23-32	butyrylcholinesterase	Rattus norvegicus	97-111
446594-1	1979	DDVP is an organophosphate pesticide whose neurotoxicity, in the form of cholinesterase inhbition, is well-known.	Organophosphates	11-26	butyrylcholinesterase	Rattus norvegicus	73-87
421888-1	1979	The motor reaction of the rectum strips in rats of 4 age groups and inhibition of its cholinesterase with proserine were studied.	Neostigmine	106-115	butyrylcholinesterase	Rattus norvegicus	86-100
421888-4	1979	The inhibition of cholinesterase occurs in all the age groups from a minimal tested proserine concentration (1.10(10) M), gaining in strength parallel with increasing concentration.	Neostigmine	84-93	butyrylcholinesterase	Rattus norvegicus	18-32
422937-8	1979	Female rats gave a consistent finding of decrease in plasma cholinesterase, shown to be related to activity against butyrylcholine but not acetyl-beta-methylcholine.	butyrylcholine	116-130	butyrylcholinesterase	Rattus norvegicus	60-74
422937-8	1979	Female rats gave a consistent finding of decrease in plasma cholinesterase, shown to be related to activity against butyrylcholine but not acetyl-beta-methylcholine.	Methacholine Chloride	139-164	butyrylcholinesterase	Rattus norvegicus	60-74
359615-0	1978	Acetylcholine and cholinesterase in submandibular glands of rats given armin and obidoxime.	Obidoxime Chloride	81-90	butyrylcholinesterase	Rattus norvegicus	18-32
734975-1	1978	Content of organophosphorous inhibitors (with the structure RO/CH3/P/O/SC2H4SC2H5) of cholinesterase as well as their hydrophobic properties (distribution coefficient in hexan/water system) were studied in subcellular fractions of rat brain.	organophosphorous	11-28	butyrylcholinesterase	Rattus norvegicus	86-100
668812-1	1978	The bisquaternary mono-oxime HI-6, and to a lesser extent HS-6, caused functional recovery of neuromuscular transmission in vivo and in vitro when given 60 min after soman, i.e. when the soman-cholinesterase (AChE) complex is said to be fully "aged".	mono-oxime hi-6	18-33	butyrylcholinesterase	Rattus norvegicus	193-207
214351-1	1978	The organophosphate cholinesterase inhibitor paraoxon produces a dose-dependent necrosis in rat skeletal muscle fibers after a single administration.	Paraoxon	45-53	butyrylcholinesterase	Rattus norvegicus	20-34
219652-2	1978	Physostigmine was less effective in augmenting twitch height in preparations from alloxan diabetic rats and such preparations had a significantly lowered total cholinesterase activity compared with control preparations.	Physostigmine	0-13	butyrylcholinesterase	Rattus norvegicus	160-174
705794-0	1978	Comparative effects of dietary parathion on the activities of cholinesterase and lecithin: cholesterol acyltransferase in rat plasma.	Parathion	31-40	butyrylcholinesterase	Rattus norvegicus	62-76
26742-5	1978	AcHC-3 was shown to be a substrate for cholinesterase enzymes although the rate of hydrolysis was much less than the rate of hydrolysis of acetylcholine.	Acetylcholine	139-152	butyrylcholinesterase	Rattus norvegicus	39-53
359615-2	1978	The results indicate that obidoxime-induced reactivation of phosphorylated cholinesterase can suppress completely the increase in the concentration of acetylcholine that develops within the submandibular gland after administration of armin alone.	Obidoxime Chloride	26-35	butyrylcholinesterase	Rattus norvegicus	75-89
359615-2	1978	The results indicate that obidoxime-induced reactivation of phosphorylated cholinesterase can suppress completely the increase in the concentration of acetylcholine that develops within the submandibular gland after administration of armin alone.	Acetylcholine	151-164	butyrylcholinesterase	Rattus norvegicus	75-89
83128-3	1978	After oral administration of pesticides Parathion-methyl, Carbaryl, Lindane and their combinations were investigated the activities of enzyme SGOT, SGPT, Alkaline Phosphatase and Cholinesterase.	Hexachlorocyclohexane	68-75	butyrylcholinesterase	Rattus norvegicus	179-193
674813-0	1978	Rat hippocampal norepinephrine response to cholinesterase inhibition.	Norepinephrine	16-30	butyrylcholinesterase	Rattus norvegicus	43-57
674813-2	1978	Results indicate that this cholinesterase inhibiting compound caused a significant decrease (congruent to 14%) in hippocampal norepinephrine within 3 hours of exposure.	Norepinephrine	126-140	butyrylcholinesterase	Rattus norvegicus	27-41
637620-0	1978	The protective effects of ethylestrenol against acute poisoning by organophosphorus cholinesterase inhibitors in rats.	Ethylestrenol	26-39	butyrylcholinesterase	Rattus norvegicus	84-98
675690-0	1978	Depression of cholinesterase activity by ethylestrenol in organophosphorus-poisoned and normal rats.	Ethylestrenol	41-54	butyrylcholinesterase	Rattus norvegicus	14-28
675690-0	1978	Depression of cholinesterase activity by ethylestrenol in organophosphorus-poisoned and normal rats.	organophosphorus	58-74	butyrylcholinesterase	Rattus norvegicus	14-28
653747-0	1978	Effect of chlorpromazine pre-treatment on the inhibition of total cholinesterases and butyrylcholinesterase in brain of rats poisoned by physostigmine or dichlorvos.	Chlorpromazine	10-24	butyrylcholinesterase	Rattus norvegicus	86-107
727875-8	1978	Long-term inhibition of plasma cholinesterase was recorded from rats and mice in after to oral administration of Etephon, but cholinesterases were not inhibited the erythrocytes and brain.	etephon	113-120	butyrylcholinesterase	Rattus norvegicus	31-45
83128-6	1978	The activity of cholinesterase is significantly lower in the combinations of Parathion-methyl/Lindane, Lindane/Carbaryl and Carbaryl/Parathion-methyl.	Methyl Parathion	77-93	butyrylcholinesterase	Rattus norvegicus	16-30
83128-6	1978	The activity of cholinesterase is significantly lower in the combinations of Parathion-methyl/Lindane, Lindane/Carbaryl and Carbaryl/Parathion-methyl.	Hexachlorocyclohexane	94-101	butyrylcholinesterase	Rattus norvegicus	16-30
83128-6	1978	The activity of cholinesterase is significantly lower in the combinations of Parathion-methyl/Lindane, Lindane/Carbaryl and Carbaryl/Parathion-methyl.	Hexachlorocyclohexane	103-110	butyrylcholinesterase	Rattus norvegicus	16-30
83128-6	1978	The activity of cholinesterase is significantly lower in the combinations of Parathion-methyl/Lindane, Lindane/Carbaryl and Carbaryl/Parathion-methyl.	Carbaryl	111-119	butyrylcholinesterase	Rattus norvegicus	16-30
83128-6	1978	The activity of cholinesterase is significantly lower in the combinations of Parathion-methyl/Lindane, Lindane/Carbaryl and Carbaryl/Parathion-methyl.	Carbaryl	124-132	butyrylcholinesterase	Rattus norvegicus	16-30
646658-1	1978	Karnovsky and Roots offer to use potassium ferricianide for coloured detecting the products of acetylcholine hydrolysis by cholinesterase.	potassium ferricianide	33-55	butyrylcholinesterase	Rattus norvegicus	123-137
83128-6	1978	The activity of cholinesterase is significantly lower in the combinations of Parathion-methyl/Lindane, Lindane/Carbaryl and Carbaryl/Parathion-methyl.	Methyl Parathion	133-149	butyrylcholinesterase	Rattus norvegicus	16-30
646658-1	1978	Karnovsky and Roots offer to use potassium ferricianide for coloured detecting the products of acetylcholine hydrolysis by cholinesterase.	Acetylcholine	95-108	butyrylcholinesterase	Rattus norvegicus	123-137
755675-2	1978	When pyridostigmine (P) was used as a prophylactic adjunct, it reduced blood ChE activity to 31.6% of control, failed to significantly alter brain ChE activity, and protected more than 70% of the blood (but not brain enzyme) from phosphonylation by soman.	Pyridostigmine Bromide	5-19	butyrylcholinesterase	Rattus norvegicus	77-80
618734-0	1978	Effects of cholinesterase inhibitors on the spasmogenic action of acetate esters on rat uterus.	acetate esters	66-80	butyrylcholinesterase	Rattus norvegicus	11-25
618734-2	1978	These contractions were selectively and reversibly inhibited by carbamate-type cholinesterase inhibitors, such as neostigmine and eserine, and quaternary ammonium compounds, such as tetraethylammonium and decamethonium.	Neostigmine	114-125	butyrylcholinesterase	Rattus norvegicus	79-93
618734-2	1978	These contractions were selectively and reversibly inhibited by carbamate-type cholinesterase inhibitors, such as neostigmine and eserine, and quaternary ammonium compounds, such as tetraethylammonium and decamethonium.	Physostigmine	130-137	butyrylcholinesterase	Rattus norvegicus	79-93
618734-3	1978	After treatment with organophosphorus cholinesterase inhibitors, such as di-isopropyl fluorophosphate and tetraethyl pyrophosphate, the uterus failed to respond to the acetate esters, even when high concentrations of choline were present.	Isoflurophate	73-101	butyrylcholinesterase	Rattus norvegicus	38-52
755675-2	1978	When pyridostigmine (P) was used as a prophylactic adjunct, it reduced blood ChE activity to 31.6% of control, failed to significantly alter brain ChE activity, and protected more than 70% of the blood (but not brain enzyme) from phosphonylation by soman.	Pyridostigmine Bromide	21-22	butyrylcholinesterase	Rattus norvegicus	77-80
618734-3	1978	After treatment with organophosphorus cholinesterase inhibitors, such as di-isopropyl fluorophosphate and tetraethyl pyrophosphate, the uterus failed to respond to the acetate esters, even when high concentrations of choline were present.	tetraethyl pyrophosphate	106-130	butyrylcholinesterase	Rattus norvegicus	38-52
406635-1	1977	The interaction between the reversible cholinesterase inhibitor, physostigmine, and lithium chloride was studied in adult male rats.	Lithium Chloride	84-100	butyrylcholinesterase	Rattus norvegicus	39-53
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	acetate esters	164-178	butyrylcholinesterase	Rattus norvegicus	97-111
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	acetate esters	164-178	butyrylcholinesterase	Rattus norvegicus	296-310
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	Choline	97-104	butyrylcholinesterase	Rattus norvegicus	296-310
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	Organophosphates	230-246	butyrylcholinesterase	Rattus norvegicus	97-111
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	Organophosphates	230-246	butyrylcholinesterase	Rattus norvegicus	296-310
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	Carbamates	248-258	butyrylcholinesterase	Rattus norvegicus	97-111
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	Quaternary Ammonium Compounds	263-292	butyrylcholinesterase	Rattus norvegicus	97-111
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	acetate esters	388-402	butyrylcholinesterase	Rattus norvegicus	97-111
618734-7	1978	These findings suggest that some esterase having an anionic site and an esteratic site, probably cholinesterase, may mediate in the uterine contractions induced by acetate esters in the presence of choline, and that inhibition by organophosphates, carbamates and quaternary ammonium compounds of cholinesterase activity in the preparation may impede the initiation of contractions by the acetate esters in the presence of choline.	Choline	198-205	butyrylcholinesterase	Rattus norvegicus	97-111
22876-0	1977	[Effects of benzodiazepine derivatives on cholinesterase activity of rat blood].	Benzodiazepines	12-26	butyrylcholinesterase	Rattus norvegicus	42-56
612605-0	1977	Effect of fenitrothion on magnesium level and cholinesterase activity in rats.	Fenitrothion	10-22	butyrylcholinesterase	Rattus norvegicus	46-60
567191-5	1978	1-DS and 7-DS produced a short-lived inhibition of blood ChE activity and 7-DS also of cardiac ChE activity.	1-ds	0-4	butyrylcholinesterase	Rattus norvegicus	57-60
567191-5	1978	1-DS and 7-DS produced a short-lived inhibition of blood ChE activity and 7-DS also of cardiac ChE activity.	1-ds	0-4	butyrylcholinesterase	Rattus norvegicus	95-98
567191-5	1978	1-DS and 7-DS produced a short-lived inhibition of blood ChE activity and 7-DS also of cardiac ChE activity.	7-ds	9-13	butyrylcholinesterase	Rattus norvegicus	57-60
567191-5	1978	1-DS and 7-DS produced a short-lived inhibition of blood ChE activity and 7-DS also of cardiac ChE activity.	7-ds	9-13	butyrylcholinesterase	Rattus norvegicus	95-98
567191-6	1978	Inhibition of ChE activity was probably related to release of adrenaline from adrenal medulla.	Epinephrine	62-72	butyrylcholinesterase	Rattus norvegicus	14-17
202984-4	1977	Coadministration of the peripheral cholinesterase inhibitor neostigmine salicylate (0.005 mg/kg) attenuated (+)-amphetamine neurotoxicity [30 (26.4-34.1)].	neostigmine salicylate	60-82	butyrylcholinesterase	Rattus norvegicus	35-49
202984-4	1977	Coadministration of the peripheral cholinesterase inhibitor neostigmine salicylate (0.005 mg/kg) attenuated (+)-amphetamine neurotoxicity [30 (26.4-34.1)].	Amphetamine	108-123	butyrylcholinesterase	Rattus norvegicus	35-49
145765-6	1977	The blockator of cholinesterase physostigmine had opposite effects.	Physostigmine	32-45	butyrylcholinesterase	Rattus norvegicus	17-31
913528-4	1977	The cholinesterase inhibitors, physostigmine and diisopropylfluorophosphate reduced both seizure activity and interictal spiking in these cobalt-treated rats.	Cobalt	138-144	butyrylcholinesterase	Rattus norvegicus	4-18
195659-0	1977	The generation of nerve and muscle repetivie activity in the rat phrenic nerve-diaphragm preparation following inhibition of cholinesterase by ecothiopate.	Echothiophate	143-154	butyrylcholinesterase	Rattus norvegicus	125-139
195659-2	1977	The contractions of the diaphragm were also recorded.2 In the curarized diaphragm, the introduction of ecothiopate, a non-competitive inhibitor of cholinesterase, caused a threefold increase in the amplitude of the end-plate current and an eightfold increase in the duration at half the peak amplitude.3 In the non-curarized diaphragm, the introduction of ecothiopate caused the generation of repetitive activity (RA) in first the phrenic nerve: this was then followed by RA in the diaphragm.	Echothiophate	103-114	butyrylcholinesterase	Rattus norvegicus	147-161
193712-1	1977	Human serum beta-lipoproteins, isolated by percipitation with heparin-calcium mixture, showed cholinesterase activity.	Heparin	62-69	butyrylcholinesterase	Rattus norvegicus	94-108
195659-5	1977	Steady exposure to acetylcholine abolished both forms of RA.5 Two competitive inhibitors of cholinesterase, neostigmine and ambenonium, were also shown to evoke RA in nerve and muscle.	Acetylcholine	19-32	butyrylcholinesterase	Rattus norvegicus	92-106
195659-5	1977	Steady exposure to acetylcholine abolished both forms of RA.5 Two competitive inhibitors of cholinesterase, neostigmine and ambenonium, were also shown to evoke RA in nerve and muscle.	Radium	57-59	butyrylcholinesterase	Rattus norvegicus	92-106
195659-5	1977	Steady exposure to acetylcholine abolished both forms of RA.5 Two competitive inhibitors of cholinesterase, neostigmine and ambenonium, were also shown to evoke RA in nerve and muscle.	Neostigmine	108-119	butyrylcholinesterase	Rattus norvegicus	92-106
195659-5	1977	Steady exposure to acetylcholine abolished both forms of RA.5 Two competitive inhibitors of cholinesterase, neostigmine and ambenonium, were also shown to evoke RA in nerve and muscle.	Ambenonium Chloride	124-134	butyrylcholinesterase	Rattus norvegicus	92-106
195659-5	1977	Steady exposure to acetylcholine abolished both forms of RA.5 Two competitive inhibitors of cholinesterase, neostigmine and ambenonium, were also shown to evoke RA in nerve and muscle.	Radium	161-163	butyrylcholinesterase	Rattus norvegicus	92-106
195659-6	1977	The generation times for nerve RA and muscle RA were similar to those following ecothiopate.6 It was concluded that nerve RA and muscle RA were generated after the inhibition of cholinesterase by ecothiopate as a result of the prolonged action of acetylcholine upon cholinoceptive sites on the nerve terminal and motor endplate respectively.	Radium	31-33	butyrylcholinesterase	Rattus norvegicus	178-192
195659-6	1977	The generation times for nerve RA and muscle RA were similar to those following ecothiopate.6 It was concluded that nerve RA and muscle RA were generated after the inhibition of cholinesterase by ecothiopate as a result of the prolonged action of acetylcholine upon cholinoceptive sites on the nerve terminal and motor endplate respectively.	Echothiophate	196-207	butyrylcholinesterase	Rattus norvegicus	178-192
195659-6	1977	The generation times for nerve RA and muscle RA were similar to those following ecothiopate.6 It was concluded that nerve RA and muscle RA were generated after the inhibition of cholinesterase by ecothiopate as a result of the prolonged action of acetylcholine upon cholinoceptive sites on the nerve terminal and motor endplate respectively.	Acetylcholine	247-260	butyrylcholinesterase	Rattus norvegicus	178-192
193712-1	1977	Human serum beta-lipoproteins, isolated by percipitation with heparin-calcium mixture, showed cholinesterase activity.	Calcium	70-77	butyrylcholinesterase	Rattus norvegicus	94-108
193712-3	1977	Rats, treated with neostigmine, a cholinesterase inhibitor, showed a significant decrease in serum beta-lipoprotein and in the incorporation of H3-lysine into the lipoprotein compared to untreated controls.	Neostigmine	19-30	butyrylcholinesterase	Rattus norvegicus	34-48
193712-3	1977	Rats, treated with neostigmine, a cholinesterase inhibitor, showed a significant decrease in serum beta-lipoprotein and in the incorporation of H3-lysine into the lipoprotein compared to untreated controls.	h3-lysine	144-153	butyrylcholinesterase	Rattus norvegicus	34-48
837006-7	1977	6 The inhibition of cholinesterase did not increase the occupation of muscarinic receptors by the transmitter; however, after large quantities of transmitter were released by the long stimulus trains the association between the receptors and acetylcholine was prolonged.	Acetylcholine	242-255	butyrylcholinesterase	Rattus norvegicus	20-34
870206-2	1977	Biochemical assays indicate that the ChE activity in the superior cervical ganglia of adult rats and hamsters is 57.19 and 28.63 respectively (expressed in micron moles acetylcholine hydrolyzed per min per g of tissue); two weeks after preganglionic denervation, about 50% and 60% of ChE activity are lost respectively.	Acetylcholine	169-182	butyrylcholinesterase	Rattus norvegicus	37-40
857254-1	1977	Decreases in rat plasma, erythrocyte and brain cholinesterase levels after intraperitoneal injection of 1 to 5 mg/kg of 4-benzothienyl-N-methylcarbamate (MOBAM) were compared with decrements in both spontaneous motor activity and conditioned avoidance performance produced by this compound.	4-benzothienyl-n-methylcarbamate	120-152	butyrylcholinesterase	Rattus norvegicus	47-61
857254-1	1977	Decreases in rat plasma, erythrocyte and brain cholinesterase levels after intraperitoneal injection of 1 to 5 mg/kg of 4-benzothienyl-N-methylcarbamate (MOBAM) were compared with decrements in both spontaneous motor activity and conditioned avoidance performance produced by this compound.	MOBAM	154-159	butyrylcholinesterase	Rattus norvegicus	47-61
577162-1	1977	N-[(1-Ethyl-pyrrolidin-2-yl)-methyl]-2-methoxy-5-sulf-amoyl-benzamide (sulpiride, Dogmatil) inhibits acetylcholinesterase of rat brain in a mixed-type manner (Ki 0.3 mM; Ki 1.8 mM) as well as serum cholinesterase of the rat competitively (Ki 0.37 mM).	n-[(1-ethyl-pyrrolidin-2-yl)-methyl	0-35	butyrylcholinesterase	Rattus norvegicus	107-121
577162-1	1977	N-[(1-Ethyl-pyrrolidin-2-yl)-methyl]-2-methoxy-5-sulf-amoyl-benzamide (sulpiride, Dogmatil) inhibits acetylcholinesterase of rat brain in a mixed-type manner (Ki 0.3 mM; Ki 1.8 mM) as well as serum cholinesterase of the rat competitively (Ki 0.37 mM).	-5-sulf-amoyl-benzamide	46-69	butyrylcholinesterase	Rattus norvegicus	107-121
577162-1	1977	N-[(1-Ethyl-pyrrolidin-2-yl)-methyl]-2-methoxy-5-sulf-amoyl-benzamide (sulpiride, Dogmatil) inhibits acetylcholinesterase of rat brain in a mixed-type manner (Ki 0.3 mM; Ki 1.8 mM) as well as serum cholinesterase of the rat competitively (Ki 0.37 mM).	Sulpiride	71-80	butyrylcholinesterase	Rattus norvegicus	107-121
311577-1	1977	Cholinesterase activity of albino rats with acute local oedematous inflammation induced by turpentine, croton oil or Freund"s adjuvant was elevated in the liver homogenate but decreased in the serum.	Turpentine	91-101	butyrylcholinesterase	Rattus norvegicus	0-14
311577-1	1977	Cholinesterase activity of albino rats with acute local oedematous inflammation induced by turpentine, croton oil or Freund"s adjuvant was elevated in the liver homogenate but decreased in the serum.	Croton Oil	103-113	butyrylcholinesterase	Rattus norvegicus	0-14
603347-1	1977	Two kinetic evidences revealed that two cholinesterase forms are present in rat brain homogenate and involved in the hydrolysis of acetylthiocholine.	Acetylthiocholine	131-148	butyrylcholinesterase	Rattus norvegicus	40-54
982614-1	1976	The activity of cholinesterase in different areas of the rat brain was studied as affected by two organophosphophorous inhibitors of the enzyme from the group of O-alkyl-S-hexylthiophosphonates, GA-89 and GA-95.	o-alkyl-s-hexylthiophosphonates	162-193	butyrylcholinesterase	Rattus norvegicus	16-30
63385-0	1976	Effects of paraoxon on axoplasmic transport of cholinesterase in rat sciatic nerve.	Paraoxon	11-19	butyrylcholinesterase	Rattus norvegicus	47-61
991993-1	1976	Cholinesterase reactivators - trimedoxim, methoxim and obidoxim - injected in the dose of 20 mg/kg s.c., increase muscle glycogen concentration in normal, but not in adrenalectomized rats.	trimedoxim	30-40	butyrylcholinesterase	Rattus norvegicus	0-14
991993-1	1976	Cholinesterase reactivators - trimedoxim, methoxim and obidoxim - injected in the dose of 20 mg/kg s.c., increase muscle glycogen concentration in normal, but not in adrenalectomized rats.	Glycogen	121-129	butyrylcholinesterase	Rattus norvegicus	0-14
963327-0	1976	Effect of cholinesterase inhibitor malathion on whole body irradiated rats.	Malathion	35-44	butyrylcholinesterase	Rattus norvegicus	10-24
18422-4	1977	Both acetyl cholinesterase and butiryl-cholinesterase markedly decreased in the plasma of the vitamin B12-deficient rats.	Vitamin B 12	94-105	butyrylcholinesterase	Rattus norvegicus	12-26
18422-4	1977	Both acetyl cholinesterase and butiryl-cholinesterase markedly decreased in the plasma of the vitamin B12-deficient rats.	Vitamin B 12	94-105	butyrylcholinesterase	Rattus norvegicus	39-53
1022721-0	1976	Iodide, thiocyanate and cyanide ions as capturing reagents in one-step copper-thiocholine method for cytochemical localization of cholinesterase activity.	Iodides	0-6	butyrylcholinesterase	Rattus norvegicus	130-144
1022721-0	1976	Iodide, thiocyanate and cyanide ions as capturing reagents in one-step copper-thiocholine method for cytochemical localization of cholinesterase activity.	thiocyanate	8-19	butyrylcholinesterase	Rattus norvegicus	130-144
1022721-0	1976	Iodide, thiocyanate and cyanide ions as capturing reagents in one-step copper-thiocholine method for cytochemical localization of cholinesterase activity.	Cyanides	24-31	butyrylcholinesterase	Rattus norvegicus	130-144
1022721-0	1976	Iodide, thiocyanate and cyanide ions as capturing reagents in one-step copper-thiocholine method for cytochemical localization of cholinesterase activity.	copper-thiocholine	71-89	butyrylcholinesterase	Rattus norvegicus	130-144
982614-1	1976	The activity of cholinesterase in different areas of the rat brain was studied as affected by two organophosphophorous inhibitors of the enzyme from the group of O-alkyl-S-hexylthiophosphonates, GA-89 and GA-95.	Gallium	195-197	butyrylcholinesterase	Rattus norvegicus	16-30
982614-1	1976	The activity of cholinesterase in different areas of the rat brain was studied as affected by two organophosphophorous inhibitors of the enzyme from the group of O-alkyl-S-hexylthiophosphonates, GA-89 and GA-95.	Gallium	205-207	butyrylcholinesterase	Rattus norvegicus	16-30
982614-3	1976	Under the effect of GA-89 inhibition of cholinesterase in the brain is considerably higher than in blood, under the effect of GA-95 an inverse relation is observed.	Gallium	20-22	butyrylcholinesterase	Rattus norvegicus	40-54
982615-3	1976	With an increase in R from the ethyl to butyl one the ability to the  additional inhibition of the brain own cholinesterase lowers due to incubation of homogenate at 37 degrees C, that evidences for an essential drop in the studied series of the free OPI fraction relative to the free OPI extracted by chloroform.	Pantothenyl-Aminoethanol-11-Pivalic Acid	251-254	butyrylcholinesterase	Rattus norvegicus	109-123
982615-3	1976	With an increase in R from the ethyl to butyl one the ability to the  additional inhibition of the brain own cholinesterase lowers due to incubation of homogenate at 37 degrees C, that evidences for an essential drop in the studied series of the free OPI fraction relative to the free OPI extracted by chloroform.	Pantothenyl-Aminoethanol-11-Pivalic Acid	285-288	butyrylcholinesterase	Rattus norvegicus	109-123
982615-3	1976	With an increase in R from the ethyl to butyl one the ability to the  additional inhibition of the brain own cholinesterase lowers due to incubation of homogenate at 37 degrees C, that evidences for an essential drop in the studied series of the free OPI fraction relative to the free OPI extracted by chloroform.	Chloroform	302-312	butyrylcholinesterase	Rattus norvegicus	109-123
6755-0	1976	The effect of cholinesterase inhibitors on the antimuscarinic effect of hemicholinium-3 (HC-3) in the rat.	Hemicholinium 3	72-87	butyrylcholinesterase	Rattus norvegicus	14-28
6755-0	1976	The effect of cholinesterase inhibitors on the antimuscarinic effect of hemicholinium-3 (HC-3) in the rat.	Hemicholinium 3	89-93	butyrylcholinesterase	Rattus norvegicus	14-28
6755-13	1976	It is concluded that in addition to an inhibitory action on the post-junctional muscarinic receptor HC-3 may interfere with the anticholinesterase activity of some cholinesterase inhibitors such as physostigmine and DFP but not edrophonium.	Isoflurophate	216-219	butyrylcholinesterase	Rattus norvegicus	132-146
1262899-0	1976	Testosterone-induced changes of choline acetyl-transferase and cholinesterase activities in rat levator ani muscle.	Testosterone	0-12	butyrylcholinesterase	Rattus norvegicus	63-77
1262899-4	1976	Treatment with testosterone rapidly increased the activity of ChAc and the weight of the muscle near to control values; the restoration of ChE was less complete.	Testosterone	15-27	butyrylcholinesterase	Rattus norvegicus	139-142
1262899-5	1976	Testosterone produced an increase in the size of the muscle fibres and increased the histochemically observed activity of ChE in the postsynaptic part of the motor end-plates.	Testosterone	0-12	butyrylcholinesterase	Rattus norvegicus	122-125
1262900-0	1976	Effects of castration, testosterone and immobilization on the activities of choline acetyltransferase and cholinesterase in rat limb muscles.	Testosterone	23-35	butyrylcholinesterase	Rattus norvegicus	106-120
944516-0	1976	[The role of catecholamines, acetylcholine and cholinesterase activity in the development of the cataleptic action of triftazin following repeated administration].	Trifluoperazine	118-127	butyrylcholinesterase	Rattus norvegicus	47-61
130244-7	1976	Cassaine inhibited the cholinesterase activity of rat brain microsomes with a Ki of about 5 x 10(-5) M, but his inhibition was fully reversible.	cassaine	0-8	butyrylcholinesterase	Rattus norvegicus	23-37
799866-2	1976	Described is an activating affect (observed for the first time in vivo) on ChE preduced by low and very low concentrations of reactivators of the group of oximes.	Oximes	155-161	butyrylcholinesterase	Rattus norvegicus	75-78
799866-4	1976	The low concentrations of the specific oxime ractivators of ChE, followed up by ChDT, can be used as sensitive quantitative indicators of the activity of ChE.	Oximes	39-44	butyrylcholinesterase	Rattus norvegicus	60-63
944516-1	1976	Catalepsy occurring in rats in a singular and repeated introduction of triftasine has a manifold mechanism, the main components of which are related to the metabolism of dophamine, acetylcholine and cholinesterase activity.	triftasine	71-81	butyrylcholinesterase	Rattus norvegicus	199-213
799866-4	1976	The low concentrations of the specific oxime ractivators of ChE, followed up by ChDT, can be used as sensitive quantitative indicators of the activity of ChE.	Oximes	39-44	butyrylcholinesterase	Rattus norvegicus	154-157
1205634-0	1975	Effect of S-methylfenitrothion on the activity of cholinesterase and on the excretion of its metabolites in rats.	S-methylfenitrothion	10-30	butyrylcholinesterase	Rattus norvegicus	50-64
126628-3	1975	Acute delta9-THC treatment reduced the total catecholamine content (including noradrenaline) of the gland, was accompanied by increased ATP-ase, AChE, BChE activities and increased calcium distribution in the gland.	Dronabinol	6-16	butyrylcholinesterase	Rattus norvegicus	151-155
126628-5	1975	The calcium content and ATPase activity were increased along with a concomitant increase in AChE and BChE activities.	Calcium	4-11	butyrylcholinesterase	Rattus norvegicus	101-105
1187454-0	1975	Inhibitory effects of beta-hydroxyethyl 2,4-dinitrophenyl disulphide on rat brain cholinesterase activity.	beta-hydroxyethyl 2,4-dinitrophenyl disulphide	22-68	butyrylcholinesterase	Rattus norvegicus	82-96
1237331-0	1975	Reduction in the cholinesterase activity of the rat anococcygeus muscle produced by corticosterone.	Corticosterone	84-98	butyrylcholinesterase	Rattus norvegicus	17-31
1237331-1	1975	1 Administration of corticosterone caused a 47% reduction in the cholinesterase (ChE) activity of homogenates of the rat anococcygeus muscle.	Corticosterone	20-34	butyrylcholinesterase	Rattus norvegicus	65-79
1237331-1	1975	1 Administration of corticosterone caused a 47% reduction in the cholinesterase (ChE) activity of homogenates of the rat anococcygeus muscle.	Corticosterone	20-34	butyrylcholinesterase	Rattus norvegicus	81-84
1237331-2	1975	2 ChE activity was also reduced by morphine withdrawal and this effect was abolished by the corticosteroid synthesis inhibitor, metyrapone.	Morphine	35-43	butyrylcholinesterase	Rattus norvegicus	2-5
1237331-2	1975	2 ChE activity was also reduced by morphine withdrawal and this effect was abolished by the corticosteroid synthesis inhibitor, metyrapone.	Metyrapone	128-138	butyrylcholinesterase	Rattus norvegicus	2-5
1237331-3	1975	3 A single dose of reserpine reduced ChE activity in normal but not in adrenalectomized rats.	Reserpine	19-28	butyrylcholinesterase	Rattus norvegicus	37-40
1237331-4	1975	4 ChE activity was increased by adrenalectomy or by metyrapone treatment.	Metyrapone	52-62	butyrylcholinesterase	Rattus norvegicus	2-5
1237331-6	1975	6 The reduction in ChE activity produced by corticosterone, morphine withdrawal, or a single dose of reserpine might explain the leftward shift of the dose-% response curve to acetylcholine produced by these procedures in the isolated anococcygeus muscle of the rat.	Corticosterone	44-58	butyrylcholinesterase	Rattus norvegicus	19-22
1237331-6	1975	6 The reduction in ChE activity produced by corticosterone, morphine withdrawal, or a single dose of reserpine might explain the leftward shift of the dose-% response curve to acetylcholine produced by these procedures in the isolated anococcygeus muscle of the rat.	Morphine	60-68	butyrylcholinesterase	Rattus norvegicus	19-22
1237331-6	1975	6 The reduction in ChE activity produced by corticosterone, morphine withdrawal, or a single dose of reserpine might explain the leftward shift of the dose-% response curve to acetylcholine produced by these procedures in the isolated anococcygeus muscle of the rat.	Reserpine	101-110	butyrylcholinesterase	Rattus norvegicus	19-22
1237331-6	1975	6 The reduction in ChE activity produced by corticosterone, morphine withdrawal, or a single dose of reserpine might explain the leftward shift of the dose-% response curve to acetylcholine produced by these procedures in the isolated anococcygeus muscle of the rat.	Acetylcholine	176-189	butyrylcholinesterase	Rattus norvegicus	19-22
1188955-0	1975	Dietary fat alteration of plasma cholinesterase response to malathion.	Malathion	60-69	butyrylcholinesterase	Rattus norvegicus	33-47
1188955-1	1975	This study revealed the influence of organophosphate pesticides on cholinesterase levels of male Sprague-Dawley rats.	Organophosphates	37-52	butyrylcholinesterase	Rattus norvegicus	67-81
1188955-4	1975	Malathion was chosen because it is the least toxic of the organophosphate cholinesterase-inhibiting pesticides.	Malathion	0-9	butyrylcholinesterase	Rattus norvegicus	74-88
1188955-5	1975	Stastical analysis of the data showed that malathion does inhibit blood cholinesterase to the greatest degree in normal-fat diet animals, with the least effect on high-fat groups and fat-free subjects fall in between the two groups.	Malathion	43-52	butyrylcholinesterase	Rattus norvegicus	72-86
1151764-1	1975	Paraoxon, an irreversible organophosphorus inhibitor of cholinesterase, produces a myopathy beginning at the neuromuscular junction in rat diaphragm muscles.	Paraoxon	0-8	butyrylcholinesterase	Rattus norvegicus	56-70
1151764-1	1975	Paraoxon, an irreversible organophosphorus inhibitor of cholinesterase, produces a myopathy beginning at the neuromuscular junction in rat diaphragm muscles.	organophosphorus	26-42	butyrylcholinesterase	Rattus norvegicus	56-70
1151764-11	1975	It is concluded that inhibition of neuromuscular cholinesterase by paraoxon leads to an alteration of transmitter release, and this may be associated with ultrastructural abnormalities observed at the motor endplate.	Paraoxon	67-75	butyrylcholinesterase	Rattus norvegicus	49-63
805051-0	1975	Further studies on the therapy of organophosphorous anti-cholinesterase intoxication with veratrinic compounds; the role of calcium.	organophosphorous	34-51	butyrylcholinesterase	Rattus norvegicus	57-71
1191768-1	1975	The capacity of reversible inhibitors--galanthamine and tacrine--to protect the cholinesterase of rat and mouse brain from the thermal denaturation with the action of the temperature of 56 and 58 degrees C was revealed.	Galantamine	39-51	butyrylcholinesterase	Rattus norvegicus	80-94
1191768-1	1975	The capacity of reversible inhibitors--galanthamine and tacrine--to protect the cholinesterase of rat and mouse brain from the thermal denaturation with the action of the temperature of 56 and 58 degrees C was revealed.	Tacrine	56-63	butyrylcholinesterase	Rattus norvegicus	80-94
168694-0	1975	[A spectrophotometric method for the determination of serum cholinesterase variants with succinyl choline as substrate (author"s transl)].	Succinylcholine	89-105	butyrylcholinesterase	Rattus norvegicus	60-74
168694-1	1975	A simple and rapid method for the estimation of the hydrolysis of succinyl choline by serum cholinesterase variants is described.	Succinylcholine	66-82	butyrylcholinesterase	Rattus norvegicus	92-106
164530-3	1975	Similarly, a lack of change in choline acetylase activity coupled with constantly high acetylcholine levels (140%) and low cholinesterase activity (28.5%) tends to eliminate end-product inhibition of acetylcholine synthesis as a primary mechanism of tolerance to DFP.	Acetylcholine	200-213	butyrylcholinesterase	Rattus norvegicus	123-137
1143526-0	1975	Proceedings: Binding of 3H-diisopropylfluorophosphate (DFP) to purified human serum cholinesterase and to rat brain homogenate.	3h-diisopropylfluorophosphate	24-53	butyrylcholinesterase	Rattus norvegicus	84-98
1143526-0	1975	Proceedings: Binding of 3H-diisopropylfluorophosphate (DFP) to purified human serum cholinesterase and to rat brain homogenate.	Isoflurophate	55-58	butyrylcholinesterase	Rattus norvegicus	84-98
805051-0	1975	Further studies on the therapy of organophosphorous anti-cholinesterase intoxication with veratrinic compounds; the role of calcium.	veratrinic	90-100	butyrylcholinesterase	Rattus norvegicus	57-71
1162259-0	1975	[Changes in cholinesterase and carboxylesterase activity in rats poisoned with enolophosphate insecticides IPO-63 and IPO-597].	enolophosphate	79-93	butyrylcholinesterase	Rattus norvegicus	12-26
1135178-1	1975	Changes in the sum total activity of cholinesterase of the plasma and erythrocytes (AC substrate) and also separately of acetyl- and pseudocholinesterase (MeC and ByC substrates) were studied in experiments on rats with thyrotoxin toxicosis and 6-methylthiouracil hypothyroidism.	thyrotoxin	220-230	butyrylcholinesterase	Rattus norvegicus	37-51
1135178-1	1975	Changes in the sum total activity of cholinesterase of the plasma and erythrocytes (AC substrate) and also separately of acetyl- and pseudocholinesterase (MeC and ByC substrates) were studied in experiments on rats with thyrotoxin toxicosis and 6-methylthiouracil hypothyroidism.	Methylthiouracil	245-263	butyrylcholinesterase	Rattus norvegicus	37-51
1162259-0	1975	[Changes in cholinesterase and carboxylesterase activity in rats poisoned with enolophosphate insecticides IPO-63 and IPO-597].	methylbromfenvinphos	107-113	butyrylcholinesterase	Rattus norvegicus	12-26
1162259-0	1975	[Changes in cholinesterase and carboxylesterase activity in rats poisoned with enolophosphate insecticides IPO-63 and IPO-597].	IPO-597	118-125	butyrylcholinesterase	Rattus norvegicus	12-26
4631952-0	1972	[Histochemical and biochemical study of the effects of thyroid deficiency and of thyroxine on the development of cholinesterase activity in the cerebellum of young rats].	Thyroxine	81-90	butyrylcholinesterase	Rattus norvegicus	113-127
4435038-0	1974	Effect of paraoxon on cholinesterase activity in certain brain regions of diabetic rats.	Paraoxon	10-18	butyrylcholinesterase	Rattus norvegicus	22-36
4478151-0	1974	[Changes in serum cholinesterase activity in rats exposed to carbon tetrachloride and several cytotoxic sera].	Carbon Tetrachloride	61-81	butyrylcholinesterase	Rattus norvegicus	18-32
4764290-0	1973	Response of the rat ileum, uterus and vas deferens to carbachol and acetylcholine following repeated daily administration of a cholinesterase inhibitor.	Carbachol	54-63	butyrylcholinesterase	Rattus norvegicus	127-141
4764290-3	1973	administration, for eight days, of the cholinesterase inhibitor disulfoton to rats produced mild to moderate signs of intoxication (tremors, incontinence and diarrhoea) but no deaths.2.	Disulfoton	64-74	butyrylcholinesterase	Rattus norvegicus	39-53
4347708-0	1972	Actions of the selective inhibitor of cholinesterase tetramonoisopropyl pyrophosphortetramide on the rat phrenic nerve-diaphragm preparation.	tetramonoisopropyl pyrophosphortetramide	53-93	butyrylcholinesterase	Rattus norvegicus	38-52
4437728-0	1974	Reduced behavioural effects of intrahippocampally administered carbachol in rats with low cholinesterase activity.	Carbachol	63-72	butyrylcholinesterase	Rattus norvegicus	90-104
4219941-0	1974	Changes in cholinesterase activity in white rats, after several injections of TMB-4 and atropine, following treatment with parathion.	Trimedoxime	78-83	butyrylcholinesterase	Rattus norvegicus	11-25
4219941-0	1974	Changes in cholinesterase activity in white rats, after several injections of TMB-4 and atropine, following treatment with parathion.	Atropine	88-96	butyrylcholinesterase	Rattus norvegicus	11-25
4219941-0	1974	Changes in cholinesterase activity in white rats, after several injections of TMB-4 and atropine, following treatment with parathion.	Parathion	123-132	butyrylcholinesterase	Rattus norvegicus	11-25
4736357-0	1973	[Inhibition of rat blood cholinesterase activity by ethyl parathion].	Parathion	52-67	butyrylcholinesterase	Rattus norvegicus	25-39
4345588-0	1972	[Metabolism of individual phospholipid fractions in the brains of rats poisoned by phosphoorganic cholinesterase inhibitors].	Phospholipids	26-38	butyrylcholinesterase	Rattus norvegicus	98-112
4347708-2	1972	Tetramonoisopropyl pyrophosphortetramide (iso-OMPA) added for 15 min to the rat isolated phrenic nerve-diaphragm in a concentration of 30 muM, produced a complete selective and stable inhibition of cholinesterase.	tetramonoisopropyl pyrophosphortetramide	0-40	butyrylcholinesterase	Rattus norvegicus	198-212
4347708-2	1972	Tetramonoisopropyl pyrophosphortetramide (iso-OMPA) added for 15 min to the rat isolated phrenic nerve-diaphragm in a concentration of 30 muM, produced a complete selective and stable inhibition of cholinesterase.	Tetraisopropylpyrophosphamide	42-50	butyrylcholinesterase	Rattus norvegicus	198-212
4347708-4	1972	Inhibition of cholinesterase was associated with a sustained increase in the neuromuscular blocking action of exogenous butyrylcholine but not of exogenous acetylcholine.	butyrylcholine	120-134	butyrylcholinesterase	Rattus norvegicus	14-28
4347708-10	1972	It is concluded that iso-OMPA, in concentrations (3 and 30 muM) which in 15 min give near maximal or maximal selective inhibition of cholinesterase, has no effect on the transmission of nerve impulses at the neuromuscular junction, but enhances reversibly the amplitude of the contractile response to stimulation by a direct action upon the muscle fibre, which involves a mechanism related to but not identical with that by which caffeine potentiates twitch tension.	Tetraisopropylpyrophosphamide	21-29	butyrylcholinesterase	Rattus norvegicus	133-147
5579460-2	1971	In cortical slices from rat brain incubated in a medium containing the irreversible cholinesterase inhibitor, soman (0.005 mM) and a high concentration of KCl (25 mM), atropine exerts a stimulating action on the release of acetylcholine (ACh).2.	Atropine	168-176	butyrylcholinesterase	Rattus norvegicus	84-98
4646034-0	1972	[Effect of reserpine and serotonin on hexokinase and cholinesterase activity in rat myocardium].	Reserpine	11-20	butyrylcholinesterase	Rattus norvegicus	53-67
4646034-0	1972	[Effect of reserpine and serotonin on hexokinase and cholinesterase activity in rat myocardium].	Serotonin	25-34	butyrylcholinesterase	Rattus norvegicus	53-67
5571018-0	1971	[Comparative study of the effects of zinc and cadmium on cholinesterase activities in rat tissues].	Cadmium	46-53	butyrylcholinesterase	Rattus norvegicus	57-71
4656608-5	1972	Only slices from physostigmine-treated rats had a significantly lower cholinesterase activity.4.	Physostigmine	17-30	butyrylcholinesterase	Rattus norvegicus	70-84
5487003-0	1970	Inhibition of brain cholinesterase activity after the injection of organophosphorus compounds in the rat.	organophosphorus	67-83	butyrylcholinesterase	Rattus norvegicus	20-34
5508083-0	1970	[Erythrocytic acetylcholinesterase and serum cholinesterase activity in rats treated with lead nitrate].	lead nitrate	90-102	butyrylcholinesterase	Rattus norvegicus	20-34
5579460-2	1971	In cortical slices from rat brain incubated in a medium containing the irreversible cholinesterase inhibitor, soman (0.005 mM) and a high concentration of KCl (25 mM), atropine exerts a stimulating action on the release of acetylcholine (ACh).2.	Soman	110-115	butyrylcholinesterase	Rattus norvegicus	84-98
5315345-2	1971	From a comparison of the hypothermia-reducing effects of five cholinesterase-reactivating oximes when injected intraperitoneally or subarachnoidally into rats pretreated with DFP or soman it was possible to distinguish central and peripheral actions of the oximes.	Oximes	90-96	butyrylcholinesterase	Rattus norvegicus	62-76
5315345-2	1971	From a comparison of the hypothermia-reducing effects of five cholinesterase-reactivating oximes when injected intraperitoneally or subarachnoidally into rats pretreated with DFP or soman it was possible to distinguish central and peripheral actions of the oximes.	Oximes	257-263	butyrylcholinesterase	Rattus norvegicus	62-76
5497792-2	1970	Cortical slices from rat brain were incubated in media containing the irreversible cholinesterase inhibitor soman and a high KCl concentration, and the release and synthesis of acetylcholine (ACh) were determined.2.	Soman	108-113	butyrylcholinesterase	Rattus norvegicus	83-97
5632802-0	1967	[Inhibition of cholinesterase and acetylcholinesterase in rats by dibucaine].	Dibucaine	66-75	butyrylcholinesterase	Rattus norvegicus	15-29
4254786-0	1970	Release of cholinesterase from rat liver by nicotinamide and carbon tetrachloride.	Niacinamide	44-56	butyrylcholinesterase	Rattus norvegicus	11-25
4254786-0	1970	Release of cholinesterase from rat liver by nicotinamide and carbon tetrachloride.	Carbon Tetrachloride	61-81	butyrylcholinesterase	Rattus norvegicus	11-25
5768084-3	1969	The cholinesterase activity of the slices had been inhibited by pretreatment with 3,3-dimethyl-n-butyl 2-methylphosphonofluoridate (soman).2.	3,3-dimethyl-n-butyl 2-methylphosphonofluoridate	82-130	butyrylcholinesterase	Rattus norvegicus	4-18
5768084-3	1969	The cholinesterase activity of the slices had been inhibited by pretreatment with 3,3-dimethyl-n-butyl 2-methylphosphonofluoridate (soman).2.	Soman	132-137	butyrylcholinesterase	Rattus norvegicus	4-18
5346520-0	1969	Effect of dipterex on the acetylcholine content and cholinesterase activity of the brain of male albino rats.	Trichlorfon	10-18	butyrylcholinesterase	Rattus norvegicus	52-66
4248648-0	1970	Alterations in the activity & regulation of cholinesterase of the nervous tissue of rats of various ages.	Adenosine Monophosphate	29-32	butyrylcholinesterase	Rattus norvegicus	48-62
5505285-0	1970	[Effects of tritox contained in water on the activity of serum cholinesterase in rats].	trichloroacetonitrile	12-18	butyrylcholinesterase	Rattus norvegicus	63-77
5505285-0	1970	[Effects of tritox contained in water on the activity of serum cholinesterase in rats].	Water	32-37	butyrylcholinesterase	Rattus norvegicus	63-77
5665486-0	1968	[Analysis of the cholinesterase activity in full blood samples from pregnant rats receiving subtoxic doses of physostigmine salicylate].	physostigmine salicylate	110-134	butyrylcholinesterase	Rattus norvegicus	17-31
5599887-0	1967	[Effect of pH and ionic strength on the rats of reaction between organophosphorus compounds and serum cholinesterase].	organophosphorus	65-81	butyrylcholinesterase	Rattus norvegicus	102-116
6064562-0	1967	[Cholinesterase activity in the rat kidney during experimental uranyl nitrate poisoning (biochemical and histochemical study)].	Uranyl Nitrate	63-77	butyrylcholinesterase	Rattus norvegicus	1-15
5986763-0	1966	Effects of chronic feeding of organic phosphorous compounds on tissue cholinesterase in rats.	Phosphinidene	38-49	butyrylcholinesterase	Rattus norvegicus	70-84
6016627-0	1967	The detection of cholinesterase inhibition in erythrocytes of rats fed low levels of the carbamate Banol.	carbamate banol	89-104	butyrylcholinesterase	Rattus norvegicus	17-31
5993685-0	1966	[The persistence of the inhibition of the cholinesterase activity of the blood and brain in the albino rat treated with Parathion.	Parathion	120-129	butyrylcholinesterase	Rattus norvegicus	42-56
5972309-0	1966	The effect of various chemicals on rat brain cholinesterase inhibition by parathion.	Parathion	74-83	butyrylcholinesterase	Rattus norvegicus	45-59
5913716-0	1966	The effect of acute and chronic treatment with diisopropyl fluorophosphate on cholinesterase activities of some tissues of the rat.	Isoflurophate	47-74	butyrylcholinesterase	Rattus norvegicus	78-92
5909313-0	1966	Effects of acute and chronic inhibition of cholinesterase upon body weight, food intake, and water intake in the rat.	Water	93-98	butyrylcholinesterase	Rattus norvegicus	43-57
5920543-0	1966	[Changes in the activity of cholinesterase of the spinal cord in rats treated with uranyl nitrate].	Uranyl Nitrate	83-97	butyrylcholinesterase	Rattus norvegicus	28-42
5962089-0	1966	Reactivation of paraoxon-inactivated cholinesterase in the rat cerebral cortex by pralidoxime chloride.	pralidoxime	82-102	butyrylcholinesterase	Rattus norvegicus	37-51
5927092-0	1966	[Reactivation of phosphoryl cholinesterase in the cerebral cortex of rats following parenteral administration of pralidoxime (PAM-2) and toxogonine (LuH-6)].	pralidoxime	113-124	butyrylcholinesterase	Rattus norvegicus	28-42
5218627-0	1966	[Changes in the cholinesterase activity of rats following prolonged inhalation of nitrogen oxides].	Nitrogen Oxides	82-97	butyrylcholinesterase	Rattus norvegicus	16-30
5927092-0	1966	[Reactivation of phosphoryl cholinesterase in the cerebral cortex of rats following parenteral administration of pralidoxime (PAM-2) and toxogonine (LuH-6)].	pam-2	126-131	butyrylcholinesterase	Rattus norvegicus	28-42
5927092-0	1966	[Reactivation of phosphoryl cholinesterase in the cerebral cortex of rats following parenteral administration of pralidoxime (PAM-2) and toxogonine (LuH-6)].	OBIDOXIME CHLORIDE	137-147	butyrylcholinesterase	Rattus norvegicus	28-42
5927092-0	1966	[Reactivation of phosphoryl cholinesterase in the cerebral cortex of rats following parenteral administration of pralidoxime (PAM-2) and toxogonine (LuH-6)].	luh-6)	149-155	butyrylcholinesterase	Rattus norvegicus	28-42
13997570-0	1962	[Excretion of p-nitrophenol and the behavior of cholinesterase following repeated administrations of parathion in rats].	Parathion	101-110	butyrylcholinesterase	Rattus norvegicus	48-62
14222810-4	1964	Cholinesterase activity in formalin-fixed heart muscle was localized: (a) in longitudinal elements of the sarcoplasmic reticulum, but not in the T, or transverse, elements; and (b) in the A band, with virtually no activity noted in the M band, or in the H zone.	Formaldehyde	27-35	butyrylcholinesterase	Rattus norvegicus	0-14
14086761-8	1963	A possible connection between the spatial spread of cholinesterase activity and the enlargement of the acetylcholine-sensitive surface is discussed.	Acetylcholine	103-116	butyrylcholinesterase	Rattus norvegicus	52-66
13511233-0	1958	A histochemical and biochemical study of the polysaccharidic substances of the developing nervous system of the rat in relation with the appearance of cholinesterase activity.	polysaccharidic	45-60	butyrylcholinesterase	Rattus norvegicus	151-165
13618543-2	1958	Monoisonitrosoacetone and diacetylmonoxime given before sarin protected blood and brain cholinesterase from inhibition.	isonitrosoacetone	0-21	butyrylcholinesterase	Rattus norvegicus	88-102
13618543-2	1958	Monoisonitrosoacetone and diacetylmonoxime given before sarin protected blood and brain cholinesterase from inhibition.	diacetylmonoxime	26-42	butyrylcholinesterase	Rattus norvegicus	88-102
13618543-3	1958	Monoisonitrosoacetone given after the appearance of signs of poisoning caused a rapid reactivation of brain cholinesterase.	isonitrosoacetone	0-21	butyrylcholinesterase	Rattus norvegicus	108-122
13618543-4	1958	Diacetylmonoxime, at an equimolar dose, produced only a slight increase in enzyme activity, and pyridine-2-aldoxime methiodide, the best reactivator in vitro, reactivated blood but not brain cholinesterase.	pralidoxime	96-126	butyrylcholinesterase	Rattus norvegicus	191-205
13893192-0	1962	[Cholinesterase activity following repeated applications of small doses of parathion in rats].	Parathion	75-84	butyrylcholinesterase	Rattus norvegicus	1-15
13738328-0	1961	[Effect of vitamin A and thyroidin on catalase and cholinesterase activity in white rats].	Vitamin A	11-20	butyrylcholinesterase	Rattus norvegicus	51-65
13203106-0	1954	[Effect of ether anesthesia and operative stress on cholinesterase level in liver and blood of impuberal rats].	Ether	11-16	butyrylcholinesterase	Rattus norvegicus	52-66
13315214-2	1956	Return of cholinesterase activity in the rat after inhibition by carbamoyl fluorides.	carbamoyl fluorides	65-84	butyrylcholinesterase	Rattus norvegicus	10-24
13207351-0	1954	Decreased cholinesterase activity of rat kidney following adrenalectomy and its reactivation in vitro by certain steroids.	Steroids	113-121	butyrylcholinesterase	Rattus norvegicus	10-24
13505825-0	1957	Inhibition of rat cholinesterase by tritolyl phosphates.	Tritolyl Phosphates	36-55	butyrylcholinesterase	Rattus norvegicus	18-32
14389245-0	1955	Return of cholinesterase activity in the rat after inhibition by organophosphorus compounds.	organophosphorus	65-81	butyrylcholinesterase	Rattus norvegicus	10-24
24538112-0	1950	[Research in the relation between the defense action of certain antianemic substances (vitamin B12, pteroylglutamic acid) and the cholinesterase effect of the serum in experimental anemia of the rat].	Vitamin B 12	87-98	butyrylcholinesterase	Rattus norvegicus	130-144
13058955-0	1953	Return of cholinesterase activity in the rat after inhibition by organophosphorus compounds.	organophosphorus	65-81	butyrylcholinesterase	Rattus norvegicus	10-24
24538112-0	1950	[Research in the relation between the defense action of certain antianemic substances (vitamin B12, pteroylglutamic acid) and the cholinesterase effect of the serum in experimental anemia of the rat].	Folic Acid	100-120	butyrylcholinesterase	Rattus norvegicus	130-144
15391661-0	1949	Mechanism of the inhibition of rat brain cholinesterase by diisopropylfluorophosphate, tetraethylpyrophosphate, and eserine.	Isoflurophate	59-85	butyrylcholinesterase	Rattus norvegicus	41-55
18885609-0	1948	The inhibition of the cholinesterase of rat brain by methadon.	Methadone	53-61	butyrylcholinesterase	Rattus norvegicus	22-36
15391661-0	1949	Mechanism of the inhibition of rat brain cholinesterase by diisopropylfluorophosphate, tetraethylpyrophosphate, and eserine.	tetraethyl pyrophosphate	87-110	butyrylcholinesterase	Rattus norvegicus	41-55
16991869-0	1949	The influence of magnesium on respiration, glycolysis and cholinesterase activity in rat brain.	Magnesium	17-26	butyrylcholinesterase	Rattus norvegicus	58-72
18150766-0	1949	Influence of antipyrine on respiration, glycolysis and cholinesterase activity in rat brain.	Antipyrine	13-23	butyrylcholinesterase	Rattus norvegicus	55-69
33953291-2	2021	We investigated whether cholinergic stimulation with pyridostigmine, a cholinesterase inhibitor, modulates heart and spleen immune responses and cardiac remodeling after AMI in spontaneous hypertensive rats (SHRs).	Pyridostigmine Bromide	53-67	butyrylcholinesterase	Rattus norvegicus	71-85
20276262-0	1946	Effects of castration and treatment with sex steroids on the synthesis of serum cholinesterase in the rat.	Steroids	45-53	butyrylcholinesterase	Rattus norvegicus	80-94
33420969-0	2021	Chromone-lipoic acid conjugate: Neuroprotective agent having acceptable butyrylcholinesterase inhibition, antioxidant and copper-chelation activities.	Chromones	0-8	butyrylcholinesterase	Rattus norvegicus	72-93
33420969-0	2021	Chromone-lipoic acid conjugate: Neuroprotective agent having acceptable butyrylcholinesterase inhibition, antioxidant and copper-chelation activities.	Thioctic Acid	9-20	butyrylcholinesterase	Rattus norvegicus	72-93
33420969-12	2021	A new chromone-lipoic acid hybrid was synthesized as anti-Alzheimer agent with BuChE inhibitory activity, anti-Abeta aggregation, metal-chelation and antioxidant properties.	Chromones	6-14	butyrylcholinesterase	Rattus norvegicus	79-84
33420969-12	2021	A new chromone-lipoic acid hybrid was synthesized as anti-Alzheimer agent with BuChE inhibitory activity, anti-Abeta aggregation, metal-chelation and antioxidant properties.	Thioctic Acid	15-26	butyrylcholinesterase	Rattus norvegicus	79-84
34032549-2	2021	Galantamine hydrobromide (GH) is an anti-Alzheimer cholinesterase inhibitor that has an intrinsic antioxidant effect.	Galantamine	0-24	butyrylcholinesterase	Rattus norvegicus	51-65
33129804-0	2021	Effects of low-level imidacloprid oral exposure on cholinesterase activity, oxidative stress responses, and primary DNA damage in the blood and brain of male Wistar rats.	imidacloprid	21-33	butyrylcholinesterase	Rattus norvegicus	51-65
33887253-4	2021	The cholinesterase inhibitor, tacrine, was used as a comparator.	Tacrine	30-37	butyrylcholinesterase	Rattus norvegicus	4-18
33380269-7	2021	G4-N significantly lowered (29%) butyrylcholinesterase (BChE) in male plasma, but this effect was resolved during recovery.	g4-n	0-4	butyrylcholinesterase	Rattus norvegicus	56-60
33725758-4	2021	RESULTS: The result of the study showed that untreated STZ-induced diabetic rats have increased acetylcholinesterase (AChE), butyrylcholinesterase (BChE), monoamine oxidase (MAO) activities, and malonylaldehyde (MDA) level, with concomitant decrease of superoxide dismutase (SOD), glutathione peroxidase (GPx) activities, and glutathione (GSH) level.	Streptozocin	55-58	butyrylcholinesterase	Rattus norvegicus	125-146
33545185-3	2021	Based on in vitro assays, K869 is a potent AChE and butyrylcholinesterase (BChE) reactivator.	1,3-Bis(chloromethyl)-1,1,3,3-tetramethyldisiloxane	26-30	butyrylcholinesterase	Rattus norvegicus	52-73
33545185-3	2021	Based on in vitro assays, K869 is a potent AChE and butyrylcholinesterase (BChE) reactivator.	1,3-Bis(chloromethyl)-1,1,3,3-tetramethyldisiloxane	26-30	butyrylcholinesterase	Rattus norvegicus	75-79
33497710-5	2021	Serine esterases, such as carboxylesterase (CaE) and butyrylcholinesterase (BChE), play a prominent role in OP detoxication.	Serine	0-6	butyrylcholinesterase	Rattus norvegicus	53-74
33497710-5	2021	Serine esterases, such as carboxylesterase (CaE) and butyrylcholinesterase (BChE), play a prominent role in OP detoxication.	Serine	0-6	butyrylcholinesterase	Rattus norvegicus	76-80
33725758-4	2021	RESULTS: The result of the study showed that untreated STZ-induced diabetic rats have increased acetylcholinesterase (AChE), butyrylcholinesterase (BChE), monoamine oxidase (MAO) activities, and malonylaldehyde (MDA) level, with concomitant decrease of superoxide dismutase (SOD), glutathione peroxidase (GPx) activities, and glutathione (GSH) level.	Streptozocin	55-58	butyrylcholinesterase	Rattus norvegicus	148-152
32372339-0	2020	Design, synthesis, and evaluation of novel cinnamic acid-tryptamine hybrid for inhibition of acetylcholinesterase and butyrylcholinesterase.	cinnamic acid	43-56	butyrylcholinesterase	Rattus norvegicus	118-139
32628296-4	2021	STZ-induced diabetic rats exhibited memory deficits, elevated brain cholinesterase, arginase activity in comparison with nondiabetic rats.	Streptozocin	0-3	butyrylcholinesterase	Rattus norvegicus	68-82
32602568-7	2021	Treatment of diabetic rats with donepezil led to a significant decrease in both amyloid-beta deposition and the raised hippocampal activity of cholinesterase (ChE).	Donepezil	32-41	butyrylcholinesterase	Rattus norvegicus	143-157
32602568-7	2021	Treatment of diabetic rats with donepezil led to a significant decrease in both amyloid-beta deposition and the raised hippocampal activity of cholinesterase (ChE).	Donepezil	32-41	butyrylcholinesterase	Rattus norvegicus	159-162
33460720-0	2021	Non-linear model analysis of the relationship between cholinesterase activity in rats exposed to 2, 2-dichlorovinyl dimethylphosphate (dichlorvos) and its metabolite concentrations in urine.	Dichlorvos	97-133	butyrylcholinesterase	Rattus norvegicus	54-68
33460720-0	2021	Non-linear model analysis of the relationship between cholinesterase activity in rats exposed to 2, 2-dichlorovinyl dimethylphosphate (dichlorvos) and its metabolite concentrations in urine.	Dichlorvos	135-145	butyrylcholinesterase	Rattus norvegicus	54-68
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	dimethyl phosphate	82-99	butyrylcholinesterase	Rattus norvegicus	164-178
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	dimethyl phosphate	82-99	butyrylcholinesterase	Rattus norvegicus	180-183
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	dimethyl phosphate	101-104	butyrylcholinesterase	Rattus norvegicus	164-178
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	dimethyl phosphate	101-104	butyrylcholinesterase	Rattus norvegicus	180-183
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	Dichlorvos	123-133	butyrylcholinesterase	Rattus norvegicus	164-178
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	Dichlorvos	123-133	butyrylcholinesterase	Rattus norvegicus	180-183
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	Dichlorvos	135-139	butyrylcholinesterase	Rattus norvegicus	164-178
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	Dichlorvos	135-139	butyrylcholinesterase	Rattus norvegicus	180-183
33460720-3	2021	The present study aimed to clarify the relationship between the amount of urinary dimethylphosphate (DMP), a metabolite of dichlorvos (DDVP), and the inhibition of cholinesterase (ChE) activity in rats exposed to DDVP.	Dichlorvos	213-217	butyrylcholinesterase	Rattus norvegicus	180-183
33460720-4	2021	The relationship was analyzed using a nonlinear model analysis, and the excretion level of urinary DMP equivalent to ChE 20% inhibition (EL20) and the lower limit of the 95% confidence interval of EL20 (ELL20) were estimated.	dimethyl phosphate	99-102	butyrylcholinesterase	Rattus norvegicus	117-120
33460720-5	2021	EL20 and ELL20 (mg/24 h urine) of brain, erythrocyte, and plasma ChE activities after 10-day administration of DDVP were 0.21 and 0.15, 0.11 and 0.06, and 0.23 and 0.09, respectively.	Dichlorvos	111-115	butyrylcholinesterase	Rattus norvegicus	65-68
32602568-13	2021	These findings suggest that donepezil treatment could ameliorate learning and memory impairment in T2D rats through reversal of some of the AD-related alterations, including reduction of amyloid-beta burden and ChE activity as well as restoration of glutamate receptor expression.	Donepezil	28-37	butyrylcholinesterase	Rattus norvegicus	211-214
32372339-0	2020	Design, synthesis, and evaluation of novel cinnamic acid-tryptamine hybrid for inhibition of acetylcholinesterase and butyrylcholinesterase.	tryptamine	57-67	butyrylcholinesterase	Rattus norvegicus	118-139
32372339-4	2020	RESULT AND DISCUSSION: A new series of cinnamic acids-tryptamine hybrid was designed, synthesized, and evaluated as dual cholinesterase inhibitors.	cinnamic acid	39-53	butyrylcholinesterase	Rattus norvegicus	121-135
32372339-4	2020	RESULT AND DISCUSSION: A new series of cinnamic acids-tryptamine hybrid was designed, synthesized, and evaluated as dual cholinesterase inhibitors.	tryptamine	54-64	butyrylcholinesterase	Rattus norvegicus	121-135
32372339-12	2020	Graphical abstract A new series of cinnamic-derived acids-tryptamine hybrid derivatives were designed, synthesized and evaluated as butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) inhibitors and neuroprotective agents.	acids-tryptamine	52-68	butyrylcholinesterase	Rattus norvegicus	132-153
32372339-12	2020	Graphical abstract A new series of cinnamic-derived acids-tryptamine hybrid derivatives were designed, synthesized and evaluated as butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) inhibitors and neuroprotective agents.	acids-tryptamine	52-68	butyrylcholinesterase	Rattus norvegicus	155-159
32522946-9	2020	Primrose/fish oil mixture was superior in reducing ESR, brain MDA, plasma activity of BChE and brain histopathological changes along with elevating plasma magnesium.	Fish Oils	9-17	butyrylcholinesterase	Rattus norvegicus	86-90
32911022-3	2020	As an insecticide, diazinon (DZN) may alter the proportion of ECM by cholinesterase activity inhibition and oxidative stress.	Diazinon	19-27	butyrylcholinesterase	Rattus norvegicus	69-83
32911022-3	2020	As an insecticide, diazinon (DZN) may alter the proportion of ECM by cholinesterase activity inhibition and oxidative stress.	Diazinon	29-32	butyrylcholinesterase	Rattus norvegicus	69-83
32911022-9	2020	Diazinon reduced the distribution of fibronectin and laminin and significantly inhibited cholinesterase activity in the renal tubules.	Diazinon	0-8	butyrylcholinesterase	Rattus norvegicus	89-103
32911022-11	2020	ALA in the co-treatment group enhanced cholinesterase activity and distribution of both glycoproteins in the renal tubules.	Thioctic Acid	0-3	butyrylcholinesterase	Rattus norvegicus	39-53
32911022-13	2020	The nephrotoxic effect of diazinon in vivo was the reduced distribution of laminin and fibronectin, probably induced by cholinesterase activity inhibition.	Diazinon	26-34	butyrylcholinesterase	Rattus norvegicus	120-134
32011735-1	2020	Acetylcholine (ACh) spillover from motor endplates occurs after neuronal firing bursts being potentiated by cholinesterase inhibitors (e.g. neostigmine).	Acetylcholine	0-13	butyrylcholinesterase	Rattus norvegicus	108-122
32011735-1	2020	Acetylcholine (ACh) spillover from motor endplates occurs after neuronal firing bursts being potentiated by cholinesterase inhibitors (e.g. neostigmine).	Acetylcholine	15-18	butyrylcholinesterase	Rattus norvegicus	108-122
32011735-1	2020	Acetylcholine (ACh) spillover from motor endplates occurs after neuronal firing bursts being potentiated by cholinesterase inhibitors (e.g. neostigmine).	Neostigmine	140-151	butyrylcholinesterase	Rattus norvegicus	108-122
32847424-7	2022	Also, there was a significant decrease in the activity of adenosine monophosphohydrolase (AMPase) with a simultaneous increase in activities of adenosine deaminase (ADA), adenosine triphosphate diphosphohydrolase (ATPdase), acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in scopolamine-induced rats when compared with the control.	Adenosine	58-67	butyrylcholinesterase	Rattus norvegicus	256-277
32847424-7	2022	Also, there was a significant decrease in the activity of adenosine monophosphohydrolase (AMPase) with a simultaneous increase in activities of adenosine deaminase (ADA), adenosine triphosphate diphosphohydrolase (ATPdase), acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in scopolamine-induced rats when compared with the control.	Adenosine	58-67	butyrylcholinesterase	Rattus norvegicus	279-283
32671342-2	2020	This study evaluates the disease-modifying potential of scopoletin against multiple factors associated with AD such as cholinesterase enzymes, Abeta peptides, and neuroprotective properties against Abeta- and H2O2-induced cytotoxicity under in vitro conditions.	Scopoletin	56-66	butyrylcholinesterase	Rattus norvegicus	119-133
32230815-6	2020	Molecular interactions of limonene as the major compound in MO with the active site of butyrylcholinesterase (BChE) was explored via molecular docking experiments, and Van der Waals (vdW) contacts were observed between limonene and the active site residues SER198, HIS438, LEU286, VAL288, and PHE329.	Limonene	26-34	butyrylcholinesterase	Rattus norvegicus	87-108
32303805-7	2020	DFP significantly inhibited cholinesterase activity in the cortex, hippocampus, and amygdala to the same extent in low and high responders.	Isoflurophate	0-3	butyrylcholinesterase	Rattus norvegicus	28-42
32406811-0	2022	Phytol loaded PLGA nanoparticles ameliorate scopolamine-induced cognitive dysfunction by attenuating cholinesterase activity, oxidative stress and apoptosis in Wistar rat.	Phytol	0-6	butyrylcholinesterase	Rattus norvegicus	101-115
31875337-0	2020	Identification of two arylimides as cholinesterase inhibitors and testing of propranolol addition on impaired rat memory.	arylimides	22-32	butyrylcholinesterase	Rattus norvegicus	36-50
32244635-7	2020	Reserpine is a more potent dual cholinesterase inhibitor than ajmalicine (IC50 values of 1.7 muM (AChE) and 2.8 muM (BuChE)).	Reserpine	0-9	butyrylcholinesterase	Rattus norvegicus	32-46
32554834-6	2020	Nevertheless, treatment with simvastatin, CFA and CGA normalized altered AChE, BChE and arginase activities as well as improved antioxidant status in hypercholesterolemic rats.	Simvastatin	29-40	butyrylcholinesterase	Rattus norvegicus	79-83
32543989-11	2022	In scopolamine-treated rats, AChE, BChE, MAO and NTPdases activities, and antioxidant status were upturned in rats pretreated with BLAE.	Scopolamine	3-14	butyrylcholinesterase	Rattus norvegicus	35-39
32550202-10	2020	Results: Treatment with metformin/donepezil combination significantly reduced the activities of AchE, BchE as well as levels of malondialdehyde, TNF-alpha and IL-6, while the activities of SOD, GPx and catalase were significantly increased in the brain.	Metformin	24-33	butyrylcholinesterase	Rattus norvegicus	102-106
32550202-10	2020	Results: Treatment with metformin/donepezil combination significantly reduced the activities of AchE, BchE as well as levels of malondialdehyde, TNF-alpha and IL-6, while the activities of SOD, GPx and catalase were significantly increased in the brain.	Donepezil	34-43	butyrylcholinesterase	Rattus norvegicus	102-106
32230733-4	2020	Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27.	Physostigmine	74-87	butyrylcholinesterase	Rattus norvegicus	47-61
32230733-4	2020	Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27.	Pyridostigmine Bromide	89-103	butyrylcholinesterase	Rattus norvegicus	47-61
32230733-4	2020	Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27.	Ranitidine	105-115	butyrylcholinesterase	Rattus norvegicus	47-61
32230815-6	2020	Molecular interactions of limonene as the major compound in MO with the active site of butyrylcholinesterase (BChE) was explored via molecular docking experiments, and Van der Waals (vdW) contacts were observed between limonene and the active site residues SER198, HIS438, LEU286, VAL288, and PHE329.	Limonene	26-34	butyrylcholinesterase	Rattus norvegicus	110-114
32230733-4	2020	Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27.	Tacrine	117-124	butyrylcholinesterase	Rattus norvegicus	47-61
32230815-6	2020	Molecular interactions of limonene as the major compound in MO with the active site of butyrylcholinesterase (BChE) was explored via molecular docking experiments, and Van der Waals (vdW) contacts were observed between limonene and the active site residues SER198, HIS438, LEU286, VAL288, and PHE329.	Limonene	219-227	butyrylcholinesterase	Rattus norvegicus	87-108
32230815-6	2020	Molecular interactions of limonene as the major compound in MO with the active site of butyrylcholinesterase (BChE) was explored via molecular docking experiments, and Van der Waals (vdW) contacts were observed between limonene and the active site residues SER198, HIS438, LEU286, VAL288, and PHE329.	Limonene	219-227	butyrylcholinesterase	Rattus norvegicus	110-114
31791679-3	2020	Specifically, compound 4g exhibited the potent ability to inhibit cholinesterase (ChE) (IC50, 19.7 nM for hAChE and 0.66 muM for hBuChE) and the good Abeta aggregation inhibition (49.2% at 20 muM), and it was also a good antioxidant (1.26 trolox equivalents).	6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	239-245	butyrylcholinesterase	Rattus norvegicus	82-85
31836556-12	2020	Moreso, cadmium increased cholinesterase (AChE and BChE) activities and level of oxidative stress markers in the brain, with a concomitant decrease in nitric oxide level.	Cadmium	8-15	butyrylcholinesterase	Rattus norvegicus	26-40
31836556-12	2020	Moreso, cadmium increased cholinesterase (AChE and BChE) activities and level of oxidative stress markers in the brain, with a concomitant decrease in nitric oxide level.	Cadmium	8-15	butyrylcholinesterase	Rattus norvegicus	51-55
31836556-13	2020	However, treatment with rutin decreased cholinesterase activities and the level of oxidative stress markers in cadmium-exposed rats.	Rutin	24-29	butyrylcholinesterase	Rattus norvegicus	40-54
31836556-13	2020	However, treatment with rutin decreased cholinesterase activities and the level of oxidative stress markers in cadmium-exposed rats.	Cadmium	111-118	butyrylcholinesterase	Rattus norvegicus	40-54
33479629-0	2020	Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer"s disease.	Chromones	0-8	butyrylcholinesterase	Rattus norvegicus	50-64
33479629-0	2020	Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer"s disease.	Donepezil	13-22	butyrylcholinesterase	Rattus norvegicus	50-64
33479629-1	2020	A series of chromone and donepezil hybrids were designed, synthesized, and evaluated as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential therapy of Alzheimer"s disease (AD).	Chromones	12-20	butyrylcholinesterase	Rattus norvegicus	100-114
33479629-1	2020	A series of chromone and donepezil hybrids were designed, synthesized, and evaluated as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential therapy of Alzheimer"s disease (AD).	Chromones	12-20	butyrylcholinesterase	Rattus norvegicus	116-119
33479629-1	2020	A series of chromone and donepezil hybrids were designed, synthesized, and evaluated as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential therapy of Alzheimer"s disease (AD).	Donepezil	25-34	butyrylcholinesterase	Rattus norvegicus	100-114
33479629-1	2020	A series of chromone and donepezil hybrids were designed, synthesized, and evaluated as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential therapy of Alzheimer"s disease (AD).	Donepezil	25-34	butyrylcholinesterase	Rattus norvegicus	116-119
32164301-0	2020	Pharmacokinetics of Two Chlorine-Substituted Bis-Pyridinium Mono-Aldoximes with Regenerating Effect on Butyrylcholinesterase.	Chlorine	24-32	butyrylcholinesterase	Rattus norvegicus	103-124
32164301-0	2020	Pharmacokinetics of Two Chlorine-Substituted Bis-Pyridinium Mono-Aldoximes with Regenerating Effect on Butyrylcholinesterase.	substituted	33-44	butyrylcholinesterase	Rattus norvegicus	103-124
32164301-0	2020	Pharmacokinetics of Two Chlorine-Substituted Bis-Pyridinium Mono-Aldoximes with Regenerating Effect on Butyrylcholinesterase.	bis-pyridinium	45-59	butyrylcholinesterase	Rattus norvegicus	103-124
31922239-0	2020	Combining antioxidant astaxantin and cholinesterase inhibitor huperzine A boosts neuroprotection.	huperzine A	62-73	butyrylcholinesterase	Rattus norvegicus	37-51
31922239-2	2020	In this study, the antioxidative effects of the antioxidant astaxanthin (AXT) in combination with huperzine A (HupA), which is used as a cholinesterase inhibitor for the treatment of Alzheimer"s disease, were investigated.	astaxanthine	60-71	butyrylcholinesterase	Rattus norvegicus	137-151
31922239-2	2020	In this study, the antioxidative effects of the antioxidant astaxanthin (AXT) in combination with huperzine A (HupA), which is used as a cholinesterase inhibitor for the treatment of Alzheimer"s disease, were investigated.	astaxanthine	73-76	butyrylcholinesterase	Rattus norvegicus	137-151
31922239-2	2020	In this study, the antioxidative effects of the antioxidant astaxanthin (AXT) in combination with huperzine A (HupA), which is used as a cholinesterase inhibitor for the treatment of Alzheimer"s disease, were investigated.	huperzine A	98-109	butyrylcholinesterase	Rattus norvegicus	137-151
31922239-2	2020	In this study, the antioxidative effects of the antioxidant astaxanthin (AXT) in combination with huperzine A (HupA), which is used as a cholinesterase inhibitor for the treatment of Alzheimer"s disease, were investigated.	huperzine A	111-115	butyrylcholinesterase	Rattus norvegicus	137-151
31845170-8	2020	Our findings showed that these thiazolidin-4-ones, especially those containing the propylpiperidine core, have a potential cholinesterase inhibitory activity and can be considered good candidates for future Alzheimer"s therapy.	thiazolidin-4-ones	31-49	butyrylcholinesterase	Rattus norvegicus	123-137
31845170-8	2020	Our findings showed that these thiazolidin-4-ones, especially those containing the propylpiperidine core, have a potential cholinesterase inhibitory activity and can be considered good candidates for future Alzheimer"s therapy.	1-PROPYLPIPERIDINE	83-99	butyrylcholinesterase	Rattus norvegicus	123-137
31586704-0	2019	Design, synthesis, biological evaluation, and molecular modeling studies of quinoline-ferulic acid hybrids as cholinesterase inhibitors.	ferulic acid	76-98	butyrylcholinesterase	Rattus norvegicus	110-124
31586704-1	2019	A series of quinoline-ferulic acid hybrids has been designed, synthesized, and evaluated as cholinesterase inhibitors.	ferulic acid	12-34	butyrylcholinesterase	Rattus norvegicus	92-106
31398601-2	2019	In the present study, we synthesized a series of compounds comprising the carbazole backbone linked to the benzyl piperazine, benzyl piperidine, pyridine, quinoline, or isoquinoline moiety through an aliphatic linker and evaluated as cholinesterase inhibitors.	carbazole	74-83	butyrylcholinesterase	Rattus norvegicus	234-248
31867220-0	2019	Impact of chronic low dose exposure of monocrotophos in rat brain: Oxidative/ nitrosative stress, neuronal changes and cholinesterase activity.	Monocrotophos	39-52	butyrylcholinesterase	Rattus norvegicus	119-133
31867220-4	2019	We studied the effects of low dose long term exposure to MCP on oxidative/nitrosative stress, cholinesterase activity and neuronal loss in rat.	Monocrotophos	57-60	butyrylcholinesterase	Rattus norvegicus	94-108
29648463-6	2019	DZN-induced oxidative damage and elevated the levels of the cardiac markers CK-MB, TPI, MDA and LDH and decreased SOD, CAT and cholinesterase activity and GSH level compared with the control group.	Diazinon	0-3	butyrylcholinesterase	Rattus norvegicus	127-141
31422512-10	2019	In summary, safranal treatment of intrahippocampal amyloid beta1-40-microinjected rats could prevent learning and memory decline via neuronal protection and at a molecular level through amelioration of apoptosis, oxidative stress, inflammation, cholinesterase activity, neutrophil infiltration, and also by preservation of mitochondrial integrity.	safranal	12-20	butyrylcholinesterase	Rattus norvegicus	245-259
31867220-11	2019	It can be concluded from the study that low dose long term exposure (lower than No Observed Effect Level) of MCP may lead to the generation of oxidative stress by elevation of pro-oxidants markers and depletion of antioxidant enzymes markers along with inhibition of cholinesterase activity.	Monocrotophos	109-112	butyrylcholinesterase	Rattus norvegicus	267-281
31446239-0	2019	Novel N-benzylpyridinium moiety linked to arylisoxazole derivatives as selective butyrylcholinesterase inhibitors: Synthesis, biological evaluation, and docking study.	n-benzylpyridinium	6-24	butyrylcholinesterase	Rattus norvegicus	81-102
31446239-0	2019	Novel N-benzylpyridinium moiety linked to arylisoxazole derivatives as selective butyrylcholinesterase inhibitors: Synthesis, biological evaluation, and docking study.	arylisoxazole	42-55	butyrylcholinesterase	Rattus norvegicus	81-102
31446239-1	2019	A novel series of N-benzylpyridinium moiety linked to arylisoxazole ring were designed, synthesized, and evaluated for their in vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities.	n-benzylpyridinium	18-36	butyrylcholinesterase	Rattus norvegicus	166-187
31446239-1	2019	A novel series of N-benzylpyridinium moiety linked to arylisoxazole ring were designed, synthesized, and evaluated for their in vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities.	n-benzylpyridinium	18-36	butyrylcholinesterase	Rattus norvegicus	189-193
29648463-9	2019	Administration of Thy as a natural antioxidant decreased DZN cardio-toxicity and improved cholinesterase activity in rats through the mechanism of free radical scavenging.	thymoquinone	18-21	butyrylcholinesterase	Rattus norvegicus	90-104
31152871-1	2019	BACKGROUND: The most commonly used insecticides and pesticides worldwide are organophosphate compounds, chemicals that irreversibly inhibit the cholinesterase enzyme.	Organophosphates	77-92	butyrylcholinesterase	Rattus norvegicus	144-158
31454121-3	2019	alpha-Glycosidase, butyrylcholinesterase, aldose reductase, acetylcholinesterase, paraoxonase-1, and carbonic anhydrase enzyme activities were significantly (P < .05) decreased in VCM group when compared with the control group.	Vancomycin	183-186	butyrylcholinesterase	Rattus norvegicus	19-40
31292874-4	2019	In the present study, the aim was to investigate the effect of NG against CYP-induced liver, brain, kidney, heart, and testis toxicities on some metabolic enzyme activities such as AChE, BChE, CA, alpha-Gly, and AR.	naringin	63-65	butyrylcholinesterase	Rattus norvegicus	187-191
31516541-2	2019	In this study, we investigated the effects of a new oxime, (3Z)-5-Chloro-3-(Hydroxyimino)indolin-2-one (OXIME) against the alterations induced by malathion, an OP insecticide, acute exposure on markers of hepatic damage, glucose homeostasis, oxidative stress in rats cholinesterase (ChE) activity in rats.	Oximes	52-57	butyrylcholinesterase	Rattus norvegicus	267-281
31516541-2	2019	In this study, we investigated the effects of a new oxime, (3Z)-5-Chloro-3-(Hydroxyimino)indolin-2-one (OXIME) against the alterations induced by malathion, an OP insecticide, acute exposure on markers of hepatic damage, glucose homeostasis, oxidative stress in rats cholinesterase (ChE) activity in rats.	Oximes	52-57	butyrylcholinesterase	Rattus norvegicus	283-286
31516541-2	2019	In this study, we investigated the effects of a new oxime, (3Z)-5-Chloro-3-(Hydroxyimino)indolin-2-one (OXIME) against the alterations induced by malathion, an OP insecticide, acute exposure on markers of hepatic damage, glucose homeostasis, oxidative stress in rats cholinesterase (ChE) activity in rats.	5-Chloro-1H-indole-2,3-dione 3-oxime	59-102	butyrylcholinesterase	Rattus norvegicus	267-281
31516541-2	2019	In this study, we investigated the effects of a new oxime, (3Z)-5-Chloro-3-(Hydroxyimino)indolin-2-one (OXIME) against the alterations induced by malathion, an OP insecticide, acute exposure on markers of hepatic damage, glucose homeostasis, oxidative stress in rats cholinesterase (ChE) activity in rats.	5-Chloro-1H-indole-2,3-dione 3-oxime	59-102	butyrylcholinesterase	Rattus norvegicus	283-286
31516541-2	2019	In this study, we investigated the effects of a new oxime, (3Z)-5-Chloro-3-(Hydroxyimino)indolin-2-one (OXIME) against the alterations induced by malathion, an OP insecticide, acute exposure on markers of hepatic damage, glucose homeostasis, oxidative stress in rats cholinesterase (ChE) activity in rats.	Oximes	104-109	butyrylcholinesterase	Rattus norvegicus	267-281
31516541-2	2019	In this study, we investigated the effects of a new oxime, (3Z)-5-Chloro-3-(Hydroxyimino)indolin-2-one (OXIME) against the alterations induced by malathion, an OP insecticide, acute exposure on markers of hepatic damage, glucose homeostasis, oxidative stress in rats cholinesterase (ChE) activity in rats.	Oximes	104-109	butyrylcholinesterase	Rattus norvegicus	283-286
30724803-3	2019	This study evaluated its effects on cocaine-reinforced and food-reinforced behaviors in rats, using the cholinesterase inhibitor tacrine as a comparator.	Tacrine	129-136	butyrylcholinesterase	Rattus norvegicus	104-118
31010235-0	2019	DNA Damaging Effects, Oxidative Stress Responses and Cholinesterase Activity in Blood and Brain of Wistar Rats Exposed to Delta9-Tetrahydrocannabinol.	Dronabinol	122-149	butyrylcholinesterase	Rattus norvegicus	53-67
31194956-0	2019	Flavanone glycosides inhibit beta-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Abeta aggregation in the amyloidogenic pathway.	flavanone glycosides	0-20	butyrylcholinesterase	Rattus norvegicus	87-101
31194956-4	2019	All four flavonoids displayed promising inhibitory activity against AChE, BChE, and BACE1.	Flavonoids	9-19	butyrylcholinesterase	Rattus norvegicus	74-78
31028989-8	2019	Pentylcurcumene demonstrated anticholinesterase activities e.g. IC50 of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition were 73.12 +- 0.56 and 97.65 +- 0.46 mug/ml, respectively.	pentylcurcumene	0-15	butyrylcholinesterase	Rattus norvegicus	127-131
31028989-9	2019	To better understand enzyme kinetics, Lineweaver-Burk plot of Pentylcurcumene displayed the highest affinity with competitive inhibition (reversible) towards both AChE (Vmax 0.8) and BChE (Vmax 0.6).	pentylcurcumene	62-77	butyrylcholinesterase	Rattus norvegicus	183-187
31028989-11	2019	Molecular docking simulations of Pentylcurcumene (ligand) and enzymes (proteins) exhibited the binding of ligand at active sites of AChE (human/rat) and BChE (human/homology) efficiently and also predicted the hydrophobic interaction of drug towards different amino acid residue within proteins.	pentylcurcumene	33-48	butyrylcholinesterase	Rattus norvegicus	153-157
30853371-3	2019	In this model, rats are typically pretreated with pyridostigmine bromide (PB), a reversible cholinesterase inhibitor, to enhance survival.	Pyridostigmine Bromide	50-72	butyrylcholinesterase	Rattus norvegicus	92-106
30853371-3	2019	In this model, rats are typically pretreated with pyridostigmine bromide (PB), a reversible cholinesterase inhibitor, to enhance survival.	Pyridostigmine Bromide	74-76	butyrylcholinesterase	Rattus norvegicus	92-106
31431637-2	2019	The cholinesterase inhibitor, donepezil (Aricept), reverses AIE effects on dendritic spines, possibly by interacting with inflammatory and/or epigenetic mediators after AIE exposure.	Donepezil	30-39	butyrylcholinesterase	Rattus norvegicus	4-18
31431637-2	2019	The cholinesterase inhibitor, donepezil (Aricept), reverses AIE effects on dendritic spines, possibly by interacting with inflammatory and/or epigenetic mediators after AIE exposure.	Donepezil	41-48	butyrylcholinesterase	Rattus norvegicus	4-18
30953774-5	2019	Rats with a history of PB treatment exhibited potentiated increases in C-reactive protein levels in response to a submaximal LPS challenge compared to control rats, indicating that prior treatment with this cholinesterase inhibitor leads to exacerbated inflammatory responses to a subsequent immune challenge.	Pyridostigmine Bromide	23-25	butyrylcholinesterase	Rattus norvegicus	207-221
31209743-7	2019	AD induced by AlCl3 in rats was depicted by the significant increase in the neurotransmitters levels which is accompanied with high degree of oxidative stress that was revealed in the elevated level of urinary 8-OHdG along with significant elevation in AOPP, TBARS, and cholinesterase levels and a significant decrease in SOD and GSH; these results are confirmed by immunohistochemistry analysis of COX 1 and 2.	Aluminum Chloride	14-19	butyrylcholinesterase	Rattus norvegicus	270-284
31054435-1	2019	This current study described the design and synthesis of a series of derivatives based on a natural pyranoisaflavone, which was obtained from the seeds of Millettia pachycarpa and displayed attractive BChE inhibition and high selectivity in our previous study.	pyranoisaflavone	100-116	butyrylcholinesterase	Rattus norvegicus	201-205
30703413-5	2019	Exposure to Pb acetate adversely affected the measured acetyl cholinesterase enzyme activity, oxidative stress and lipid peroxidation parameters as well as caspase-3 gene expression in brain tissue (cerebrum and cerebellum).	pb acetate	12-22	butyrylcholinesterase	Rattus norvegicus	62-76
30956215-0	2019	Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats.	Simvastatin	11-22	butyrylcholinesterase	Rattus norvegicus	42-63
30995784-0	2019	Comparison of the Respiratory Toxicity and Total Cholinesterase Activities in Dimethyl Versus Diethyl Paraoxon-Poisoned Rats.	Paraoxon	94-110	butyrylcholinesterase	Rattus norvegicus	49-63
30995784-8	2019	Both organophosphates decreased cholinesterase activities from 10 to 180 min post-injection with the same degree of inhibition of total cholinesterase within an onset at the same times after injection.	Organophosphates	5-21	butyrylcholinesterase	Rattus norvegicus	32-46
30995784-8	2019	Both organophosphates decreased cholinesterase activities from 10 to 180 min post-injection with the same degree of inhibition of total cholinesterase within an onset at the same times after injection.	Organophosphates	5-21	butyrylcholinesterase	Rattus norvegicus	136-150
30956215-0	2019	Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats.	Fenofibrate	27-38	butyrylcholinesterase	Rattus norvegicus	42-63
30956215-1	2019	The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and hyperlipidemic rats.	Simvastatin	52-63	butyrylcholinesterase	Rattus norvegicus	108-129
30956215-1	2019	The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and hyperlipidemic rats.	Simvastatin	52-63	butyrylcholinesterase	Rattus norvegicus	131-136
30956215-1	2019	The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and hyperlipidemic rats.	Fenofibrate	68-79	butyrylcholinesterase	Rattus norvegicus	108-129
30956215-1	2019	The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and hyperlipidemic rats.	Fenofibrate	68-79	butyrylcholinesterase	Rattus norvegicus	131-136
30956215-4	2019	Simvastatin and fenofibrate caused an increase in brain BuChE activity in both normo- and hyperlipidemic rats regardless of the substrate.	Simvastatin	0-11	butyrylcholinesterase	Rattus norvegicus	56-61
30956215-4	2019	Simvastatin and fenofibrate caused an increase in brain BuChE activity in both normo- and hyperlipidemic rats regardless of the substrate.	Fenofibrate	16-27	butyrylcholinesterase	Rattus norvegicus	56-61
30956215-6	2019	Simvastatin and fenofibrate also increased liver and plasma BuChE activity in both normolipidemic and hyperlipidemic rats regardless of the substrate.	Simvastatin	0-11	butyrylcholinesterase	Rattus norvegicus	60-65
30956215-6	2019	Simvastatin and fenofibrate also increased liver and plasma BuChE activity in both normolipidemic and hyperlipidemic rats regardless of the substrate.	Fenofibrate	16-27	butyrylcholinesterase	Rattus norvegicus	60-65
29364753-0	2019	The effects of some antibiotics from cephalosporin groups on the acetylcholinesterase and butyrylcholinesterase enzymes activities in different tissues of rats.	Cephalosporins	37-50	butyrylcholinesterase	Rattus norvegicus	90-111
31353570-6	2019	MTX-induced neurotoxic alterations were significantly abrogated by MOO and VCO supplementation via inhibition of cholinesterase, oxidative stress, and anti-inflammatory mechanisms.	Methotrexate	0-3	butyrylcholinesterase	Rattus norvegicus	113-127
29364753-1	2019	In our study, it was aimed to investigate the effects of cefazolin, cefuroxime, and cefoperazon injected to rats on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzyme activities in the heart, brain, eye, liver, and kidney tissues of rats.	Cefazolin	57-66	butyrylcholinesterase	Rattus norvegicus	148-169
29364753-1	2019	In our study, it was aimed to investigate the effects of cefazolin, cefuroxime, and cefoperazon injected to rats on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzyme activities in the heart, brain, eye, liver, and kidney tissues of rats.	Cefazolin	57-66	butyrylcholinesterase	Rattus norvegicus	171-175
29364753-1	2019	In our study, it was aimed to investigate the effects of cefazolin, cefuroxime, and cefoperazon injected to rats on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzyme activities in the heart, brain, eye, liver, and kidney tissues of rats.	Cefuroxime	68-78	butyrylcholinesterase	Rattus norvegicus	148-169
29364753-1	2019	In our study, it was aimed to investigate the effects of cefazolin, cefuroxime, and cefoperazon injected to rats on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzyme activities in the heart, brain, eye, liver, and kidney tissues of rats.	Cefoperazone	84-95	butyrylcholinesterase	Rattus norvegicus	148-169
29364753-1	2019	In our study, it was aimed to investigate the effects of cefazolin, cefuroxime, and cefoperazon injected to rats on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzyme activities in the heart, brain, eye, liver, and kidney tissues of rats.	Cefoperazone	84-95	butyrylcholinesterase	Rattus norvegicus	171-175
29364753-5	2019	BChE activity is measured in tissues increased within the first three hours and decreased significantly within the first hour in the cefoperazone group (p <.05).	Cefoperazone	133-145	butyrylcholinesterase	Rattus norvegicus	0-4
30460743-1	2019	In this work, a novel series of arylisoxazole-phenylpiperazines were designed, synthesized, and evaluated toward acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).	arylisoxazole-phenylpiperazines	32-63	butyrylcholinesterase	Rattus norvegicus	145-166
30460743-1	2019	In this work, a novel series of arylisoxazole-phenylpiperazines were designed, synthesized, and evaluated toward acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).	arylisoxazole-phenylpiperazines	32-63	butyrylcholinesterase	Rattus norvegicus	168-172
30460743-3	2019	It should be noted that most of synthesized compounds showed no BChE inhibitory activity and [5-(2-fluorophenyl)-1,2-oxazol-3-yl](4-phenylpiperazin-1-yl)methanone (5a) was the most active anti-BChE derivative (IC50 =51.66 mum).	[5-(2-fluorophenyl)-1,2-oxazol-3-yl](4-phenylpiperazin-1-yl)methanone	93-162	butyrylcholinesterase	Rattus norvegicus	193-197
30460743-4	2019	Also, kinetic studies for the AChE and BChE inhibitory activity of compounds 5c and 5a confirmed that they have simultaneously bound to the catalytic site (CS) and peripheral anionic site (PAS) of both AChE and BChE.	Aminosalicylic Acid	189-192	butyrylcholinesterase	Rattus norvegicus	39-43
30460743-4	2019	Also, kinetic studies for the AChE and BChE inhibitory activity of compounds 5c and 5a confirmed that they have simultaneously bound to the catalytic site (CS) and peripheral anionic site (PAS) of both AChE and BChE.	Aminosalicylic Acid	189-192	butyrylcholinesterase	Rattus norvegicus	211-215
30243730-3	2019	Our results show that dimethoate (0.1, 1 and 10 muM) induced a concentration-dependent inhibition of cholinesterase enzymatic activity at all concentrations tested.	Dimethoate	22-32	butyrylcholinesterase	Rattus norvegicus	101-115
31353640-1	2019	In our work, it was purposed to investigate the effects of sodium arsenite (SA) and hesperidin (HSP) administered to rats on some metabolic enzymes including carbonic anhydrase (CA), aldose reductase (AR), paraoxonase-1 (PON1), alpha-glycosidase (alpha-Gly), butyrylcholine esterase (BChE), acetylcholine esterase (AChE) enzymes activities in the brain, heart, liver, testis, and kidney tissues of rats.	sodium arsenite	59-74	butyrylcholinesterase	Rattus norvegicus	259-282
31353640-1	2019	In our work, it was purposed to investigate the effects of sodium arsenite (SA) and hesperidin (HSP) administered to rats on some metabolic enzymes including carbonic anhydrase (CA), aldose reductase (AR), paraoxonase-1 (PON1), alpha-glycosidase (alpha-Gly), butyrylcholine esterase (BChE), acetylcholine esterase (AChE) enzymes activities in the brain, heart, liver, testis, and kidney tissues of rats.	sodium arsenite	59-74	butyrylcholinesterase	Rattus norvegicus	284-288
31353640-1	2019	In our work, it was purposed to investigate the effects of sodium arsenite (SA) and hesperidin (HSP) administered to rats on some metabolic enzymes including carbonic anhydrase (CA), aldose reductase (AR), paraoxonase-1 (PON1), alpha-glycosidase (alpha-Gly), butyrylcholine esterase (BChE), acetylcholine esterase (AChE) enzymes activities in the brain, heart, liver, testis, and kidney tissues of rats.	sodium arsenite	76-78	butyrylcholinesterase	Rattus norvegicus	259-282
31353640-1	2019	In our work, it was purposed to investigate the effects of sodium arsenite (SA) and hesperidin (HSP) administered to rats on some metabolic enzymes including carbonic anhydrase (CA), aldose reductase (AR), paraoxonase-1 (PON1), alpha-glycosidase (alpha-Gly), butyrylcholine esterase (BChE), acetylcholine esterase (AChE) enzymes activities in the brain, heart, liver, testis, and kidney tissues of rats.	sodium arsenite	76-78	butyrylcholinesterase	Rattus norvegicus	284-288
31353640-1	2019	In our work, it was purposed to investigate the effects of sodium arsenite (SA) and hesperidin (HSP) administered to rats on some metabolic enzymes including carbonic anhydrase (CA), aldose reductase (AR), paraoxonase-1 (PON1), alpha-glycosidase (alpha-Gly), butyrylcholine esterase (BChE), acetylcholine esterase (AChE) enzymes activities in the brain, heart, liver, testis, and kidney tissues of rats.	Hesperidin	84-94	butyrylcholinesterase	Rattus norvegicus	259-282
31353640-1	2019	In our work, it was purposed to investigate the effects of sodium arsenite (SA) and hesperidin (HSP) administered to rats on some metabolic enzymes including carbonic anhydrase (CA), aldose reductase (AR), paraoxonase-1 (PON1), alpha-glycosidase (alpha-Gly), butyrylcholine esterase (BChE), acetylcholine esterase (AChE) enzymes activities in the brain, heart, liver, testis, and kidney tissues of rats.	Hesperidin	84-94	butyrylcholinesterase	Rattus norvegicus	284-288
30292885-1	2018	Paraoxon (POX) is an extremely neurotoxic organophosphorous compound (OP) which main toxic mechanism is the irreversible inhibition of cholinesterase.	Paraoxon	0-8	butyrylcholinesterase	Rattus norvegicus	135-149
30118774-16	2019	In conclusion, the observed effects might be attributed to the cholinesterase inhibitory activity of bergenin coupled with its antioxidant effect, anti-inflammatory activity and reduction of Abeta-1-42 and p-tau levels which could have collectively helped in the attenuation of cognitive deficits.	bergenin	101-109	butyrylcholinesterase	Rattus norvegicus	63-77
30557385-0	2018	Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors.	Rivastigmine	25-37	butyrylcholinesterase	Rattus norvegicus	0-14
30557385-1	2018	Rivastigmine (Riv) is a potent and selective cholinesterase (acetylcholinesterase, AChE and butyrylcholinesterase, BuChE) inhibitor developed for the treatment of Alzheimer"s disease (AD).	Rivastigmine	0-12	butyrylcholinesterase	Rattus norvegicus	45-59
30557385-1	2018	Rivastigmine (Riv) is a potent and selective cholinesterase (acetylcholinesterase, AChE and butyrylcholinesterase, BuChE) inhibitor developed for the treatment of Alzheimer"s disease (AD).	Rivastigmine	0-3	butyrylcholinesterase	Rattus norvegicus	45-59
31797759-10	2019	The insilico analysis also revealed positive interactions of Cinerin C with targeted enzymes (DPP4 and cholinesterase).	cinerin C	61-70	butyrylcholinesterase	Rattus norvegicus	103-117
30458229-7	2019	At this time (24 h), chlorpyrifos decreased plasma butyrylcholinesterase (BChE) activity and hippocampal, striatal and prefrontal cortical AChE activity in rats.	Chlorpyrifos	21-33	butyrylcholinesterase	Rattus norvegicus	51-72
30458229-7	2019	At this time (24 h), chlorpyrifos decreased plasma butyrylcholinesterase (BChE) activity and hippocampal, striatal and prefrontal cortical AChE activity in rats.	Chlorpyrifos	21-33	butyrylcholinesterase	Rattus norvegicus	74-78
30389473-1	2018	Pre-administration of physostigmine can prevent poisoning against nerve agent exposure by reversibly binding to cholinesterase.	Physostigmine	22-35	butyrylcholinesterase	Rattus norvegicus	112-126
30389473-14	2018	Moreover, PEG liposomes showed higher plasma concentration of physostigmine and cholinesterase inhibition ratio compared to the control liposomes.	Polyethylene Glycols	10-13	butyrylcholinesterase	Rattus norvegicus	80-94
30389473-15	2018	These results suggest that PEG liposomes have potential to enhance the duration of cholinesterase-protecting effect of physostigmine.	Polyethylene Glycols	27-30	butyrylcholinesterase	Rattus norvegicus	83-97
30389473-15	2018	These results suggest that PEG liposomes have potential to enhance the duration of cholinesterase-protecting effect of physostigmine.	Physostigmine	119-132	butyrylcholinesterase	Rattus norvegicus	83-97
30292885-1	2018	Paraoxon (POX) is an extremely neurotoxic organophosphorous compound (OP) which main toxic mechanism is the irreversible inhibition of cholinesterase.	Paraoxon	10-13	butyrylcholinesterase	Rattus norvegicus	135-149
30292885-1	2018	Paraoxon (POX) is an extremely neurotoxic organophosphorous compound (OP) which main toxic mechanism is the irreversible inhibition of cholinesterase.	organophosphorous	42-59	butyrylcholinesterase	Rattus norvegicus	135-149
30021372-5	2018	The present study was aimed to investigate the role of these triterpenes content in CA extract on the antioxidant, cholinesterase modulation and anti-amnesic properties.	Triterpenes	61-72	butyrylcholinesterase	Rattus norvegicus	115-129
30190181-0	2018	Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.	carbazole	69-78	butyrylcholinesterase	Rattus norvegicus	85-106
30190181-3	2018	A new series of Carbazole-Benzyl Pyridine derivatives were designed synthesized and evaluated as butyrylcholinesterase (BChE) inhibitors.	carbazole-benzyl pyridine	16-41	butyrylcholinesterase	Rattus norvegicus	97-118
30190181-3	2018	A new series of Carbazole-Benzyl Pyridine derivatives were designed synthesized and evaluated as butyrylcholinesterase (BChE) inhibitors.	carbazole-benzyl pyridine	16-41	butyrylcholinesterase	Rattus norvegicus	120-124
30190181-5	2018	3-((9H-Carbazol-9-yl)methyl)-1-(4-chlorobenzyl)pyridin-1-ium chloride (compound 8f) had the most potent anti-BChE activity (IC50 value = 0.073 muM), the highest BChE selectivity and mixed-type inhibition.	3-((9h-carbazol-9-yl)methyl)-1-(4-chlorobenzyl)pyridin-1-ium chloride	0-69	butyrylcholinesterase	Rattus norvegicus	109-113
30190181-5	2018	3-((9H-Carbazol-9-yl)methyl)-1-(4-chlorobenzyl)pyridin-1-ium chloride (compound 8f) had the most potent anti-BChE activity (IC50 value = 0.073 muM), the highest BChE selectivity and mixed-type inhibition.	3-((9h-carbazol-9-yl)methyl)-1-(4-chlorobenzyl)pyridin-1-ium chloride	0-69	butyrylcholinesterase	Rattus norvegicus	161-165
30021372-11	2018	The methanolic extract (CAE) was found to perform best among all three fractions for in vitro free radical scavenging, cholinesterase inhibition, improvement of scopolamine-induced amnesia and also in vivo antioxidant effect and cholinesterase inhibitory activities.	methanolic	4-14	butyrylcholinesterase	Rattus norvegicus	119-133
30021372-11	2018	The methanolic extract (CAE) was found to perform best among all three fractions for in vitro free radical scavenging, cholinesterase inhibition, improvement of scopolamine-induced amnesia and also in vivo antioxidant effect and cholinesterase inhibitory activities.	methanolic	4-14	butyrylcholinesterase	Rattus norvegicus	229-243
29710552-0	2018	Bergenia ciliata ameliorates streptozotocin-induced spatial memory deficits through dual cholinesterase inhibition and attenuation of oxidative stress in rats.	Streptozocin	29-43	butyrylcholinesterase	Rattus norvegicus	89-103
29852246-5	2018	In the second experiment ovariectomized rats received daily intraperitoneal injections of the cholinesterase inhibitors donepezil or galantamine for 1 week.	Donepezil	120-129	butyrylcholinesterase	Rattus norvegicus	94-108
29796810-1	2018	Parameters of cardiac activity after administration of the cholinesterase inhibitor physostigmine were analyzed in newborn rats and on day 16 of postnatal development.	Physostigmine	84-97	butyrylcholinesterase	Rattus norvegicus	59-73
29336496-2	2018	Donepezil (Aricept), a cholinesterase inhibitor, is used clinically to ameliorate memory-related cognitive deficits.	Donepezil	0-9	butyrylcholinesterase	Rattus norvegicus	23-37
29336496-2	2018	Donepezil (Aricept), a cholinesterase inhibitor, is used clinically to ameliorate memory-related cognitive deficits.	Donepezil	11-18	butyrylcholinesterase	Rattus norvegicus	23-37
28585866-0	2017	Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer"s disease.	cinnamic acid	42-55	butyrylcholinesterase	Rattus norvegicus	122-136
28503953-0	2018	Effect of deltamethrin and fluoride co-exposure on the brain antioxidant status and cholinesterase activity in Wistar rats.	decamethrin	10-22	butyrylcholinesterase	Rattus norvegicus	84-98
28503953-0	2018	Effect of deltamethrin and fluoride co-exposure on the brain antioxidant status and cholinesterase activity in Wistar rats.	Fluorides	27-35	butyrylcholinesterase	Rattus norvegicus	84-98
28503953-1	2018	The study evaluated the effect of commercial preparation of deltamethrin, Butox , and fluoride (F-) co-exposure on the brain antioxidant status and cholinesterase activity in rats.	decamethrin	60-72	butyrylcholinesterase	Rattus norvegicus	148-162
28503953-1	2018	The study evaluated the effect of commercial preparation of deltamethrin, Butox , and fluoride (F-) co-exposure on the brain antioxidant status and cholinesterase activity in rats.	Fluorine	96-98	butyrylcholinesterase	Rattus norvegicus	148-162
29435808-6	2018	There were marked increase in AChE, BChE, arginase, ACE and concomitant decrease in catalase, GST, GSH-Px, activities and NO levels in STZ-diabetic group compared with the control.	Streptozocin	135-138	butyrylcholinesterase	Rattus norvegicus	36-40
29023733-7	2017	Nanoinjections of the muscarinic acetylcholine receptor (mAChR) agonist, oxotremorine, or the cholinesterase inhibitor, neostigmine (NEOS), in the rRPa of anaesthetized rats decreased cold-evoked BAT sympathetic nerve activity (SNA, nadirs: -72 and -95%), BAT temperature (Tbat, -0.5 and -0.6 C), expired CO2 (Exp.	Neostigmine	120-131	butyrylcholinesterase	Rattus norvegicus	94-108
28980111-6	2017	In addition, Curcumin administration protects rats against acetamiprid-induced cerebellum toxicity such as increase in AChE and BChE activities, decrease on cells viability, oxidative stress, and an increase of intracellular calcium.	Curcumin	13-21	butyrylcholinesterase	Rattus norvegicus	128-132
28980111-6	2017	In addition, Curcumin administration protects rats against acetamiprid-induced cerebellum toxicity such as increase in AChE and BChE activities, decrease on cells viability, oxidative stress, and an increase of intracellular calcium.	acetamiprid	59-70	butyrylcholinesterase	Rattus norvegicus	128-132
29024569-10	2018	Overall, our simulations provided a design concept for identifying proline-rich peptides that promote the rBChE tetramerization in CHO cells.	Proline	67-74	butyrylcholinesterase	Rattus norvegicus	106-111
29768876-7	2018	Brain AChE activity remained unchanged but BChE activity showed 18.3% increment after 400 mug/kg neostigmine.	Neostigmine	97-108	butyrylcholinesterase	Rattus norvegicus	43-47
28815802-4	2017	Our data showed that DOX-induced significant elevation of brain malondialdehyde, tumor necrosis factor-alpha (TNF-alpha), inducible nitric oxide synthase (iNOS), caspase-3, and cholinesterase associated with significant reduction in reduced glutathione, monoamines namely serotonin, dopamine, as well as norepinephrine.	Doxorubicin	21-24	butyrylcholinesterase	Rattus norvegicus	177-191
28585866-0	2017	Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer"s disease.	n-benzyl pyridinium	76-95	butyrylcholinesterase	Rattus norvegicus	122-136
28585866-1	2017	A novel family of cinnamic acid derivatives has been developed to be multifunctional cholinesterase inhibitors against AD by fusing N-benzyl pyridinium moiety and different substituted cinnamic acids.	cinnamic acid	18-31	butyrylcholinesterase	Rattus norvegicus	85-99
28585866-1	2017	A novel family of cinnamic acid derivatives has been developed to be multifunctional cholinesterase inhibitors against AD by fusing N-benzyl pyridinium moiety and different substituted cinnamic acids.	n-benzyl pyridinium	132-151	butyrylcholinesterase	Rattus norvegicus	85-99
28585866-1	2017	A novel family of cinnamic acid derivatives has been developed to be multifunctional cholinesterase inhibitors against AD by fusing N-benzyl pyridinium moiety and different substituted cinnamic acids.	cinnamic acid	185-199	butyrylcholinesterase	Rattus norvegicus	85-99
28760642-2	2017	Acetylcholine is a neurotransmitter in the central nervous system and cholinesterase inhibitors have demonstrated a positive action over HI induced deficits.	Acetylcholine	0-13	butyrylcholinesterase	Rattus norvegicus	70-84
29251619-10	2017	The results showed that rats from the group consuming food after enzymatic removal of chlorpyrifos, had comparable acetyl cholinesterase activity in blood of rats consuming pure food (without any OP intoxication).	Chlorpyrifos	86-98	butyrylcholinesterase	Rattus norvegicus	122-136
28760642-2	2017	Acetylcholine is a neurotransmitter in the central nervous system and cholinesterase inhibitors have demonstrated a positive action over HI induced deficits.	hi	137-139	butyrylcholinesterase	Rattus norvegicus	70-84
28760642-3	2017	In order to evaluate the effects of pre and post-hypoxia administrations of galantamine, a cholinesterase inhibitor, in a model of perinatal HI, Wistar rats in the post-natal day 7 (PND7) were subjected to a combination of unilateral occlusion of the right carotid artery with the exposure to a 1h hypoxia.	Galantamine	76-87	butyrylcholinesterase	Rattus norvegicus	91-105
28647186-6	2017	There were also marked and significant inhibition of brain PON-1 and BChE activities and increased Il-1beta in brain of rotenone-treated rats.	Rotenone	120-128	butyrylcholinesterase	Rattus norvegicus	69-73
28942826-15	2017	AChE activity decreased by the higher dose of 7-NI while either dose of 7-NI resulted in decreased BChE activity.	7-nitroindazole	72-76	butyrylcholinesterase	Rattus norvegicus	99-103
28586512-7	2017	Doxorubicin decreased testicular relative weight, sperm count, motility, serum testosterone, testicular glycogen, and sialic acid with increased incidence of histopathological changes, oxidative stress, tumor necrosis factor-alpha, as well as cholinesterase activity.	Doxorubicin	0-11	butyrylcholinesterase	Rattus norvegicus	243-257
28655305-0	2017	Effect of pomegranate extracts on brain antioxidant markers and cholinesterase activity in high fat-high fructose diet induced obesity in rat model.	Fructose	105-113	butyrylcholinesterase	Rattus norvegicus	64-78
28388521-1	2017	A series of new donepezil derivatives were designed synthesized and evaluated as multifunctional cholinesterase inhibitors against Alzheimer"s disease (AD).	Donepezil	16-25	butyrylcholinesterase	Rattus norvegicus	97-111
28235599-7	2017	Because we used the cholinesterase inhibition benchmark, the absolute dose of diazinon was much higher than that of parathion, since the latter is a more potent cholinesterase inhibitor.	Diazinon	78-86	butyrylcholinesterase	Rattus norvegicus	161-175
28102474-1	2017	Recently, combination therapy involving cholinesterase (ChE) inhibitor with other neuroprotective agents has shown better desirable effect in the management/prevention of dementia but limited information is available on their effect with dietary polyphenols.	Polyphenols	246-257	butyrylcholinesterase	Rattus norvegicus	56-59
28102474-2	2017	Hence, this study sought to assess the combined pretreatment effect of curcumin, the major polyphenolic compound of turmeric (Curcuma longa) rhizomes, with donepezil, a cholinesterase inhibitor, on cognitive function in scopolamine-induced memory impairment in rats.	Curcumin	71-79	butyrylcholinesterase	Rattus norvegicus	169-183
28302511-0	2017	Design, synthesis and biological evaluation of multifunctional tacrine-curcumin hybrids as new cholinesterase inhibitors with metal ions-chelating and neuroprotective property.	Tacrine	63-70	butyrylcholinesterase	Rattus norvegicus	95-109
28302511-0	2017	Design, synthesis and biological evaluation of multifunctional tacrine-curcumin hybrids as new cholinesterase inhibitors with metal ions-chelating and neuroprotective property.	Curcumin	71-79	butyrylcholinesterase	Rattus norvegicus	95-109
28302511-0	2017	Design, synthesis and biological evaluation of multifunctional tacrine-curcumin hybrids as new cholinesterase inhibitors with metal ions-chelating and neuroprotective property.	Metals	126-131	butyrylcholinesterase	Rattus norvegicus	95-109
28235599-1	2017	Organophosphate pesticides elicit developmental neurotoxicity through mechanisms over and above their shared property as cholinesterase inhibitors.	Organophosphates	0-15	butyrylcholinesterase	Rattus norvegicus	121-135
28235599-7	2017	Because we used the cholinesterase inhibition benchmark, the absolute dose of diazinon was much higher than that of parathion, since the latter is a more potent cholinesterase inhibitor.	Diazinon	78-86	butyrylcholinesterase	Rattus norvegicus	20-34
28089589-1	2017	New thymol and carvacrol derivatives with the carbamate moiety were synthesized and their inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) were evaluated.	carvacrol	15-24	butyrylcholinesterase	Rattus norvegicus	144-165
28413513-2	2017	The current study aimed to examine the effects of huperzine A, a cholinesterase inhibitor, on behavioral sensitization induced by repeated morphine administration and relapse induced by contextual conditioning.	huperzine A	50-61	butyrylcholinesterase	Rattus norvegicus	65-79
28049095-8	2017	It is concluded that riluzole could exert a protective effect against memory decline induced by intrahippocampal Abeta25-35 through anti-oxidative, anti-cholinesterase, and neuroprotective potential and its beneficial effect is possibly independent of cholinoceptor activation.	Riluzole	21-29	butyrylcholinesterase	Rattus norvegicus	153-167
28121480-13	2017	However, the correlation between BuChE and glucose levels was not significant (P > .05).	Glucose	43-50	butyrylcholinesterase	Rattus norvegicus	33-38
28063643-11	2017	Pretreatment with Tritone (Livosone) shows significant reduction in serum SGOT, SGPT, ALP and total bilirubin levels and shows significant elevation in total protein and cholinesterase (ChE) levels compared to groups treated with hepatotoxic agents.	tritone	18-25	butyrylcholinesterase	Rattus norvegicus	170-184
28063643-11	2017	Pretreatment with Tritone (Livosone) shows significant reduction in serum SGOT, SGPT, ALP and total bilirubin levels and shows significant elevation in total protein and cholinesterase (ChE) levels compared to groups treated with hepatotoxic agents.	tritone	18-25	butyrylcholinesterase	Rattus norvegicus	186-189
28063643-11	2017	Pretreatment with Tritone (Livosone) shows significant reduction in serum SGOT, SGPT, ALP and total bilirubin levels and shows significant elevation in total protein and cholinesterase (ChE) levels compared to groups treated with hepatotoxic agents.	livosone	27-35	butyrylcholinesterase	Rattus norvegicus	170-184
28063643-11	2017	Pretreatment with Tritone (Livosone) shows significant reduction in serum SGOT, SGPT, ALP and total bilirubin levels and shows significant elevation in total protein and cholinesterase (ChE) levels compared to groups treated with hepatotoxic agents.	livosone	27-35	butyrylcholinesterase	Rattus norvegicus	186-189
28121480-2	2017	Quercetin, a flavonoid with antioxidant potential, inhibits butyrylcholinesterase (BuChE), which is positively associated with hyperglycemia.	Quercetin	0-9	butyrylcholinesterase	Rattus norvegicus	60-81
28121480-2	2017	Quercetin, a flavonoid with antioxidant potential, inhibits butyrylcholinesterase (BuChE), which is positively associated with hyperglycemia.	Quercetin	0-9	butyrylcholinesterase	Rattus norvegicus	83-88
28121480-2	2017	Quercetin, a flavonoid with antioxidant potential, inhibits butyrylcholinesterase (BuChE), which is positively associated with hyperglycemia.	Flavonoids	13-22	butyrylcholinesterase	Rattus norvegicus	60-81
28121480-2	2017	Quercetin, a flavonoid with antioxidant potential, inhibits butyrylcholinesterase (BuChE), which is positively associated with hyperglycemia.	Flavonoids	13-22	butyrylcholinesterase	Rattus norvegicus	83-88
28121480-11	2017	The BuChE activity decreased in the intestine at all tested doses of quercetin coadministered with tamoxifen (P < .01); however, in adipose tissue, there was a biphasic activity with a decrease (P < .05) and increase (P < .05) in activity at doses of 7.5 and 22.5 mg.kg-1 b.w.	Quercetin	69-78	butyrylcholinesterase	Rattus norvegicus	4-9
28121480-11	2017	The BuChE activity decreased in the intestine at all tested doses of quercetin coadministered with tamoxifen (P < .01); however, in adipose tissue, there was a biphasic activity with a decrease (P < .05) and increase (P < .05) in activity at doses of 7.5 and 22.5 mg.kg-1 b.w.	Tamoxifen	99-108	butyrylcholinesterase	Rattus norvegicus	4-9
28126439-1	2017	Series of some 3,5-dimethoxy-N-methylenebenzenamine and 4-(methyleneamino)benzoic acid derivatives comprising of N-methylenebenzenamine nucleus were designed, synthesized, characterized, and assessed for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE) inhibitory, and antioxidant activity thereby improving learning and memory in rats.	3,5-dimethoxy-n-methylenebenzenamine	15-51	butyrylcholinesterase	Rattus norvegicus	262-266
28089589-1	2017	New thymol and carvacrol derivatives with the carbamate moiety were synthesized and their inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) were evaluated.	carvacrol	15-24	butyrylcholinesterase	Rattus norvegicus	167-172
27769869-1	2016	Organophosphates affect brain function through a variety of mechanisms beyond their shared role as cholinesterase inhibitors.	Organophosphates	0-16	butyrylcholinesterase	Rattus norvegicus	99-113
27799040-1	2017	BACKGROUND: Reversible cholinesterase inhibitors, when given prophylactically before exposure to organophosphates, are able to decrease organophosphate-induced mortality.	Organophosphates	97-113	butyrylcholinesterase	Rattus norvegicus	23-37
27799040-1	2017	BACKGROUND: Reversible cholinesterase inhibitors, when given prophylactically before exposure to organophosphates, are able to decrease organophosphate-induced mortality.	Organophosphates	97-112	butyrylcholinesterase	Rattus norvegicus	23-37
27387540-0	2016	Efficacy of novel phenoxyalkyl pyridinium oximes as brain-penetrating reactivators of cholinesterase inhibited by surrogates of sarin and VX.	phenoxyalkyl pyridinium oximes	18-48	butyrylcholinesterase	Rattus norvegicus	86-100
27387540-1	2016	Pyridinium oximes are strong nucleophiles and many are effective reactivators of organophosphate-inhibited cholinesterase (ChE).	pyridinium oximes	0-17	butyrylcholinesterase	Rattus norvegicus	107-121
27387540-1	2016	Pyridinium oximes are strong nucleophiles and many are effective reactivators of organophosphate-inhibited cholinesterase (ChE).	pyridinium oximes	0-17	butyrylcholinesterase	Rattus norvegicus	123-126
27387540-1	2016	Pyridinium oximes are strong nucleophiles and many are effective reactivators of organophosphate-inhibited cholinesterase (ChE).	Organophosphates	81-96	butyrylcholinesterase	Rattus norvegicus	107-121
27387540-1	2016	Pyridinium oximes are strong nucleophiles and many are effective reactivators of organophosphate-inhibited cholinesterase (ChE).	Organophosphates	81-96	butyrylcholinesterase	Rattus norvegicus	123-126
27387540-4	2016	The first 35 of the series were found to have similar in vitro efficacy as reactivators of ChE inhibited by a sarin surrogate (phthalimidyl isopropyl methylphosphonate, PIMP) or a VX surrogate (nitrophenyl ethyl methylphosphonate, NEMP) in bovine brain preparations as previously observed in rat brain preparations.	pimp	169-173	butyrylcholinesterase	Rattus norvegicus	91-94
27387540-5	2016	A number of these novel oximes have shown the ability to decrease the level of ChE inhibition in the brains of rats treated with a high sublethal dosage of either a sarin surrogate (nitrophenyl isopropyl methylphosphonate, NIMP) or the VX surrogate NEMP.	Oximes	24-30	butyrylcholinesterase	Rattus norvegicus	79-82
27387540-5	2016	A number of these novel oximes have shown the ability to decrease the level of ChE inhibition in the brains of rats treated with a high sublethal dosage of either a sarin surrogate (nitrophenyl isopropyl methylphosphonate, NIMP) or the VX surrogate NEMP.	nitrophenyl isopropyl methylphosphonate	182-221	butyrylcholinesterase	Rattus norvegicus	79-82
27387540-5	2016	A number of these novel oximes have shown the ability to decrease the level of ChE inhibition in the brains of rats treated with a high sublethal dosage of either a sarin surrogate (nitrophenyl isopropyl methylphosphonate, NIMP) or the VX surrogate NEMP.	nimp	223-227	butyrylcholinesterase	Rattus norvegicus	79-82
27387540-8	2016	Therefore these novel oximes have demonstrated an ability to reactivate inhibited ChE in brain preparations from two species and in vivo data support their ability to enter the brain and provide a therapeutic action.	Oximes	22-28	butyrylcholinesterase	Rattus norvegicus	82-85
26991753-4	2016	The objective of this study was to test the hypothesis that physostigmine, a centrally acting cholinesterase inhibitor, induces reanimation from isoflurane anesthesia in adult rats.	Physostigmine	60-73	butyrylcholinesterase	Rattus norvegicus	94-108
27890370-1	2016	OBJECTIVE: To investigate the effect of Cannabis sativa resin and/or tramadol, two commonly drugs of abuse on acetylcholinesterase and butyrylcholinesterase activities as a possible cholinergic biomarkers of neurotoxicity induced by these agents.	Tramadol	69-77	butyrylcholinesterase	Rattus norvegicus	135-156
27376896-0	2016	Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.	Donepezil	27-36	butyrylcholinesterase	Rattus norvegicus	0-14
26438716-0	2016	Antioxidative Properties and Effect of Quercetin and Its Glycosylated Form (Rutin) on Acetylcholinesterase and Butyrylcholinesterase Activities.	Quercetin	39-48	butyrylcholinesterase	Rattus norvegicus	111-132
26438716-3	2016	Quercetin had significantly higher AChE and BChE inhibitory abilities than rutin.	Quercetin	0-9	butyrylcholinesterase	Rattus norvegicus	44-48
26700313-5	2016	The study revealed significant (P < .05) increases in the MDA content and all enzymes" (AChE, BChE, MAO, and Na(+)/K(+)-ATPase) activity investigated following cadmium administration.	Cadmium	163-170	butyrylcholinesterase	Rattus norvegicus	97-101
27376896-0	2016	Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.	Rivastigmine	41-53	butyrylcholinesterase	Rattus norvegicus	0-14
27376896-0	2016	Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.	Ethanol	134-141	butyrylcholinesterase	Rattus norvegicus	0-14
27379103-6	2016	The acidic extraction buffer yielded >95% enzymatically active tetrameric rBChE as verified by Coomassie stained and native gel electrophoresis.	coomassie	98-107	butyrylcholinesterase	Rattus norvegicus	77-82
27913166-2	2016	However, it is not known whether more diffuse pharmacological stimulation with donepezil, a cholinesterase inhibitor, is an efficient tool for enhancing visual processing and perception.	Donepezil	79-88	butyrylcholinesterase	Rattus norvegicus	92-106
27493717-2	2016	Hence, in this study, we investigate the differential effects of black seed oil on cholinesterase [acetylcholinesterase (AChE) and butrylcholinesterase (BuChE), ectonucleotidase (5"-nucleotidase), lactate dehydrogenase (LDH) and monoamine oxidase (MAO)] activities and relevant markers of oxidative stress in the cerebrum of haloperidol-induced neuronal-damaged rats.	black seed oil	65-79	butyrylcholinesterase	Rattus norvegicus	83-97
27097732-0	2016	Acquisition and reinstatement of ethanol-induced conditioned place preference in rats: Effects of the cholinesterase inhibitors donepezil and rivastigmine.	Donepezil	128-137	butyrylcholinesterase	Rattus norvegicus	102-116
27097732-1	2016	The present study examined the influence of the cholinesterase inhibitors donepezil (a selective inhibitor of acetylcholinesterase) and rivastigmine (also an inhibitor of butyrylcholinesterase) on the acquisition and reinstatement of ethanol-induced conditioned place preference (CPP) in rats.	Donepezil	74-83	butyrylcholinesterase	Rattus norvegicus	48-62
27097732-1	2016	The present study examined the influence of the cholinesterase inhibitors donepezil (a selective inhibitor of acetylcholinesterase) and rivastigmine (also an inhibitor of butyrylcholinesterase) on the acquisition and reinstatement of ethanol-induced conditioned place preference (CPP) in rats.	Ethanol	234-241	butyrylcholinesterase	Rattus norvegicus	48-62
27097732-10	2016	The cholinesterase inhibitors were equally effective in increasing (dose dependently) the acquisition of ethanol-induced CPP.	Ethanol	105-112	butyrylcholinesterase	Rattus norvegicus	4-18
27097732-12	2016	These effects of both cholinesterase inhibitors were reversed by mecamylamine (3 mg/kg, i.p.	Mecamylamine	65-77	butyrylcholinesterase	Rattus norvegicus	22-36
27441453-7	2016	Administration of menadione to rats reduces metabolism of parathion, as well as parathion-induced inhibition of brain cholinesterase activity.	Vitamin K 3	18-27	butyrylcholinesterase	Rattus norvegicus	118-132
27441453-7	2016	Administration of menadione to rats reduces metabolism of parathion, as well as parathion-induced inhibition of brain cholinesterase activity.	Parathion	80-89	butyrylcholinesterase	Rattus norvegicus	118-132
27648190-0	2016	Evaluating the protective effects of vitamin C on serum and erythrocyte cholinesterase activity of male rats exposed to malathion.	Ascorbic Acid	37-46	butyrylcholinesterase	Rattus norvegicus	72-86
27648190-0	2016	Evaluating the protective effects of vitamin C on serum and erythrocyte cholinesterase activity of male rats exposed to malathion.	Malathion	120-129	butyrylcholinesterase	Rattus norvegicus	72-86
27648190-1	2016	INTRODUCTION: Malathion is one of organophosphate poisons (OPPs) that inhibit cholinesterase activity and induce oxidative stress in target organs, such as the reproductive system.	Malathion	14-23	butyrylcholinesterase	Rattus norvegicus	78-92
27648190-1	2016	INTRODUCTION: Malathion is one of organophosphate poisons (OPPs) that inhibit cholinesterase activity and induce oxidative stress in target organs, such as the reproductive system.	Organophosphates	34-49	butyrylcholinesterase	Rattus norvegicus	78-92
27648190-2	2016	The aim of this study was to assess the effects of Malathion on serum and erythrocyte cholinesterase activity in male rats and also to assess the protective effects of vitamin C in this regard.	Malathion	51-60	butyrylcholinesterase	Rattus norvegicus	86-100
27648190-8	2016	RESULTS: The activities of serum and erythrocyte cholinesterase were inhibited significantly in the Malathion exposed group compared to the control group (p < 0.001).	Malathion	100-109	butyrylcholinesterase	Rattus norvegicus	49-63
27648190-9	2016	The administration of Vitamin C alone significantly increased the activities of serum and erythrocyte cholinesterase.	Ascorbic Acid	22-31	butyrylcholinesterase	Rattus norvegicus	102-116
27648190-10	2016	The serum and erythrocyte cholinesterase inhibition showed improvement in the group that received both Malathion and Vitamin C.	Malathion	103-112	butyrylcholinesterase	Rattus norvegicus	26-40
27648190-10	2016	The serum and erythrocyte cholinesterase inhibition showed improvement in the group that received both Malathion and Vitamin C.	Ascorbic Acid	117-126	butyrylcholinesterase	Rattus norvegicus	26-40
27648190-11	2016	CONCLUSION: Malathion reduced the activities of serum and erythrocyte cholinesterase in exposed animals.	Malathion	12-21	butyrylcholinesterase	Rattus norvegicus	70-84
27648190-13	2016	Improvement of cholinesterase activity by antioxidant effects of Vitamin C suggests that Vitamin C supplementation can be used to decrease side effects of OPP exposure.	Ascorbic Acid	65-74	butyrylcholinesterase	Rattus norvegicus	15-29
27648190-13	2016	Improvement of cholinesterase activity by antioxidant effects of Vitamin C suggests that Vitamin C supplementation can be used to decrease side effects of OPP exposure.	Ascorbic Acid	89-98	butyrylcholinesterase	Rattus norvegicus	15-29
27153507-0	2016	Novel brain-penetrating oximes for reactivation of cholinesterase inhibited by sarin and VX surrogates.	Oximes	24-30	butyrylcholinesterase	Rattus norvegicus	51-65
26964684-2	2016	This is the first study to investigate the effects of the non-selective muscarinic antagonist scopolamine and the cholinesterase inhibitor donepezil (also in combination with scopolamine) on ASSR.	Donepezil	139-148	butyrylcholinesterase	Rattus norvegicus	114-128
27153507-1	2016	Current oxime reactivators for organophosphate-inhibited cholinesterase (ChE) do not effectively cross the blood-brain barrier and therefore cannot restore brain ChE activity in vivo.	Oximes	8-13	butyrylcholinesterase	Rattus norvegicus	57-71
27153507-1	2016	Current oxime reactivators for organophosphate-inhibited cholinesterase (ChE) do not effectively cross the blood-brain barrier and therefore cannot restore brain ChE activity in vivo.	Oximes	8-13	butyrylcholinesterase	Rattus norvegicus	73-76
27153507-1	2016	Current oxime reactivators for organophosphate-inhibited cholinesterase (ChE) do not effectively cross the blood-brain barrier and therefore cannot restore brain ChE activity in vivo.	Organophosphates	31-46	butyrylcholinesterase	Rattus norvegicus	57-71
27153507-1	2016	Current oxime reactivators for organophosphate-inhibited cholinesterase (ChE) do not effectively cross the blood-brain barrier and therefore cannot restore brain ChE activity in vivo.	Organophosphates	31-46	butyrylcholinesterase	Rattus norvegicus	73-76
27153507-3	2016	Our laboratories have developed novel substituted phenoxyalkyl pyridinium oximes that lead to reduced ChE inhibition in the brains of rats challenged with a high sublethal dosage of the sarin surrogate, whereas 2-PAM did not, using a paradigm designed to demonstrate brain penetration.	phenoxyalkyl pyridinium oximes	50-80	butyrylcholinesterase	Rattus norvegicus	102-105
26900785-7	2016	Our results indicate that lycopene appears to be highly effective in relieving the toxic effects of MSG by inhibiting lipid peroxidation and inducing modifications in the activity of cholinesterase and antioxidant pathways.	Lycopene	26-34	butyrylcholinesterase	Rattus norvegicus	183-197
26968195-1	2016	A promising approach in treating cocaine abuse is to metabolize cocaine in the blood using a mutated butyrylcholinesterase (BChE) that functions as a cocaine hydrolase (CocH).	Cocaine	33-40	butyrylcholinesterase	Rattus norvegicus	101-122
26968195-1	2016	A promising approach in treating cocaine abuse is to metabolize cocaine in the blood using a mutated butyrylcholinesterase (BChE) that functions as a cocaine hydrolase (CocH).	Cocaine	33-40	butyrylcholinesterase	Rattus norvegicus	124-128
26797524-2	2016	We synthesized some isoalloxazine derivatives and evaluated them using in vitro cholinesterase inhibition assay.	isoalloxazine	20-33	butyrylcholinesterase	Rattus norvegicus	80-94
26900785-7	2016	Our results indicate that lycopene appears to be highly effective in relieving the toxic effects of MSG by inhibiting lipid peroxidation and inducing modifications in the activity of cholinesterase and antioxidant pathways.	Sodium Glutamate	100-103	butyrylcholinesterase	Rattus norvegicus	183-197
26721196-5	2016	Diazinon-induced cholinesterase inhibition was greatest in the DRN, the brain"s major source of 5-HT neurones.	Diazinon	0-8	butyrylcholinesterase	Rattus norvegicus	17-31
26721196-11	2016	Together these data indicate that 1) acute OP exposure inhibits DRN cholinesterase, leading to acetylcholine accumulation, 2) the acetylcholine activates nicotinic receptors on 5-HT neurones and also on glutamatergic neurones, thus releasing glutamate and activating 5-HT neuronal AMPA/kainate receptors 3) the increase in 5-HT neuronal activity, and resulting 5-HT release, may lead to 5-HT1A autoreceptor down-regulation.	Acetylcholine	95-108	butyrylcholinesterase	Rattus norvegicus	68-82
26721196-11	2016	Together these data indicate that 1) acute OP exposure inhibits DRN cholinesterase, leading to acetylcholine accumulation, 2) the acetylcholine activates nicotinic receptors on 5-HT neurones and also on glutamatergic neurones, thus releasing glutamate and activating 5-HT neuronal AMPA/kainate receptors 3) the increase in 5-HT neuronal activity, and resulting 5-HT release, may lead to 5-HT1A autoreceptor down-regulation.	Acetylcholine	130-143	butyrylcholinesterase	Rattus norvegicus	68-82
26705700-1	2016	Novel substituted phenoxyalkyl pyridinium oximes, previously shown to reactivate brain cholinesterase in rats treated with high sublethal dosages of surrogates of sarin and VX, were tested for their ability to prevent mortality from lethal doses of these two surrogates.	phenoxyalkyl pyridinium oximes	18-48	butyrylcholinesterase	Rattus norvegicus	87-101
26708634-0	2016	Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer"s disease treatment?	Tacrine	17-24	butyrylcholinesterase	Rattus norvegicus	33-47
26708634-0	2016	Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats--Is there a potential for Alzheimer"s disease treatment?	3-quinuclidinyl 4-fluoromethylbenzilate	78-103	butyrylcholinesterase	Rattus norvegicus	33-47
26705700-5	2016	Brain cholinesterase inhibition was slightly less in novel oxime treated rats compared to 2-PAM in the 24h survivors.	Oximes	59-64	butyrylcholinesterase	Rattus norvegicus	6-20
27974891-8	2016	Fenitrothion also caused a decrease in cholinesterase activity in serum, lung, and brain activity associated with a state of oxidative stress in all tested organs and hyperammonemia.	Fenitrothion	0-12	butyrylcholinesterase	Rattus norvegicus	39-53
26673833-5	2016	The results demonstrated that DC reduced the hyperglycemia, inhibited the cholinesterase activity in the hippocampal tissue homogenates, and improved the cognitive performance in spatial memory related Barnes maze task.	Deoxycytidine	30-32	butyrylcholinesterase	Rattus norvegicus	74-88
27384289-0	2016	Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer"s disease.	Donepezil	44-53	butyrylcholinesterase	Rattus norvegicus	74-88
26596326-1	2016	The physiological function of butyrylcholinesterase (EC 3.1.1.8, BChE) is not clearly understood, but a role was suggested in the fat utilization process, resulting in positive correlation between plasma triglyceride (TG) levels and BChE activity.	Triglycerides	218-220	butyrylcholinesterase	Rattus norvegicus	30-51
26596326-1	2016	The physiological function of butyrylcholinesterase (EC 3.1.1.8, BChE) is not clearly understood, but a role was suggested in the fat utilization process, resulting in positive correlation between plasma triglyceride (TG) levels and BChE activity.	Triglycerides	218-220	butyrylcholinesterase	Rattus norvegicus	65-69
26596326-0	2016	Betaine increases the butyrylcholinesterase activity in rat plasma.	Betaine	0-7	butyrylcholinesterase	Rattus norvegicus	22-43
26596326-2	2016	Consequently we tested the hypothesis that regular intake of betaine, a natural compound intervening in the liver TG metabolism could influence the BChE activity.	Betaine	61-68	butyrylcholinesterase	Rattus norvegicus	148-152
26596326-1	2016	The physiological function of butyrylcholinesterase (EC 3.1.1.8, BChE) is not clearly understood, but a role was suggested in the fat utilization process, resulting in positive correlation between plasma triglyceride (TG) levels and BChE activity.	Triglycerides	204-216	butyrylcholinesterase	Rattus norvegicus	30-51
26596326-1	2016	The physiological function of butyrylcholinesterase (EC 3.1.1.8, BChE) is not clearly understood, but a role was suggested in the fat utilization process, resulting in positive correlation between plasma triglyceride (TG) levels and BChE activity.	Triglycerides	204-216	butyrylcholinesterase	Rattus norvegicus	65-69
26596326-2	2016	Consequently we tested the hypothesis that regular intake of betaine, a natural compound intervening in the liver TG metabolism could influence the BChE activity.	Triglycerides	114-116	butyrylcholinesterase	Rattus norvegicus	148-152
26596326-3	2016	The BChE activity was estimated spectrophotometrically in plasma of rats fed with betaine enriched standard (B) or high-fat diet (HFB).	Betaine	82-89	butyrylcholinesterase	Rattus norvegicus	4-8
26596326-5	2016	The BChE activity increased significantly with betaine administration, however the change was more distinct in the HFB group (0.84+/-0.34 (HFB) vs. 0.22+/-0.04 (control) O.D./min/mg; p<0.001 and 0.41+/-0.11 (B) vs. 0.22+/-0.04 (control) O.D./min/mg; p=0.001).	Betaine	47-54	butyrylcholinesterase	Rattus norvegicus	4-8
26596326-5	2016	The BChE activity increased significantly with betaine administration, however the change was more distinct in the HFB group (0.84+/-0.34 (HFB) vs. 0.22+/-0.04 (control) O.D./min/mg; p<0.001 and 0.41+/-0.11 (B) vs. 0.22+/-0.04 (control) O.D./min/mg; p=0.001).	hexafluorobenzene	115-118	butyrylcholinesterase	Rattus norvegicus	4-8
26596326-6	2016	In conclusion, betaine intake led to elevated BChE activity in plasma and this effect was potentiated by the HF diet.	Betaine	15-22	butyrylcholinesterase	Rattus norvegicus	46-50
26596326-7	2016	Since betaine is in general used as a supplement in the treatment of liver diseases accompanied by TG overload, its impact on the BChE activity in the role of the liver function marker should be taken into account.	Betaine	6-13	butyrylcholinesterase	Rattus norvegicus	130-134
26212258-8	2015	Administration of menadione bisulfite (40mg/kg, ip) to rats also reduced parathion-induced inhibition of brain cholinesterase activity, as well as parathion-induced tremors and the progression of other signs and symptoms of parathion poisoning.	Vitamin K 3	18-37	butyrylcholinesterase	Rattus norvegicus	111-125
26362636-10	2015	Taken together, these findings conclude that some possible mechanisms by which EOMABRL elicits neuronal disorder in male rat could be through the activation of AChE and BuChE and induction of oxidative stress with necrosis of neuronal cells.	eomabrl	79-86	butyrylcholinesterase	Rattus norvegicus	169-174
26174159-1	2015	This study examined whether chronic administration of pyridostigmine, a reversible cholinesterase inhibitor, would exacerbate episodes of spontaneous atrial tachyarrhythmia (AT) in conscious, aging, spontaneously hypertensive rats (SHRs).	Pyridostigmine Bromide	54-68	butyrylcholinesterase	Rattus norvegicus	83-97
25690521-9	2015	RESULTS: QNB significantly impaired the performance of the rats within 48 h. The four novel cholinesterase inhibitors attenuated the effect of QNB at 1 h, 24 h and 48 h test intervals.	Quinuclidinyl Benzilate	9-12	butyrylcholinesterase	Rattus norvegicus	92-106
25690521-9	2015	RESULTS: QNB significantly impaired the performance of the rats within 48 h. The four novel cholinesterase inhibitors attenuated the effect of QNB at 1 h, 24 h and 48 h test intervals.	Quinuclidinyl Benzilate	143-146	butyrylcholinesterase	Rattus norvegicus	92-106
26578914-9	2015	By contrast, the muscarinic agonist oxotremorine, the cholinesterase inhibitor physostigmine, the KCNQ channel blocker XE-991, and ghrelin all increased the durations of licking bouts when infused into the mPFC.	Physostigmine	79-92	butyrylcholinesterase	Rattus norvegicus	54-68
26212258-8	2015	Administration of menadione bisulfite (40mg/kg, ip) to rats also reduced parathion-induced inhibition of brain cholinesterase activity, as well as parathion-induced tremors and the progression of other signs and symptoms of parathion poisoning.	Parathion	73-82	butyrylcholinesterase	Rattus norvegicus	111-125
26159088-3	2015	Berberine, an isoquinoline alkaloid is reported to exhibit antioxidant effect and cholinesterase (ChE) inhibitor activity.	Berberine	0-9	butyrylcholinesterase	Rattus norvegicus	82-96
27486373-0	2015	Local salt substitutes "Obu-otoyo" activate acetylcholinesterase and butyrylcholinesterase and induce lipid peroxidation in rat brain.	Salts	6-10	butyrylcholinesterase	Rattus norvegicus	69-90
27486373-5	2015	The results revealed that the salt substitutes caused a significant (p<0.05) increase in both AChE and BChE activity and also induced lipid peroxidation in the brain of rats in vivo as well as under in vitro condition in a dose-dependent manner.	Salts	30-34	butyrylcholinesterase	Rattus norvegicus	106-110
27486373-6	2015	The effect of the salt substitutes on AChE and BChE activities could be attributed to the presence of some toxic heavy metals.	Salts	18-22	butyrylcholinesterase	Rattus norvegicus	47-51
27486373-7	2015	Therefore, the ability of the salt substitutes to induce lipid peroxidation and activate AChE and BChE activities could provide some possible mechanism for their neurotoxic effect.	Salts	30-34	butyrylcholinesterase	Rattus norvegicus	98-102
26159088-3	2015	Berberine, an isoquinoline alkaloid is reported to exhibit antioxidant effect and cholinesterase (ChE) inhibitor activity.	Berberine	0-9	butyrylcholinesterase	Rattus norvegicus	98-101
26159088-3	2015	Berberine, an isoquinoline alkaloid is reported to exhibit antioxidant effect and cholinesterase (ChE) inhibitor activity.	Tubocurarine	14-35	butyrylcholinesterase	Rattus norvegicus	82-96
26159088-3	2015	Berberine, an isoquinoline alkaloid is reported to exhibit antioxidant effect and cholinesterase (ChE) inhibitor activity.	Tubocurarine	14-35	butyrylcholinesterase	Rattus norvegicus	98-101
26159088-7	2015	Forty five days after ethanol treated rats showed a severe deficit in learning and memory associated with increased lipid peroxidation, decreased glutathione, and elevated ChE activity.	Ethanol	22-29	butyrylcholinesterase	Rattus norvegicus	172-175
26159088-8	2015	In contrast, chronic treatment with berberine (25-100mg/kg, p.o., once a day for 45days) improved cognitive performance, and lowered oxidative stress and ChE activity in ethanol treated rats.	Berberine	36-45	butyrylcholinesterase	Rattus norvegicus	154-157
26159088-9	2015	In another set of experiments, berberine (100mg/kg) treatment during training trials also improved learning and memory, and lowered oxidative stress and ChE activity.	Berberine	31-40	butyrylcholinesterase	Rattus norvegicus	153-156
26159088-10	2015	Chronic treatment (45days) with vitamin C, and donepezil during training trials also improved ethanol-induced memory impairment and reduced oxidative stress and/or cholinesterase activity.	Ascorbic Acid	32-41	butyrylcholinesterase	Rattus norvegicus	164-178
26159088-10	2015	Chronic treatment (45days) with vitamin C, and donepezil during training trials also improved ethanol-induced memory impairment and reduced oxidative stress and/or cholinesterase activity.	Donepezil	47-56	butyrylcholinesterase	Rattus norvegicus	164-178
26159088-11	2015	In conclusion, the present study demonstrates that treatment with berberine prevents the changes in oxidative stress and ChE activity, and consequently memory impairment in ethanol treated rats.	Berberine	66-75	butyrylcholinesterase	Rattus norvegicus	121-124
26316710-3	2015	The data showed that organic extraction from drinking water remarkably impaired rat liver function, evident from the increase in the serum level of alanine aminotransferase, aspartate aminotransferase, and cholinesterase, and decrease in the serum level of total protein and albumin.	Drinking Water	45-59	butyrylcholinesterase	Rattus norvegicus	206-220
25797537-5	2015	The known saponins 12, 16 and 18 displayed the enhancing potential of neurite outgrowth of NGF-mediated PC12 cells at a concentration of 10 muM, while 20 exhibited acetyl cholinesterase inhibitory activity, with IC50 value of 13.97 muM.	Saponins	10-18	butyrylcholinesterase	Rattus norvegicus	171-185
25257697-2	2015	Recent reports have implicated triazine derivatives as cholinesterase inhibitors.	Triazines	31-39	butyrylcholinesterase	Rattus norvegicus	55-69
24863738-7	2015	Metabolic clearance and cholinesterase (ChE) interaction parameters for carbaryl were measured in rat and human tissues.	Carbaryl	72-80	butyrylcholinesterase	Rattus norvegicus	24-38
24863738-7	2015	Metabolic clearance and cholinesterase (ChE) interaction parameters for carbaryl were measured in rat and human tissues.	Carbaryl	72-80	butyrylcholinesterase	Rattus norvegicus	40-43
24863738-9	2015	The PBPK model was then used to predict the kinetics and ChE inhibition dynamics of carbaryl in vivo.	Carbaryl	84-92	butyrylcholinesterase	Rattus norvegicus	57-60
26345866-11	2015	In conclusion, PS decreased cholinesterase, improved memory, and improved hippocampal inflammation injury in AD brains by increasing SOD and OH(-) levels.	Phosphatidylserines	15-17	butyrylcholinesterase	Rattus norvegicus	28-42
25863844-0	2015	Fluoride and aluminium disturb neuronal morphology, transport functions, cholinesterase, lysosomal and cell cycle activities.	Fluorides	0-8	butyrylcholinesterase	Rattus norvegicus	73-87
25863844-0	2015	Fluoride and aluminium disturb neuronal morphology, transport functions, cholinesterase, lysosomal and cell cycle activities.	Aluminum	13-22	butyrylcholinesterase	Rattus norvegicus	73-87
25186309-0	2015	Reversible cholinesterase inhibitors as pre-treatment for exposure to organophosphates: assessment using azinphos-methyl.	Organophosphates	70-86	butyrylcholinesterase	Rattus norvegicus	11-25
25186309-0	2015	Reversible cholinesterase inhibitors as pre-treatment for exposure to organophosphates: assessment using azinphos-methyl.	Azinphosmethyl	105-120	butyrylcholinesterase	Rattus norvegicus	11-25
25849329-0	2015	In vitro and in vivo metabolism and inhibitory activities of vasicine, a potent acetylcholinesterase and butyrylcholinesterase inhibitor.	vasicine	61-69	butyrylcholinesterase	Rattus norvegicus	105-126
25849329-1	2015	Vasicine (VAS), a potential natural cholinesterase inhibitor, exhibited promising anticholinesterase activity in preclinical models and has been in development for treatment of Alzheimer"s disease.	vasicine	0-8	butyrylcholinesterase	Rattus norvegicus	36-50
25849329-9	2015	The acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities of VAS and its main metabolites were also evaluated.	vasicine	90-93	butyrylcholinesterase	Rattus norvegicus	36-57
25849329-1	2015	Vasicine (VAS), a potential natural cholinesterase inhibitor, exhibited promising anticholinesterase activity in preclinical models and has been in development for treatment of Alzheimer"s disease.	vasicine	10-13	butyrylcholinesterase	Rattus norvegicus	36-50
25849329-9	2015	The acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities of VAS and its main metabolites were also evaluated.	vasicine	90-93	butyrylcholinesterase	Rattus norvegicus	59-63
25665942-8	2015	In addition, pratensein significantly decreased the activity of cholinesterase, then subsequently elevated the level of acetylcholine.	4'-methoxy-3',5,7-trihydroxyisoflavone	13-23	butyrylcholinesterase	Rattus norvegicus	64-78
25849329-11	2015	VAS undergoes metabolic inactivation process in vivo in respect to cholinesterase inhibitory activity.	vasicine	0-3	butyrylcholinesterase	Rattus norvegicus	67-81
25835709-2	2015	In a recent large rat genome-wide expression profiling and linkage analysis we found co-regulation of complement C3 immediately downstream of butyrylcholinesterase (BuChE), an enzyme hydrolyzing acetylcholine (ACh), a classical neurotransmitter with immunoregulatory effects.	Acetylcholine	195-208	butyrylcholinesterase	Rattus norvegicus	142-163
25835709-2	2015	In a recent large rat genome-wide expression profiling and linkage analysis we found co-regulation of complement C3 immediately downstream of butyrylcholinesterase (BuChE), an enzyme hydrolyzing acetylcholine (ACh), a classical neurotransmitter with immunoregulatory effects.	Acetylcholine	195-208	butyrylcholinesterase	Rattus norvegicus	165-170
25835709-2	2015	In a recent large rat genome-wide expression profiling and linkage analysis we found co-regulation of complement C3 immediately downstream of butyrylcholinesterase (BuChE), an enzyme hydrolyzing acetylcholine (ACh), a classical neurotransmitter with immunoregulatory effects.	Acetylcholine	210-213	butyrylcholinesterase	Rattus norvegicus	142-163
25835709-2	2015	In a recent large rat genome-wide expression profiling and linkage analysis we found co-regulation of complement C3 immediately downstream of butyrylcholinesterase (BuChE), an enzyme hydrolyzing acetylcholine (ACh), a classical neurotransmitter with immunoregulatory effects.	Acetylcholine	210-213	butyrylcholinesterase	Rattus norvegicus	165-170
25665942-9	2015	In summary, our study indicated that pratensein may have a likely protective effect against Alzheimer"s disease (AD) via improving synaptic plasticity and increasing cholinesterase activity.	4'-methoxy-3',5,7-trihydroxyisoflavone	37-47	butyrylcholinesterase	Rattus norvegicus	166-180
24975276-1	2015	Our previous in vivo studies showed that chlorpyrifos (CPF) and cypermethrin (CM) in a mixture dermally administered, strongly inhibited cholinesterase activity in plasma and the brain and were very toxic to the rat central nervous system.	Chlorpyrifos	41-53	butyrylcholinesterase	Rattus norvegicus	137-151
24975276-1	2015	Our previous in vivo studies showed that chlorpyrifos (CPF) and cypermethrin (CM) in a mixture dermally administered, strongly inhibited cholinesterase activity in plasma and the brain and were very toxic to the rat central nervous system.	Chlorpyrifos	55-58	butyrylcholinesterase	Rattus norvegicus	137-151
24975276-1	2015	Our previous in vivo studies showed that chlorpyrifos (CPF) and cypermethrin (CM) in a mixture dermally administered, strongly inhibited cholinesterase activity in plasma and the brain and were very toxic to the rat central nervous system.	cypermethrin	64-76	butyrylcholinesterase	Rattus norvegicus	137-151
24975276-1	2015	Our previous in vivo studies showed that chlorpyrifos (CPF) and cypermethrin (CM) in a mixture dermally administered, strongly inhibited cholinesterase activity in plasma and the brain and were very toxic to the rat central nervous system.	cypermethrin	78-80	butyrylcholinesterase	Rattus norvegicus	137-151
26351819-4	2015	Pretreatment of rats with DAS in the Hg-treated group also inhibited an increase in lipid peroxidation and elevated acetyl cholinesterase and glutathione content.	allyl sulfide	26-29	butyrylcholinesterase	Rattus norvegicus	123-137
26862258-14	2015	The protein content and ChE enzyme activity in brain of fluoride exposed rats diminished as compared to control whereas the same was found to be elevated in E. officinalis fed rats.	Fluorides	56-64	butyrylcholinesterase	Rattus norvegicus	24-27
25747977-1	2015	Although the cholinesterase inhibitor tacrine has been successfully used for the treatment of Alzheimer"s disease, it is known to have hepatotoxic effects.	Tacrine	38-45	butyrylcholinesterase	Rattus norvegicus	13-27
25196089-1	2014	Chlorpyrifos (CPF) is an organophosphorus cholinesterase inhibitor widely used as an insecticide.	Chlorpyrifos	0-12	butyrylcholinesterase	Rattus norvegicus	42-56
25720026-7	2014	Co-exposure (90-min pre-treatment) with piperonyl butoxide or menadione revealed tissue-specific effect of imidacloprid on total cholinesterase activity.	Piperonyl Butoxide	40-58	butyrylcholinesterase	Rattus norvegicus	129-143
25720026-7	2014	Co-exposure (90-min pre-treatment) with piperonyl butoxide or menadione revealed tissue-specific effect of imidacloprid on total cholinesterase activity.	Vitamin K 3	62-71	butyrylcholinesterase	Rattus norvegicus	129-143
25720026-7	2014	Co-exposure (90-min pre-treatment) with piperonyl butoxide or menadione revealed tissue-specific effect of imidacloprid on total cholinesterase activity.	imidacloprid	107-119	butyrylcholinesterase	Rattus norvegicus	129-143
25720026-8	2014	Increased cholinesterase activity in the kidney could be an adaptive response to imidacloprid-induced oxidative stress.	imidacloprid	81-93	butyrylcholinesterase	Rattus norvegicus	10-24
25196089-1	2014	Chlorpyrifos (CPF) is an organophosphorus cholinesterase inhibitor widely used as an insecticide.	Chlorpyrifos	14-17	butyrylcholinesterase	Rattus norvegicus	42-56
25064450-6	2014	AChE, BChE, and MPO activities ex vivo presented an increase in the Cd-exposed group when compared to the control group, and the treatment with quercetin 5, 25, and 50 mg/kg prevented this increase caused by Cd exposure.	Cadmium	68-70	butyrylcholinesterase	Rattus norvegicus	6-10
25440827-0	2014	Reactivity of diabetic urinary bladder to the cholinesterase inhibitor neostigmine.	Neostigmine	71-82	butyrylcholinesterase	Rattus norvegicus	46-60
25282654-1	2014	A series of tacrine-(beta-carboline) hybrids (11a-q) were designed, synthesized and evaluated as multifunctional cholinesterase inhibitors against Alzheimer"s disease (AD).	11a-q	46-51	butyrylcholinesterase	Rattus norvegicus	113-127
25064450-6	2014	AChE, BChE, and MPO activities ex vivo presented an increase in the Cd-exposed group when compared to the control group, and the treatment with quercetin 5, 25, and 50 mg/kg prevented this increase caused by Cd exposure.	Quercetin	144-153	butyrylcholinesterase	Rattus norvegicus	6-10
24373905-1	2014	The prevailing dogma is that chlorpyrifos (CPF) mediates its toxicity through inhibition of cholinesterase (ChE).	Chlorpyrifos	29-41	butyrylcholinesterase	Rattus norvegicus	92-106
23418109-6	2014	The results showed that ChE activity significantly decreased in all treated rats except the rats treated with low dose carbaryl.	Carbaryl	119-127	butyrylcholinesterase	Rattus norvegicus	24-27
24916051-7	2014	These studies demonstrated that 90-98% of purified rBChE (65 muM) could be assembled into tetramers when incubated with synthetic 17-mer or 50-mer polyproline peptides (100 muM) for 1.5 h at 25 C. However, rBChE tetramerization was inefficient with smaller 8-mer polyproline peptides and larger 300-mer polyproline proteins.	polyproline peptides	147-167	butyrylcholinesterase	Rattus norvegicus	51-56
24916051-7	2014	These studies demonstrated that 90-98% of purified rBChE (65 muM) could be assembled into tetramers when incubated with synthetic 17-mer or 50-mer polyproline peptides (100 muM) for 1.5 h at 25 C. However, rBChE tetramerization was inefficient with smaller 8-mer polyproline peptides and larger 300-mer polyproline proteins.	polyproline peptides	263-283	butyrylcholinesterase	Rattus norvegicus	51-56
24916051-7	2014	These studies demonstrated that 90-98% of purified rBChE (65 muM) could be assembled into tetramers when incubated with synthetic 17-mer or 50-mer polyproline peptides (100 muM) for 1.5 h at 25 C. However, rBChE tetramerization was inefficient with smaller 8-mer polyproline peptides and larger 300-mer polyproline proteins.	polyproline	147-158	butyrylcholinesterase	Rattus norvegicus	51-56
24618259-5	2014	In particular, we show here that co-expression of BChE with a novel gene-stacking vector, carrying six mammalian genes necessary for in planta protein sialylation, resulted in the generation of rBChE decorated with sialylated N-glycans.	n-glycans	226-235	butyrylcholinesterase	Rattus norvegicus	194-199
24618259-6	2014	The N-glycosylation profile of monomeric rBChE secreted to the apoplast largely resembles the plasma-derived orthologue.	Nitrogen	4-5	butyrylcholinesterase	Rattus norvegicus	41-46
24618259-8	2014	Biochemical analyses and live-cell imaging experiments indicated that impaired N-glycan processing is due to aberrant deposition of rBChE oligomers in the endoplasmic reticulum or endoplasmic-reticulum-derived compartments.	n-glycan	79-87	butyrylcholinesterase	Rattus norvegicus	132-137
24980117-0	2014	Synthesis of alpha, beta-unsaturated carbonyl based compounds as acetylcholinesterase and butyrylcholinesterase inhibitors: characterization, molecular modeling, QSAR studies and effect against amyloid beta-induced cytotoxicity.	alpha, beta-unsaturated carbonyl based	13-51	butyrylcholinesterase	Rattus norvegicus	90-111
24941128-0	2014	Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives.	7-hydroxycoumarin	50-67	butyrylcholinesterase	Rattus norvegicus	19-33
24941128-1	2014	A series of 7-hydroxycoumarin derivatives connected by an amidic linker to the different amines were designed and synthesized as cholinesterase inhibitors.	7-hydroxycoumarin	12-29	butyrylcholinesterase	Rattus norvegicus	129-143
24941128-1	2014	A series of 7-hydroxycoumarin derivatives connected by an amidic linker to the different amines were designed and synthesized as cholinesterase inhibitors.	Amines	89-95	butyrylcholinesterase	Rattus norvegicus	129-143
24755308-0	2014	Influence of cholinesterase inhibitors, donepezil and rivastigmine on the acquisition, expression, and reinstatement of morphine-induced conditioned place preference in rats.	Morphine	120-128	butyrylcholinesterase	Rattus norvegicus	13-27
24755308-1	2014	The influence of systemic administration of cholinesterase inhibitors, donepezil and rivastigmine on the acquisition, expression, and reinstatement of morphine-induced conditioned place preference (CPP) was examined in rats.	Morphine	151-159	butyrylcholinesterase	Rattus norvegicus	44-58
24755308-7	2014	Our results indicated that both inhibitors of cholinesterase attenuated the acquisition and expression of morphine CPP.	Morphine	106-114	butyrylcholinesterase	Rattus norvegicus	46-60
24755308-10	2014	These properties of both cholinesterase inhibitors were reversed by mecamylamine (3 mg/kg, i.p.	Mecamylamine	68-80	butyrylcholinesterase	Rattus norvegicus	25-39
24755308-14	2014	Our results suggest beneficial role of cholinesterase inhibitors in reduction of morphine reward and morphine-induced seeking behavior.	Morphine	81-89	butyrylcholinesterase	Rattus norvegicus	39-53
24755308-14	2014	Our results suggest beneficial role of cholinesterase inhibitors in reduction of morphine reward and morphine-induced seeking behavior.	Morphine	101-109	butyrylcholinesterase	Rattus norvegicus	39-53
24755308-15	2014	Finally, we found that the efficacy of cholinesterase inhibitors in attenuating reinstatement of morphine CPP provoked by priming injection may be due to stimulation of nicotinic acetylcholine receptors.	Morphine	97-105	butyrylcholinesterase	Rattus norvegicus	39-53
24373905-1	2014	The prevailing dogma is that chlorpyrifos (CPF) mediates its toxicity through inhibition of cholinesterase (ChE).	Chlorpyrifos	29-41	butyrylcholinesterase	Rattus norvegicus	108-111
24373905-1	2014	The prevailing dogma is that chlorpyrifos (CPF) mediates its toxicity through inhibition of cholinesterase (ChE).	Chlorpyrifos	43-46	butyrylcholinesterase	Rattus norvegicus	92-106
24373905-1	2014	The prevailing dogma is that chlorpyrifos (CPF) mediates its toxicity through inhibition of cholinesterase (ChE).	Chlorpyrifos	43-46	butyrylcholinesterase	Rattus norvegicus	108-111
24534338-5	2014	HI-6-dimethanesulfonate has shown a higher level of solubility with similar potency to reactivate acetyl cholinesterase and a similar pharmacokinetics profile compared with HI-6 dichloride.	hi-6-dimethanesulfonate	0-23	butyrylcholinesterase	Rattus norvegicus	105-119
24428128-1	2014	BACKGROUND AND PURPOSE: Eye exposure to the organophosphorus (OP) irreversible cholinesterase inhibitor sarin results in long-term miosis and impaired visual function.	organophosphorus	44-60	butyrylcholinesterase	Rattus norvegicus	79-93
24407266-5	2014	Pretreatment with the selective BChE and CocH inhibitor iso-OMPA (1.5 mg/kg) restored cocaine intake; therefore, the decline in self-administration was likely due to rapid CocH-mediated cocaine metabolism.	Cocaine	86-93	butyrylcholinesterase	Rattus norvegicus	32-36
24407266-5	2014	Pretreatment with the selective BChE and CocH inhibitor iso-OMPA (1.5 mg/kg) restored cocaine intake; therefore, the decline in self-administration was likely due to rapid CocH-mediated cocaine metabolism.	Cocaine	186-193	butyrylcholinesterase	Rattus norvegicus	32-36
23479073-7	2014	RESULTS: A significant rise in acetylcholinesterase activity was observed in lymphocytes and whole blood as well as in serum butyrylcholinesterase activity in the L-NAME group when compared with the other groups (P < 0.05), and the increase in cholinesterase activities was positively correlated with the rise in blood pressure (r = 0.5721, r = 0.6121, and r = 0.5811, respectively).	NG-Nitroarginine Methyl Ester	163-169	butyrylcholinesterase	Rattus norvegicus	125-146
23479073-7	2014	RESULTS: A significant rise in acetylcholinesterase activity was observed in lymphocytes and whole blood as well as in serum butyrylcholinesterase activity in the L-NAME group when compared with the other groups (P < 0.05), and the increase in cholinesterase activities was positively correlated with the rise in blood pressure (r = 0.5721, r = 0.6121, and r = 0.5811, respectively).	NG-Nitroarginine Methyl Ester	163-169	butyrylcholinesterase	Rattus norvegicus	37-51
24130173-4	2014	Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue.	Sugars	14-19	butyrylcholinesterase	Rattus norvegicus	60-65
24130173-4	2014	Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue.	n-glycans	155-164	butyrylcholinesterase	Rattus norvegicus	60-65
24130173-5	2014	Attempts to increase that sialylation content of rBChE by the over-expression of an additional glycosylation enzyme that generates branched N-glycans (i.e. beta1,4-N-acetylglucosaminyl-transferase IV), allowed the production of rBChE decorated with tri-sialylated structures (up to 70%).	n-glycans	140-149	butyrylcholinesterase	Rattus norvegicus	49-54
24643080-4	2014	Donepezil-a highly CNS-penetrating cholinesterase inhibitor-prevents the negative BOLD and cognitive deficits regardless whether the provoking agent is scopolamine or butylscopolamine.	donepezil-a	0-11	butyrylcholinesterase	Rattus norvegicus	35-49
24643080-5	2014	Interestingly, the non-BBB-penetrating cholinesterase inhibitor neostigmine also prevents or substantially inhibits those cognitive and fMRI changes.	Neostigmine	64-75	butyrylcholinesterase	Rattus norvegicus	39-53
24247035-4	2014	We hypothesized that the inhibition of cholinesterase activity might increase acetylcholine bioavailability and consequently cholinoceptor activation, leading to concomitant adenosine release from nerve endings and skeletal muscle fibers.	Acetylcholine	78-91	butyrylcholinesterase	Rattus norvegicus	39-53
24295433-1	2014	The potency of two newly developed oximes (K361 and K378) to reactivate tabun-inhibited cholinesterase and to reduce acute toxicity of tabun was compared with the oxime K203 and trimedoxime using in vivo methods.	Oximes	35-41	butyrylcholinesterase	Rattus norvegicus	88-102
24295433-1	2014	The potency of two newly developed oximes (K361 and K378) to reactivate tabun-inhibited cholinesterase and to reduce acute toxicity of tabun was compared with the oxime K203 and trimedoxime using in vivo methods.	Oximes	35-40	butyrylcholinesterase	Rattus norvegicus	88-102
24295433-2	2014	The study determining percentage of reactivation of tabun-inhibited diaphragm cholinesterase in poisoned rats showed that the reactivating efficacy of the oxime K378 is slightly lower than the reactivating potency of the oxime K203 and trimedoxime while the ability of the oxime K361 to reactivate tabun-inhibited cholinesterase is markedly lower compared with the oxime K203 and trimedoxime.	oxime k378	155-165	butyrylcholinesterase	Rattus norvegicus	78-92
24295433-2	2014	The study determining percentage of reactivation of tabun-inhibited diaphragm cholinesterase in poisoned rats showed that the reactivating efficacy of the oxime K378 is slightly lower than the reactivating potency of the oxime K203 and trimedoxime while the ability of the oxime K361 to reactivate tabun-inhibited cholinesterase is markedly lower compared with the oxime K203 and trimedoxime.	oxime k378	155-165	butyrylcholinesterase	Rattus norvegicus	314-328
24295433-3	2014	In the brain, the potency of both newly developed oximes to reactivate tabun-inhibited cholinesterase was negligible.	Oximes	50-56	butyrylcholinesterase	Rattus norvegicus	87-101
24247035-4	2014	We hypothesized that the inhibition of cholinesterase activity might increase acetylcholine bioavailability and consequently cholinoceptor activation, leading to concomitant adenosine release from nerve endings and skeletal muscle fibers.	Adenosine	174-183	butyrylcholinesterase	Rattus norvegicus	39-53
25558570-0	2014	Protective role of caffeic acid phenethyl ester on serum cholinesterase inhibition by acute exposure to diazinon in rats.	caffeic acid phenethyl ester	19-47	butyrylcholinesterase	Rattus norvegicus	57-71
24818142-4	2014	However, exposure to these carbamates produced alterations in water consumption, hematocrit, percentages of reticulocytes, plasma proteins, some biochemical parameters (aspartate aminotransferase, gamma-glutamyl transpeptidase, cholinesterase, and creatinine activities), thiobarbituric acid reactive substances, and the relative weight of the spleen.	Carbamates	27-37	butyrylcholinesterase	Rattus norvegicus	228-242
23736080-3	2014	The aim of this study is to investigate the effects of physostigmine, a cholinesterase inhibitor, on the intestinal microcirculation and vascular contractility in experimental endotoxemia.	Physostigmine	55-68	butyrylcholinesterase	Rattus norvegicus	72-86
24599102-1	2014	This study sought to investigate the effects of essential oil from lemon (Citrus limoni) peels on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities in vitro.	Oils, Volatile	48-61	butyrylcholinesterase	Rattus norvegicus	153-157
24599102-4	2014	The essential oil inhibited AChE and BChE activities in a concentration-dependent manner.	Oils, Volatile	4-17	butyrylcholinesterase	Rattus norvegicus	37-41
24599102-7	2014	The inhibition of AChE and BChE activities, inhibition of pro-oxidant induced lipid peroxidation and antioxidant activities could be possible mechanisms for the use of the essential oil in the management and prevention of oxidative stress-induced neurodegeneration.	Oils, Volatile	172-185	butyrylcholinesterase	Rattus norvegicus	27-31
25558570-0	2014	Protective role of caffeic acid phenethyl ester on serum cholinesterase inhibition by acute exposure to diazinon in rats.	Diazinon	104-112	butyrylcholinesterase	Rattus norvegicus	57-71
25558570-1	2014	AIM: To evaluate whether caffeic acid phenethyl ester (CAPE), a flavonoid-like natural compound plentifully found in beeswax, has a protective effect on diazinon-induced serum cholinesterase (ChE) inhibition in rats.	caffeic acid phenethyl ester	25-53	butyrylcholinesterase	Rattus norvegicus	176-190
25558570-1	2014	AIM: To evaluate whether caffeic acid phenethyl ester (CAPE), a flavonoid-like natural compound plentifully found in beeswax, has a protective effect on diazinon-induced serum cholinesterase (ChE) inhibition in rats.	caffeic acid phenethyl ester	25-53	butyrylcholinesterase	Rattus norvegicus	192-195
25558570-1	2014	AIM: To evaluate whether caffeic acid phenethyl ester (CAPE), a flavonoid-like natural compound plentifully found in beeswax, has a protective effect on diazinon-induced serum cholinesterase (ChE) inhibition in rats.	caffeic acid phenethyl ester	55-59	butyrylcholinesterase	Rattus norvegicus	176-190
25558570-1	2014	AIM: To evaluate whether caffeic acid phenethyl ester (CAPE), a flavonoid-like natural compound plentifully found in beeswax, has a protective effect on diazinon-induced serum cholinesterase (ChE) inhibition in rats.	caffeic acid phenethyl ester	55-59	butyrylcholinesterase	Rattus norvegicus	192-195
25558570-1	2014	AIM: To evaluate whether caffeic acid phenethyl ester (CAPE), a flavonoid-like natural compound plentifully found in beeswax, has a protective effect on diazinon-induced serum cholinesterase (ChE) inhibition in rats.	Diazinon	153-161	butyrylcholinesterase	Rattus norvegicus	176-190
25558570-1	2014	AIM: To evaluate whether caffeic acid phenethyl ester (CAPE), a flavonoid-like natural compound plentifully found in beeswax, has a protective effect on diazinon-induced serum cholinesterase (ChE) inhibition in rats.	Diazinon	153-161	butyrylcholinesterase	Rattus norvegicus	192-195
25558570-7	2014	RESULTS: Analysis of the animal blood samples obtained 48 h after diazinon administration revealed that diazinon decreased serum ChE activity by 75%, while CAPE administration 24 h prior to and 30 min following diazinon application improved serum ChE activity by 25%-32% as compared to levels with diazinon administration only.	Diazinon	104-112	butyrylcholinesterase	Rattus norvegicus	129-132
25558570-7	2014	RESULTS: Analysis of the animal blood samples obtained 48 h after diazinon administration revealed that diazinon decreased serum ChE activity by 75%, while CAPE administration 24 h prior to and 30 min following diazinon application improved serum ChE activity by 25%-32% as compared to levels with diazinon administration only.	caffeic acid phenethyl ester	156-160	butyrylcholinesterase	Rattus norvegicus	247-250
25558570-7	2014	RESULTS: Analysis of the animal blood samples obtained 48 h after diazinon administration revealed that diazinon decreased serum ChE activity by 75%, while CAPE administration 24 h prior to and 30 min following diazinon application improved serum ChE activity by 25%-32% as compared to levels with diazinon administration only.	Diazinon	104-112	butyrylcholinesterase	Rattus norvegicus	129-132
25558570-7	2014	RESULTS: Analysis of the animal blood samples obtained 48 h after diazinon administration revealed that diazinon decreased serum ChE activity by 75%, while CAPE administration 24 h prior to and 30 min following diazinon application improved serum ChE activity by 25%-32% as compared to levels with diazinon administration only.	Diazinon	104-112	butyrylcholinesterase	Rattus norvegicus	129-132
25558570-8	2014	In silico studies suggest that CAPE prevents diazinon from binding to butyryl ChE due to a higher binding affinity than that of diazinon.	caffeic acid phenethyl ester	31-35	butyrylcholinesterase	Rattus norvegicus	78-81
25558570-8	2014	In silico studies suggest that CAPE prevents diazinon from binding to butyryl ChE due to a higher binding affinity than that of diazinon.	Diazinon	45-53	butyrylcholinesterase	Rattus norvegicus	78-81
25558570-9	2014	CONCLUSION: Our laboratory findings suggest that CAPE plays a protective role against butyryl ChE inhibition by diazinon.	caffeic acid phenethyl ester	49-53	butyrylcholinesterase	Rattus norvegicus	94-97
25558570-9	2014	CONCLUSION: Our laboratory findings suggest that CAPE plays a protective role against butyryl ChE inhibition by diazinon.	Diazinon	112-120	butyrylcholinesterase	Rattus norvegicus	94-97
23994545-0	2013	Cholinesterase inhibitor, donepezil, improves visual contrast detectability in freely behaving rats.	Donepezil	26-35	butyrylcholinesterase	Rattus norvegicus	0-14
23832386-10	2013	The hydroalcoholic extract of C. ternatea prevented STZ-induced cognitive impairment dose dependently by reducing oxidative stress, cholinesterase activity, and ROCK II expression.	Streptozocin	52-55	butyrylcholinesterase	Rattus norvegicus	132-146
23933531-7	2013	Cholinesterase inhibition was extensive in hippocampus with PS (89-90%) and CPF (78-83%) exposure.	Phosphorus	60-62	butyrylcholinesterase	Rattus norvegicus	0-14
23933531-7	2013	Cholinesterase inhibition was extensive in hippocampus with PS (89-90%) and CPF (78-83%) exposure.	Chlorpyrifos	76-79	butyrylcholinesterase	Rattus norvegicus	0-14
23510099-6	2013	Besides, aluminum chloride treatment significantly increased acetyl cholinesterase activity and aluminum concentration in the brain as compared to sham.	Aluminum Chloride	9-26	butyrylcholinesterase	Rattus norvegicus	68-82
23510099-6	2013	Besides, aluminum chloride treatment significantly increased acetyl cholinesterase activity and aluminum concentration in the brain as compared to sham.	Aluminum	9-17	butyrylcholinesterase	Rattus norvegicus	68-82
23510099-7	2013	Chronic administration of naringin significantly improved cognitive performance and attenuated mitochondria oxidative damage, acetyl cholinesterase activity, and aluminum concentration in aluminum-treated rats as compared to control rats.	naringin	26-34	butyrylcholinesterase	Rattus norvegicus	133-147
23874878-5	2013	However, despite recovery to normal body weight, liver weight and NAS score, both serum CHE and TG levels of non-treated and cell-treated rats with PHx after MCD diet remained significantly lower as compared to those of control rats.	PHX	148-151	butyrylcholinesterase	Rattus norvegicus	88-91
22974558-2	2013	This is the first study to investigate the effects of the non-selective muscarinic antagonist scopolamine, the muscarinic M1 antagonist biperiden and the cholinesterase inhibitor donepezil (also in combination with scopolamine and biperiden) on auditory evoked potentials (AEPs) and sensory gating.	Donepezil	179-188	butyrylcholinesterase	Rattus norvegicus	154-168
24052154-0	2013	Partial protection from organophosphate-induced cholinesterase inhibition by metyrapone treatment.	Organophosphates	24-39	butyrylcholinesterase	Rattus norvegicus	48-62
24052154-0	2013	Partial protection from organophosphate-induced cholinesterase inhibition by metyrapone treatment.	Metyrapone	77-87	butyrylcholinesterase	Rattus norvegicus	48-62
23072555-5	2013	The introduction of phenylcarbamate moiety to coumarin template also significantly increased BuChE inhibitory activity, albeit less than AChE inhibitory activity with approximate BuChE/AChE selectivity ratio of 20.	Phenylcarbamates	20-35	butyrylcholinesterase	Rattus norvegicus	93-98
23072555-5	2013	The introduction of phenylcarbamate moiety to coumarin template also significantly increased BuChE inhibitory activity, albeit less than AChE inhibitory activity with approximate BuChE/AChE selectivity ratio of 20.	Phenylcarbamates	20-35	butyrylcholinesterase	Rattus norvegicus	179-184
23072555-5	2013	The introduction of phenylcarbamate moiety to coumarin template also significantly increased BuChE inhibitory activity, albeit less than AChE inhibitory activity with approximate BuChE/AChE selectivity ratio of 20.	coumarin	46-54	butyrylcholinesterase	Rattus norvegicus	93-98
22611016-0	2013	Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon.	Paraoxon	138-146	butyrylcholinesterase	Rattus norvegicus	52-66
21849351-10	2013	In contrast, increase in endogenous ACh with cholinesterase inhibitor pyridostigmine (30 mg/kg/day) increased angiogenesis after MI.	Acetylcholine	36-39	butyrylcholinesterase	Rattus norvegicus	45-59
21849351-10	2013	In contrast, increase in endogenous ACh with cholinesterase inhibitor pyridostigmine (30 mg/kg/day) increased angiogenesis after MI.	Pyridostigmine Bromide	70-84	butyrylcholinesterase	Rattus norvegicus	45-59
23325108-1	2013	UNLABELLED: The current study determined the effects of chronic treatment of aging rats with ladostigil, a cholinesterase (ChE) and monoamine oxidase (MAO) inhibitor, at doses of 1 and 8.5 mg/kg/day, on novel object recognition (NOR) and reference memory in the Morris water maze (MWM).	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	93-103	butyrylcholinesterase	Rattus norvegicus	107-121
25206404-8	2013	These effects of eleutheroside B or E may be mediated by activation of cholinesterase or enhanced reuse of choline to accelerate the synthesis of acetylcholine in hippocampal neurons.	syringin	17-32	butyrylcholinesterase	Rattus norvegicus	71-85
23220589-5	2013	The difficulties in reactivation of ChE activity and slight antidote effect regarding intoxication with some OPC are some of the reasons for continuous efforts to obtain new reactivators of ChE.	Organophosphorus Compounds	109-112	butyrylcholinesterase	Rattus norvegicus	190-193
23220589-6	2013	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM).	tabun	109-114	butyrylcholinesterase	Rattus norvegicus	66-69
23220589-6	2013	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM).	Paraoxon	116-124	butyrylcholinesterase	Rattus norvegicus	66-69
23220589-6	2013	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM).	Dichlorvos	129-139	butyrylcholinesterase	Rattus norvegicus	66-69
23220589-6	2013	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM).	Oximes	233-239	butyrylcholinesterase	Rattus norvegicus	66-69
23220589-6	2013	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM).	Obidoxime Chloride	241-250	butyrylcholinesterase	Rattus norvegicus	66-69
23220589-6	2013	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM).	asoxime chloride	252-256	butyrylcholinesterase	Rattus norvegicus	66-69
23220589-6	2013	The aim of the present study was to evaluate the efficacy of some ChE reactivators against OPC intoxication (tabun, paraoxon and dichlorvos) in in vitro experiments and to compare their activity to that known for some currently used oximes (obidoxime, HI-6, 2-PAM).	pralidoxime	258-263	butyrylcholinesterase	Rattus norvegicus	66-69
23325108-1	2013	UNLABELLED: The current study determined the effects of chronic treatment of aging rats with ladostigil, a cholinesterase (ChE) and monoamine oxidase (MAO) inhibitor, at doses of 1 and 8.5 mg/kg/day, on novel object recognition (NOR) and reference memory in the Morris water maze (MWM).	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	93-103	butyrylcholinesterase	Rattus norvegicus	123-126
23325108-4	2013	Ladostigil (8.5 mg/kg/day) inhibited brain ChE by  30 % and MAO A and B by 55-59 %, and had a similar, or greater effect than the low dose on microglia, but was less effective in preventing the decline in NOR.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-10	butyrylcholinesterase	Rattus norvegicus	43-46
23325108-5	2013	Ladostigil (8.5 mg/kg/day) may have caused too much cortical ChE inhibition and acetylcholine elevation at 16 months when NOR was intact.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-10	butyrylcholinesterase	Rattus norvegicus	61-64
23184188-2	2013	The result revealed that caffeic acid and chlorogenic acid inhibited AChE and BChE activities in dose-dependent manner; however, caffeic acid had a higher inhibitory effect on AChE and BChE activities than chlorogenic acid.	caffeic acid	25-37	butyrylcholinesterase	Rattus norvegicus	78-82
23184188-2	2013	The result revealed that caffeic acid and chlorogenic acid inhibited AChE and BChE activities in dose-dependent manner; however, caffeic acid had a higher inhibitory effect on AChE and BChE activities than chlorogenic acid.	caffeic acid	25-37	butyrylcholinesterase	Rattus norvegicus	185-189
23184188-1	2013	This study sought to investigate and compare the interaction of caffeic acid and chlorogenic acid on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), and some pro-oxidants (FeSO(4), sodium nitroprusside and quinolinic acid) induced oxidative stress in rat brain in vitro.	caffeic acid	64-76	butyrylcholinesterase	Rattus norvegicus	133-154
23184188-1	2013	This study sought to investigate and compare the interaction of caffeic acid and chlorogenic acid on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), and some pro-oxidants (FeSO(4), sodium nitroprusside and quinolinic acid) induced oxidative stress in rat brain in vitro.	caffeic acid	64-76	butyrylcholinesterase	Rattus norvegicus	156-160
23184188-2	2013	The result revealed that caffeic acid and chlorogenic acid inhibited AChE and BChE activities in dose-dependent manner; however, caffeic acid had a higher inhibitory effect on AChE and BChE activities than chlorogenic acid.	Chlorogenic Acid	42-58	butyrylcholinesterase	Rattus norvegicus	78-82
23184188-1	2013	This study sought to investigate and compare the interaction of caffeic acid and chlorogenic acid on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), and some pro-oxidants (FeSO(4), sodium nitroprusside and quinolinic acid) induced oxidative stress in rat brain in vitro.	Chlorogenic Acid	81-97	butyrylcholinesterase	Rattus norvegicus	133-154
23184188-2	2013	The result revealed that caffeic acid and chlorogenic acid inhibited AChE and BChE activities in dose-dependent manner; however, caffeic acid had a higher inhibitory effect on AChE and BChE activities than chlorogenic acid.	Chlorogenic Acid	42-58	butyrylcholinesterase	Rattus norvegicus	185-189
23184188-1	2013	This study sought to investigate and compare the interaction of caffeic acid and chlorogenic acid on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), and some pro-oxidants (FeSO(4), sodium nitroprusside and quinolinic acid) induced oxidative stress in rat brain in vitro.	Chlorogenic Acid	81-97	butyrylcholinesterase	Rattus norvegicus	156-160
23184188-2	2013	The result revealed that caffeic acid and chlorogenic acid inhibited AChE and BChE activities in dose-dependent manner; however, caffeic acid had a higher inhibitory effect on AChE and BChE activities than chlorogenic acid.	caffeic acid	129-141	butyrylcholinesterase	Rattus norvegicus	78-82
23184188-2	2013	The result revealed that caffeic acid and chlorogenic acid inhibited AChE and BChE activities in dose-dependent manner; however, caffeic acid had a higher inhibitory effect on AChE and BChE activities than chlorogenic acid.	caffeic acid	129-141	butyrylcholinesterase	Rattus norvegicus	185-189
23184188-2	2013	The result revealed that caffeic acid and chlorogenic acid inhibited AChE and BChE activities in dose-dependent manner; however, caffeic acid had a higher inhibitory effect on AChE and BChE activities than chlorogenic acid.	Chlorogenic Acid	206-222	butyrylcholinesterase	Rattus norvegicus	78-82
23184188-3	2013	Combination of the phenolic acids inhibited AChE and BChE activities antagonistically.	phenolic acid	19-33	butyrylcholinesterase	Rattus norvegicus	53-57
23184188-5	2013	Inhibition of AChE and BChE activities slows down acetylcholine and butyrylcholine breakdown in the brain.	Acetylcholine	50-63	butyrylcholinesterase	Rattus norvegicus	23-27
23184188-5	2013	Inhibition of AChE and BChE activities slows down acetylcholine and butyrylcholine breakdown in the brain.	butyrylcholine	68-82	butyrylcholinesterase	Rattus norvegicus	23-27
23184188-6	2013	Therefore, one possible mechanism through which the phenolic acids exert their neuroprotective properties is by inhibiting AChE and BChE activities as well as preventing oxidative stress-induced neurodegeneration.	phenolic acid	52-66	butyrylcholinesterase	Rattus norvegicus	132-136
23257163-1	2013	Donepezil is a cholinesterase inhibitor widely used for the treatment of Alzheimer"s disease.	Donepezil	0-9	butyrylcholinesterase	Rattus norvegicus	15-29
23524625-1	2013	OBJECTIVES: We previously demonstrated that the direct microinjection of cholinesterase inhibitor (neostigmine) into the hippocampus in rats activated the hypothalamo-pituitary -adrenal axis and increased the level of norepinephrine in the plasma.	Neostigmine	99-110	butyrylcholinesterase	Rattus norvegicus	73-87
23221863-2	2013	In this study, the authors tested the spinal mechanisms underlying the antihypersensitivity effects of donepezil, a central nervous system-penetrating cholinesterase inhibitor, in a rat model of neuropathic pain.	Donepezil	103-112	butyrylcholinesterase	Rattus norvegicus	151-165
24279816-2	2013	Tissue (brain, plasma, liver) levels of the N-methyl carbamate carbaryl, and its metabolite 1-naphthol, were determined and related to brain and RBC cholinesterase (ChE) inhibition in the same animals.	n-methyl carbamate carbaryl	44-71	butyrylcholinesterase	Rattus norvegicus	149-163
24279816-8	2013	Brain ChE inhibition closely tracked brain carbaryl concentrations regardless of the time after dosing, but there was more variability in the relationship between RBC ChE and plasma carbaryl levels.	Carbaryl	182-190	butyrylcholinesterase	Rattus norvegicus	167-170
24279816-9	2013	Within-subject analyses suggested somewhat more brain ChE inhibition at lower carbaryl levels only in the PND18 rats.	Carbaryl	78-86	butyrylcholinesterase	Rattus norvegicus	54-57
23531217-1	2013	K203 is an experimental bis-pyridinium mono-aldoxime type cholinesterase reactivator of potential use in organophosphate/ organophosphonate poisoning.	2-Methyl-5-phenylbenzothiazole	0-4	butyrylcholinesterase	Rattus norvegicus	58-72
23531217-1	2013	K203 is an experimental bis-pyridinium mono-aldoxime type cholinesterase reactivator of potential use in organophosphate/ organophosphonate poisoning.	bis-pyridinium	24-38	butyrylcholinesterase	Rattus norvegicus	58-72
23531217-1	2013	K203 is an experimental bis-pyridinium mono-aldoxime type cholinesterase reactivator of potential use in organophosphate/ organophosphonate poisoning.	Organophosphates	105-120	butyrylcholinesterase	Rattus norvegicus	58-72
23531217-1	2013	K203 is an experimental bis-pyridinium mono-aldoxime type cholinesterase reactivator of potential use in organophosphate/ organophosphonate poisoning.	Organophosphonates	122-139	butyrylcholinesterase	Rattus norvegicus	58-72
23524625-1	2013	OBJECTIVES: We previously demonstrated that the direct microinjection of cholinesterase inhibitor (neostigmine) into the hippocampus in rats activated the hypothalamo-pituitary -adrenal axis and increased the level of norepinephrine in the plasma.	Norepinephrine	218-232	butyrylcholinesterase	Rattus norvegicus	73-87
23469045-2	2013	We investigated the ability of a cholinesterase (ChE) inhibitor rivastigmine, to improve the pathology of ulcerative colitis by increasing the concentration of extracellular acetylcholine in the brain and periphery.	Rivastigmine	64-76	butyrylcholinesterase	Rattus norvegicus	33-47
23469045-2	2013	We investigated the ability of a cholinesterase (ChE) inhibitor rivastigmine, to improve the pathology of ulcerative colitis by increasing the concentration of extracellular acetylcholine in the brain and periphery.	Rivastigmine	64-76	butyrylcholinesterase	Rattus norvegicus	49-52
23469045-8	2013	Rivastigmine 1 and 2 mg given rectally to rats with colitis induced by rectal administration of 30 mg dintrobezene sulfonic acid (DNBS) also caused a dose related reduction in ChE activity in blood and colon, the number of ulcers and area of ulceration, levels of TNF-alpha and in MPO activity.	Rivastigmine	0-12	butyrylcholinesterase	Rattus norvegicus	176-179
23469045-2	2013	We investigated the ability of a cholinesterase (ChE) inhibitor rivastigmine, to improve the pathology of ulcerative colitis by increasing the concentration of extracellular acetylcholine in the brain and periphery.	Acetylcholine	174-187	butyrylcholinesterase	Rattus norvegicus	33-47
23469045-2	2013	We investigated the ability of a cholinesterase (ChE) inhibitor rivastigmine, to improve the pathology of ulcerative colitis by increasing the concentration of extracellular acetylcholine in the brain and periphery.	Acetylcholine	174-187	butyrylcholinesterase	Rattus norvegicus	49-52
22991071-1	2012	The present study aimed to investigate the influence of N-acetylcysteine (NAC) on cadmium (Cd) poisoning by evaluating Cd concentration in tissues, hematological indices as well as the activity of NTPDase, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes of rats exposed to Cd and co-treated with NAC.	Acetylcysteine	74-77	butyrylcholinesterase	Rattus norvegicus	238-259
23469045-8	2013	Rivastigmine 1 and 2 mg given rectally to rats with colitis induced by rectal administration of 30 mg dintrobezene sulfonic acid (DNBS) also caused a dose related reduction in ChE activity in blood and colon, the number of ulcers and area of ulceration, levels of TNF-alpha and in MPO activity.	dintrobezene sulfonic acid	102-128	butyrylcholinesterase	Rattus norvegicus	176-179
23469045-8	2013	Rivastigmine 1 and 2 mg given rectally to rats with colitis induced by rectal administration of 30 mg dintrobezene sulfonic acid (DNBS) also caused a dose related reduction in ChE activity in blood and colon, the number of ulcers and area of ulceration, levels of TNF-alpha and in MPO activity.	2,4-dinitrofluorobenzene sulfonic acid	130-134	butyrylcholinesterase	Rattus norvegicus	176-179
23469045-9	2013	The study revealed that the ChE inhibitor rivastigmine is able to reduce gastro-intestinal inflammation by actions at various sites at which it preserves ACh.	Rivastigmine	42-54	butyrylcholinesterase	Rattus norvegicus	28-31
23469045-9	2013	The study revealed that the ChE inhibitor rivastigmine is able to reduce gastro-intestinal inflammation by actions at various sites at which it preserves ACh.	Acetylcholine	154-157	butyrylcholinesterase	Rattus norvegicus	28-31
22999973-10	2012	Cholinergic function was improved by naringenin through the inhibition of elevated ChE activity.	naringenin	37-47	butyrylcholinesterase	Rattus norvegicus	83-86
22999973-11	2012	In conclusion, the present study suggests that naringenin acts as an antioxidant and ChE inhibitor against type-2 diabetes-induced memory dysfunction.	naringenin	47-57	butyrylcholinesterase	Rattus norvegicus	85-88
22991071-1	2012	The present study aimed to investigate the influence of N-acetylcysteine (NAC) on cadmium (Cd) poisoning by evaluating Cd concentration in tissues, hematological indices as well as the activity of NTPDase, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes of rats exposed to Cd and co-treated with NAC.	Acetylcysteine	74-77	butyrylcholinesterase	Rattus norvegicus	261-265
22991071-11	2012	Cd caused a decrease in the activities of lymphocyte AChE, whole blood AChE and serum BChE.	Cadmium	0-2	butyrylcholinesterase	Rattus norvegicus	86-90
23122842-0	2012	Oxidative stress and cholinesterase inhibition in plasma, erythrocyte and brain of rats" pups following lactational exposure to malathion.	Malathion	128-137	butyrylcholinesterase	Rattus norvegicus	21-35
23122842-8	2012	Our results showed that the malathion exposure during lactation induced a high inhibitory effect of the brain, plasma and erythrocyte AChE and BChE activities in rat pups.	Malathion	28-37	butyrylcholinesterase	Rattus norvegicus	143-147
22917606-6	2012	The combination of an ineffective dose of intrathecal dexmedetomidine with intraperitoneal donepezil, which is a cholinesterase inhibitor, decreased neuropathic hypersensitivity.	Dexmedetomidine	54-69	butyrylcholinesterase	Rattus norvegicus	113-127
22668071-4	2012	This study attempted to investigate the effect of CAP on the pharmacokinetics of galantamine, a competitive and reversible cholinesterase inhibitor.	Galantamine	81-92	butyrylcholinesterase	Rattus norvegicus	123-137
22922167-3	2012	Assays were carried out for AChE and BuChE activity in the presence of their specific chemical inhibitors, BW284C51 and iso-OMPA, respectively.	Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide	107-115	butyrylcholinesterase	Rattus norvegicus	37-42
22922167-3	2012	Assays were carried out for AChE and BuChE activity in the presence of their specific chemical inhibitors, BW284C51 and iso-OMPA, respectively.	Tetraisopropylpyrophosphamide	120-128	butyrylcholinesterase	Rattus norvegicus	37-42
22917606-6	2012	The combination of an ineffective dose of intrathecal dexmedetomidine with intraperitoneal donepezil, which is a cholinesterase inhibitor, decreased neuropathic hypersensitivity.	Donepezil	91-100	butyrylcholinesterase	Rattus norvegicus	113-127
22280345-0	2012	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer"s disease treatment.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-10	butyrylcholinesterase	Rattus norvegicus	57-71
22871176-5	2012	The result of this study shows that DZN at higher doses increased the level of malondialdehyde, superoxide dismutase and glutathione S-transferase activities and decreased glutathione (GSH) level, lactate dehydrogenase, and cholinesterase activities in the brain, heart, and spleen of both rat strains.	Diazinon	36-39	butyrylcholinesterase	Rattus norvegicus	224-238
22941479-0	2012	Design and synthesis of novel 1,4-benzodiazepine derivatives and their biological evaluation as cholinesterase inhibitors.	Bz-423	30-48	butyrylcholinesterase	Rattus norvegicus	96-110
22624880-8	2012	The tacrine-silibinin codrug shows high AChE and BChE inhibition, neuroprotective effects, lacks tacrine"s hepatotoxicity in vitro and in vivo, and shows the same pro-cognitive effects in vivo as tacrine, being superior to the physical mixture of tacrine and silibinin in all these regards.	Tacrine	4-11	butyrylcholinesterase	Rattus norvegicus	49-53
22624880-8	2012	The tacrine-silibinin codrug shows high AChE and BChE inhibition, neuroprotective effects, lacks tacrine"s hepatotoxicity in vitro and in vivo, and shows the same pro-cognitive effects in vivo as tacrine, being superior to the physical mixture of tacrine and silibinin in all these regards.	Silybin	12-21	butyrylcholinesterase	Rattus norvegicus	49-53
22705881-1	2012	Donepezil hydrochloride is a reversible acetyl cholinesterase inhibitor approved for Alzheimer disease treatment.	Donepezil	0-23	butyrylcholinesterase	Rattus norvegicus	47-61
22504667-0	2012	Cholinesterase inhibition and toxicokinetics in immature and adult rats after acute or repeated exposures to chlorpyrifos or chlorpyrifos-oxon.	Chlorpyrifos	109-121	butyrylcholinesterase	Rattus norvegicus	0-14
22504667-0	2012	Cholinesterase inhibition and toxicokinetics in immature and adult rats after acute or repeated exposures to chlorpyrifos or chlorpyrifos-oxon.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	125-142	butyrylcholinesterase	Rattus norvegicus	0-14
22504667-1	2012	The effect of age or dose regimen on cholinesterase inhibition (ChEI) from chlorpyrifos (CPF) or CPF-oxon (CPFO) was studied in Crl:CD(SD) rats.	Chlorpyrifos	75-87	butyrylcholinesterase	Rattus norvegicus	37-51
22504667-1	2012	The effect of age or dose regimen on cholinesterase inhibition (ChEI) from chlorpyrifos (CPF) or CPF-oxon (CPFO) was studied in Crl:CD(SD) rats.	Chlorpyrifos	89-92	butyrylcholinesterase	Rattus norvegicus	37-51
22570941-3	2012	Elevated BChE activity in obese individuals correlates with some parameters of lipid metabolism including increased levels of triacylglycerols (TAG) and cholesterol.	Triglycerides	126-142	butyrylcholinesterase	Rattus norvegicus	9-13
22570941-4	2012	The aim of this study was to estimate the BChE activity in rats on subcellular and inter-organ levels under the conditions of untreated and treated primary hypertriacylglycerolemia with the TAG lowering agent fenofibrate.	Fenofibrate	209-220	butyrylcholinesterase	Rattus norvegicus	42-46
22570941-3	2012	Elevated BChE activity in obese individuals correlates with some parameters of lipid metabolism including increased levels of triacylglycerols (TAG) and cholesterol.	Cholesterol	153-164	butyrylcholinesterase	Rattus norvegicus	9-13
22570941-6	2012	However fenofibrate administration led to significant increase of BChE activity in all examined tissues (plasma, liver, white adipose tissue).	Fenofibrate	8-19	butyrylcholinesterase	Rattus norvegicus	66-70
22247004-4	2012	NEMP, PIMP, and NIMP were potent inhibitors of rat brain, skeletal muscle, diaphragm, and serum AChE as well as human erythrocyte AChE and serum BuChE in vitro.	nemp	0-4	butyrylcholinesterase	Rattus norvegicus	145-150
22570941-7	2012	The impact of lipid metabolic imbalance on BChE biotransformation ability was tested by measuring the rate of hydrolysis of 0,1 to 8 mM concentrations of the antimicrobial agent N-(2-benzoyloxyethyl)-ethyldimethylammonium bromide (BCH2).	n-(2-benzoyloxyethyl)-ethyldimethylammonium bromide	178-229	butyrylcholinesterase	Rattus norvegicus	43-47
22570941-7	2012	The impact of lipid metabolic imbalance on BChE biotransformation ability was tested by measuring the rate of hydrolysis of 0,1 to 8 mM concentrations of the antimicrobial agent N-(2-benzoyloxyethyl)-ethyldimethylammonium bromide (BCH2).	bch2	231-235	butyrylcholinesterase	Rattus norvegicus	43-47
22570941-10	2012	In contrast, in animals treated with fenofibrate the BChE efficiency increased in liver 1,6-fold.	Fenofibrate	37-48	butyrylcholinesterase	Rattus norvegicus	53-57
22247004-4	2012	NEMP, PIMP, and NIMP were potent inhibitors of rat brain, skeletal muscle, diaphragm, and serum AChE as well as human erythrocyte AChE and serum BuChE in vitro.	nimp	16-20	butyrylcholinesterase	Rattus norvegicus	145-150
21295576-3	2011	This study tested whether combining the cholinesterase inhibitor donepezil with estradiol treatment can enhance/restore estradiol effects on cognitive performance in young ovariectomized rats with selective lesions of septal cholinergic neurons.	Donepezil	65-74	butyrylcholinesterase	Rattus norvegicus	40-54
22044027-1	2012	The aim of the study was mainly to investigate the relationship between concentration of rivastigmine and its inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) following intranasal (IN) and intravenous (IV) administration in rats, and to provide a novel nasal delivery route for the brain disease therapy.	Rivastigmine	89-101	butyrylcholinesterase	Rattus norvegicus	156-177
22044027-1	2012	The aim of the study was mainly to investigate the relationship between concentration of rivastigmine and its inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) following intranasal (IN) and intravenous (IV) administration in rats, and to provide a novel nasal delivery route for the brain disease therapy.	Rivastigmine	89-101	butyrylcholinesterase	Rattus norvegicus	179-184
22044027-8	2012	Based on these findings, it was concluded that rivastigmine could cause relatively strong inhibition of AChE and BuChE in plasma and brain tissues, especially in hippocampus, cortex and cerebrum.	Rivastigmine	47-59	butyrylcholinesterase	Rattus norvegicus	113-118
22138106-6	2012	Distigmine bromide, a peripheral, non-selective cholinesterase inhibitor (0.01mg/kg), was administered subcutaneously 90 min after surgery.	distigmine	0-18	butyrylcholinesterase	Rattus norvegicus	48-62
22138106-12	2012	CONCLUSIONS: The cholinesterase inhibitor distigmine inhibited induction of inflammatory cytokines and catecholamines as well as HRV suppression in a rat CLP model, suggesting that an agent modulating the cholinergic anti-inflammatory pathway can control excess cytokine production involved in the pathogenesis of severe sepsis/septic shock.	distigmine	42-52	butyrylcholinesterase	Rattus norvegicus	17-31
22138106-12	2012	CONCLUSIONS: The cholinesterase inhibitor distigmine inhibited induction of inflammatory cytokines and catecholamines as well as HRV suppression in a rat CLP model, suggesting that an agent modulating the cholinergic anti-inflammatory pathway can control excess cytokine production involved in the pathogenesis of severe sepsis/septic shock.	Catecholamines	103-117	butyrylcholinesterase	Rattus norvegicus	17-31
22033501-8	2012	In contrast, the higher dose (100 mM solution) of atropine, the cholinergic agonist carbachol (32 mM solution), and the cholinesterase inhibitor physostigmine (13 mM solution) all decreased the number of UP states, delta power (0-3 Hz) and MUA.	Physostigmine	145-158	butyrylcholinesterase	Rattus norvegicus	120-134
22191561-17	2012	Differences in the activity of the cholinergic precursor and AChE inhibitor investigated on CHT and VAChT suggests that association between choline alphoscerate and AChE/cholinesterase inhibitors may represent a strategy for potentiating deficient cholinergic neurotransmission worthwhile of being investigated in clinical trials.	Glycerylphosphorylcholine	140-160	butyrylcholinesterase	Rattus norvegicus	170-184
22912888-7	2012	This suppression of locomotor activity required active enzyme, as it was lost after pretreatment with iso-OMPA, a selective BChE inhibitor.	Tetraisopropylpyrophosphamide	102-110	butyrylcholinesterase	Rattus norvegicus	124-128
21571001-1	2011	Dichlorvos (DDVP) causes neurotoxicity primarily by inhibiting cholinesterase (ChE) which is the characteristic feature of organophosphate pesticides.	Organophosphates	123-138	butyrylcholinesterase	Rattus norvegicus	63-77
21571001-1	2011	Dichlorvos (DDVP) causes neurotoxicity primarily by inhibiting cholinesterase (ChE) which is the characteristic feature of organophosphate pesticides.	Organophosphates	123-138	butyrylcholinesterase	Rattus norvegicus	79-82
21889940-2	2011	This study tested whether galanthamine, a cholinesterase inhibitor used to treat memory impairment associated with Alzheimer"s disease, could enhance or restore estradiol effects on cognitive performance in aged rats that had been ovariectomized in middle-age.	Galantamine	26-38	butyrylcholinesterase	Rattus norvegicus	42-56
21889940-13	2011	The data suggest that treating with a cholinesterase inhibitor can enhance the effects of estradiol on acquisition of a DMP task by old rats following a long period of hormone deprivation.	Estradiol	90-99	butyrylcholinesterase	Rattus norvegicus	38-52
21889940-13	2011	The data suggest that treating with a cholinesterase inhibitor can enhance the effects of estradiol on acquisition of a DMP task by old rats following a long period of hormone deprivation.	dmp	120-123	butyrylcholinesterase	Rattus norvegicus	38-52
21723789-7	2011	The significant decrease in cholinesterase activity observed in the PTZ and MES models was significantly reversed by pretreatment with HEZJ.	Pentylenetetrazole	68-71	butyrylcholinesterase	Rattus norvegicus	28-42
21723789-7	2011	The significant decrease in cholinesterase activity observed in the PTZ and MES models was significantly reversed by pretreatment with HEZJ.	2-(N-morpholino)ethanesulfonic acid	76-79	butyrylcholinesterase	Rattus norvegicus	28-42
21723789-7	2011	The significant decrease in cholinesterase activity observed in the PTZ and MES models was significantly reversed by pretreatment with HEZJ.	hezj	135-139	butyrylcholinesterase	Rattus norvegicus	28-42
21507991-7	2011	At 4-h postexposure on day 16, forebrain cholinesterase (ChE) activity and hydrolysis of 2-AG and AEA were inhibited in a dose-related manner, and the extent of inhibition from highest to lowest level was AEA hydrolysis > ChE activity > 2-AG hydrolysis.	anandamide	205-208	butyrylcholinesterase	Rattus norvegicus	41-55
21507991-7	2011	At 4-h postexposure on day 16, forebrain cholinesterase (ChE) activity and hydrolysis of 2-AG and AEA were inhibited in a dose-related manner, and the extent of inhibition from highest to lowest level was AEA hydrolysis > ChE activity > 2-AG hydrolysis.	anandamide	205-208	butyrylcholinesterase	Rattus norvegicus	57-60
21507991-8	2011	The extent of inhibition of AEA hydrolysis was approximately twice than that of ChE activity with AEA hydrolysis being virtually eliminated by 2.5 and 5.0 mg/kg and 1.0 mg/kg causing 40% inhibition.	anandamide	98-101	butyrylcholinesterase	Rattus norvegicus	80-83
20488854-6	2011	There were non-significant changes in the activity of cholinesterase enzyme in cerebellum and medulla, while in midbrain and hypothalamus the CLO, DHA and EPA enhanced the activity by 75%, 100% and 78%, respectively.	Cod Liver Oil	142-145	butyrylcholinesterase	Rattus norvegicus	54-68
20488854-6	2011	There were non-significant changes in the activity of cholinesterase enzyme in cerebellum and medulla, while in midbrain and hypothalamus the CLO, DHA and EPA enhanced the activity by 75%, 100% and 78%, respectively.	Eicosapentaenoic Acid	155-158	butyrylcholinesterase	Rattus norvegicus	54-68
22222554-2	2012	We administered chlorpyrifos or diazinon to newborn rats on postnatal days 1-4, in doses straddling the threshold for barely-detectable cholinesterase inhibition, and evaluated gene expression in the cell cycle and apoptosis pathways on postnatal day 5.	Diazinon	32-40	butyrylcholinesterase	Rattus norvegicus	136-150
22012612-0	2012	Chronic methylphenidate administration alters antioxidant defenses and butyrylcholinesterase activity in blood of juvenile rats.	Methylphenidate	8-23	butyrylcholinesterase	Rattus norvegicus	71-92
23569832-7	2012	The cholinesterase activity was inhibited, but the activities of alkaline and acid phosphates and lactate dehydrogenase were stimulated, while plasma glucose level was elevated as a result of lead acetate intoxication.	Acetates	197-204	butyrylcholinesterase	Rattus norvegicus	4-18
20976626-0	2011	Synthesis and preliminary evaluation of piperidinyl and pyrrolidinyl iodobenzoates as imaging agents for butyrylcholinesterase.	piperidino	40-51	butyrylcholinesterase	Rattus norvegicus	105-126
20976626-0	2011	Synthesis and preliminary evaluation of piperidinyl and pyrrolidinyl iodobenzoates as imaging agents for butyrylcholinesterase.	pyrrolidinyl iodobenzoates	56-82	butyrylcholinesterase	Rattus norvegicus	105-126
20976626-4	2011	PROCEDURES: Iodobenzoate esters were synthesized and tested, through spectrophotometric analysis, as specific substrates for BuChE.	iodobenzoate esters	12-31	butyrylcholinesterase	Rattus norvegicus	125-130
20976626-8	2011	RESULTS: The three iodobenzoate esters studied were specific substrates for BuChE.	iodobenzoate esters	19-38	butyrylcholinesterase	Rattus norvegicus	76-81
20976626-11	2011	CONCLUSION: BuChE-specific radiolabeled iodobenzoates enter the brain and, in general, label areas known to exhibit BuChE activity in histochemical studies.	Iodobenzoates	40-53	butyrylcholinesterase	Rattus norvegicus	12-17
20976626-11	2011	CONCLUSION: BuChE-specific radiolabeled iodobenzoates enter the brain and, in general, label areas known to exhibit BuChE activity in histochemical studies.	Iodobenzoates	40-53	butyrylcholinesterase	Rattus norvegicus	116-121
21679767-1	2011	Age-related differences in the acute neurotoxicity of cholinesterase (ChE)-inhibiting pesticides have been well-studied for a few organophosphates, but not for many others.	Organophosphates	130-146	butyrylcholinesterase	Rattus norvegicus	54-68
21679767-1	2011	Age-related differences in the acute neurotoxicity of cholinesterase (ChE)-inhibiting pesticides have been well-studied for a few organophosphates, but not for many others.	Organophosphates	130-146	butyrylcholinesterase	Rattus norvegicus	70-73
21440537-3	2011	In this study we investigated the behavioral effects of aluminum in rats and the possible effect of rivastigmine, a cholinesterase inhibitor, on the aluminum-induced behavioral changes.	Rivastigmine	100-112	butyrylcholinesterase	Rattus norvegicus	116-130
21340455-1	2011	The in vivo and in vitro effects of the pesticide endosulfan on the cholinesterase (ChE) activity were investigated in rats.	Endosulfan	50-60	butyrylcholinesterase	Rattus norvegicus	68-82
21340455-1	2011	The in vivo and in vitro effects of the pesticide endosulfan on the cholinesterase (ChE) activity were investigated in rats.	Endosulfan	50-60	butyrylcholinesterase	Rattus norvegicus	84-87
21340455-2	2011	ChE activity decreased in dams and in male pups within 65 days corresponding to 35% and 32% of inhibition respectively in the higher endosulfan dose (1.5 mg/kg).	Endosulfan	133-143	butyrylcholinesterase	Rattus norvegicus	0-3
21340455-4	2011	The results suggest that endosulfan is able to inhibit the ChE activity and to cross the placental barrier and/or to be eliminated through milk affecting the enzyme activity in male rat pups.	Endosulfan	25-35	butyrylcholinesterase	Rattus norvegicus	59-62
21094673-1	2011	The ubiquitous cholinesterase (ChE) enzymes, functioning in the termination of acetylcholine mediated neural transmission, are also reported to have additional functions.	Acetylcholine	79-92	butyrylcholinesterase	Rattus norvegicus	15-29
21094673-1	2011	The ubiquitous cholinesterase (ChE) enzymes, functioning in the termination of acetylcholine mediated neural transmission, are also reported to have additional functions.	Acetylcholine	79-92	butyrylcholinesterase	Rattus norvegicus	31-34
21094673-6	2011	Forskolin-stimulated R28 cells displayed a robust cholinergic response, as detected by both electrophysiology and ChE expression, and changed the activation status of PKC/ERK signaling pathways.	Colforsin	0-9	butyrylcholinesterase	Rattus norvegicus	114-117
21148081-0	2011	Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.	Donepezil	76-85	butyrylcholinesterase	Rattus norvegicus	50-64
21148081-0	2011	Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.	Tacrine	87-94	butyrylcholinesterase	Rattus norvegicus	50-64
21148081-0	2011	Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.	Galantamine	100-111	butyrylcholinesterase	Rattus norvegicus	50-64
22173266-0	2011	Reversible and persistent decreases in cocaine self-administration after cholinesterase inhibition:  different effects of donepezil and rivastigmine.	Cocaine	39-46	butyrylcholinesterase	Rattus norvegicus	73-87
22173266-3	2011	This study was carried out to evaluate the effects of donepezil (which selectively inhibits AChE) and rivastigmine (which inhibits both AChE and butyrylcholinesterase) on cocaine self-administration.	Cocaine	171-178	butyrylcholinesterase	Rattus norvegicus	145-166
22173266-1	2011	We recently observed that pretreatment with the cholinesterase inhibitor, tacrine can produce long-lasting reductions in cocaine-reinforced behavior, described as persistent attenuation.	Tacrine	74-81	butyrylcholinesterase	Rattus norvegicus	48-62
22173266-1	2011	We recently observed that pretreatment with the cholinesterase inhibitor, tacrine can produce long-lasting reductions in cocaine-reinforced behavior, described as persistent attenuation.	Cocaine	121-128	butyrylcholinesterase	Rattus norvegicus	48-62
22173266-3	2011	This study was carried out to evaluate the effects of donepezil (which selectively inhibits AChE) and rivastigmine (which inhibits both AChE and butyrylcholinesterase) on cocaine self-administration.	Rivastigmine	102-114	butyrylcholinesterase	Rattus norvegicus	145-166
21343668-9	2011	The amelioration was accompanied by a reversal of the infarction-induced reduction of cholinesterase-positive nerves and M(2)-receptor expression and B(max) in the adenine sulfate high dose group.	ADENINE SULFATE	164-179	butyrylcholinesterase	Rattus norvegicus	86-100
20971004-4	2010	Moreover, combination studies with a cholinesterase inhibitor show apparent synergistic effects on working memory impairment induced by scopolamine.	Scopolamine	136-147	butyrylcholinesterase	Rattus norvegicus	37-51
32272538-9	2011	The amelioration was accompanied by a reversal of the infarction-induced reduction of cholinesterase-positive nerves and M2-receptor expression and Bmax in the adenine sulfate high dose group.	ADENINE SULFATE	160-175	butyrylcholinesterase	Rattus norvegicus	86-100
20816709-7	2010	Paraoxon-induced ChE inhibition depresses excitatory synaptic transmission and facilitates somatic excitability mediated by mAChRs, and the latter counteracts influence of the depressed synaptic transmission on somatic action potentials.	Paraoxon	0-8	butyrylcholinesterase	Rattus norvegicus	17-20
20890617-2	2010	The present study was undertaken in the rat spared nerve injury model of neuropathic pain to evaluate the effect of the cholinesterase inhibitor donepezil when administered (1) alone and (2) as low-dose in combination with the first-line recommendation gabapentin.	Donepezil	145-154	butyrylcholinesterase	Rattus norvegicus	120-134
20816720-1	2010	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and seizure-related brain damage (SRBD) in which acetylcholine and glutamate are involved.	organophosphorus	4-20	butyrylcholinesterase	Rattus norvegicus	58-72
20816720-1	2010	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and seizure-related brain damage (SRBD) in which acetylcholine and glutamate are involved.	organophosphorus	4-20	butyrylcholinesterase	Rattus norvegicus	74-77
20816720-1	2010	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and seizure-related brain damage (SRBD) in which acetylcholine and glutamate are involved.	srbd	162-166	butyrylcholinesterase	Rattus norvegicus	58-72
20816720-1	2010	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and seizure-related brain damage (SRBD) in which acetylcholine and glutamate are involved.	srbd	162-166	butyrylcholinesterase	Rattus norvegicus	74-77
20816720-1	2010	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and seizure-related brain damage (SRBD) in which acetylcholine and glutamate are involved.	Acetylcholine	177-190	butyrylcholinesterase	Rattus norvegicus	58-72
20816720-1	2010	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and seizure-related brain damage (SRBD) in which acetylcholine and glutamate are involved.	Acetylcholine	177-190	butyrylcholinesterase	Rattus norvegicus	74-77
20816720-1	2010	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and seizure-related brain damage (SRBD) in which acetylcholine and glutamate are involved.	Glutamic Acid	195-204	butyrylcholinesterase	Rattus norvegicus	74-77
20816720-8	2010	Furthermore, the administration, immediately after soman, of a three-drug therapy composed of atropine sulfate, HI-6 and avizafone abolished the convulsions, the transient drop of DPOAEs at 4h and the occurrence of SRBD at 28 h without modifying brain ChE inhibition.	Atropine	94-110	butyrylcholinesterase	Rattus norvegicus	252-255
20816720-8	2010	Furthermore, the administration, immediately after soman, of a three-drug therapy composed of atropine sulfate, HI-6 and avizafone abolished the convulsions, the transient drop of DPOAEs at 4h and the occurrence of SRBD at 28 h without modifying brain ChE inhibition.	asoxime chloride	112-116	butyrylcholinesterase	Rattus norvegicus	252-255
20816720-8	2010	Furthermore, the administration, immediately after soman, of a three-drug therapy composed of atropine sulfate, HI-6 and avizafone abolished the convulsions, the transient drop of DPOAEs at 4h and the occurrence of SRBD at 28 h without modifying brain ChE inhibition.	pro-diazepam	121-130	butyrylcholinesterase	Rattus norvegicus	252-255
20599604-0	2010	Guanidino compounds inhibit acetylcholinesterase and butyrylcholinesterase activities: effect neuroprotector of vitamins E plus C. Hyperargininemia is a metabolic disorder biochemically characterized by tissue accumulating of arginine and other guanidino compounds.	guanidino compounds	0-19	butyrylcholinesterase	Rattus norvegicus	53-74
20708061-0	2010	Relationship between brain and plasma carbaryl levels and cholinesterase inhibition.	Carbaryl	38-46	butyrylcholinesterase	Rattus norvegicus	58-72
20708061-1	2010	Carbaryl is a N-methylcarbamate pesticide and, like others in this class, is a reversible inhibitor of cholinesterase (ChE) enzymes.	Carbaryl	0-8	butyrylcholinesterase	Rattus norvegicus	103-117
20708061-1	2010	Carbaryl is a N-methylcarbamate pesticide and, like others in this class, is a reversible inhibitor of cholinesterase (ChE) enzymes.	Carbaryl	0-8	butyrylcholinesterase	Rattus norvegicus	119-122
20708061-2	2010	Although studied for many years, there is a surprising lack of information relating tissue levels of carbaryl with ChE activity in the same animals.	Carbaryl	101-109	butyrylcholinesterase	Rattus norvegicus	115-118
20708061-4	2010	Additionally, the time-course of plasma ChE activity and carbaryl levels in adult rats was determined after a 30 mg/kg dosage of carbaryl.	Carbaryl	129-137	butyrylcholinesterase	Rattus norvegicus	40-43
20708061-9	2010	Finally, the dose-related relationship between tissue levels of carbaryl and ChE activity was described using a first order exponential decay function with an asymptote.	Carbaryl	64-72	butyrylcholinesterase	Rattus norvegicus	77-80
20708061-11	2010	This indicates that age-related differences in brain ChE inhibition by carbaryl are unlikely to be the result of greater tissue levels of the pesticide in PND11 animals.	Carbaryl	71-79	butyrylcholinesterase	Rattus norvegicus	53-56
20708061-12	2010	These are the first studies to report the relationship between brain and plasma tissue levels of carbaryl and ChE activity on an individual animal basis.	Carbaryl	97-105	butyrylcholinesterase	Rattus norvegicus	110-113
20634259-2	2010	The neurotoxic effects of TCA were evaluated by measuring the activities of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).	Trichloroacetic Acid	26-29	butyrylcholinesterase	Rattus norvegicus	108-129
20634259-2	2010	The neurotoxic effects of TCA were evaluated by measuring the activities of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).	Trichloroacetic Acid	26-29	butyrylcholinesterase	Rattus norvegicus	131-135
20634259-4	2010	Results showed that the administrations of TCA decreased BChE activities in heart and lungs tissue of the rats treated with TCA.	Trichloroacetic Acid	43-46	butyrylcholinesterase	Rattus norvegicus	57-61
20634259-4	2010	Results showed that the administrations of TCA decreased BChE activities in heart and lungs tissue of the rats treated with TCA.	Trichloroacetic Acid	124-127	butyrylcholinesterase	Rattus norvegicus	57-61
20634259-6	2010	The observations presented led us to conclude that the administration of TCA at subchronic was decreased BChE and ADA activities whereas increased MPO activity in various tissues of rats.	Trichloroacetic Acid	73-76	butyrylcholinesterase	Rattus norvegicus	105-109
20599604-7	2010	Results showed that these antioxidants were able to prevent the alteration on acetylcholinesterase and butyrylcholinesterase activities caused by guanidine compounds studied, suggesting that alterations on these cholinesterases were probably mediated by free radicals.	Guanidine	146-155	butyrylcholinesterase	Rattus norvegicus	103-124
20599604-3	2010	In the present study we initially investigated the in vitro effect of arginine, homoarginine, N-acetylarginine and argininic acid on acetylcholinesterase and butyrylcholinesterase in hippocampus and serum of 15-, 30- and 60-day-old rats.	Arginine	70-78	butyrylcholinesterase	Rattus norvegicus	158-179
20599604-3	2010	In the present study we initially investigated the in vitro effect of arginine, homoarginine, N-acetylarginine and argininic acid on acetylcholinesterase and butyrylcholinesterase in hippocampus and serum of 15-, 30- and 60-day-old rats.	Homoarginine	80-92	butyrylcholinesterase	Rattus norvegicus	158-179
20599604-3	2010	In the present study we initially investigated the in vitro effect of arginine, homoarginine, N-acetylarginine and argininic acid on acetylcholinesterase and butyrylcholinesterase in hippocampus and serum of 15-, 30- and 60-day-old rats.	N-acetyl-L-arginine	94-110	butyrylcholinesterase	Rattus norvegicus	158-179
20599604-3	2010	In the present study we initially investigated the in vitro effect of arginine, homoarginine, N-acetylarginine and argininic acid on acetylcholinesterase and butyrylcholinesterase in hippocampus and serum of 15-, 30- and 60-day-old rats.	argininic acid	115-129	butyrylcholinesterase	Rattus norvegicus	158-179
20599604-5	2010	On the other hand, butyrylcholinesterase was inhibited by homoarginine in serum of 15-day-old rats.	Homoarginine	58-70	butyrylcholinesterase	Rattus norvegicus	19-40
19784758-4	2010	Similarly, administration of methyl parathion (MP) resulted in neurotoxicity in the rats as evidenced from the inhibition of acetyl cholinesterase activity in their blood.	Methyl Parathion	29-45	butyrylcholinesterase	Rattus norvegicus	132-146
20605227-3	2010	Chronic oral administration of HC also significantly reversed the decline in acetyl cholinesterase and glutathione (GSH) activity induced by streptozotocin (STZ) injection.	Streptozocin	141-155	butyrylcholinesterase	Rattus norvegicus	84-98
20819637-0	2010	Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis.	Galantamine	35-47	butyrylcholinesterase	Rattus norvegicus	10-24
20819637-2	2010	Galanthamine is a cholinesterase inhibitor and one of the centrally acting cholinergic agents available in clinic.	Galantamine	0-12	butyrylcholinesterase	Rattus norvegicus	18-32
20819637-12	2010	CONCLUSION: Cholinesterase inhibitor galanthamine has an inhibitory effect on TNF-alpha release in rats with lipopolysaccharide-induced peritonitis, and the vagus nerve plays a role in the process of the action of galanthamine.	Galantamine	37-49	butyrylcholinesterase	Rattus norvegicus	12-26
20819637-12	2010	CONCLUSION: Cholinesterase inhibitor galanthamine has an inhibitory effect on TNF-alpha release in rats with lipopolysaccharide-induced peritonitis, and the vagus nerve plays a role in the process of the action of galanthamine.	Galantamine	214-226	butyrylcholinesterase	Rattus norvegicus	12-26
19850433-11	2010	Drospirenone cleavage in rat serum was effected by butyrylcholinesterase (BChE) and paraoxonase 1 (PON1) as we deduced from the high efficacy of certain serine hydrolase and metallohydrolase inhibitors, respectively.	drospirenone	0-12	butyrylcholinesterase	Rattus norvegicus	51-72
19850433-11	2010	Drospirenone cleavage in rat serum was effected by butyrylcholinesterase (BChE) and paraoxonase 1 (PON1) as we deduced from the high efficacy of certain serine hydrolase and metallohydrolase inhibitors, respectively.	drospirenone	0-12	butyrylcholinesterase	Rattus norvegicus	74-78
19504058-7	2010	Serum cholinesterase levels were markedly depressed with dichlorvos, and further suppressed markedly with magnesium sulfate pretreatment.	Magnesium Sulfate	106-123	butyrylcholinesterase	Rattus norvegicus	6-20
20088648-4	2010	MATERIALS AND METHODS: Animals fed an aflatoxin-contaminated diet (2.5 mg/kg diet) showed a significant decrease in all hematological parameters, cholesterol, triglycerides, cholinesterase, total protein, albumin, zinc and copper concentrations.	Aflatoxins	38-47	butyrylcholinesterase	Rattus norvegicus	174-188
20381606-6	2010	The results showed that in the rat offspring exposed to higher fluoride as compared to controls, the learning and memory ability declined; the cholinesterase activities in the brains were inhibited; the protein levels of alpha3, alpha4 and alpha7 nAChR subunits were decreased which showed certain significant correlations with the declined learning and memory ability; and the mRNA levels of alpha3 and alpha4 nAChRs were decreased, whereas the alpha7 mRNA increased.	Fluorides	63-71	butyrylcholinesterase	Rattus norvegicus	143-157
20600679-1	2010	The developmental neurotoxicity of organophosphates involves mechanisms other than their shared property as cholinesterase inhibitors, among which are excitotoxicity and oxidative stress.	Organophosphates	35-51	butyrylcholinesterase	Rattus norvegicus	108-122
20015457-3	2010	We administered parathion to rat pups on postnatal days 1-4, at doses spanning the threshold for the initial signs of systemic toxicity and for barely detectable cholinesterase inhibition (0.1 or 0.2 mg/kg/day).	Parathion	16-25	butyrylcholinesterase	Rattus norvegicus	162-176
20097188-3	2010	The objective of this study was to evaluate the impact of repeated nicotine exposure on the pharmacokinetics of chlorpyrifos (CPF) and its major metabolite, 3,5,6-trichloro-2-pyridinol (TCPy) in blood and urine and also to determine the impact on cholinesterase (ChE) activity in plasma and brain.	Chlorpyrifos	112-124	butyrylcholinesterase	Rattus norvegicus	247-261
20097188-3	2010	The objective of this study was to evaluate the impact of repeated nicotine exposure on the pharmacokinetics of chlorpyrifos (CPF) and its major metabolite, 3,5,6-trichloro-2-pyridinol (TCPy) in blood and urine and also to determine the impact on cholinesterase (ChE) activity in plasma and brain.	Chlorpyrifos	112-124	butyrylcholinesterase	Rattus norvegicus	263-266
20097188-3	2010	The objective of this study was to evaluate the impact of repeated nicotine exposure on the pharmacokinetics of chlorpyrifos (CPF) and its major metabolite, 3,5,6-trichloro-2-pyridinol (TCPy) in blood and urine and also to determine the impact on cholinesterase (ChE) activity in plasma and brain.	Chlorpyrifos	126-129	butyrylcholinesterase	Rattus norvegicus	247-261
20097188-3	2010	The objective of this study was to evaluate the impact of repeated nicotine exposure on the pharmacokinetics of chlorpyrifos (CPF) and its major metabolite, 3,5,6-trichloro-2-pyridinol (TCPy) in blood and urine and also to determine the impact on cholinesterase (ChE) activity in plasma and brain.	Chlorpyrifos	126-129	butyrylcholinesterase	Rattus norvegicus	263-266
19784758-4	2010	Similarly, administration of methyl parathion (MP) resulted in neurotoxicity in the rats as evidenced from the inhibition of acetyl cholinesterase activity in their blood.	Methyl Parathion	47-49	butyrylcholinesterase	Rattus norvegicus	132-146
19560506-1	2009	The Flinders Sensitive Line (FSL) of rats, developed as a line of rats with behavioral supersensitivity to diisopropyl fluorophosphates, a cholinesterase inhibitor, has been used as a rat model of depression.	Isoflurophate	107-135	butyrylcholinesterase	Rattus norvegicus	139-153
20648918-2	2010	In vitro, the two tacrine-ferulic acid hybrids show higher acetylcholinesterase (AChE) inhibitory activity and comparable butyrylcholinesterase (BChE) inhibitory activity compared to tacrine (CAS 1684-40-8).	Tacrine	18-25	butyrylcholinesterase	Rattus norvegicus	122-143
20648918-2	2010	In vitro, the two tacrine-ferulic acid hybrids show higher acetylcholinesterase (AChE) inhibitory activity and comparable butyrylcholinesterase (BChE) inhibitory activity compared to tacrine (CAS 1684-40-8).	Tacrine	18-25	butyrylcholinesterase	Rattus norvegicus	145-149
19949913-0	2010	Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure.	Donepezil	39-48	butyrylcholinesterase	Rattus norvegicus	14-28
20684482-0	2010	Effects of stress pretreatment on the dynamics of blood cholinesterase activity after exposure to an organophosphorus pesticide in the rat.	organophosphorus	101-117	butyrylcholinesterase	Rattus norvegicus	56-70
20684482-5	2010	The aim of the present work was to discover whether and in what way the IF pretreatment affects i) the cholinesterase activity in blood, and ii) the dynamics of the alterations in the cholinesterase (ChE) activity following the CVP exposure.	Chlorfenvinphos	228-231	butyrylcholinesterase	Rattus norvegicus	184-198
20684482-5	2010	The aim of the present work was to discover whether and in what way the IF pretreatment affects i) the cholinesterase activity in blood, and ii) the dynamics of the alterations in the cholinesterase (ChE) activity following the CVP exposure.	Chlorfenvinphos	228-231	butyrylcholinesterase	Rattus norvegicus	200-203
20648918-2	2010	In vitro, the two tacrine-ferulic acid hybrids show higher acetylcholinesterase (AChE) inhibitory activity and comparable butyrylcholinesterase (BChE) inhibitory activity compared to tacrine (CAS 1684-40-8).	ferulic acid	26-38	butyrylcholinesterase	Rattus norvegicus	122-143
20648918-2	2010	In vitro, the two tacrine-ferulic acid hybrids show higher acetylcholinesterase (AChE) inhibitory activity and comparable butyrylcholinesterase (BChE) inhibitory activity compared to tacrine (CAS 1684-40-8).	ferulic acid	26-38	butyrylcholinesterase	Rattus norvegicus	145-149
19839597-0	2009	Biomonitoring of organophosphorus agent exposure by reactivation of cholinesterase enzyme based on carbon nanotube-enhanced flow-injection amperometric detection.	organophosphorus	17-33	butyrylcholinesterase	Rattus norvegicus	68-82
19839597-0	2009	Biomonitoring of organophosphorus agent exposure by reactivation of cholinesterase enzyme based on carbon nanotube-enhanced flow-injection amperometric detection.	Carbon	99-105	butyrylcholinesterase	Rattus norvegicus	68-82
19839597-1	2009	A portable, rapid, and sensitive assessment of subclinical organophosphorus (OP) agent exposure based on reactivation of cholinesterase (ChE) from OP-inhibited ChE using rat saliva (in vitro) was developed using an electrochemical sensor coupled with a microflow-injection system.	organophosphorus	59-75	butyrylcholinesterase	Rattus norvegicus	121-135
19839597-1	2009	A portable, rapid, and sensitive assessment of subclinical organophosphorus (OP) agent exposure based on reactivation of cholinesterase (ChE) from OP-inhibited ChE using rat saliva (in vitro) was developed using an electrochemical sensor coupled with a microflow-injection system.	organophosphorus	59-75	butyrylcholinesterase	Rattus norvegicus	137-140
19839597-1	2009	A portable, rapid, and sensitive assessment of subclinical organophosphorus (OP) agent exposure based on reactivation of cholinesterase (ChE) from OP-inhibited ChE using rat saliva (in vitro) was developed using an electrochemical sensor coupled with a microflow-injection system.	organophosphorus	59-75	butyrylcholinesterase	Rattus norvegicus	160-163
19839597-4	2009	This manuscript describes an alternative strategy where reactivation of the phosphorylated enzyme was exploited to enable measurement of both inhibited and baseline ChE activity (after reactivation by an oxime, i.e., pralidoxime iodide) in the same sample.	pralidoxime	217-235	butyrylcholinesterase	Rattus norvegicus	165-168
19839597-7	2009	Some experimental parameters, e.g., inhibition and reactivation time, have been optimized such that 92-95% of ChE reactivation can be achieved over a broad range of ChE inhibition (5-94%) with paraoxon.	Paraoxon	193-201	butyrylcholinesterase	Rattus norvegicus	110-113
19839597-7	2009	Some experimental parameters, e.g., inhibition and reactivation time, have been optimized such that 92-95% of ChE reactivation can be achieved over a broad range of ChE inhibition (5-94%) with paraoxon.	Paraoxon	193-201	butyrylcholinesterase	Rattus norvegicus	165-168
19698738-0	2009	Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration.	Cocaine	26-33	butyrylcholinesterase	Rattus norvegicus	83-97
19728005-6	2009	Butylcholinesterase (BChE; EC 3.1.1.8) in plasma was inhibited less rapidly and only by 10-20%, 20 min after RVX.	S-(N,N-diethylaminoethyl) isobutyl methylphosphothiolate	109-112	butyrylcholinesterase	Rattus norvegicus	0-19
19728005-6	2009	Butylcholinesterase (BChE; EC 3.1.1.8) in plasma was inhibited less rapidly and only by 10-20%, 20 min after RVX.	S-(N,N-diethylaminoethyl) isobutyl methylphosphothiolate	109-112	butyrylcholinesterase	Rattus norvegicus	21-25
19433115-0	2009	Gulf War illness: Effects of repeated stress and pyridostigmine treatment on blood-brain barrier permeability and cholinesterase activity in rat brain.	Pyridostigmine Bromide	49-63	butyrylcholinesterase	Rattus norvegicus	114-128
19698738-0	2009	Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration.	Tacrine	108-115	butyrylcholinesterase	Rattus norvegicus	83-97
19698738-1	2009	Tacrine is a centrally acting, reversible cholinesterase inhibitor that increases synaptic levels of acetylcholine (ACh) and can potentiate the actions of dopamine (DA).	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	42-56
19698738-1	2009	Tacrine is a centrally acting, reversible cholinesterase inhibitor that increases synaptic levels of acetylcholine (ACh) and can potentiate the actions of dopamine (DA).	Dopamine	165-167	butyrylcholinesterase	Rattus norvegicus	42-56
19723529-1	2009	AIMS: It is well known that physostigmine (PHY) and other anticholinesterase (anti-ChE) agents induce hypothermia in rodents but little is known about the mechanism of action.	Physostigmine	28-41	butyrylcholinesterase	Rattus norvegicus	83-86
19930879-0	2009	[Therapeutic effects of benthiactzine against respiratory failure induced by cholinesterase inhibitor in rats].	benthiactzine	24-37	butyrylcholinesterase	Rattus norvegicus	77-91
19930879-1	2009	OBJECTIVE: To investigate the therapeutic effects of benthiactzine against respiratory failure induced by cholinesterase inhibitor dimethyl dichloro-vinyl phosphate (DDVP) in rats.	benthiactzine	53-66	butyrylcholinesterase	Rattus norvegicus	106-120
19930879-1	2009	OBJECTIVE: To investigate the therapeutic effects of benthiactzine against respiratory failure induced by cholinesterase inhibitor dimethyl dichloro-vinyl phosphate (DDVP) in rats.	Dichlorvos	131-164	butyrylcholinesterase	Rattus norvegicus	106-120
19738498-3	2009	Because corticotropin-releasing hormone is related to appetite control, we focused on the activation of the hypothalamo-pituitary-adrenal system and food intake following the administration of the cholinesterase inhibitor, donepezil, in rats.	Donepezil	223-232	butyrylcholinesterase	Rattus norvegicus	197-211
19578388-0	2009	Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors.	huperzine B	49-60	butyrylcholinesterase	Rattus norvegicus	78-92
19445928-3	2009	Rivastigmine, a well known cholinesterase inhibitor used in the management of Alzheimer"s disease in a clinical practice.	Rivastigmine	0-12	butyrylcholinesterase	Rattus norvegicus	27-41
19464315-7	2009	Both isoforms of vitamin E effectively attenuated the reduction in glutathione and catalase and reduced the malonaldehyde, nitrite as well as cholinesterase activity in the brains of ICV STZ rats in a dose dependent manner.	Vitamin E	17-26	butyrylcholinesterase	Rattus norvegicus	142-156
19338015-6	2009	The evaluation of cholinesterases activity showed good reactivation potency of blood AChE and plasma BChE by commercially available obidoxime and newly synthesized K347.	Obidoxime Chloride	132-141	butyrylcholinesterase	Rattus norvegicus	101-105
19338015-6	2009	The evaluation of cholinesterases activity showed good reactivation potency of blood AChE and plasma BChE by commercially available obidoxime and newly synthesized K347.	3-benzoylbenzoyl chloride	164-168	butyrylcholinesterase	Rattus norvegicus	101-105
19272400-14	2009	Furthermore, the proliferation/migration of cells containing high amounts of cholinesterase just adjacent to a dialysis probe could affect the recovery and thus detection of extracellular acetylcholine in microdialysis studies.	Acetylcholine	188-201	butyrylcholinesterase	Rattus norvegicus	77-91
19245810-1	2009	Plasma butyrylcholinesterase (BChE) hydrolyzes ester-containing compounds such as succinylcholine, as well as acting as a scavenger against neurotoxic organophosphates (OPs).	Succinylcholine	82-97	butyrylcholinesterase	Rattus norvegicus	7-28
19245810-1	2009	Plasma butyrylcholinesterase (BChE) hydrolyzes ester-containing compounds such as succinylcholine, as well as acting as a scavenger against neurotoxic organophosphates (OPs).	Organophosphates	151-167	butyrylcholinesterase	Rattus norvegicus	7-28
19245810-1	2009	Plasma butyrylcholinesterase (BChE) hydrolyzes ester-containing compounds such as succinylcholine, as well as acting as a scavenger against neurotoxic organophosphates (OPs).	Organophosphates	169-172	butyrylcholinesterase	Rattus norvegicus	7-28
19423342-0	2009	Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition.	Amines	75-81	butyrylcholinesterase	Rattus norvegicus	16-30
19423342-1	2009	Conjugation of the phenol derived from rivastigmine with amphetamines gave access to novel carbamate cholinesterase inhibitors.	Rivastigmine	39-51	butyrylcholinesterase	Rattus norvegicus	101-115
19423342-1	2009	Conjugation of the phenol derived from rivastigmine with amphetamines gave access to novel carbamate cholinesterase inhibitors.	Amphetamines	57-69	butyrylcholinesterase	Rattus norvegicus	101-115
19423342-3	2009	Compound 4a, incorporating d-amphetamine, caused significant inhibition of cholinesterase in vivo at doses that were well tolerated.	Dextroamphetamine	27-40	butyrylcholinesterase	Rattus norvegicus	75-89
19423342-4	2009	Release of amphetamine from 4a was demonstrated following in vitro and in vivo inhibition of cholinesterase.	Amphetamine	11-22	butyrylcholinesterase	Rattus norvegicus	93-107
19272400-0	2009	Cholinesterase inhibition and acetylcholine accumulation following intracerebral administration of paraoxon in rats.	Paraoxon	99-107	butyrylcholinesterase	Rattus norvegicus	0-14
19272400-1	2009	We evaluated the inhibition of striatal cholinesterase activity following intracerebral administration of paraoxon assaying activity either in tissue homogenates ex vivo or by substrate hydrolysis in situ.	Paraoxon	106-114	butyrylcholinesterase	Rattus norvegicus	40-54
19367692-1	2009	INTRODUCTION: Exposure to irreversible cholinesterase (ChE)-inhibiting compounds, such as organophosphates may produce neuromuscular dysfunction.	Organophosphates	90-106	butyrylcholinesterase	Rattus norvegicus	39-53
19272400-3	2009	High paraoxon concentrations were needed to inhibit ipsilateral striatal cholinesterase activity (no inhibition at <0.1 mM; 27% at 0.1 mM; 79% at 1 mM paraoxon).	Paraoxon	5-13	butyrylcholinesterase	Rattus norvegicus	73-87
19329372-5	2009	In addition, K203 reversibly inhibited AChE (Ki = 0.090 mmol L(-1)) and BChE (K(i) = 0.91 mmol L(-1)), and exhibited its protective effect against phosphorylation of AChE by tabun in vitro.	2-Methyl-5-phenylbenzothiazole	13-17	butyrylcholinesterase	Rattus norvegicus	72-76
19329372-7	2009	Moreover, K203 showed high therapeutic potency in tabun-poisoned rats, preserving cholinesterase activity in rat plasma up to 60 min after poisoning.	2-Methyl-5-phenylbenzothiazole	10-14	butyrylcholinesterase	Rattus norvegicus	82-96
19442822-2	2009	The neurotoxic effects of IBA were evaluated by measuring the activities of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).	indolebutyric acid	26-29	butyrylcholinesterase	Rattus norvegicus	108-129
19442822-2	2009	The neurotoxic effects of IBA were evaluated by measuring the activities of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).	indolebutyric acid	26-29	butyrylcholinesterase	Rattus norvegicus	131-135
19442822-6	2009	The observations presented led us to conclude that the administrations of IBA at subacute and subchronic exposure decreased AChE, BChE and ADA activities whereas increased MPO activity in various tissues of rats.	indolebutyric acid	74-77	butyrylcholinesterase	Rattus norvegicus	130-134
19440498-8	2009	CONCLUSIONS: Our results point to underlying mechanisms by which different organophosphates produce disparate neurotoxic outcomes despite their shared property as cholinesterase inhibitors.	Organophosphates	75-91	butyrylcholinesterase	Rattus norvegicus	163-177
19368821-7	2009	Our findings provide some of the first evidence for a specific mechanistic cascade contributing to the cholinesterase-independent developmental neurotoxicant actions of chlorpyrifos and its differences from diazinon, while at the same time identifying mechanistic convergence between otherwise unrelated toxicants that provides predictions about common neurodevelopmental outcomes.	Chlorpyrifos	169-181	butyrylcholinesterase	Rattus norvegicus	103-117
19367692-1	2009	INTRODUCTION: Exposure to irreversible cholinesterase (ChE)-inhibiting compounds, such as organophosphates may produce neuromuscular dysfunction.	Organophosphates	90-106	butyrylcholinesterase	Rattus norvegicus	55-58
19367692-11	2009	Treatment with physostigmine resulted in at least 50% inhibition of muscle ChE activity, but produced minimal changes in the MCD values in adults or juveniles.	Physostigmine	15-28	butyrylcholinesterase	Rattus norvegicus	75-78
18515453-5	2009	Furthermore, distigmine bromide was an equipotent inhibitor of AChE and butyrylcholinesterase (BuChE) activities in the present study.	distigmine	13-31	butyrylcholinesterase	Rattus norvegicus	72-93
18515453-5	2009	Furthermore, distigmine bromide was an equipotent inhibitor of AChE and butyrylcholinesterase (BuChE) activities in the present study.	distigmine	13-31	butyrylcholinesterase	Rattus norvegicus	95-100
18515453-6	2009	From these findings, it is suggested that distigmine bromide may produce centrally mediated behavioural signs by increasing the ACh levels in the brain, resulting from its AChE and BuChE inhibitions.	distigmine	42-60	butyrylcholinesterase	Rattus norvegicus	181-186
18515453-6	2009	From these findings, it is suggested that distigmine bromide may produce centrally mediated behavioural signs by increasing the ACh levels in the brain, resulting from its AChE and BuChE inhibitions.	Acetylcholine	128-131	butyrylcholinesterase	Rattus norvegicus	181-186
18796314-2	2009	Due to its faculty to protect cholinesterase (ChE) activity against irreversible inactivation by OP, pyridostigmine bromide (PB) was used as a prophylaxis treatment during the first Persian Gulf War.	Pyridostigmine Bromide	101-123	butyrylcholinesterase	Rattus norvegicus	30-44
18796314-2	2009	Due to its faculty to protect cholinesterase (ChE) activity against irreversible inactivation by OP, pyridostigmine bromide (PB) was used as a prophylaxis treatment during the first Persian Gulf War.	Pyridostigmine Bromide	101-123	butyrylcholinesterase	Rattus norvegicus	46-49
18796314-2	2009	Due to its faculty to protect cholinesterase (ChE) activity against irreversible inactivation by OP, pyridostigmine bromide (PB) was used as a prophylaxis treatment during the first Persian Gulf War.	Pyridostigmine Bromide	125-127	butyrylcholinesterase	Rattus norvegicus	30-44
18796314-2	2009	Due to its faculty to protect cholinesterase (ChE) activity against irreversible inactivation by OP, pyridostigmine bromide (PB) was used as a prophylaxis treatment during the first Persian Gulf War.	Pyridostigmine Bromide	125-127	butyrylcholinesterase	Rattus norvegicus	46-49
18796314-6	2009	PB treatment (1.5 mg/kg/day) was orally administered 30 min before each stress session to inhibit 40% of blood ChE as recommended by NATO.	Pyridostigmine Bromide	0-2	butyrylcholinesterase	Rattus norvegicus	111-114
18608756-3	2008	The antidepressants paroxetine, imipramine, clomipramine and sertraline inhibited both venom AChE as well as human serum BChE in a concentration-dependent manner but had no effect on AChE in the rat brain striatum.	Paroxetine	20-30	butyrylcholinesterase	Rattus norvegicus	121-125
18773955-1	2009	Neonatal exposures to organophosphates that are not acutely symptomatic or that produce little or no cholinesterase inhibition can nevertheless compromise the development and later function of critical neural pathways, including serotonin (5HT) systems that regulate emotional behaviors.	Organophosphates	22-38	butyrylcholinesterase	Rattus norvegicus	101-115
18773955-2	2009	We administered parathion to newborn rats on postnatal days (PN) 1-4 at doses spanning the threshold for detectable cholinesterase inhibition (0.1 mg/kg/day) and the first signs of loss of viability (0.2 mg/kg/day).	Parathion	16-25	butyrylcholinesterase	Rattus norvegicus	116-130
19371524-5	2009	Serum cholinesterase levels were suppressed with dichlorvos, and these reductions were inhibited with atropine and/or pralidoxime pretreatment.	Dichlorvos	49-59	butyrylcholinesterase	Rattus norvegicus	6-20
19371524-5	2009	Serum cholinesterase levels were suppressed with dichlorvos, and these reductions were inhibited with atropine and/or pralidoxime pretreatment.	Atropine	102-110	butyrylcholinesterase	Rattus norvegicus	6-20
19331513-1	2009	Derivative of 6-methyluracil, selective cholinesterase inhibitor C-547 potentiates miniature endplate currents (MEPCs) in rat external intercostal muscles (external ICM) more effectively than in internal intercostal muscles (internal ICM).	6-methyluracil	14-28	butyrylcholinesterase	Rattus norvegicus	40-54
19331513-1	2009	Derivative of 6-methyluracil, selective cholinesterase inhibitor C-547 potentiates miniature endplate currents (MEPCs) in rat external intercostal muscles (external ICM) more effectively than in internal intercostal muscles (internal ICM).	c-547	65-70	butyrylcholinesterase	Rattus norvegicus	40-54
18976927-8	2008	Interestingly, some derivatives displayed a moderate ability to inhibit rat brain cholinesterase, for example compound 12 (1-[2-(4"-piperidinomethyl-biphenyl-4-yl)ethyl]piperidine) has a pIC(50)=5.96 for cholinesterase inhibition and high H(3) receptor binding affinity and antagonist potency (pK(i)=8.70; pK(B)=9.28).	(1-(2-(4'-piperidinomethyl-biphenyl-4-yl)ethyl)piperidine)	123-179	butyrylcholinesterase	Rattus norvegicus	82-96
18976927-8	2008	Interestingly, some derivatives displayed a moderate ability to inhibit rat brain cholinesterase, for example compound 12 (1-[2-(4"-piperidinomethyl-biphenyl-4-yl)ethyl]piperidine) has a pIC(50)=5.96 for cholinesterase inhibition and high H(3) receptor binding affinity and antagonist potency (pK(i)=8.70; pK(B)=9.28).	(1-(2-(4'-piperidinomethyl-biphenyl-4-yl)ethyl)piperidine)	123-179	butyrylcholinesterase	Rattus norvegicus	204-218
18976927-9	2008	These compounds can be considered as rigid analogs of a recently reported class of dual-acting compounds and as a promising starting point for the design of new H(3)-antagonists with anti-cholinesterase activity.	HS 3	161-165	butyrylcholinesterase	Rattus norvegicus	188-202
18608756-3	2008	The antidepressants paroxetine, imipramine, clomipramine and sertraline inhibited both venom AChE as well as human serum BChE in a concentration-dependent manner but had no effect on AChE in the rat brain striatum.	Imipramine	32-42	butyrylcholinesterase	Rattus norvegicus	121-125
18608756-3	2008	The antidepressants paroxetine, imipramine, clomipramine and sertraline inhibited both venom AChE as well as human serum BChE in a concentration-dependent manner but had no effect on AChE in the rat brain striatum.	Clomipramine	44-56	butyrylcholinesterase	Rattus norvegicus	121-125
18608756-3	2008	The antidepressants paroxetine, imipramine, clomipramine and sertraline inhibited both venom AChE as well as human serum BChE in a concentration-dependent manner but had no effect on AChE in the rat brain striatum.	Sertraline	61-71	butyrylcholinesterase	Rattus norvegicus	121-125
18941570-1	2008	BACKGROUND: Organophosphates elicit developmental neurotoxicity through multiple mechanisms other than their shared property as cholinesterase inhibitors.	Organophosphates	12-28	butyrylcholinesterase	Rattus norvegicus	128-142
18991751-0	2008	Pyridinium oxime reactivators of cholinesterase inhibited by diisopropyl-fluorophosphate (DFP): predictive value of in-vitro testing for in-vivo efficacy.	pyridinium oxime	0-16	butyrylcholinesterase	Rattus norvegicus	33-47
18991751-0	2008	Pyridinium oxime reactivators of cholinesterase inhibited by diisopropyl-fluorophosphate (DFP): predictive value of in-vitro testing for in-vivo efficacy.	Isoflurophate	61-88	butyrylcholinesterase	Rattus norvegicus	33-47
18991751-0	2008	Pyridinium oxime reactivators of cholinesterase inhibited by diisopropyl-fluorophosphate (DFP): predictive value of in-vitro testing for in-vivo efficacy.	Isoflurophate	90-93	butyrylcholinesterase	Rattus norvegicus	33-47
18789379-5	2008	The activity of hepatic drug-metabolizing enzymes and expression of hepatic cytochrome P450 (CYP) 1A2, CYP3A2 and CYP2D1, which oxidize DZN to DZN-oxon, a potent ChE inhibitor, were measured before DZN injection.	Diazinon	136-139	butyrylcholinesterase	Rattus norvegicus	162-165
18789379-5	2008	The activity of hepatic drug-metabolizing enzymes and expression of hepatic cytochrome P450 (CYP) 1A2, CYP3A2 and CYP2D1, which oxidize DZN to DZN-oxon, a potent ChE inhibitor, were measured before DZN injection.	diazoxon	143-151	butyrylcholinesterase	Rattus norvegicus	162-165
18703558-0	2008	Effect of different administration paradigms on cholinesterase inhibition following repeated chlorpyrifos exposure in late preweanling rats.	Chlorpyrifos	93-105	butyrylcholinesterase	Rattus norvegicus	48-62
18941570-7	2008	Superimposed on this general pattern, the cerebrocortical effects showed a nonmonotonic dose-response relationship, with regression of the defects at the higher parathion dose; this relationship has been seen also after comparable treatments with chlorpyrifos and diazinon and likely represents the involvement of cholinesterase-related actions that mask or offset the effects of lower doses.	Parathion	161-170	butyrylcholinesterase	Rattus norvegicus	314-328
18941570-8	2008	CONCLUSIONS: Neonatal exposure to parathion, at doses straddling the threshold for cholinesterase inhibition, compromises indices of ACh synaptic function in adolescence and adulthood.	Parathion	34-43	butyrylcholinesterase	Rattus norvegicus	83-97
18987577-4	2008	METHODS: In our work, we have investigated an influence of HI-6 on the acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and on the muscarinic receptors in vitro.	asoxime chloride	59-63	butyrylcholinesterase	Rattus norvegicus	100-121
18199998-2	2008	This albumin-BChE prevented seizures in rats given a normally lethal cocaine injection (100 mg/kg, i.p.	Cocaine	69-76	butyrylcholinesterase	Rattus norvegicus	13-17
18987577-4	2008	METHODS: In our work, we have investigated an influence of HI-6 on the acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and on the muscarinic receptors in vitro.	asoxime chloride	59-63	butyrylcholinesterase	Rattus norvegicus	123-127
18496672-2	2008	In vitro functional and binding studies revealed that several derivatives were selective H(3)-antagonists with nanomolar potency at human and guinea-pig histamine receptors, able to inhibit rat brain cholinesterase at micromolar concentrations and devoid of any cytotoxicity on cultured cells.	HS 3	89-93	butyrylcholinesterase	Rattus norvegicus	200-214
21783871-4	2008	The results obtained show that carbofuran administered to rats caused a significant decrease in water consumption as well as in brain, serum and erythrocyte cholinesterase activities.	Carbofuran	31-41	butyrylcholinesterase	Rattus norvegicus	157-171
18580182-0	2008	Cholinesterase inhibitor donepezil dilates cerebral parenchymal arterioles via the activation of neuronal nitric oxide synthase.	Donepezil	25-34	butyrylcholinesterase	Rattus norvegicus	0-14
18655563-6	2008	A decreasing trend of AchE and BchE activity presented in the high- and middle-dose JNYZD groups, but insignificant difference was shown as compared these indexes respectively with those in the Donepezil group.	jnyzd	84-89	butyrylcholinesterase	Rattus norvegicus	31-35
18505017-0	2008	Carbon nanotube-based electrochemical sensor for assay of salivary cholinesterase enzyme activity: an exposure biomarker of organophosphate pesticides and nerve agents.	Carbon	0-6	butyrylcholinesterase	Rattus norvegicus	67-81
18522896-7	2008	VX-induced neuronal cell death could not be solely attributed to acetylcholinesterase (AChE) inhibition, since neither the reversible pharmacological cholinesterase inhibitor, physostigmine, nor the muscarinic receptor antagonist, atropine, affected VX-induced cell death.	VX	0-2	butyrylcholinesterase	Rattus norvegicus	71-85
18394709-0	2008	Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat.	Chlorpyrifos	158-170	butyrylcholinesterase	Rattus norvegicus	108-122
18394709-0	2008	Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat.	Diazinon	175-183	butyrylcholinesterase	Rattus norvegicus	108-122
18505017-0	2008	Carbon nanotube-based electrochemical sensor for assay of salivary cholinesterase enzyme activity: an exposure biomarker of organophosphate pesticides and nerve agents.	Organophosphates	124-139	butyrylcholinesterase	Rattus norvegicus	67-81
18505017-9	2008	The dynamics of the ChE enzyme activity in saliva with organophosphate pesticides was further studied using this sensor.	Organophosphates	55-70	butyrylcholinesterase	Rattus norvegicus	20-23
18335101-9	2008	The patterns seen here differ substantially from those seen in earlier work with chlorpyrifos, reinforcing the concept that the various organophosphates have fundamentally different effects on the developmental trajectories of specific neurotransmitter systems, unrelated to their shared action as cholinesterase inhibitors.	Organophosphates	136-152	butyrylcholinesterase	Rattus norvegicus	298-312
18589789-5	2008	CONCLUSION: Sinapine could significantly inhibit the cerebral AChE activity and may be a promising drug used for prevention and cure of Alzheimer"s disease as a cholinesterase inhibitor.	sinapine	12-20	butyrylcholinesterase	Rattus norvegicus	161-175
18355640-2	2008	We exposed neonatal rats to daily doses of diazinon on postnatal days 1-4, using doses (0.5 or 2mg/kg) spanning the threshold for barely-detectable cholinesterase inhibition.	Diazinon	43-51	butyrylcholinesterase	Rattus norvegicus	148-162
18355640-5	2008	This pattern differed substantially from that seen in earlier work with another organophosphate, chlorpyrifos, which at pharmacodynamically similar doses spanning the threshold for cholinesterase inhibition, evoked a much more substantial, global upregulation of 5HT receptor expression; with chlorpyrifos, effects on receptors were seen in females, albeit to a lesser extent than in males, and were also regionally distinct.	Organophosphates	80-95	butyrylcholinesterase	Rattus norvegicus	181-195
18355640-5	2008	This pattern differed substantially from that seen in earlier work with another organophosphate, chlorpyrifos, which at pharmacodynamically similar doses spanning the threshold for cholinesterase inhibition, evoked a much more substantial, global upregulation of 5HT receptor expression; with chlorpyrifos, effects on receptors were seen in females, albeit to a lesser extent than in males, and were also regionally distinct.	Chlorpyrifos	97-109	butyrylcholinesterase	Rattus norvegicus	181-195
18355640-6	2008	The effects of diazinon were nonmonotonic, showing larger alterations at the lower dose, likely reflecting positive trophic effects of cholinergic stimulation once the threshold for cholinesterase inhibition is exceeded.	Diazinon	15-23	butyrylcholinesterase	Rattus norvegicus	182-196
18096154-0	2008	CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline.	piperidine alkaloid	80-99	butyrylcholinesterase	Rattus norvegicus	29-43
18096154-0	2008	CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline.	spectaline	100-114	butyrylcholinesterase	Rattus norvegicus	29-43
18096154-1	2008	LASSBio-767 [(-)-3-O-acetyl-spectaline] and LASSBio-822 [(-)-3-O-tert-Boc-spectaline] were recently described as cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline, obtained from the flowers of Senna spectabilis (Fabaceae).	3-O-acetylspectaline	0-11	butyrylcholinesterase	Rattus norvegicus	113-127
18096154-1	2008	LASSBio-767 [(-)-3-O-acetyl-spectaline] and LASSBio-822 [(-)-3-O-tert-Boc-spectaline] were recently described as cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline, obtained from the flowers of Senna spectabilis (Fabaceae).	3-O-acetylspectaline	13-38	butyrylcholinesterase	Rattus norvegicus	113-127
18096154-1	2008	LASSBio-767 [(-)-3-O-acetyl-spectaline] and LASSBio-822 [(-)-3-O-tert-Boc-spectaline] were recently described as cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline, obtained from the flowers of Senna spectabilis (Fabaceae).	3-O-tert-butoxycarbonylspectaline	44-55	butyrylcholinesterase	Rattus norvegicus	113-127
18096154-1	2008	LASSBio-767 [(-)-3-O-acetyl-spectaline] and LASSBio-822 [(-)-3-O-tert-Boc-spectaline] were recently described as cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline, obtained from the flowers of Senna spectabilis (Fabaceae).	(-)-3-o-tert-boc-spectaline	57-84	butyrylcholinesterase	Rattus norvegicus	113-127
18096154-1	2008	LASSBio-767 [(-)-3-O-acetyl-spectaline] and LASSBio-822 [(-)-3-O-tert-Boc-spectaline] were recently described as cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline, obtained from the flowers of Senna spectabilis (Fabaceae).	piperidine alkaloid	164-183	butyrylcholinesterase	Rattus norvegicus	113-127
18096154-1	2008	LASSBio-767 [(-)-3-O-acetyl-spectaline] and LASSBio-822 [(-)-3-O-tert-Boc-spectaline] were recently described as cholinesterase inhibitors derived from the natural piperidine alkaloid (-)-spectaline, obtained from the flowers of Senna spectabilis (Fabaceae).	spectaline	184-198	butyrylcholinesterase	Rattus norvegicus	113-127
18096154-3	2008	Competition assays with the substrate acetylthiocholine showed a concentration-dependent reduction in rat brain cholinesterase Vmax without changes in apparent Km.	Acetylthiocholine	38-55	butyrylcholinesterase	Rattus norvegicus	112-126
18096154-13	2008	Thus, the (-)-spectaline derivatives are potent cholinergic agents in vivo, with a unique profile combining noncompetitive cholinesterase inhibition and CNS selectivity, with few peripheral side effects.	spectaline	10-24	butyrylcholinesterase	Rattus norvegicus	123-137
17786550-1	2008	(1) This study was to evaluate the anti-cholinesterase (ChE), cognition enhancing and neuroprotective effects of FS-0311, a bis-huperzine B derivative.	FS 0311	113-120	butyrylcholinesterase	Rattus norvegicus	40-54
18324340-5	2008	TCP given alone as pretreatment, 5 min before soman, seems to be superior in the protection of cholinesterase (ChE) catalytic activity in the plasma than in brain, especially after administration of the lower dose of soman.	N-(3,4,5-trichlorophenyl)succinimide	0-3	butyrylcholinesterase	Rattus norvegicus	95-109
17112636-1	2008	The NMDA antagonist, memantine (Namenda), and the cholinesterase inhibitor, donepezil (Aricept), are currently being used widely, either individually or in combination, for treatment of Alzheimer"s disease (AD).	Donepezil	76-85	butyrylcholinesterase	Rattus norvegicus	50-64
17112636-1	2008	The NMDA antagonist, memantine (Namenda), and the cholinesterase inhibitor, donepezil (Aricept), are currently being used widely, either individually or in combination, for treatment of Alzheimer"s disease (AD).	Donepezil	87-94	butyrylcholinesterase	Rattus norvegicus	50-64
17717685-1	2008	Tricyclic quinazolinimines as a novel class of potent inhibitors of cholinesterases in vitro are micro- and sub-micromolar inhibitors with activities at both acetyl- (AChE) and butyrylcholinesterase (BChE) or at BChE only.	quinazolinimine	10-26	butyrylcholinesterase	Rattus norvegicus	177-198
17717685-1	2008	Tricyclic quinazolinimines as a novel class of potent inhibitors of cholinesterases in vitro are micro- and sub-micromolar inhibitors with activities at both acetyl- (AChE) and butyrylcholinesterase (BChE) or at BChE only.	quinazolinimine	10-26	butyrylcholinesterase	Rattus norvegicus	200-204
17717685-1	2008	Tricyclic quinazolinimines as a novel class of potent inhibitors of cholinesterases in vitro are micro- and sub-micromolar inhibitors with activities at both acetyl- (AChE) and butyrylcholinesterase (BChE) or at BChE only.	quinazolinimine	10-26	butyrylcholinesterase	Rattus norvegicus	212-216
18158111-1	2008	Developmental exposure to the organophosphorus pesticides chlorpyrifos and diazinon (DZN) alters serotonergic synaptic function at doses below the threshold for cholinesterase inhibition, however there are some indications that the two agents may differ in several important attributes.	organophosphorus	30-46	butyrylcholinesterase	Rattus norvegicus	161-175
18158111-1	2008	Developmental exposure to the organophosphorus pesticides chlorpyrifos and diazinon (DZN) alters serotonergic synaptic function at doses below the threshold for cholinesterase inhibition, however there are some indications that the two agents may differ in several important attributes.	Chlorpyrifos	58-70	butyrylcholinesterase	Rattus norvegicus	161-175
18158111-1	2008	Developmental exposure to the organophosphorus pesticides chlorpyrifos and diazinon (DZN) alters serotonergic synaptic function at doses below the threshold for cholinesterase inhibition, however there are some indications that the two agents may differ in several important attributes.	Diazinon	75-83	butyrylcholinesterase	Rattus norvegicus	161-175
18158111-1	2008	Developmental exposure to the organophosphorus pesticides chlorpyrifos and diazinon (DZN) alters serotonergic synaptic function at doses below the threshold for cholinesterase inhibition, however there are some indications that the two agents may differ in several important attributes.	Diazinon	85-88	butyrylcholinesterase	Rattus norvegicus	161-175
18324340-5	2008	TCP given alone as pretreatment, 5 min before soman, seems to be superior in the protection of cholinesterase (ChE) catalytic activity in the plasma than in brain, especially after administration of the lower dose of soman.	N-(3,4,5-trichlorophenyl)succinimide	0-3	butyrylcholinesterase	Rattus norvegicus	111-114
17950890-13	2008	Inhibition of brain ChE activity occurred at dosages greater than 0.05 mg/kg physostigmine, 1mg/kg carbaryl, and 0.3 mg/kg propoxur.	Physostigmine	77-90	butyrylcholinesterase	Rattus norvegicus	20-23
19453088-1	2008	The protective effect of the reversible cholinesterase inhibitors tacrine and pyridostigmine alone or in combination with different drugs against acetylcholinesterase inhibition in the pontomedullar area and cerebellum of rats caused by VX agent (O-ethyl S-2-diisopropylaminoethyl methyl phosphonothiolate) in vivo (2xLD50) was studied along with survival of animals pretreated with different combinations of the drugs used.	Tacrine	66-73	butyrylcholinesterase	Rattus norvegicus	40-54
19453088-1	2008	The protective effect of the reversible cholinesterase inhibitors tacrine and pyridostigmine alone or in combination with different drugs against acetylcholinesterase inhibition in the pontomedullar area and cerebellum of rats caused by VX agent (O-ethyl S-2-diisopropylaminoethyl methyl phosphonothiolate) in vivo (2xLD50) was studied along with survival of animals pretreated with different combinations of the drugs used.	Pyridostigmine Bromide	78-92	butyrylcholinesterase	Rattus norvegicus	40-54
18704829-1	2008	Carbaryl, an N-methyl carbamate (NMC), is a common insecticide that reversibly inhibits neuronal cholinesterase activity.	Carbaryl	0-8	butyrylcholinesterase	Rattus norvegicus	97-111
18704829-1	2008	Carbaryl, an N-methyl carbamate (NMC), is a common insecticide that reversibly inhibits neuronal cholinesterase activity.	N-methylcarbamate	13-31	butyrylcholinesterase	Rattus norvegicus	97-111
18704829-1	2008	Carbaryl, an N-methyl carbamate (NMC), is a common insecticide that reversibly inhibits neuronal cholinesterase activity.	N-methylcarbamate	33-36	butyrylcholinesterase	Rattus norvegicus	97-111
18704829-3	2008	A PBPK/PD model was developed to describe the tissue dosimetry of carbaryl and its metabolites (1-naphthol and "other hydroxylated metabolites") and subsequently to predict the carbaryl-induced inhibition of cholinesterase activity, in particular in the brain and blood.	Carbaryl	177-185	butyrylcholinesterase	Rattus norvegicus	208-222
18704829-9	2008	Similar prediction results were achieved for cholinesterase inhibition by carbaryl.	Carbaryl	74-82	butyrylcholinesterase	Rattus norvegicus	45-59
19137904-2	2008	Six new tri- and tetracyclic nitrogen bridgehead compounds known to be moderate to potent inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in vitro were tested in vivo as experimental therapeutics for treatment of Alzheimer"s disease.	Nitrogen	29-37	butyrylcholinesterase	Rattus norvegicus	136-157
19137904-2	2008	Six new tri- and tetracyclic nitrogen bridgehead compounds known to be moderate to potent inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in vitro were tested in vivo as experimental therapeutics for treatment of Alzheimer"s disease.	Nitrogen	29-37	butyrylcholinesterase	Rattus norvegicus	159-163
18096363-1	2008	BACKGROUND: Developmental neurotoxicity of organophosphorous insecticides (OPs) involves multiple mechanisms in addition to cholinesterase inhibition.	organophosphorous	43-60	butyrylcholinesterase	Rattus norvegicus	124-138
17950890-13	2008	Inhibition of brain ChE activity occurred at dosages greater than 0.05 mg/kg physostigmine, 1mg/kg carbaryl, and 0.3 mg/kg propoxur.	Carbaryl	99-107	butyrylcholinesterase	Rattus norvegicus	20-23
17950890-13	2008	Inhibition of brain ChE activity occurred at dosages greater than 0.05 mg/kg physostigmine, 1mg/kg carbaryl, and 0.3 mg/kg propoxur.	Propoxur	123-131	butyrylcholinesterase	Rattus norvegicus	20-23
17931764-0	2007	Oxotremorine-induced hypothermia as a method for evaluating long-term neuronal changes following poisoning by cholinesterase inhibitors in rats.	Oxotremorine	0-12	butyrylcholinesterase	Rattus norvegicus	110-124
17917719-2	2008	Tacrine is a centrally acting, reversible cholinesterase inhibitor that also inhibits monoamine oxidase (MAO) and blocks reuptake of dopamine (DA) and serotonin.	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	42-56
17917719-2	2008	Tacrine is a centrally acting, reversible cholinesterase inhibitor that also inhibits monoamine oxidase (MAO) and blocks reuptake of dopamine (DA) and serotonin.	Dopamine	133-141	butyrylcholinesterase	Rattus norvegicus	42-56
17917719-2	2008	Tacrine is a centrally acting, reversible cholinesterase inhibitor that also inhibits monoamine oxidase (MAO) and blocks reuptake of dopamine (DA) and serotonin.	Dopamine	143-145	butyrylcholinesterase	Rattus norvegicus	42-56
17917719-2	2008	Tacrine is a centrally acting, reversible cholinesterase inhibitor that also inhibits monoamine oxidase (MAO) and blocks reuptake of dopamine (DA) and serotonin.	Serotonin	151-160	butyrylcholinesterase	Rattus norvegicus	42-56
17666426-6	2007	Reduction of ChE activity and mAChR binding by CPS or MPS was more evident in rats at PND8 than at PND4.	Chlorpyrifos	47-50	butyrylcholinesterase	Rattus norvegicus	13-16
17893459-1	2007	BACKGROUND: It is standard practice to administer a cholinesterase inhibitor (e.g., neostigmine) at the end of a surgical case to reverse suspected effects of neuromuscular blocking agents regardless of whether such residual effects are present.	Neostigmine	84-95	butyrylcholinesterase	Rattus norvegicus	52-66
17643410-0	2007	N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.	N(1)-phenethylnorcymserine	0-24	butyrylcholinesterase	Rattus norvegicus	38-59
17643410-13	2007	The importance of butyrylcholinesterase as a "co-regulator" of synaptic acetylcholine levels should thus be reconsidered.	Acetylcholine	72-85	butyrylcholinesterase	Rattus norvegicus	18-39
17893459-9	2007	CONCLUSIONS: The cholinesterase inhibitor neostigmine markedly impairs upper airway dilator volume, genioglossus muscle function, diaphragmatic function, and breathing when given after recovery from vecuronium-induced neuromuscular block.	Neostigmine	42-53	butyrylcholinesterase	Rattus norvegicus	17-31
17893459-9	2007	CONCLUSIONS: The cholinesterase inhibitor neostigmine markedly impairs upper airway dilator volume, genioglossus muscle function, diaphragmatic function, and breathing when given after recovery from vecuronium-induced neuromuscular block.	Vecuronium Bromide	199-209	butyrylcholinesterase	Rattus norvegicus	17-31
17618030-1	2007	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and brain damage in which the neurotransmitters acetylcholine and glutamate are involved.	organophosphorus	4-20	butyrylcholinesterase	Rattus norvegicus	58-72
17644233-0	2007	Comparative effects of oral chlorpyrifos exposure on cholinesterase activity and muscarinic receptor binding in neonatal and adult rat heart.	Chlorpyrifos	28-40	butyrylcholinesterase	Rattus norvegicus	53-67
17644233-10	2007	In vitro inhibition studies indicated that ChE in neonatal tissues was markedly more sensitive to inhibition by the active metabolite of chlorpyrifos (i.e., chlorpyrifos oxon, CPO) than enzyme in adult tissues (IC(50) values: neonates, 17 nM; adults, 200 nM).	Chlorpyrifos	137-149	butyrylcholinesterase	Rattus norvegicus	43-46
17618030-1	2007	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and brain damage in which the neurotransmitters acetylcholine and glutamate are involved.	organophosphorus	4-20	butyrylcholinesterase	Rattus norvegicus	74-77
17644233-10	2007	In vitro inhibition studies indicated that ChE in neonatal tissues was markedly more sensitive to inhibition by the active metabolite of chlorpyrifos (i.e., chlorpyrifos oxon, CPO) than enzyme in adult tissues (IC(50) values: neonates, 17 nM; adults, 200 nM).	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	157-174	butyrylcholinesterase	Rattus norvegicus	43-46
17618030-1	2007	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and brain damage in which the neurotransmitters acetylcholine and glutamate are involved.	Acetylcholine	176-189	butyrylcholinesterase	Rattus norvegicus	58-72
17644233-10	2007	In vitro inhibition studies indicated that ChE in neonatal tissues was markedly more sensitive to inhibition by the active metabolite of chlorpyrifos (i.e., chlorpyrifos oxon, CPO) than enzyme in adult tissues (IC(50) values: neonates, 17 nM; adults, 200 nM).	cpo	176-179	butyrylcholinesterase	Rattus norvegicus	43-46
17618030-1	2007	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and brain damage in which the neurotransmitters acetylcholine and glutamate are involved.	Acetylcholine	176-189	butyrylcholinesterase	Rattus norvegicus	74-77
17618030-1	2007	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and brain damage in which the neurotransmitters acetylcholine and glutamate are involved.	Glutamic Acid	194-203	butyrylcholinesterase	Rattus norvegicus	58-72
17618030-1	2007	The organophosphorus nerve agent soman is an irreversible cholinesterase (ChE) inhibitor that can produce long-lasting seizures and brain damage in which the neurotransmitters acetylcholine and glutamate are involved.	Glutamic Acid	194-203	butyrylcholinesterase	Rattus norvegicus	74-77
17504769-0	2007	Comparison of acute neurobehavioral and cholinesterase inhibitory effects of N-methylcarbamates in rat.	N-methylcarbamate	77-95	butyrylcholinesterase	Rattus norvegicus	40-54
17304644-1	2007	There is a clear need for broad-spectrum cholinesterase reactivators (active against a multitude of organophosphorus ester enzyme inhibitors) with a higher efficacy than pralidoxime.	organophosphorus ester	100-122	butyrylcholinesterase	Rattus norvegicus	41-55
17304644-1	2007	There is a clear need for broad-spectrum cholinesterase reactivators (active against a multitude of organophosphorus ester enzyme inhibitors) with a higher efficacy than pralidoxime.	pralidoxime	170-181	butyrylcholinesterase	Rattus norvegicus	41-55
17304644-2	2007	The purpose of the study was to quantify in vivo the extent of oxime-conferred protection, using methyl-paraoxon [dimethyl p-nitrophenyl phosphate; (methyl-POX)] as a cholinesterase inhibitor.	Oximes	63-68	butyrylcholinesterase	Rattus norvegicus	167-181
17304644-2	2007	The purpose of the study was to quantify in vivo the extent of oxime-conferred protection, using methyl-paraoxon [dimethyl p-nitrophenyl phosphate; (methyl-POX)] as a cholinesterase inhibitor.	methylparaoxon	97-112	butyrylcholinesterase	Rattus norvegicus	167-181
17504769-1	2007	While the cholinesterase-inhibiting N-methyl carbamate pesticides have been widely used, there are few studies evaluating direct functional and biochemical consequences of exposure.	N-methylcarbamate	36-54	butyrylcholinesterase	Rattus norvegicus	10-24
17504769-5	2007	In general, motor activity was a sensitive measure of ChE inhibition for all these carbamate pesticides, and vertical activity showed the greatest magnitude of effect at the highest doses compared to either horizontal activity or ChE inhibition.	Carbamates	83-92	butyrylcholinesterase	Rattus norvegicus	54-57
17504769-9	2007	Thus, motor activity decreases are highly predictive of ChE inhibition for N-methyl carbamates, and vice versa.	N-methylcarbamate	75-94	butyrylcholinesterase	Rattus norvegicus	56-59
17442507-1	2007	The effect of diazinon (DZN) on the activities of cholinesterase (ChE) in plasma and acetylcholinesterase (AChE) in erythrocyte and brain was investigated in normal and streptozotocin-induced diabetic rats.	Diazinon	14-22	butyrylcholinesterase	Rattus norvegicus	50-64
17383138-11	2007	This includes the 5-HT6 receptor antagonist, SB-271046, and the cholinesterase inhibitor, donepezil.	Donepezil	90-99	butyrylcholinesterase	Rattus norvegicus	64-78
17525597-2	2007	The authors tested the relevance of these findings to oral therapy by examining the efficacy of oral gabapentin to reduce hypersensitivity after nerve injury in rats and its interaction with the clinically used cholinesterase inhibitor, donepezil.	Donepezil	237-246	butyrylcholinesterase	Rattus norvegicus	211-225
17481843-0	2007	Homocysteine reduces cholinesterase activity in rat and human serum.	Homocysteine	0-12	butyrylcholinesterase	Rattus norvegicus	21-35
17481843-1	2007	In the present study we investigated the effect of homocysteine administration, the main metabolite accumulating in homocystinuria, on cholinesterase activity in rat and human serum.	Homocysteine	51-63	butyrylcholinesterase	Rattus norvegicus	135-149
17481843-5	2007	We also observed that 500 microM homocysteine added to the incubation medium (in vitro study) significantly inhibited cholinesterase activity both in serum of rats and humans.	Homocysteine	33-45	butyrylcholinesterase	Rattus norvegicus	118-132
17442507-1	2007	The effect of diazinon (DZN) on the activities of cholinesterase (ChE) in plasma and acetylcholinesterase (AChE) in erythrocyte and brain was investigated in normal and streptozotocin-induced diabetic rats.	Diazinon	14-22	butyrylcholinesterase	Rattus norvegicus	66-69
17442507-1	2007	The effect of diazinon (DZN) on the activities of cholinesterase (ChE) in plasma and acetylcholinesterase (AChE) in erythrocyte and brain was investigated in normal and streptozotocin-induced diabetic rats.	Diazinon	24-27	butyrylcholinesterase	Rattus norvegicus	50-64
17442507-1	2007	The effect of diazinon (DZN) on the activities of cholinesterase (ChE) in plasma and acetylcholinesterase (AChE) in erythrocyte and brain was investigated in normal and streptozotocin-induced diabetic rats.	Diazinon	24-27	butyrylcholinesterase	Rattus norvegicus	66-69
17159234-2	2007	For improved accuracy while using fewer subjects, we developed an assay based on the recognized ability of carbamates to protect cholinesterase from irreversible inactivation.	Carbamates	107-117	butyrylcholinesterase	Rattus norvegicus	129-143
17457135-2	2007	Here, the authors tested whether donepezil, a central nervous system penetrant cholinesterase inhibitor with a low incidence of gastrointestinal side effects, would relieve hypersensitivity in an animal model of neuropathic pain.	Donepezil	33-42	butyrylcholinesterase	Rattus norvegicus	79-93
17457135-9	2007	CONCLUSIONS: Donepezil, a well-tolerated cholinesterase inhibitor used in the treatment of Alzheimer dementia, reduces hypersensitivity in this rat model of neuropathic pain by actions on muscarinic receptors in the spinal cord.	Donepezil	13-22	butyrylcholinesterase	Rattus norvegicus	41-55
17303509-1	2007	Previous functional investigations in rats failed to demonstrate that the classical cholinesterase inhibitor, physostigmine, can compensate for cortical cholinergic deficit induced by deafferentation from the nucleus basalis magnocellularis (NBM).	Physostigmine	110-123	butyrylcholinesterase	Rattus norvegicus	84-98
17255466-0	2007	Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.	phenserine	59-69	butyrylcholinesterase	Rattus norvegicus	89-103
17056080-1	2007	Recently, the FDA approved the medical use of oral pyridostigmine as prophylactic treatment of possible nerve agent exposure: the concept is to block the cholinesterase transitorily using the carbamate (pyridostigmine) in order to deny access to the active site of the enzyme to the irreversible inhibitor (nerve agent) on subsequent exposure.	Pyridostigmine Bromide	51-65	butyrylcholinesterase	Rattus norvegicus	154-168
17056080-1	2007	Recently, the FDA approved the medical use of oral pyridostigmine as prophylactic treatment of possible nerve agent exposure: the concept is to block the cholinesterase transitorily using the carbamate (pyridostigmine) in order to deny access to the active site of the enzyme to the irreversible inhibitor (nerve agent) on subsequent exposure.	Carbamates	192-201	butyrylcholinesterase	Rattus norvegicus	154-168
17056080-1	2007	Recently, the FDA approved the medical use of oral pyridostigmine as prophylactic treatment of possible nerve agent exposure: the concept is to block the cholinesterase transitorily using the carbamate (pyridostigmine) in order to deny access to the active site of the enzyme to the irreversible inhibitor (nerve agent) on subsequent exposure.	Pyridostigmine Bromide	203-217	butyrylcholinesterase	Rattus norvegicus	154-168
17197007-0	2007	Time course of cholinesterase inhibition in adult rats treated acutely with carbaryl, carbofuran, formetanate, methomyl, methiocarb, oxamyl or propoxur.	Methiocarb	121-131	butyrylcholinesterase	Rattus norvegicus	15-29
17197007-0	2007	Time course of cholinesterase inhibition in adult rats treated acutely with carbaryl, carbofuran, formetanate, methomyl, methiocarb, oxamyl or propoxur.	oxamyl	133-139	butyrylcholinesterase	Rattus norvegicus	15-29
17197007-0	2007	Time course of cholinesterase inhibition in adult rats treated acutely with carbaryl, carbofuran, formetanate, methomyl, methiocarb, oxamyl or propoxur.	Propoxur	143-151	butyrylcholinesterase	Rattus norvegicus	15-29
16944100-10	2007	Cholinesterase activity was significantly inhibited in blood (47-50%) and diaphragm (80%) following pyridostigmine exposure regardless of stress conditions.	Pyridostigmine Bromide	100-114	butyrylcholinesterase	Rattus norvegicus	0-14
16944100-11	2007	Slight but significant inhibition (11-15%) of cerebellar cholinesterase activity was observed following pyridostigmine exposure, but inhibition was not influenced by stress.	Pyridostigmine Bromide	104-118	butyrylcholinesterase	Rattus norvegicus	57-71
17454568-1	2007	Organophosphate (OP) and carbamate (CB) insecticides inhibit cholinesterase (ChE) activity and induce acute hypothermia in adult rats.	Organophosphates	0-15	butyrylcholinesterase	Rattus norvegicus	61-75
17454568-1	2007	Organophosphate (OP) and carbamate (CB) insecticides inhibit cholinesterase (ChE) activity and induce acute hypothermia in adult rats.	Organophosphates	0-15	butyrylcholinesterase	Rattus norvegicus	77-80
17454568-1	2007	Organophosphate (OP) and carbamate (CB) insecticides inhibit cholinesterase (ChE) activity and induce acute hypothermia in adult rats.	Carbamates	25-34	butyrylcholinesterase	Rattus norvegicus	61-75
17454568-1	2007	Organophosphate (OP) and carbamate (CB) insecticides inhibit cholinesterase (ChE) activity and induce acute hypothermia in adult rats.	Carbamates	25-34	butyrylcholinesterase	Rattus norvegicus	77-80
17197007-0	2007	Time course of cholinesterase inhibition in adult rats treated acutely with carbaryl, carbofuran, formetanate, methomyl, methiocarb, oxamyl or propoxur.	Carbaryl	76-84	butyrylcholinesterase	Rattus norvegicus	15-29
17197007-0	2007	Time course of cholinesterase inhibition in adult rats treated acutely with carbaryl, carbofuran, formetanate, methomyl, methiocarb, oxamyl or propoxur.	Carbofuran	86-96	butyrylcholinesterase	Rattus norvegicus	15-29
17197007-0	2007	Time course of cholinesterase inhibition in adult rats treated acutely with carbaryl, carbofuran, formetanate, methomyl, methiocarb, oxamyl or propoxur.	formetanate	98-109	butyrylcholinesterase	Rattus norvegicus	15-29
17197007-0	2007	Time course of cholinesterase inhibition in adult rats treated acutely with carbaryl, carbofuran, formetanate, methomyl, methiocarb, oxamyl or propoxur.	Methomyl	111-119	butyrylcholinesterase	Rattus norvegicus	15-29
17159234-6	2007	As a result, carbamate-protection assays can demonstrate a statistically significant 2-3% inhibition of brain cholinesterase in a single experimental group of modest size.	Carbamates	13-22	butyrylcholinesterase	Rattus norvegicus	110-124
17207478-16	2007	We also examined the effects of antimuscarinic drugs on learning enhanced by the cholinesterase inhibitor donepezil at a dose of 0.1 mg/kg i.v.	Donepezil	106-115	butyrylcholinesterase	Rattus norvegicus	81-95
20020971-4	2007	Administration of diazinon increased blood glucose, hepatic glycogen phosphorylase (GP), and phosphoenol pyruvate carboxykinase (PEPCK) by 160.65%, 117.2%, and 93.5%, respectively, while it decreased plasma cholinesterase (ChE) by 53.82%.	Diazinon	18-26	butyrylcholinesterase	Rattus norvegicus	207-221
17458646-13	2007	CONCLUSION: SCh potentiated ACh-induced, but not CCh-induced, contractile and PI responses, and enhanced EFS-induced contraction of rat trachea, suggesting that competition for butyrylcholinesterase (BChE) in airway smooth muscle could be involved in the potentiation by SCh of ACh-induced airway smooth muscle contraction.	Succinylcholine	12-15	butyrylcholinesterase	Rattus norvegicus	177-198
17458646-13	2007	CONCLUSION: SCh potentiated ACh-induced, but not CCh-induced, contractile and PI responses, and enhanced EFS-induced contraction of rat trachea, suggesting that competition for butyrylcholinesterase (BChE) in airway smooth muscle could be involved in the potentiation by SCh of ACh-induced airway smooth muscle contraction.	Succinylcholine	12-15	butyrylcholinesterase	Rattus norvegicus	200-204
16904919-7	2007	Similarly, pre-training injections of physostigmine, a cholinesterase inhibitor, enhanced acquisition of trace conditioning in 25-day-old rats but had no effect on long-delay conditioning in rats this age (Experiment 2).	Physostigmine	38-51	butyrylcholinesterase	Rattus norvegicus	55-69
20020971-8	2007	Pentoxifylline also recovered a diazinon-induced decrease in liver and muscle total antioxidant capacity and plasma ChE by 122.33%, 56.44%, and 115.62%, respectively.	Pentoxifylline	0-14	butyrylcholinesterase	Rattus norvegicus	116-119
17125927-0	2007	Changes of cholinesterase activities in the plasma and some tissues following administration of L-carnitine and galanthamine to rats.	Carnitine	96-107	butyrylcholinesterase	Rattus norvegicus	11-25
17125927-0	2007	Changes of cholinesterase activities in the plasma and some tissues following administration of L-carnitine and galanthamine to rats.	Galantamine	112-124	butyrylcholinesterase	Rattus norvegicus	11-25
17018647-0	2007	Age-related brain cholinesterase inhibition kinetics following in vitro incubation with chlorpyrifos-oxon and diazinon-oxon.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	88-105	butyrylcholinesterase	Rattus norvegicus	18-32
17018647-0	2007	Age-related brain cholinesterase inhibition kinetics following in vitro incubation with chlorpyrifos-oxon and diazinon-oxon.	diazoxon	110-123	butyrylcholinesterase	Rattus norvegicus	18-32
17018647-2	2007	The study objectives were to assess the in vitro age-related inhibition kinetics of neonatal rat brain cholinesterase (ChE) for CPO and DZO by estimating the bimolecular inhibitory rate constant (k(i)) values.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	128-131	butyrylcholinesterase	Rattus norvegicus	103-117
17018647-2	2007	The study objectives were to assess the in vitro age-related inhibition kinetics of neonatal rat brain cholinesterase (ChE) for CPO and DZO by estimating the bimolecular inhibitory rate constant (k(i)) values.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	128-131	butyrylcholinesterase	Rattus norvegicus	119-122
17018647-2	2007	The study objectives were to assess the in vitro age-related inhibition kinetics of neonatal rat brain cholinesterase (ChE) for CPO and DZO by estimating the bimolecular inhibitory rate constant (k(i)) values.	diazoxon	136-139	butyrylcholinesterase	Rattus norvegicus	103-117
17018647-2	2007	The study objectives were to assess the in vitro age-related inhibition kinetics of neonatal rat brain cholinesterase (ChE) for CPO and DZO by estimating the bimolecular inhibitory rate constant (k(i)) values.	diazoxon	136-139	butyrylcholinesterase	Rattus norvegicus	119-122
17018647-5	2007	CPO caused a greater ChE inhibition than DZO as evidenced from the estimated k(i) values of both compounds.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	0-3	butyrylcholinesterase	Rattus norvegicus	21-24
17018647-6	2007	Neonatal brain ChE inhibition kinetics exhibited a marked age-related sensitivity to CPO, with the order of ChE inhibition being PND 5 > PND 7 > PND 17 with k(i) values of 0.95, 0.50, and 0.22 nM(-1)hr(-1), respectively.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	85-88	butyrylcholinesterase	Rattus norvegicus	15-18
20020971-8	2007	Pentoxifylline also recovered a diazinon-induced decrease in liver and muscle total antioxidant capacity and plasma ChE by 122.33%, 56.44%, and 115.62%, respectively.	Diazinon	32-40	butyrylcholinesterase	Rattus norvegicus	116-119
20020971-10	2007	It is concluded that pentoxifylline is a good choice for the alleviation of acute toxic stress of diazinon in muscle and liver and ChE in plasma, while it is unable to recover diazinon-induced hyperglycemia.	Pentoxifylline	21-35	butyrylcholinesterase	Rattus norvegicus	131-134
17018647-6	2007	Neonatal brain ChE inhibition kinetics exhibited a marked age-related sensitivity to CPO, with the order of ChE inhibition being PND 5 > PND 7 > PND 17 with k(i) values of 0.95, 0.50, and 0.22 nM(-1)hr(-1), respectively.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	85-88	butyrylcholinesterase	Rattus norvegicus	108-111
20020971-4	2007	Administration of diazinon increased blood glucose, hepatic glycogen phosphorylase (GP), and phosphoenol pyruvate carboxykinase (PEPCK) by 160.65%, 117.2%, and 93.5%, respectively, while it decreased plasma cholinesterase (ChE) by 53.82%.	Diazinon	18-26	butyrylcholinesterase	Rattus norvegicus	223-226
17035140-0	2006	Organophosphate insecticides target the serotonergic system in developing rat brain regions: disparate effects of diazinon and parathion at doses spanning the threshold for cholinesterase inhibition.	Organophosphates	0-15	butyrylcholinesterase	Rattus norvegicus	173-187
17159811-0	2006	Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues.	Galantamine	10-21	butyrylcholinesterase	Rattus norvegicus	50-71
17159811-0	2006	Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues.	Carnitine	102-113	butyrylcholinesterase	Rattus norvegicus	50-71
16798104-0	2006	Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart.	Doxorubicin	76-86	butyrylcholinesterase	Rattus norvegicus	42-56
16798104-6	2006	Our results show that the cholinesterase-positive nerve system was downregulated in the adriamycin-induced failing heart group, while the density of M(2) receptors was increased in the carvedilol 3- and 10-mg/kg body weight groups, especially in the endocardial tissues of the left-ventricular free wall.	Doxorubicin	88-98	butyrylcholinesterase	Rattus norvegicus	26-40
17040217-1	2006	Weak and reversible inhibitors of cholinesterase, when co-administered in large doses, can act in a protective manner against more potent inhibitors such as organophosphates.	Organophosphates	157-173	butyrylcholinesterase	Rattus norvegicus	34-48
16777161-1	2006	This study examined the acute effects of chlorpyrifos (CPF) on cholinesterase inhibition and acetylcholine levels in the striatum of freely moving rats using in vivo microdialysis.	Chlorpyrifos	55-58	butyrylcholinesterase	Rattus norvegicus	63-77
16777161-10	2006	Substantially higher acetylcholine levels were noted when an exogenous cholinesterase inhibitor was included in the perfusion buffer, but CPF treatment-related differences were substantially lower in magnitude under those conditions.	Acetylcholine	21-34	butyrylcholinesterase	Rattus norvegicus	71-85
16482470-8	2006	Female offspring from mothers treated with a combination of nicotine and chlorpyrifos showed significant increase in plasma BChE activity.	Nicotine	60-68	butyrylcholinesterase	Rattus norvegicus	124-128
16482470-8	2006	Female offspring from mothers treated with a combination of nicotine and chlorpyrifos showed significant increase in plasma BChE activity.	Chlorpyrifos	73-85	butyrylcholinesterase	Rattus norvegicus	124-128
16452682-10	2006	Atropine enhanced the glutamatergic EPSCs during repetitive stimulation by 25 +/- 6%; the anti-cholinesterase neostigmine reduced the train EPSCs by 37 +/- 6%.	Neostigmine	110-121	butyrylcholinesterase	Rattus norvegicus	95-109
16343727-7	2006	Of particular importance was the observation that even in rats as young as PND-5, the CYP450 metabolic capacity was adequate to metabolize CPF to both TCP and CPF-oxon based on the detection of TCP in blood and extensive ChE inhibition (biomarker of CPF-oxon) at all ages.	oxon	163-167	butyrylcholinesterase	Rattus norvegicus	221-224
16844206-1	2006	Pyridostigmine bromide (PB), a peripheral cholinesterase inhibitor, has been shown to support odor-potentiated startle responding in rats.	Pyridostigmine Bromide	0-22	butyrylcholinesterase	Rattus norvegicus	42-56
16844206-1	2006	Pyridostigmine bromide (PB), a peripheral cholinesterase inhibitor, has been shown to support odor-potentiated startle responding in rats.	Pyridostigmine Bromide	24-26	butyrylcholinesterase	Rattus norvegicus	42-56
16479322-3	2006	Recently, the FDA approved, based on animal experiments, for military combat medical use oral pyridostigmine (PSTG) for pre-exposure treatment of soman; the concept is to block the cholinesterase reversibly using the carbamate pyridostigmine in order to deny access to the active site of the enzyme to the irreversible inhibitor (OPC) on subsequent exposure.	Pyridostigmine Bromide	94-108	butyrylcholinesterase	Rattus norvegicus	181-195
16479322-3	2006	Recently, the FDA approved, based on animal experiments, for military combat medical use oral pyridostigmine (PSTG) for pre-exposure treatment of soman; the concept is to block the cholinesterase reversibly using the carbamate pyridostigmine in order to deny access to the active site of the enzyme to the irreversible inhibitor (OPC) on subsequent exposure.	Pyridostigmine Bromide	110-114	butyrylcholinesterase	Rattus norvegicus	181-195
16479322-3	2006	Recently, the FDA approved, based on animal experiments, for military combat medical use oral pyridostigmine (PSTG) for pre-exposure treatment of soman; the concept is to block the cholinesterase reversibly using the carbamate pyridostigmine in order to deny access to the active site of the enzyme to the irreversible inhibitor (OPC) on subsequent exposure.	Carbamates	217-226	butyrylcholinesterase	Rattus norvegicus	181-195
16479322-3	2006	Recently, the FDA approved, based on animal experiments, for military combat medical use oral pyridostigmine (PSTG) for pre-exposure treatment of soman; the concept is to block the cholinesterase reversibly using the carbamate pyridostigmine in order to deny access to the active site of the enzyme to the irreversible inhibitor (OPC) on subsequent exposure.	Pyridostigmine Bromide	227-241	butyrylcholinesterase	Rattus norvegicus	181-195
16479322-3	2006	Recently, the FDA approved, based on animal experiments, for military combat medical use oral pyridostigmine (PSTG) for pre-exposure treatment of soman; the concept is to block the cholinesterase reversibly using the carbamate pyridostigmine in order to deny access to the active site of the enzyme to the irreversible inhibitor (OPC) on subsequent exposure.	Organophosphorus Compounds	330-333	butyrylcholinesterase	Rattus norvegicus	181-195
16442260-0	2006	Folic acid pretreatment prevents the reduction of Na(+),K(+)-ATPase and butyrylcholinesterase activities in rats subjected to acute hyperhomocysteinemia.	Folic Acid	0-10	butyrylcholinesterase	Rattus norvegicus	72-93
16442260-1	2006	The main objective of the present study was to evaluate the effect of folic acid pretreatment on parietal cortex Na(+),K(+)-ATPase and serum butyrylcholinesterase activities in rats subjected to acute hyperhomocysteinemia.	Folic Acid	70-80	butyrylcholinesterase	Rattus norvegicus	141-162
16442260-5	2006	Results showed that acute homocysteine administration significantly decreased the activities of Na(+),K(+)-ATPase and butyrylcholinesterase on parietal cortex and serum, respectively.	Homocysteine	26-38	butyrylcholinesterase	Rattus norvegicus	118-139
16442260-9	2006	The presented results confirm previous findings that acute hyperhomocysteinemia produces an inhibition of Na(+),K(+)-ATPase and butyrylcholinesterase activities and that pretreatment with folic acid prevents such effects.	Folic Acid	188-198	butyrylcholinesterase	Rattus norvegicus	128-149
16572919-0	2006	Changes in butyrylcholinesterase activity and serum lipids after oxprenolol and glibenclamide treatments in non-diabetic rats.	Oxprenolol	65-75	butyrylcholinesterase	Rattus norvegicus	11-32
16297435-0	2006	Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.	Glycerylphosphorylcholine	43-63	butyrylcholinesterase	Rattus norvegicus	72-86
16289293-2	2006	Since parathion has been observed to be responsible for more cases of poisoning than any other OP insecticides, it is vitally important to investigate other mechanisms, besides cholinesterase inhibition, which can potentially contribute to the neurotoxicity of parathion (or its metabolite, paraoxon).	Parathion	261-270	butyrylcholinesterase	Rattus norvegicus	177-191
16297435-0	2006	Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.	Rivastigmine	97-109	butyrylcholinesterase	Rattus norvegicus	72-86
16297435-1	2006	The effects of association of cholinergic precursors choline or choline alphoscerate with the cholinesterase inhibitor rivastigmine on acetylcholine levels and [(3)H]hemicholinium-3 binding were assessed in rat frontal cortex, hippocampus and striatum.	Rivastigmine	119-131	butyrylcholinesterase	Rattus norvegicus	94-108
16182429-2	2006	This study assessed if there is an interaction between mixtures of the anticholinesterase insecticides chlorpyrifos (CHP) and carbaryl (CAR) using hypothermia and cholinesterase (ChE) inhibition as toxicological endpoints.	Chlorpyrifos	103-115	butyrylcholinesterase	Rattus norvegicus	75-89
16572919-0	2006	Changes in butyrylcholinesterase activity and serum lipids after oxprenolol and glibenclamide treatments in non-diabetic rats.	Glyburide	80-93	butyrylcholinesterase	Rattus norvegicus	11-32
16572919-2	2006	In all treated groups a significant increase of plasma BuChE activity was obtained after 6 weeks of either OXP (46 %), or GL (36 %) treatment, or of their concurrent application (24 %).	oxp	107-110	butyrylcholinesterase	Rattus norvegicus	55-60
16572919-2	2006	In all treated groups a significant increase of plasma BuChE activity was obtained after 6 weeks of either OXP (46 %), or GL (36 %) treatment, or of their concurrent application (24 %).	glycylleucine	122-124	butyrylcholinesterase	Rattus norvegicus	55-60
16572919-12	2006	These results showed that the increase in BuChE activity might be the first sign of altered triglyceride and lipoprotein metabolism.	Triglycerides	92-104	butyrylcholinesterase	Rattus norvegicus	42-47
16510359-2	2006	It was proposed that alterations in glutamatergic, cholinergic, and monoamine neurotransmitter systems after exposure to stress are initial CNS events contributing to this impairment and that exacerbation could occur with concurrent exposure to cholinesterase inhibitors.	monoamine	68-77	butyrylcholinesterase	Rattus norvegicus	245-259
16275899-3	2005	In rats, cymserine analogs caused long-term inhibition of brain BChE and elevated extracellular ACh levels, without inhibitory effects on acetylcholinesterase.	cymserine	9-18	butyrylcholinesterase	Rattus norvegicus	64-68
16118037-7	2005	The nitroprusside-induced increase of firing rate of AHA neurons was inhibited by PHN microinjection of the cholinoceptor antagonist scopolamine and potentiated by PHN microinjection of the cholinesterase inhibitor physostigmine.	Nitroprusside	4-17	butyrylcholinesterase	Rattus norvegicus	190-204
16118037-7	2005	The nitroprusside-induced increase of firing rate of AHA neurons was inhibited by PHN microinjection of the cholinoceptor antagonist scopolamine and potentiated by PHN microinjection of the cholinesterase inhibitor physostigmine.	1,10-phenanthroline	164-167	butyrylcholinesterase	Rattus norvegicus	190-204
16118037-7	2005	The nitroprusside-induced increase of firing rate of AHA neurons was inhibited by PHN microinjection of the cholinoceptor antagonist scopolamine and potentiated by PHN microinjection of the cholinesterase inhibitor physostigmine.	Physostigmine	215-228	butyrylcholinesterase	Rattus norvegicus	190-204
16954599-5	2006	Oral administration of PPE or tacrine caused a dose-dependent inhibition of brain and plasma cholinesterase activities.	Tacrine	30-37	butyrylcholinesterase	Rattus norvegicus	93-107
16260018-6	2006	At 8 h after initial dosing, brain cholinesterase inhibition was significantly greater in the C/P group (59%) compared to the P/C group (28%).	Carbon	94-95	butyrylcholinesterase	Rattus norvegicus	35-49
16260018-6	2006	At 8 h after initial dosing, brain cholinesterase inhibition was significantly greater in the C/P group (59%) compared to the P/C group (28%).	Phosphorus	96-97	butyrylcholinesterase	Rattus norvegicus	35-49
16260018-6	2006	At 8 h after initial dosing, brain cholinesterase inhibition was significantly greater in the C/P group (59%) compared to the P/C group (28%).	Phosphorus	126-127	butyrylcholinesterase	Rattus norvegicus	35-49
16260018-6	2006	At 8 h after initial dosing, brain cholinesterase inhibition was significantly greater in the C/P group (59%) compared to the P/C group (28%).	Carbon	128-129	butyrylcholinesterase	Rattus norvegicus	35-49
16260018-9	2006	Similar sequence-dependent differences in brain cholinesterase inhibition were also noted with lower binary exposures to chlorpyrifos (2 mg/kg) and parathion (0.35 mg/kg).	Chlorpyrifos	121-133	butyrylcholinesterase	Rattus norvegicus	48-62
16260018-9	2006	Similar sequence-dependent differences in brain cholinesterase inhibition were also noted with lower binary exposures to chlorpyrifos (2 mg/kg) and parathion (0.35 mg/kg).	Parathion	148-157	butyrylcholinesterase	Rattus norvegicus	48-62
16216227-7	2005	Microinjection of the cholinoceptor agonist carbachol, the cholinesterase inhibitor physostigmine and the excitatory amino acid glutamate into the PHN caused increases in firing rate of AHA angiotensin-II-sensitive neurons in anesthetized WKY and SHR.	Physostigmine	84-97	butyrylcholinesterase	Rattus norvegicus	59-73
16086033-0	2005	The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	98-108	butyrylcholinesterase	Rattus norvegicus	54-68
16081522-8	2005	The 1+oil group animals showed ChE inhibition only in the blood, whereas the 5+oil group exhibited > or = 50% ChE inhibition in all tissues tested.	Oils	79-82	butyrylcholinesterase	Rattus norvegicus	113-116
16086033-5	2005	Chronic TV3279 (26 mg kg(-1) for 21 days) similarly inhibited approximately 50% of striatal ChE activity, but did not affect MAO activity or amine levels.	(N-propargyl-(3R) and (3S) aminoindan-5-yl)-ethyl methyl carbamate	8-14	butyrylcholinesterase	Rattus norvegicus	92-95
16086033-0	2005	The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.	Levodopa	125-131	butyrylcholinesterase	Rattus norvegicus	54-68
16086033-0	2005	The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.	Tryptophan	136-148	butyrylcholinesterase	Rattus norvegicus	54-68
16086033-1	2005	The novel drugs, ladostigil (TV3326) and TV3279, are R and S isomers, respectively, derived from a combination of the carbamate cholinesterase (ChE) inhibitor, rivastigmine, and the pharmacophore of the monoamine oxidase (MAO) B inhibitor, rasagiline.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	17-27	butyrylcholinesterase	Rattus norvegicus	128-142
16086033-1	2005	The novel drugs, ladostigil (TV3326) and TV3279, are R and S isomers, respectively, derived from a combination of the carbamate cholinesterase (ChE) inhibitor, rivastigmine, and the pharmacophore of the monoamine oxidase (MAO) B inhibitor, rasagiline.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	17-27	butyrylcholinesterase	Rattus norvegicus	144-147
16086033-1	2005	The novel drugs, ladostigil (TV3326) and TV3279, are R and S isomers, respectively, derived from a combination of the carbamate cholinesterase (ChE) inhibitor, rivastigmine, and the pharmacophore of the monoamine oxidase (MAO) B inhibitor, rasagiline.	(N-propargyl-(3R) and (3S) aminoindan-5-yl)-ethyl methyl carbamate	41-47	butyrylcholinesterase	Rattus norvegicus	128-142
16086033-1	2005	The novel drugs, ladostigil (TV3326) and TV3279, are R and S isomers, respectively, derived from a combination of the carbamate cholinesterase (ChE) inhibitor, rivastigmine, and the pharmacophore of the monoamine oxidase (MAO) B inhibitor, rasagiline.	(N-propargyl-(3R) and (3S) aminoindan-5-yl)-ethyl methyl carbamate	41-47	butyrylcholinesterase	Rattus norvegicus	144-147
16086033-4	2005	Chronic treatment of rats with ladostigil (52 mg kg(-1) for 21 days) inhibited hippocampal and striatal MAO A and B activities by >90%, increased striatal levels of dopamine and serotonin, and inhibited striatal ChE activity by approximately 50%.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	31-41	butyrylcholinesterase	Rattus norvegicus	212-215
16054679-2	2005	This study evaluated the effects of pretreatment with the oral cholinesterase inhibitor and anti-Alzheimer"s agent, donepezil (Aricept) on the hypokinetic, hypothermic and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in adult Sprague-Dawley rats.	Donepezil	116-125	butyrylcholinesterase	Rattus norvegicus	230-244
16054679-2	2005	This study evaluated the effects of pretreatment with the oral cholinesterase inhibitor and anti-Alzheimer"s agent, donepezil (Aricept) on the hypokinetic, hypothermic and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in adult Sprague-Dawley rats.	Donepezil	127-134	butyrylcholinesterase	Rattus norvegicus	230-244
15800032-15	2005	While the reduced ray for blood ChE showed greater deviation from additivity without malathion in the mixture, the non-additivity observed for the gait score was reversed when malathion was removed.	Malathion	85-94	butyrylcholinesterase	Rattus norvegicus	32-35
15967428-9	2005	Butyrylcholinesterase significantly increased plasma and brain ecgonine methylester levels and decreased cocaine plasma half-life from 26.2 min (saline) to 16.4 min (15,000 U).	Cocaine	105-112	butyrylcholinesterase	Rattus norvegicus	0-21
15967428-9	2005	Butyrylcholinesterase significantly increased plasma and brain ecgonine methylester levels and decreased cocaine plasma half-life from 26.2 min (saline) to 16.4 min (15,000 U).	Sodium Chloride	145-151	butyrylcholinesterase	Rattus norvegicus	0-21
15967428-12	2005	These findings suggest that butyrylcholinesterase treatment may have benefits in enhancing cocaine metabolism and in increasing levels of ecgonine methylester, which may have a protective action against cocaine.	Cocaine	91-98	butyrylcholinesterase	Rattus norvegicus	28-49
15967428-12	2005	These findings suggest that butyrylcholinesterase treatment may have benefits in enhancing cocaine metabolism and in increasing levels of ecgonine methylester, which may have a protective action against cocaine.	ecgonine	138-146	butyrylcholinesterase	Rattus norvegicus	28-49
15967428-12	2005	These findings suggest that butyrylcholinesterase treatment may have benefits in enhancing cocaine metabolism and in increasing levels of ecgonine methylester, which may have a protective action against cocaine.	Cocaine	203-210	butyrylcholinesterase	Rattus norvegicus	28-49
15958263-0	2005	The diacylglycerol lipase inhibitor RHC-80267 potentiates the relaxation to acetylcholine in rat mesenteric artery by anti-cholinesterase action.	Diglycerides	4-18	butyrylcholinesterase	Rattus norvegicus	123-137
15958263-0	2005	The diacylglycerol lipase inhibitor RHC-80267 potentiates the relaxation to acetylcholine in rat mesenteric artery by anti-cholinesterase action.	1,6-bis(cyclohexyloximinocarbonyl)hexane	36-45	butyrylcholinesterase	Rattus norvegicus	123-137
15958263-0	2005	The diacylglycerol lipase inhibitor RHC-80267 potentiates the relaxation to acetylcholine in rat mesenteric artery by anti-cholinesterase action.	Acetylcholine	76-89	butyrylcholinesterase	Rattus norvegicus	123-137
15958263-6	2005	Neostigmine, a cholinesterase inhibitor, produced the same effect as RHC-80267 on acetylcholine-evoked relaxation.	Neostigmine	0-11	butyrylcholinesterase	Rattus norvegicus	15-29
15958263-8	2005	These results indicate that the potentiation of acetylcholine-evoked responses by RHC-80267 in rat mesenteric artery is caused by the inhibition of the cholinesterase activity in the vascular wall.	Acetylcholine	48-61	butyrylcholinesterase	Rattus norvegicus	152-166
16179131-0	2005	Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats.	Dexamethasone	52-65	butyrylcholinesterase	Rattus norvegicus	0-21
16179131-1	2005	The paper describes the effect of glucocorticoid dexamethasone (DM) given intraperitoneally on the catalytic activity of butyrylcholinesterase (BuChE) measured in plasma, liver and white adipose tissue of rats of both sexes.	Dexamethasone	49-62	butyrylcholinesterase	Rattus norvegicus	121-142
16179131-1	2005	The paper describes the effect of glucocorticoid dexamethasone (DM) given intraperitoneally on the catalytic activity of butyrylcholinesterase (BuChE) measured in plasma, liver and white adipose tissue of rats of both sexes.	Dexamethasone	49-62	butyrylcholinesterase	Rattus norvegicus	144-149
15938128-1	2005	In the present study we investigate the effect of homocysteine (Hcy) administration, the main metabolite accumulating in homocystinuria, on butyrylcholinesterase (BuChE) activity in serum of rats.	Homocysteine	50-62	butyrylcholinesterase	Rattus norvegicus	140-161
15910416-12	2005	Plasma cholinesterase activity measured 4 hr after exposure to 25 mg/kg chlorpyrifos was inhibited to approximately 40% of control levels in both strains.	Chlorpyrifos	72-84	butyrylcholinesterase	Rattus norvegicus	7-21
15938128-1	2005	In the present study we investigate the effect of homocysteine (Hcy) administration, the main metabolite accumulating in homocystinuria, on butyrylcholinesterase (BuChE) activity in serum of rats.	Homocysteine	50-62	butyrylcholinesterase	Rattus norvegicus	163-168
15938128-1	2005	In the present study we investigate the effect of homocysteine (Hcy) administration, the main metabolite accumulating in homocystinuria, on butyrylcholinesterase (BuChE) activity in serum of rats.	Homocysteine	64-67	butyrylcholinesterase	Rattus norvegicus	140-161
15938128-1	2005	In the present study we investigate the effect of homocysteine (Hcy) administration, the main metabolite accumulating in homocystinuria, on butyrylcholinesterase (BuChE) activity in serum of rats.	Homocysteine	64-67	butyrylcholinesterase	Rattus norvegicus	163-168
15938128-8	2005	Our results showed that acute and chronic administration of Hcy significantly decreased BuChE activity.	Homocysteine	60-63	butyrylcholinesterase	Rattus norvegicus	88-93
15938128-10	2005	The data suggest that the inhibitory effect of Hcy on BuChE activity is probably mediated by free radicals, since vitamins E and C administration prevented such effect.	Homocysteine	47-50	butyrylcholinesterase	Rattus norvegicus	54-59
16187484-2	2005	Here we examined the effect of the extract on the activity of reduced brain and retinal acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in streptozotocin (STZ)-induced diabetic male Wistar rats.	Streptozocin	152-166	butyrylcholinesterase	Rattus norvegicus	120-141
15789140-1	2005	We observed here that acute proline (Pro) administration provoked a decrease (32%) of acetylcholinesterase (AChE) activity in cerebral cortex and an increase (22%) of butyrylcholinesterase (BuChE) activity in the serum of 29-day-old rats.	Proline	28-35	butyrylcholinesterase	Rattus norvegicus	167-188
15789140-1	2005	We observed here that acute proline (Pro) administration provoked a decrease (32%) of acetylcholinesterase (AChE) activity in cerebral cortex and an increase (22%) of butyrylcholinesterase (BuChE) activity in the serum of 29-day-old rats.	Proline	28-35	butyrylcholinesterase	Rattus norvegicus	190-195
15789140-1	2005	We observed here that acute proline (Pro) administration provoked a decrease (32%) of acetylcholinesterase (AChE) activity in cerebral cortex and an increase (22%) of butyrylcholinesterase (BuChE) activity in the serum of 29-day-old rats.	Proline	37-40	butyrylcholinesterase	Rattus norvegicus	167-188
15789140-1	2005	We observed here that acute proline (Pro) administration provoked a decrease (32%) of acetylcholinesterase (AChE) activity in cerebral cortex and an increase (22%) of butyrylcholinesterase (BuChE) activity in the serum of 29-day-old rats.	Proline	37-40	butyrylcholinesterase	Rattus norvegicus	190-195
16705804-0	2005	Serum acetyl cholinesterase as a biomarker of arsenic induced neurotoxicity in sprague-dawley rats.	Arsenic	46-53	butyrylcholinesterase	Rattus norvegicus	13-27
16705804-5	2005	The main objective of this study was to conduct biochemical analysis to determine the effect of arsenic trioxide on the activity of acetyl cholinesterase; a critical important nervous system enzyme that hydrolyzes the neurotransmitter acetylcholine.	Arsenic Trioxide	96-112	butyrylcholinesterase	Rattus norvegicus	139-153
16705804-5	2005	The main objective of this study was to conduct biochemical analysis to determine the effect of arsenic trioxide on the activity of acetyl cholinesterase; a critical important nervous system enzyme that hydrolyzes the neurotransmitter acetylcholine.	Acetylcholine	235-248	butyrylcholinesterase	Rattus norvegicus	139-153
16705804-10	2005	Arsenic trioxide exposure significantly decreased the activity of cholinesterase in the Sprague-Dawley rats.	Arsenic Trioxide	0-16	butyrylcholinesterase	Rattus norvegicus	66-80
16705804-11	2005	Acetyl cholinesterase activities of 6895 +/- 822, 5697 +/- 468, 5069 +/- 624, 4054 +/- 980, and 3158 +/- 648 U/L were recorded for 0, 5, 10, 15, and 20 mg/kg, respectively; indicating a gradual decrease in acetyl cholinesterase activity with increasing doses of arsenic.	Arsenic	262-269	butyrylcholinesterase	Rattus norvegicus	7-21
16705804-12	2005	These findings indicate that acetyl cholinesterase is a candidate biomarker for arsenic-induced neurotoxicity in Sprague-Dawley rats.	Arsenic	80-87	butyrylcholinesterase	Rattus norvegicus	36-50
15909902-0	2005	[Changes of parameters of functions of respiratory and cardiovascular systems of different age rats under influence of small doses of cholinesterase inhibitor Phosphacol].	Paraoxon	159-169	butyrylcholinesterase	Rattus norvegicus	134-148
15649708-0	2005	The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components.	ibuprofen-N-octyl-pyridostigmine	73-79	butyrylcholinesterase	Rattus norvegicus	26-40
15649708-2	2005	We report here that a new bifunctional compound IBU-PO, which combines a non-steroidal anti-inflammatory drug (NSAID) (Ibuprofen) and a cholinesterase (ChE) inhibitor (Octyl-Pyridostigmine), is neuroprotective against Abeta-neurotoxicity, and its activity is associated to Wnt signaling components in rat hippocampal and mouse cortical neurons.	ibuprofen-N-octyl-pyridostigmine	48-54	butyrylcholinesterase	Rattus norvegicus	136-150
15649708-2	2005	We report here that a new bifunctional compound IBU-PO, which combines a non-steroidal anti-inflammatory drug (NSAID) (Ibuprofen) and a cholinesterase (ChE) inhibitor (Octyl-Pyridostigmine), is neuroprotective against Abeta-neurotoxicity, and its activity is associated to Wnt signaling components in rat hippocampal and mouse cortical neurons.	ibuprofen-N-octyl-pyridostigmine	48-54	butyrylcholinesterase	Rattus norvegicus	152-155
15649708-2	2005	We report here that a new bifunctional compound IBU-PO, which combines a non-steroidal anti-inflammatory drug (NSAID) (Ibuprofen) and a cholinesterase (ChE) inhibitor (Octyl-Pyridostigmine), is neuroprotective against Abeta-neurotoxicity, and its activity is associated to Wnt signaling components in rat hippocampal and mouse cortical neurons.	octyl-pyridostigmine	168-188	butyrylcholinesterase	Rattus norvegicus	136-150
15649708-2	2005	We report here that a new bifunctional compound IBU-PO, which combines a non-steroidal anti-inflammatory drug (NSAID) (Ibuprofen) and a cholinesterase (ChE) inhibitor (Octyl-Pyridostigmine), is neuroprotective against Abeta-neurotoxicity, and its activity is associated to Wnt signaling components in rat hippocampal and mouse cortical neurons.	octyl-pyridostigmine	168-188	butyrylcholinesterase	Rattus norvegicus	152-155
15474645-0	2005	Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats.	Donepezil	41-50	butyrylcholinesterase	Rattus norvegicus	15-29
15474645-0	2005	Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats.	Scopolamine	70-81	butyrylcholinesterase	Rattus norvegicus	15-29
15474645-9	2005	Thus, a cholinesterase inhibitor with proven clinical efficacy can antagonize scopolamine-induced spatial memory deficits.	Scopolamine	78-89	butyrylcholinesterase	Rattus norvegicus	8-22
15474653-1	2005	The present study evaluated the effect of galanthamine, a selective competitive cholinesterase inhibitor, on histological and functional outcome after experimental stroke in rats.	Galantamine	42-54	butyrylcholinesterase	Rattus norvegicus	80-94
16249959-1	2005	Reports from Japan and India and data submissions to the US EPA indicate that exposure to cholinesterase (ChE)-inhibiting organophosphorous insecticides (OP) can produce ocular toxicity, in particular long-lasting changes in retinal physiology and anatomy.	organophosphorous	122-139	butyrylcholinesterase	Rattus norvegicus	90-104
16249959-1	2005	Reports from Japan and India and data submissions to the US EPA indicate that exposure to cholinesterase (ChE)-inhibiting organophosphorous insecticides (OP) can produce ocular toxicity, in particular long-lasting changes in retinal physiology and anatomy.	organophosphorous	122-139	butyrylcholinesterase	Rattus norvegicus	106-109
16544849-1	2005	INTRODUCTION: Tacrine is a cholinesterase inhibitor used for the treatment of Alzheimer"s disease.	Tacrine	14-21	butyrylcholinesterase	Rattus norvegicus	27-41
16544849-11	2005	They had a cholinergic character and most likely were due to endogenous acetylcholine accumulated as a result of inhibition of cholinesterase activity.	Acetylcholine	72-85	butyrylcholinesterase	Rattus norvegicus	127-141
15669039-1	2005	Weak and reversible inhibitors of cholinesterase, when coadministred in excess with a more potent inhibitor such as organophosphates, can act in a protective manner.	Organophosphates	116-132	butyrylcholinesterase	Rattus norvegicus	34-48
15848214-6	2005	The present study was designed to investigate the influence of chronic administration of donepezil (cholinesterase inhibitor, 1 and 3 mg/kg) and lercanidipine (L-type calcium channel blocker, 0.3 and 1 mg/kg) on cognitive impairment in male Sprague-Dawley rats injected twice with ICV STZ (3 mg/kg) bilaterally on days 1 and 3.	Donepezil	89-98	butyrylcholinesterase	Rattus norvegicus	100-114
15848214-8	2005	Cholinesterase activity in brain was significantly increased in ICV STZ injected rats.	Streptozocin	68-71	butyrylcholinesterase	Rattus norvegicus	0-14
15848214-9	2005	Donepezil dose-dependently inhibited cholinesterase activity and improved performance in memory tests at both the doses.	Donepezil	0-9	butyrylcholinesterase	Rattus norvegicus	37-51
16047685-0	2005	[Finding cholinesterase in endotheliocytes: cholinesterase inhibition by organophosphorus compounds leads to endotheliocyte deformation].	organophosphorus	73-89	butyrylcholinesterase	Rattus norvegicus	9-23
16047685-0	2005	[Finding cholinesterase in endotheliocytes: cholinesterase inhibition by organophosphorus compounds leads to endotheliocyte deformation].	organophosphorus	73-89	butyrylcholinesterase	Rattus norvegicus	44-58
16047685-2	2005	Cholinesterase was found in endotheliocytes and it was established that phosphacol inhibited this enzyme.	Paraoxon	72-82	butyrylcholinesterase	Rattus norvegicus	0-14
15866350-8	2005	ChE activities of the ethanol feeding rats were significantly increased as compared to control rats at the 3rd (4.8% ethanol) and 25th days of chronic ethanol (7.2%) consumption and 24th h of ethanol withdrawal.	Ethanol	22-29	butyrylcholinesterase	Rattus norvegicus	0-3
15866350-8	2005	ChE activities of the ethanol feeding rats were significantly increased as compared to control rats at the 3rd (4.8% ethanol) and 25th days of chronic ethanol (7.2%) consumption and 24th h of ethanol withdrawal.	Ethanol	117-124	butyrylcholinesterase	Rattus norvegicus	0-3
15866350-8	2005	ChE activities of the ethanol feeding rats were significantly increased as compared to control rats at the 3rd (4.8% ethanol) and 25th days of chronic ethanol (7.2%) consumption and 24th h of ethanol withdrawal.	Ethanol	117-124	butyrylcholinesterase	Rattus norvegicus	0-3
15866350-8	2005	ChE activities of the ethanol feeding rats were significantly increased as compared to control rats at the 3rd (4.8% ethanol) and 25th days of chronic ethanol (7.2%) consumption and 24th h of ethanol withdrawal.	Ethanol	117-124	butyrylcholinesterase	Rattus norvegicus	0-3
16105447-5	2005	(2) ChE activities in both treatment group with CPA [(0.49 +/- 0.05) U/ml] and non-treatment group [(0.52 +/- 0.04) U/ml] were significantly lower than that [(1.56 +/- 0.15) U/ml] of the control group (P < 0.01), but there was no significant difference between treatment group and non-treatment group (P > 0.05).	N(6)-cyclopentyladenosine	48-51	butyrylcholinesterase	Rattus norvegicus	4-7
16020401-1	2005	Organophosphate compounds act by irreversible inhibition of cholinesterase.	Organophosphates	0-15	butyrylcholinesterase	Rattus norvegicus	60-74
15734279-1	2005	Putative long-term learning and memory effects of low-dose exposure to the cholinesterase inhibitor organophosphate methamidophos (Tamaron) early in life were studied in two parallel studies in middle-aged rats.	organophosphate methamidophos	100-129	butyrylcholinesterase	Rattus norvegicus	75-89
15734279-6	2005	Exposure to methamidophos was confirmed by measurement of brain cholinesterase (ChE-B) at the end of the 16 weeks of treatment in satellite animals.	methamidophos	12-25	butyrylcholinesterase	Rattus norvegicus	64-78
15673862-1	2005	Weak and reversible inhibitors of cholinesterase(s), when coadministered in excess with a more potent inhibitor such as organophosphates, can act in a protective manner.	Organophosphates	120-136	butyrylcholinesterase	Rattus norvegicus	34-48
15620572-0	2005	The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats.	phenserine	30-40	butyrylcholinesterase	Rattus norvegicus	4-18
15620572-0	2005	The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats.	Scopolamine	84-95	butyrylcholinesterase	Rattus norvegicus	4-18
15620572-1	2005	Male Fischer-344 rats (n = 38) at 5 months old were tested in a Morris water maze to determine if treatment with the cholinesterase inhibitor, phenserine (PHEN), would overcome a learning impairment induced by scopolamine (SCOP), a muscarinic cholinergic receptor antagonist.	phenserine	143-153	butyrylcholinesterase	Rattus norvegicus	117-131
15620572-1	2005	Male Fischer-344 rats (n = 38) at 5 months old were tested in a Morris water maze to determine if treatment with the cholinesterase inhibitor, phenserine (PHEN), would overcome a learning impairment induced by scopolamine (SCOP), a muscarinic cholinergic receptor antagonist.	phenserine	155-159	butyrylcholinesterase	Rattus norvegicus	117-131
16187484-2	2005	Here we examined the effect of the extract on the activity of reduced brain and retinal acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in streptozotocin (STZ)-induced diabetic male Wistar rats.	Streptozocin	152-166	butyrylcholinesterase	Rattus norvegicus	143-147
16187484-2	2005	Here we examined the effect of the extract on the activity of reduced brain and retinal acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in streptozotocin (STZ)-induced diabetic male Wistar rats.	Streptozocin	168-171	butyrylcholinesterase	Rattus norvegicus	120-141
16187484-2	2005	Here we examined the effect of the extract on the activity of reduced brain and retinal acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in streptozotocin (STZ)-induced diabetic male Wistar rats.	Streptozocin	168-171	butyrylcholinesterase	Rattus norvegicus	143-147
15556140-3	2004	The doses of combinational regimen in minipumps were optimized to achieve 30-35% inhibition of blood cholinesterase activity by physostigmine and 50-100 ng/ml of blood concentrations of procyclidine as clinically available doses, respectively.	Physostigmine	128-141	butyrylcholinesterase	Rattus norvegicus	101-115
15527875-14	2005	CPF and its metabolites, especially CPF-oxon, contribute to the inhibition of CaE and ChE activity, as well as the alteration of BBB integrity and structure.	Chlorpyrifos	0-3	butyrylcholinesterase	Rattus norvegicus	86-89
15527875-14	2005	CPF and its metabolites, especially CPF-oxon, contribute to the inhibition of CaE and ChE activity, as well as the alteration of BBB integrity and structure.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	36-44	butyrylcholinesterase	Rattus norvegicus	86-89
15350833-9	2004	The above-mentioned neuroprotective effects are also observed with tacrine (THA, 1 microM), suggesting that the neuroprotective effects of cholinesterase inhibitor might partly contribute to the clinical efficacy in AD treatment.	Tacrine	67-74	butyrylcholinesterase	Rattus norvegicus	139-153
15350833-9	2004	The above-mentioned neuroprotective effects are also observed with tacrine (THA, 1 microM), suggesting that the neuroprotective effects of cholinesterase inhibitor might partly contribute to the clinical efficacy in AD treatment.	Tacrine	76-79	butyrylcholinesterase	Rattus norvegicus	139-153
15300712-0	2004	In vivo metoclopramide protection of cholinesterase from paraoxon inhibition: direct comparison with pralidoxime in subchronic low-dose exposure.	Metoclopramide	8-22	butyrylcholinesterase	Rattus norvegicus	37-51
15045467-6	2004	Plasma butyrylcholinesterase (BChE) activity in the female offspring from chlorpyrifos treated mothers showed a significant increase (approximately 183% of control).	Chlorpyrifos	74-86	butyrylcholinesterase	Rattus norvegicus	30-34
15163438-2	2004	Metrifonate, a cholinesterase inhibitor with reported cognitive enhancing properties in many animal models of learning and memory, was tested in the PI procedure.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	15-29
15258105-1	2004	Tacrine, a cholinesterase inhibitor, was approved for the treatment of Alzheimer"s disease.	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	11-25
15031137-2	2004	The dialysis probes were perfused with Ringer solution containing a cholinesterase inhibitor, neostigmine.	Neostigmine	94-105	butyrylcholinesterase	Rattus norvegicus	68-82
15300712-1	2004	The benzamide compound metoclopramide (MCP) protects against cholinesterase inhibition by paraoxon (POX) both in vitro and in vivo.	benzamide	4-13	butyrylcholinesterase	Rattus norvegicus	61-75
15300712-1	2004	The benzamide compound metoclopramide (MCP) protects against cholinesterase inhibition by paraoxon (POX) both in vitro and in vivo.	Metoclopramide	23-37	butyrylcholinesterase	Rattus norvegicus	61-75
15300712-1	2004	The benzamide compound metoclopramide (MCP) protects against cholinesterase inhibition by paraoxon (POX) both in vitro and in vivo.	Paraoxon	90-98	butyrylcholinesterase	Rattus norvegicus	61-75
15300712-1	2004	The benzamide compound metoclopramide (MCP) protects against cholinesterase inhibition by paraoxon (POX) both in vitro and in vivo.	Paraoxon	100-103	butyrylcholinesterase	Rattus norvegicus	61-75
15113602-0	2004	Differential profiles of cholinesterase inhibition and neurobehavioral effects in rats exposed to fenamiphos or profenofos.	fenamiphos	98-108	butyrylcholinesterase	Rattus norvegicus	25-39
15296792-3	2004	The aim of this study was to verify the effects of pyridostigmine bromide, a reversible cholinesterase inhibitor, on heart rate (HR), blood pressure (BP), HR and BP variability, and baroreflex sensitivity (BS).	Pyridostigmine Bromide	51-73	butyrylcholinesterase	Rattus norvegicus	88-102
15195690-9	2004	Our data showing an increase of VAChT after treatment with rivastgmine further support the notion of an enhancement of cholinergic neurotransmission by AChE/ChE inhibitors.	rivastgmine	59-70	butyrylcholinesterase	Rattus norvegicus	153-156
15113602-0	2004	Differential profiles of cholinesterase inhibition and neurobehavioral effects in rats exposed to fenamiphos or profenofos.	profenofos	112-122	butyrylcholinesterase	Rattus norvegicus	25-39
15113602-1	2004	The relationship between cholinesterase (ChE) inhibition and neurobehavioral changes was examined using two ChE-inhibiting organophosphorus (OP) pesticides, fenamiphos and profenofos.	organophosphorus	123-139	butyrylcholinesterase	Rattus norvegicus	108-111
15113602-15	2004	Thus, the centrally mediated neurobehavioral effects of fenamiphos could not be explained based on differential regional brain ChE inhibition alone.	fenamiphos	56-66	butyrylcholinesterase	Rattus norvegicus	127-130
15019311-1	2004	The organophosphate cholinesterase (ChE) inhibitor paraoxon is the oxidized active metabolite of parathion, a pesticide whose use in agriculture has been matter of increasing concern.	Paraoxon	51-59	butyrylcholinesterase	Rattus norvegicus	20-34
15081265-8	2004	Cholinesterase inhibition in plasma, diaphragm, and frontal cortex was generally higher in rats treated sequentially with CPF first than in those treated initially with MPS from 4 to 24 h after dosing.	6-trimethylsilylthio-9-trimethylsilylpurine	169-172	butyrylcholinesterase	Rattus norvegicus	0-14
14991459-7	2004	Memory and learning can be improved in the STZ and 2VO models by estradiol, melatonin and cholinesterase inhibitors.	Streptozocin	43-46	butyrylcholinesterase	Rattus norvegicus	90-104
15071608-1	2004	The clinical usage of the cholinesterase inhibitor tacrine for treatment of Alzheimer"s disease is accompanied by adverse effects on the gastrointestinal tract.	Tacrine	51-58	butyrylcholinesterase	Rattus norvegicus	26-40
15081274-8	2004	This estimate in the rat, based on a limited data set of three organophosphates and a single carbamate, probably represents the minimum difference in the neurotoxicity of an untested cholinesterase-inhibiting pesticide that should be expected between the human neonate and adult.	Organophosphates	63-79	butyrylcholinesterase	Rattus norvegicus	183-197
15081274-8	2004	This estimate in the rat, based on a limited data set of three organophosphates and a single carbamate, probably represents the minimum difference in the neurotoxicity of an untested cholinesterase-inhibiting pesticide that should be expected between the human neonate and adult.	Carbamates	93-102	butyrylcholinesterase	Rattus norvegicus	183-197
15019311-1	2004	The organophosphate cholinesterase (ChE) inhibitor paraoxon is the oxidized active metabolite of parathion, a pesticide whose use in agriculture has been matter of increasing concern.	Paraoxon	51-59	butyrylcholinesterase	Rattus norvegicus	36-39
15019311-1	2004	The organophosphate cholinesterase (ChE) inhibitor paraoxon is the oxidized active metabolite of parathion, a pesticide whose use in agriculture has been matter of increasing concern.	Parathion	97-106	butyrylcholinesterase	Rattus norvegicus	20-34
15019311-1	2004	The organophosphate cholinesterase (ChE) inhibitor paraoxon is the oxidized active metabolite of parathion, a pesticide whose use in agriculture has been matter of increasing concern.	Parathion	97-106	butyrylcholinesterase	Rattus norvegicus	36-39
14984701-0	2004	Oxidative stress and cholinesterase inhibition in saliva and plasma of rats following subchronic exposure to malathion.	Malathion	109-118	butyrylcholinesterase	Rattus norvegicus	21-35
14751462-1	2004	Studies in animals exploring the antagonism of the cholinesterase inhibitors soman and sarin have shown that pretreatment with low doses of the centrally acting cholinesterase inhibitor, physostigmine, alone or in conjunction with the centrally acting anticholinergic agent, scopolamine, is effective against their lethality and toxicity.	Physostigmine	187-200	butyrylcholinesterase	Rattus norvegicus	51-65
14751462-1	2004	Studies in animals exploring the antagonism of the cholinesterase inhibitors soman and sarin have shown that pretreatment with low doses of the centrally acting cholinesterase inhibitor, physostigmine, alone or in conjunction with the centrally acting anticholinergic agent, scopolamine, is effective against their lethality and toxicity.	Physostigmine	187-200	butyrylcholinesterase	Rattus norvegicus	161-175
14751462-2	2004	The current study evaluated the effects of pretreatment with the oral anticholinesterase agent, donepezil (Aricept, 2.0 mg/kg), used to treat Alzheimer"s disease, with and without scopolamine in decreasing the hypothermic, hypokinetic, and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor diisopropyl fluorophosphate (DFP, 1.0 mg/kg) in adult Flinders sensitive line (FSL) male rats.	Donepezil	96-105	butyrylcholinesterase	Rattus norvegicus	74-88
14751462-2	2004	The current study evaluated the effects of pretreatment with the oral anticholinesterase agent, donepezil (Aricept, 2.0 mg/kg), used to treat Alzheimer"s disease, with and without scopolamine in decreasing the hypothermic, hypokinetic, and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor diisopropyl fluorophosphate (DFP, 1.0 mg/kg) in adult Flinders sensitive line (FSL) male rats.	Donepezil	107-114	butyrylcholinesterase	Rattus norvegicus	74-88
14751462-5	2004	Therefore, these preliminary findings are encouraging, but many additional studies are needed to establish the effectiveness of donepezil as a prophylactic agent against irreversible cholinesterase inhibition by DFP.	Donepezil	128-137	butyrylcholinesterase	Rattus norvegicus	183-197
15568740-2	2004	Butyrylcholinesterase-(BuChE)-positive nerve components of the organ were visualized by the direct thiocholine method.	Thiocholine	99-110	butyrylcholinesterase	Rattus norvegicus	0-21
15106880-11	2004	Triton X-100 inhibited more efficiently the rat intestinal BChE soluble isoform than it did the human serum BChE.	Octoxynol	0-12	butyrylcholinesterase	Rattus norvegicus	59-63
15106880-11	2004	Triton X-100 inhibited more efficiently the rat intestinal BChE soluble isoform than it did the human serum BChE.	Octoxynol	0-12	butyrylcholinesterase	Rattus norvegicus	108-112
14984701-1	2004	The aim of this study was to examine whether malathion, a commonly used organophosphate (OP), might induce oxidative stress and cholinesterase (ChE) depression in saliva and plasma in rats following subchronic exposure mimicking human exposure.	Malathion	45-54	butyrylcholinesterase	Rattus norvegicus	128-142
14984701-1	2004	The aim of this study was to examine whether malathion, a commonly used organophosphate (OP), might induce oxidative stress and cholinesterase (ChE) depression in saliva and plasma in rats following subchronic exposure mimicking human exposure.	Malathion	45-54	butyrylcholinesterase	Rattus norvegicus	144-147
14984701-4	2004	Four weeks oral administration of malathion at doses of 100 ppm, 500 ppm and 1500 ppm depressed plasma ChE activity to 45% (P<0.01), 48% (P<0.01) and 41% (P<0.01) of control, respectively.	Malathion	34-43	butyrylcholinesterase	Rattus norvegicus	103-106
14984701-5	2004	Malathion at doses of 100 ppm, 500 ppm and 1500 ppm depressed saliva ChE activity to 73% (P<0.01), 75% (P<0.01) and 78% (P<0.01) of control, respectively.	Malathion	0-9	butyrylcholinesterase	Rattus norvegicus	69-72
15359689-1	2004	The purpose of this investigation was the study of cholinesterase (ChE)-positive zones of neuromuscular synapse (NMS) in gastrocnemius and plantaris muscles of albino rats after guanethidine sympathectomy.	Guanethidine	178-190	butyrylcholinesterase	Rattus norvegicus	51-65
15359689-1	2004	The purpose of this investigation was the study of cholinesterase (ChE)-positive zones of neuromuscular synapse (NMS) in gastrocnemius and plantaris muscles of albino rats after guanethidine sympathectomy.	Guanethidine	178-190	butyrylcholinesterase	Rattus norvegicus	67-70
15359692-2	2004	Cell cross-sectional area, activities of cholinesterase (demonstrated with thioacetic acid method) monoamine oxidase (demonstrated with Glenner method) were measured in neurocytes of stellate, spinal, trigeminal and gastric ganglia in rats aged 2 to 360 days.	thioacetic acid	75-90	butyrylcholinesterase	Rattus norvegicus	41-55
14514956-0	2003	The effects of repeated oral exposures to methyl parathion on rat brain cholinesterase and muscarinic receptors during postnatal development.	Methyl Parathion	42-58	butyrylcholinesterase	Rattus norvegicus	72-86
14600285-4	2004	Peak inhibition of brain cholinesterase (ChE) for CPS and CPO was determined after acute exposure to dosages of each compound (a low and a high for each), which produced similar degrees of initial ChE inhibition.	Chlorpyrifos	50-53	butyrylcholinesterase	Rattus norvegicus	25-39
14600285-4	2004	Peak inhibition of brain cholinesterase (ChE) for CPS and CPO was determined after acute exposure to dosages of each compound (a low and a high for each), which produced similar degrees of initial ChE inhibition.	Chlorpyrifos	50-53	butyrylcholinesterase	Rattus norvegicus	41-44
14600285-4	2004	Peak inhibition of brain cholinesterase (ChE) for CPS and CPO was determined after acute exposure to dosages of each compound (a low and a high for each), which produced similar degrees of initial ChE inhibition.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	58-61	butyrylcholinesterase	Rattus norvegicus	25-39
14600285-4	2004	Peak inhibition of brain cholinesterase (ChE) for CPS and CPO was determined after acute exposure to dosages of each compound (a low and a high for each), which produced similar degrees of initial ChE inhibition.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	58-61	butyrylcholinesterase	Rattus norvegicus	41-44
14600285-6	2004	This exposure paradigm resulted in persistent ChE inhibition by CPS but only transient inhibition by CPO, suggesting that, even though the initial ChE inhibition is similar between compounds, the effects of repeated exposure differ significantly.	Chlorpyrifos	64-67	butyrylcholinesterase	Rattus norvegicus	46-49
14600285-10	2004	The data suggest that the persistent ChE inhibition and decreased mAChR binding may play a role in the decreased NGF levels following CPS exposure.	Chlorpyrifos	134-137	butyrylcholinesterase	Rattus norvegicus	37-40
14644659-1	2003	The developmental neurotoxicity of chlorpyrifos (CPF) involves mechanisms over and above cholinesterase inhibition.	Chlorpyrifos	35-47	butyrylcholinesterase	Rattus norvegicus	89-103
14644659-6	2003	In the brainstem, the response to forskolin or Mn(2+) was markedly stimulated by doses at or below the threshold for observable toxicity of CPF or for inhibition of fetal brain cholinesterase, whereas comparable effects were seen in the forebrain only at higher doses.	Colforsin	34-43	butyrylcholinesterase	Rattus norvegicus	177-191
14644659-6	2003	In the brainstem, the response to forskolin or Mn(2+) was markedly stimulated by doses at or below the threshold for observable toxicity of CPF or for inhibition of fetal brain cholinesterase, whereas comparable effects were seen in the forebrain only at higher doses.	Manganese(2+)	47-53	butyrylcholinesterase	Rattus norvegicus	177-191
14513894-0	2003	Metoclopramide protection of cholinesterase from paraoxon inhibition.	Metoclopramide	0-14	butyrylcholinesterase	Rattus norvegicus	29-43
14637119-1	2003	The aim of this study was to investigate the effect of butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) on cell survival, neurite outgrowth and voltage-dependent calcium currents in developing rat ventral mesencephalic (VM) neurons.	Calcium	175-182	butyrylcholinesterase	Rattus norvegicus	55-76
14637119-1	2003	The aim of this study was to investigate the effect of butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) on cell survival, neurite outgrowth and voltage-dependent calcium currents in developing rat ventral mesencephalic (VM) neurons.	Calcium	175-182	butyrylcholinesterase	Rattus norvegicus	78-83
14637119-7	2003	The results presented here demonstrate firstly trophic effects of BuChE and G(4)- and G(1)-AChE upon dopaminergic neurite outgrowth, secondly that BuChE and G(4)- and G(1)-AChE have an inhibitory effect on voltage-dependent calcium currents, and finally that selective voltage-dependent calcium channel inhibitors also have trophic effects upon dopaminergic neurite outgrowth.	Calcium	224-231	butyrylcholinesterase	Rattus norvegicus	66-71
14521875-17	2003	Furthermore, the cholinesterase inhibitor, physostigmine, boosts ACh action during a time when cholinergic levels need to decline for proper consolidation.	Physostigmine	43-56	butyrylcholinesterase	Rattus norvegicus	17-31
14521875-17	2003	Furthermore, the cholinesterase inhibitor, physostigmine, boosts ACh action during a time when cholinergic levels need to decline for proper consolidation.	Acetylcholine	65-68	butyrylcholinesterase	Rattus norvegicus	17-31
12893843-0	2003	Cholinesterase reactivation in vivo with a novel bis-oxime optimized by computer-aided design.	bis-oxime	49-58	butyrylcholinesterase	Rattus norvegicus	0-14
14677367-1	2003	This paper describes bioanalytical methods and biosensors which rely on cholinesterase (ChE) inhibition and can be used to detect and test the toxicity of organophosphate (OP) and carbamate pesticides.	Organophosphates	155-170	butyrylcholinesterase	Rattus norvegicus	72-86
12960556-2	2003	Spinal alpha 2 receptor agonist (clonidine) and cholinesterase inhibitor (neostigmine) are also active in the modulation of nociception.	Neostigmine	74-85	butyrylcholinesterase	Rattus norvegicus	7-62
14677367-1	2003	This paper describes bioanalytical methods and biosensors which rely on cholinesterase (ChE) inhibition and can be used to detect and test the toxicity of organophosphate (OP) and carbamate pesticides.	Organophosphates	155-170	butyrylcholinesterase	Rattus norvegicus	88-91
14677367-1	2003	This paper describes bioanalytical methods and biosensors which rely on cholinesterase (ChE) inhibition and can be used to detect and test the toxicity of organophosphate (OP) and carbamate pesticides.	Carbamates	180-189	butyrylcholinesterase	Rattus norvegicus	72-86
14677367-1	2003	This paper describes bioanalytical methods and biosensors which rely on cholinesterase (ChE) inhibition and can be used to detect and test the toxicity of organophosphate (OP) and carbamate pesticides.	Carbamates	180-189	butyrylcholinesterase	Rattus norvegicus	88-91
12932426-0	2003	(-)-9-Dehydrogalanthaminium bromide, a new cholinesterase inhibitor, enhances place and object recognition memory in young and old rats.	(-)-9-dehydrogalanthaminium bromide	0-35	butyrylcholinesterase	Rattus norvegicus	43-57
12814897-0	2003	The effects of chronic ethanol consumption and ethanol withdrawal on serum cholinesterase activity in rats.	Ethanol	23-30	butyrylcholinesterase	Rattus norvegicus	75-89
12880668-2	2003	This study was undertaken to test the hypothesis that treatment with carnitine would protect the wound tissue, which was evaluated by measuring nitrite and nitrate, thus nitric oxide, malondialdehyde and cholinesterase in blood, and examining the histopathological changes.	Carnitine	69-78	butyrylcholinesterase	Rattus norvegicus	204-218
12880668-9	2003	However, serum nitric oxide levels were close to each other in both groups (P > 0.05), while serum cholinesterase level was higher in the carnitine-administered group than in the control group (P < 0.01).	Carnitine	141-150	butyrylcholinesterase	Rattus norvegicus	102-116
12845416-3	2003	We investigated the effects on cognitive performance of combined treatments of ondansetron with either flumazenil, a GABA(A) receptor benzodiazepine site antagonist, or tacrine, a cholinesterase inhibitor, which are also able to prevent scopolamine-induced cognitive impairment.	Tacrine	169-176	butyrylcholinesterase	Rattus norvegicus	180-194
12814897-0	2003	The effects of chronic ethanol consumption and ethanol withdrawal on serum cholinesterase activity in rats.	Ethanol	47-54	butyrylcholinesterase	Rattus norvegicus	75-89
12814897-6	2003	Serum ChE activity was found significantly increased from the 3rd day of ethanol (4.8%) consumption.	Ethanol	73-80	butyrylcholinesterase	Rattus norvegicus	6-9
12814897-7	2003	Serum ChE activities of the rats receiving 7.2% ethanol also increased significantly compared with rats ingesting 4.8% ethanol.	Ethanol	48-55	butyrylcholinesterase	Rattus norvegicus	6-9
12814897-9	2003	Increased serum ChE activity (1968 U/l) was still observed (1942 U/l) after 24 h of ethanol withdrawal.	Ethanol	84-91	butyrylcholinesterase	Rattus norvegicus	16-19
12814897-10	2003	ChE activity returned to control levels (501 U/l) after 72 h of ethanol withdrawal.	Ethanol	64-71	butyrylcholinesterase	Rattus norvegicus	0-3
12814897-12	2003	CONCLUSIONS: Our results show that serum ChE activity is increased by chronic ethanol consumption in rats and that this increase is affected by ethanol concentration and duration of ethanol ingestion.	Ethanol	78-85	butyrylcholinesterase	Rattus norvegicus	41-44
12814897-12	2003	CONCLUSIONS: Our results show that serum ChE activity is increased by chronic ethanol consumption in rats and that this increase is affected by ethanol concentration and duration of ethanol ingestion.	Ethanol	144-151	butyrylcholinesterase	Rattus norvegicus	41-44
12814897-12	2003	CONCLUSIONS: Our results show that serum ChE activity is increased by chronic ethanol consumption in rats and that this increase is affected by ethanol concentration and duration of ethanol ingestion.	Ethanol	144-151	butyrylcholinesterase	Rattus norvegicus	41-44
12726885-2	2003	Here we tested if stressing rats, using an intermittent 1 hr tailshock protocol, affected the degree of brain acetylcholinesterase (AChE) inhibition caused by a subsequent single injection of PB (2.0 mg/kg) or neostigmine bromide (NB, 0.32 mg/kg), another peripheral carbamate cholinesterase inhibitor.	Pyridostigmine Bromide	192-194	butyrylcholinesterase	Rattus norvegicus	116-130
14979094-1	2003	The role of the polymorphic cytochrome P450 (CYP) 2D6 isoform in catalysing the oxidative biotransformation of the organophosphate pesticide chlorpyriphos and the carbamate aldicarb into structures that inhibit cholinesterase and induce genotoxicity has been investigated in microsomal fraction, using quinine as a specific chemical inhibitor of CYP 2D6.	Organophosphates	115-130	butyrylcholinesterase	Rattus norvegicus	211-225
14979094-1	2003	The role of the polymorphic cytochrome P450 (CYP) 2D6 isoform in catalysing the oxidative biotransformation of the organophosphate pesticide chlorpyriphos and the carbamate aldicarb into structures that inhibit cholinesterase and induce genotoxicity has been investigated in microsomal fraction, using quinine as a specific chemical inhibitor of CYP 2D6.	Chlorpyrifos	141-154	butyrylcholinesterase	Rattus norvegicus	211-225
14979094-1	2003	The role of the polymorphic cytochrome P450 (CYP) 2D6 isoform in catalysing the oxidative biotransformation of the organophosphate pesticide chlorpyriphos and the carbamate aldicarb into structures that inhibit cholinesterase and induce genotoxicity has been investigated in microsomal fraction, using quinine as a specific chemical inhibitor of CYP 2D6.	carbamate aldicarb	163-181	butyrylcholinesterase	Rattus norvegicus	211-225
14979094-3	2003	Compared to microsomes incubated without quinine, where cholinesterase activity was inhibited to a mean 53% (chlorpyriphos) and 57% (aldicarb) of control, the introduction of P450 2D6 inhibitor quinine into microsomal incubation mixture reduced cholinesterase activity to 72% of control for chlorpyriphos and to 27% for aldicarb, suggesting that P450 2D6 is involved in the activation of chlorpyriphos but does not influence aldicarb toxicity on acetylcholinesterase.	Quinine	41-48	butyrylcholinesterase	Rattus norvegicus	56-70
14979094-3	2003	Compared to microsomes incubated without quinine, where cholinesterase activity was inhibited to a mean 53% (chlorpyriphos) and 57% (aldicarb) of control, the introduction of P450 2D6 inhibitor quinine into microsomal incubation mixture reduced cholinesterase activity to 72% of control for chlorpyriphos and to 27% for aldicarb, suggesting that P450 2D6 is involved in the activation of chlorpyriphos but does not influence aldicarb toxicity on acetylcholinesterase.	Chlorpyrifos	109-122	butyrylcholinesterase	Rattus norvegicus	56-70
14979094-3	2003	Compared to microsomes incubated without quinine, where cholinesterase activity was inhibited to a mean 53% (chlorpyriphos) and 57% (aldicarb) of control, the introduction of P450 2D6 inhibitor quinine into microsomal incubation mixture reduced cholinesterase activity to 72% of control for chlorpyriphos and to 27% for aldicarb, suggesting that P450 2D6 is involved in the activation of chlorpyriphos but does not influence aldicarb toxicity on acetylcholinesterase.	Quinine	194-201	butyrylcholinesterase	Rattus norvegicus	56-70
14979094-3	2003	Compared to microsomes incubated without quinine, where cholinesterase activity was inhibited to a mean 53% (chlorpyriphos) and 57% (aldicarb) of control, the introduction of P450 2D6 inhibitor quinine into microsomal incubation mixture reduced cholinesterase activity to 72% of control for chlorpyriphos and to 27% for aldicarb, suggesting that P450 2D6 is involved in the activation of chlorpyriphos but does not influence aldicarb toxicity on acetylcholinesterase.	Chlorpyrifos	291-304	butyrylcholinesterase	Rattus norvegicus	56-70
14979094-3	2003	Compared to microsomes incubated without quinine, where cholinesterase activity was inhibited to a mean 53% (chlorpyriphos) and 57% (aldicarb) of control, the introduction of P450 2D6 inhibitor quinine into microsomal incubation mixture reduced cholinesterase activity to 72% of control for chlorpyriphos and to 27% for aldicarb, suggesting that P450 2D6 is involved in the activation of chlorpyriphos but does not influence aldicarb toxicity on acetylcholinesterase.	Aldicarb	133-141	butyrylcholinesterase	Rattus norvegicus	56-70
14979094-3	2003	Compared to microsomes incubated without quinine, where cholinesterase activity was inhibited to a mean 53% (chlorpyriphos) and 57% (aldicarb) of control, the introduction of P450 2D6 inhibitor quinine into microsomal incubation mixture reduced cholinesterase activity to 72% of control for chlorpyriphos and to 27% for aldicarb, suggesting that P450 2D6 is involved in the activation of chlorpyriphos but does not influence aldicarb toxicity on acetylcholinesterase.	Chlorpyrifos	291-304	butyrylcholinesterase	Rattus norvegicus	56-70
12957233-10	2003	According to plasma IC50, THIO, CPZ and CLO are potent cholinesterase inhibitors.	Thioridazine	26-30	butyrylcholinesterase	Rattus norvegicus	55-69
12957233-10	2003	According to plasma IC50, THIO, CPZ and CLO are potent cholinesterase inhibitors.	Chlorpromazine	32-35	butyrylcholinesterase	Rattus norvegicus	55-69
12957233-10	2003	According to plasma IC50, THIO, CPZ and CLO are potent cholinesterase inhibitors.	Clozapine	40-43	butyrylcholinesterase	Rattus norvegicus	55-69
12957233-11	2003	CLO showed the lowest potency of cholinesterase inhibition in the striatum and THIO showed the highest potency in plasma and striatum.	Clozapine	0-3	butyrylcholinesterase	Rattus norvegicus	33-47
12767693-0	2003	Characterization of the in vitro kinetic interaction of chlorpyrifos-oxon with rat salivary cholinesterase: a potential biomonitoring matrix.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	56-73	butyrylcholinesterase	Rattus norvegicus	92-106
12726885-1	2003	Pyridostigmine bromide (PB), a peripheral cholinesterase inhibitor, has been shown to have central cholinesterase inhibition properties under certain conditions (such as when ingested with other chemical compounds or following a high level of stress).	Pyridostigmine Bromide	0-22	butyrylcholinesterase	Rattus norvegicus	42-56
12726885-1	2003	Pyridostigmine bromide (PB), a peripheral cholinesterase inhibitor, has been shown to have central cholinesterase inhibition properties under certain conditions (such as when ingested with other chemical compounds or following a high level of stress).	Pyridostigmine Bromide	0-22	butyrylcholinesterase	Rattus norvegicus	99-113
12726885-1	2003	Pyridostigmine bromide (PB), a peripheral cholinesterase inhibitor, has been shown to have central cholinesterase inhibition properties under certain conditions (such as when ingested with other chemical compounds or following a high level of stress).	Pyridostigmine Bromide	24-26	butyrylcholinesterase	Rattus norvegicus	42-56
12726885-1	2003	Pyridostigmine bromide (PB), a peripheral cholinesterase inhibitor, has been shown to have central cholinesterase inhibition properties under certain conditions (such as when ingested with other chemical compounds or following a high level of stress).	Pyridostigmine Bromide	24-26	butyrylcholinesterase	Rattus norvegicus	99-113
12787840-3	2003	We prepared a novel drug, TV-3326 (N-propargyl-3R-aminoindan-5yl)-ethyl methylcarbamate), with both cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity, as potential treatment of AD and DLB.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	26-33	butyrylcholinesterase	Rattus norvegicus	100-114
12787840-3	2003	We prepared a novel drug, TV-3326 (N-propargyl-3R-aminoindan-5yl)-ethyl methylcarbamate), with both cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity, as potential treatment of AD and DLB.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	26-33	butyrylcholinesterase	Rattus norvegicus	116-119
12787840-3	2003	We prepared a novel drug, TV-3326 (N-propargyl-3R-aminoindan-5yl)-ethyl methylcarbamate), with both cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity, as potential treatment of AD and DLB.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	35-87	butyrylcholinesterase	Rattus norvegicus	100-114
12787840-3	2003	We prepared a novel drug, TV-3326 (N-propargyl-3R-aminoindan-5yl)-ethyl methylcarbamate), with both cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity, as potential treatment of AD and DLB.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	35-87	butyrylcholinesterase	Rattus norvegicus	116-119
14761523-1	2003	OBJECTIVE: To study the accumulation of fluoride in rat hippocampus and its effect on cholinesterase activity.	Fluorides	40-48	butyrylcholinesterase	Rattus norvegicus	86-100
12628316-6	2003	The first studies determined the effect of Triton X-100 or salt (NaCl) on the extraction and solubilization of cholinesterase activity from retina, brain, striated muscle, diaphragm, and heart: phosphate buffer plus detergent (1% Triton X-100) yielded the highest activity for most tissues.	Octoxynol	43-55	butyrylcholinesterase	Rattus norvegicus	111-125
12628316-6	2003	The first studies determined the effect of Triton X-100 or salt (NaCl) on the extraction and solubilization of cholinesterase activity from retina, brain, striated muscle, diaphragm, and heart: phosphate buffer plus detergent (1% Triton X-100) yielded the highest activity for most tissues.	Salts	59-63	butyrylcholinesterase	Rattus norvegicus	111-125
12628316-6	2003	The first studies determined the effect of Triton X-100 or salt (NaCl) on the extraction and solubilization of cholinesterase activity from retina, brain, striated muscle, diaphragm, and heart: phosphate buffer plus detergent (1% Triton X-100) yielded the highest activity for most tissues.	Sodium Chloride	65-69	butyrylcholinesterase	Rattus norvegicus	111-125
12628316-6	2003	The first studies determined the effect of Triton X-100 or salt (NaCl) on the extraction and solubilization of cholinesterase activity from retina, brain, striated muscle, diaphragm, and heart: phosphate buffer plus detergent (1% Triton X-100) yielded the highest activity for most tissues.	Phosphates	194-203	butyrylcholinesterase	Rattus norvegicus	111-125
12628316-6	2003	The first studies determined the effect of Triton X-100 or salt (NaCl) on the extraction and solubilization of cholinesterase activity from retina, brain, striated muscle, diaphragm, and heart: phosphate buffer plus detergent (1% Triton X-100) yielded the highest activity for most tissues.	Octoxynol	230-242	butyrylcholinesterase	Rattus norvegicus	111-125
12641742-2	2003	Non-quantal ACh secretion was estimated by the amplitude of endplate hyperpolarization (H-effect) following blockade of skeletal muscle post-synaptic nicotinic receptors by (+)-tubocurarine and cholinesterase by armin (diethoxy-p-nitrophenyl phosphate).	Acetylcholine	12-15	butyrylcholinesterase	Rattus norvegicus	120-208
12618916-3	2003	OBJECTIVE: We investigated the extent to which the cholinesterase inhibitor donepezil reversed the attentional performance deficit in nucleus basalis magnocellularis (NBM) lesioned rats.	Donepezil	76-85	butyrylcholinesterase	Rattus norvegicus	51-65
14761523-6	2003	CONCLUSION: Fluoride may go through the blood-brain barrier and accumulate in rat hippocampus, and inhibit the activity of cholinesterase.	Fluorides	12-20	butyrylcholinesterase	Rattus norvegicus	123-137
12586202-1	2003	Huperzine A is a reversible and selective cholinesterase inhibitor approved for the treatment of Alzheimer"s disease.	huperzine A	0-11	butyrylcholinesterase	Rattus norvegicus	42-56
12604688-1	2003	We tested the hypothesis that pyridostigmine bromide (PB) intake and/or low-level sarin exposure, suggested by some as causes of the symptoms experienced by Persian Gulf War veterans, induce neurobehavioral dysfunction that outlasts their effects on cholinesterase.	Pyridostigmine Bromide	30-52	butyrylcholinesterase	Rattus norvegicus	250-264
12604688-1	2003	We tested the hypothesis that pyridostigmine bromide (PB) intake and/or low-level sarin exposure, suggested by some as causes of the symptoms experienced by Persian Gulf War veterans, induce neurobehavioral dysfunction that outlasts their effects on cholinesterase.	Pyridostigmine Bromide	54-56	butyrylcholinesterase	Rattus norvegicus	250-264
12591136-1	2003	Short-term paradoxical sleep (PS) deprivation was used to examine the effects of chronic exposure to subtoxic doses of the cholinesterase inhibitor diisopropylfluorophosphate (DFP) on PS regulation.	Isoflurophate	148-174	butyrylcholinesterase	Rattus norvegicus	123-137
12591136-1	2003	Short-term paradoxical sleep (PS) deprivation was used to examine the effects of chronic exposure to subtoxic doses of the cholinesterase inhibitor diisopropylfluorophosphate (DFP) on PS regulation.	Isoflurophate	176-179	butyrylcholinesterase	Rattus norvegicus	123-137
12521672-9	2003	These results indicate that gestational exposure to chlorpyrifos results in relatively persistent inhibition of brain cholinesterase and a delayed depression of choline acetyltransferase at a time when brain cholinesterase activity had returned to control levels in the high-dosage group.	Chlorpyrifos	52-64	butyrylcholinesterase	Rattus norvegicus	118-132
12521672-9	2003	These results indicate that gestational exposure to chlorpyrifos results in relatively persistent inhibition of brain cholinesterase and a delayed depression of choline acetyltransferase at a time when brain cholinesterase activity had returned to control levels in the high-dosage group.	Chlorpyrifos	52-64	butyrylcholinesterase	Rattus norvegicus	208-222
12521673-10	2003	Diazinon doses of 50 to 300 mg/kg led to 40% to 50% inhibition in plasma cholinesterase (ChE) activity 4 h after dosing, and females displayed a significantly slower recovery of ChE activity compared to males.	Diazinon	0-8	butyrylcholinesterase	Rattus norvegicus	73-87
12521673-10	2003	Diazinon doses of 50 to 300 mg/kg led to 40% to 50% inhibition in plasma cholinesterase (ChE) activity 4 h after dosing, and females displayed a significantly slower recovery of ChE activity compared to males.	Diazinon	0-8	butyrylcholinesterase	Rattus norvegicus	89-92
12482234-1	2002	Butyrylcholinesterase (BChE) is inhibited by the plant growth regulator (2-chloroethyl)phosphonic acid (ethephon) as observed 25 years ago both in vitro and in vivo in rats and mice and more recently in subchronic studies at low doses with human subjects.	ethephon	73-102	butyrylcholinesterase	Rattus norvegicus	0-21
12490599-1	2003	This study was designed to investigate the effects of the cholinesterase inhibitors soman and pyridostigmine bromide (PB) on synaptic transmission in the CA1 field of rat hippocampal slices.	Pyridostigmine Bromide	118-120	butyrylcholinesterase	Rattus norvegicus	58-72
12490599-5	2003	After 10-15-min exposure of hippocampal slices to 100 nM PB, GABAergic transmission was facilitated and cholinesterase activity was not significantly affected.	Pyridostigmine Bromide	57-59	butyrylcholinesterase	Rattus norvegicus	104-118
12551743-0	2003	Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats.	galanthaminium bromide	24-46	butyrylcholinesterase	Rattus norvegicus	54-68
12918214-0	2003	Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.	Galantamine	20-31	butyrylcholinesterase	Rattus norvegicus	35-49
12482234-1	2002	Butyrylcholinesterase (BChE) is inhibited by the plant growth regulator (2-chloroethyl)phosphonic acid (ethephon) as observed 25 years ago both in vitro and in vivo in rats and mice and more recently in subchronic studies at low doses with human subjects.	ethephon	73-102	butyrylcholinesterase	Rattus norvegicus	23-27
12482234-5	2002	Amino acid substitutions that greatly reduce rBChE sensitivity to ethephon are G117H and G117K in the oxyanion hole (which may interfere with hydrogen bonding between glycine-N-H and ethephon dianion) and A328F, A328W, and A328Y (perhaps by impeding access to the active site gorge).	ethephon	66-74	butyrylcholinesterase	Rattus norvegicus	45-50
12482234-5	2002	Amino acid substitutions that greatly reduce rBChE sensitivity to ethephon are G117H and G117K in the oxyanion hole (which may interfere with hydrogen bonding between glycine-N-H and ethephon dianion) and A328F, A328W, and A328Y (perhaps by impeding access to the active site gorge).	Hydrogen	142-150	butyrylcholinesterase	Rattus norvegicus	45-50
12482234-5	2002	Amino acid substitutions that greatly reduce rBChE sensitivity to ethephon are G117H and G117K in the oxyanion hole (which may interfere with hydrogen bonding between glycine-N-H and ethephon dianion) and A328F, A328W, and A328Y (perhaps by impeding access to the active site gorge).	glycine-n-h	167-178	butyrylcholinesterase	Rattus norvegicus	45-50
12482234-5	2002	Amino acid substitutions that greatly reduce rBChE sensitivity to ethephon are G117H and G117K in the oxyanion hole (which may interfere with hydrogen bonding between glycine-N-H and ethephon dianion) and A328F, A328W, and A328Y (perhaps by impeding access to the active site gorge).	ethephon dianion	183-199	butyrylcholinesterase	Rattus norvegicus	45-50
14694587-1	2002	OBJECTIVE: To determine whether and to what degree the activity of cholinesterase(ChE) is inhibited by dimehypo at different doses of dimehypo [scientific name: 2-dimethylamine-1,3-bi(sodium hyposulfit)].	2-dimethylamine-1,3-bi(sodium hyposulfit)	161-202	butyrylcholinesterase	Rattus norvegicus	67-81
12376170-0	2002	Chromaproline and Chromaperidine, nicotine agonists, and Donepezil, cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats.	Donepezil	57-66	butyrylcholinesterase	Rattus norvegicus	68-82
14694588-0	2002	[The activity of blood cholinesterase in rats exposed to dimethypo after drug intervention].	dimethypo	57-66	butyrylcholinesterase	Rattus norvegicus	23-37
12384257-5	2002	These responses were inhibited and enhanced by RVLM application of the muscarinic receptor antagonist scopolamine and the cholinesterase inhibitor physostigmine, respectively.	Physostigmine	147-160	butyrylcholinesterase	Rattus norvegicus	122-136
12111444-2	2002	Eighteen h after the last administration, cholinesterase inhibition was 85, 52 and 39% after metrifonate, rivastigmine and donepezil, respectively, and was accompanied by 988, 590 and 75% increase in cortical acetylcholine level.	Trichlorfon	93-104	butyrylcholinesterase	Rattus norvegicus	42-56
12557470-0	2002	The effect of cycloheximide on butyrylcholinesterase activity in vivo.	Cycloheximide	14-27	butyrylcholinesterase	Rattus norvegicus	31-52
12557470-1	2002	The paper describes the catalytic activity of butyrylcholinesterase (BuChE) measured in plasma, liver, white adipose tissue, heart, and brain of rats intraperitoneally administered a single non-lethal dose of cycloheximide (2.0 mg/kg body weight; CHM).	Cycloheximide	209-222	butyrylcholinesterase	Rattus norvegicus	46-67
12557470-1	2002	The paper describes the catalytic activity of butyrylcholinesterase (BuChE) measured in plasma, liver, white adipose tissue, heart, and brain of rats intraperitoneally administered a single non-lethal dose of cycloheximide (2.0 mg/kg body weight; CHM).	Cycloheximide	209-222	butyrylcholinesterase	Rattus norvegicus	69-74
12130735-2	2002	Here we report pharmacokinetics of cocaine in rats treated with A328W/Y332A BChE, an excellent cocaine hydrolase designed with the aid of molecular modeling.	Cocaine	35-42	butyrylcholinesterase	Rattus norvegicus	76-80
12215670-1	2002	Pyridostigmine, a carbamate cholinesterase (ChE) inhibitor, has been used for decades in the treatment of the autoimmune disorder myasthenia gravis and was used prophylactically to protect soldiers from possible organophosphorus nerve agent exposures during the Persian Gulf War.	Pyridostigmine Bromide	0-14	butyrylcholinesterase	Rattus norvegicus	28-42
12215670-1	2002	Pyridostigmine, a carbamate cholinesterase (ChE) inhibitor, has been used for decades in the treatment of the autoimmune disorder myasthenia gravis and was used prophylactically to protect soldiers from possible organophosphorus nerve agent exposures during the Persian Gulf War.	Pyridostigmine Bromide	0-14	butyrylcholinesterase	Rattus norvegicus	44-47
12215670-1	2002	Pyridostigmine, a carbamate cholinesterase (ChE) inhibitor, has been used for decades in the treatment of the autoimmune disorder myasthenia gravis and was used prophylactically to protect soldiers from possible organophosphorus nerve agent exposures during the Persian Gulf War.	organophosphorus	212-228	butyrylcholinesterase	Rattus norvegicus	44-47
12130738-10	2002	Furthermore, the combined administration of an inactive dose of SL65.0155 with the cholinesterase inhibitor rivastigmine resulted in a significant promnesic effect, suggesting a synergistic interaction.	Rivastigmine	108-120	butyrylcholinesterase	Rattus norvegicus	83-97
12171630-1	2002	The acute lethal interaction that occurs in rodents when high doses of a peripherally restricted cholinesterase inhibitor, pyridostigmine bromide (PB), and the insect repellent N, N-diethyl-m-toluamide (DEET) are combined was first described during studies of chemical mixtures that were targeted as potential causative agents of Gulf War illnesses.	DEET	177-201	butyrylcholinesterase	Rattus norvegicus	97-111
12111444-2	2002	Eighteen h after the last administration, cholinesterase inhibition was 85, 52 and 39% after metrifonate, rivastigmine and donepezil, respectively, and was accompanied by 988, 590 and 75% increase in cortical acetylcholine level.	Rivastigmine	106-118	butyrylcholinesterase	Rattus norvegicus	42-56
12111444-2	2002	Eighteen h after the last administration, cholinesterase inhibition was 85, 52 and 39% after metrifonate, rivastigmine and donepezil, respectively, and was accompanied by 988, 590 and 75% increase in cortical acetylcholine level.	Donepezil	123-132	butyrylcholinesterase	Rattus norvegicus	42-56
12111444-2	2002	Eighteen h after the last administration, cholinesterase inhibition was 85, 52 and 39% after metrifonate, rivastigmine and donepezil, respectively, and was accompanied by 988, 590 and 75% increase in cortical acetylcholine level.	Acetylcholine	209-222	butyrylcholinesterase	Rattus norvegicus	42-56
12127022-8	2002	Surprisingly, after prolonged treatment with Al, higher V(max) was observed in all the components of soluble and membrane-bound forms of BChE in the heart and liver.	Aluminum	45-47	butyrylcholinesterase	Rattus norvegicus	137-141
12110369-2	2002	Butyrylcholinesterase (BChE), being sensitive to inhibition by some organophosphorus and carbamate pesticides, is a biomarker of toxic exposure.	organophosphorus	68-84	butyrylcholinesterase	Rattus norvegicus	0-21
12110369-2	2002	Butyrylcholinesterase (BChE), being sensitive to inhibition by some organophosphorus and carbamate pesticides, is a biomarker of toxic exposure.	organophosphorus	68-84	butyrylcholinesterase	Rattus norvegicus	23-27
12110369-2	2002	Butyrylcholinesterase (BChE), being sensitive to inhibition by some organophosphorus and carbamate pesticides, is a biomarker of toxic exposure.	Carbamates	89-98	butyrylcholinesterase	Rattus norvegicus	0-21
12110369-2	2002	Butyrylcholinesterase (BChE), being sensitive to inhibition by some organophosphorus and carbamate pesticides, is a biomarker of toxic exposure.	Carbamates	89-98	butyrylcholinesterase	Rattus norvegicus	23-27
12110369-7	2002	Arg286 was found responsible for the resistance of rat BChE to inhibition by Triton X-100.	Octoxynol	77-89	butyrylcholinesterase	Rattus norvegicus	55-59
12110369-9	2002	Wild-type rat BChE had an 8- to 9-fold higher K(m) for the positively charged substrates butyrylthiocholine, acetylthiocholine, propionylthiocholine, benzoylcholine, and cocaine compared with wild-type human BChE.	Butyrylthiocholine	89-107	butyrylcholinesterase	Rattus norvegicus	14-18
12110369-9	2002	Wild-type rat BChE had an 8- to 9-fold higher K(m) for the positively charged substrates butyrylthiocholine, acetylthiocholine, propionylthiocholine, benzoylcholine, and cocaine compared with wild-type human BChE.	Acetylthiocholine	109-126	butyrylcholinesterase	Rattus norvegicus	14-18
12110369-9	2002	Wild-type rat BChE had an 8- to 9-fold higher K(m) for the positively charged substrates butyrylthiocholine, acetylthiocholine, propionylthiocholine, benzoylcholine, and cocaine compared with wild-type human BChE.	propionylthiocholine	128-148	butyrylcholinesterase	Rattus norvegicus	14-18
12110369-9	2002	Wild-type rat BChE had an 8- to 9-fold higher K(m) for the positively charged substrates butyrylthiocholine, acetylthiocholine, propionylthiocholine, benzoylcholine, and cocaine compared with wild-type human BChE.	Benzoylcholine	150-164	butyrylcholinesterase	Rattus norvegicus	14-18
12110369-9	2002	Wild-type rat BChE had an 8- to 9-fold higher K(m) for the positively charged substrates butyrylthiocholine, acetylthiocholine, propionylthiocholine, benzoylcholine, and cocaine compared with wild-type human BChE.	Cocaine	170-177	butyrylcholinesterase	Rattus norvegicus	14-18
12110369-10	2002	Wild-type rat BChE catalyzed turnover 2- to 7-fold more rapidly than human BChE, showing the highest turnover with propionylthiocholine (201,000 min(-1)).	propionylthiocholine	115-135	butyrylcholinesterase	Rattus norvegicus	14-18
11861971-7	2002	The time course of CPF and TCP in both species was linear over the dose range evaluated, and the model reasonably simulated the dose-dependent inhibition of plasma ChE, RBC acetylcholinesterase (AChE), and brain (rat only) AChE.	Chlorpyrifos	19-22	butyrylcholinesterase	Rattus norvegicus	164-167
12164550-3	2002	scopolamine, a classical anticholinergic agent, or caramiphen, an anticonvulsant anticholinergic drug with anti-glutamatergic properties, in conjunction with pyridostigmine, a reversible cholinesterase inhibitor, were administered prior to sbman (1 LD50).	Scopolamine	0-11	butyrylcholinesterase	Rattus norvegicus	187-201
12164550-3	2002	scopolamine, a classical anticholinergic agent, or caramiphen, an anticonvulsant anticholinergic drug with anti-glutamatergic properties, in conjunction with pyridostigmine, a reversible cholinesterase inhibitor, were administered prior to sbman (1 LD50).	caramiphen	51-61	butyrylcholinesterase	Rattus norvegicus	187-201
14694629-7	2002	(4) ChE activity was significantly lower in rats with P or D poisoning while ChE inhibition was of no difference in rats with M, M + D, and M + P poisoning.	phoxim	54-55	butyrylcholinesterase	Rattus norvegicus	4-7
12011491-9	2002	In rats exposed to P=S and C=S but not MP=S, ChE inhibition was lower in PCB-treated rats than in oil-treated rats.	Carbon	27-28	butyrylcholinesterase	Rattus norvegicus	45-48
12011491-9	2002	In rats exposed to P=S and C=S but not MP=S, ChE inhibition was lower in PCB-treated rats than in oil-treated rats.	Sulfur	21-22	butyrylcholinesterase	Rattus norvegicus	45-48
12011491-15	2002	Thus, the rapid rate of inhibition of ChE by the oxons does not afford time for the increase in A-esterase hydrolysis to effectively provide protection against inhibition of ChE.	oxons	49-54	butyrylcholinesterase	Rattus norvegicus	38-41
12014965-5	2002	The pronounced enhancement of AChE inhibition potency and AChE/BChE selectivity was achieved with incorporation of a halogen at the 6-position of homodimeric tacrines.	Halogens	117-124	butyrylcholinesterase	Rattus norvegicus	63-67
12014965-5	2002	The pronounced enhancement of AChE inhibition potency and AChE/BChE selectivity was achieved with incorporation of a halogen at the 6-position of homodimeric tacrines.	Tacrine	158-166	butyrylcholinesterase	Rattus norvegicus	63-67
12166762-15	2002	Despite differences in its pharmacokinetics, methyl parathion caused similar time-dependent changes in blood and brain cholinesterase activities after intravenous or oral administration.	Methyl Parathion	45-61	butyrylcholinesterase	Rattus norvegicus	119-133
12166762-16	2002	Maximal inhibition of blood cholinesterase occurred within 15-60 min, and activities recovered within 30 - 48 h. In contrast, inhibition of blood cholinesterase caused by single dermal exposure (> or = 25 mg/kg) to methyl parathion developed gradually over 24 h, but was sustained.	Parathion	225-234	butyrylcholinesterase	Rattus norvegicus	146-160
12166762-17	2002	Cholinesterase inhibited by a lower dose (< or = 12 mg/kg) of methyl parathion required up to 21 days to recover fully.	Methyl Parathion	65-81	butyrylcholinesterase	Rattus norvegicus	0-14
11914581-1	2002	Time-dependent changes in blood cholinesterase activity caused by single intravenous, oral or dermal administration of methyl parathion to adult female rats were defined.	Methyl Parathion	119-135	butyrylcholinesterase	Rattus norvegicus	32-46
11914581-2	2002	Intravenous and oral administration of 2.5 mg/kg methyl parathion resulted in rapid (<60 min) decreases in cholinesterase activity which recovered fully in vivo within 30-48 h. In contrast, spontaneous reactivation of cholinesterase in vitro was complete within 6 h at 37 degrees C. Dermal administration of methyl parathion caused dose-dependent inhibition of cholinesterase activity which developed slowly (> or =6 h) and was prolonged (> or =48 h).	Methyl Parathion	49-65	butyrylcholinesterase	Rattus norvegicus	110-124
11914581-2	2002	Intravenous and oral administration of 2.5 mg/kg methyl parathion resulted in rapid (<60 min) decreases in cholinesterase activity which recovered fully in vivo within 30-48 h. In contrast, spontaneous reactivation of cholinesterase in vitro was complete within 6 h at 37 degrees C. Dermal administration of methyl parathion caused dose-dependent inhibition of cholinesterase activity which developed slowly (> or =6 h) and was prolonged (> or =48 h).	Methyl Parathion	49-65	butyrylcholinesterase	Rattus norvegicus	221-235
11914581-2	2002	Intravenous and oral administration of 2.5 mg/kg methyl parathion resulted in rapid (<60 min) decreases in cholinesterase activity which recovered fully in vivo within 30-48 h. In contrast, spontaneous reactivation of cholinesterase in vitro was complete within 6 h at 37 degrees C. Dermal administration of methyl parathion caused dose-dependent inhibition of cholinesterase activity which developed slowly (> or =6 h) and was prolonged (> or =48 h).	Methyl Parathion	49-65	butyrylcholinesterase	Rattus norvegicus	221-235
11914581-2	2002	Intravenous and oral administration of 2.5 mg/kg methyl parathion resulted in rapid (<60 min) decreases in cholinesterase activity which recovered fully in vivo within 30-48 h. In contrast, spontaneous reactivation of cholinesterase in vitro was complete within 6 h at 37 degrees C. Dermal administration of methyl parathion caused dose-dependent inhibition of cholinesterase activity which developed slowly (> or =6 h) and was prolonged (> or =48 h).	Methyl Parathion	311-327	butyrylcholinesterase	Rattus norvegicus	221-235
11914581-2	2002	Intravenous and oral administration of 2.5 mg/kg methyl parathion resulted in rapid (<60 min) decreases in cholinesterase activity which recovered fully in vivo within 30-48 h. In contrast, spontaneous reactivation of cholinesterase in vitro was complete within 6 h at 37 degrees C. Dermal administration of methyl parathion caused dose-dependent inhibition of cholinesterase activity which developed slowly (> or =6 h) and was prolonged (> or =48 h).	Methyl Parathion	311-327	butyrylcholinesterase	Rattus norvegicus	221-235
11914581-3	2002	Time- and route-dependent effects of methyl parathion on cholinesterase activity in brain and other tissues generally paralleled its effects on activity in blood.	Methyl Parathion	37-53	butyrylcholinesterase	Rattus norvegicus	57-71
11914581-5	2002	Recovery of cholinesterase in vivo after intravenous or oral exposure may partially reflect spontaneous reactivation and suggests a rapid clearance of methyl parathion or its active metabolite methyl paraoxon.	Methyl Parathion	151-167	butyrylcholinesterase	Rattus norvegicus	12-26
11914581-5	2002	Recovery of cholinesterase in vivo after intravenous or oral exposure may partially reflect spontaneous reactivation and suggests a rapid clearance of methyl parathion or its active metabolite methyl paraoxon.	methylparaoxon	193-208	butyrylcholinesterase	Rattus norvegicus	12-26
11914581-6	2002	The more gradual and prolonged inhibition of cholinesterase caused by dermal administration is consistent with disposition of methyl parathion at a site from which it or methyl paraoxon is only slowly distributed.	Methyl Parathion	126-142	butyrylcholinesterase	Rattus norvegicus	45-59
11914581-6	2002	The more gradual and prolonged inhibition of cholinesterase caused by dermal administration is consistent with disposition of methyl parathion at a site from which it or methyl paraoxon is only slowly distributed.	methylparaoxon	170-185	butyrylcholinesterase	Rattus norvegicus	45-59
11861971-2	2002	This model integrates target tissue dosimetry and dynamic response (i.e., esterase inhibition) describing uptake, metabolism, and disposition of CPF, CPF-oxon, and TCP and the associated cholinesterase (ChE) inhibition kinetics in blood and tissues following acute and chronic oral and dermal exposure.	Chlorpyrifos	145-148	butyrylcholinesterase	Rattus norvegicus	187-201
11861971-7	2002	The time course of CPF and TCP in both species was linear over the dose range evaluated, and the model reasonably simulated the dose-dependent inhibition of plasma ChE, RBC acetylcholinesterase (AChE), and brain (rat only) AChE.	3,5,6-trichloro-2-pyridinol	27-30	butyrylcholinesterase	Rattus norvegicus	164-167
11861982-14	2002	These results show that prophylactic treatment with PB offers some degree of protection in peripheral cholinesterase.	Pyridostigmine Bromide	52-54	butyrylcholinesterase	Rattus norvegicus	102-116
11875622-0	2002	Inhibition and recovery of maternal and fetal cholinesterase enzymes following a single oral dose of chlorpyrifos in rats.	Chlorpyrifos	101-113	butyrylcholinesterase	Rattus norvegicus	46-60
11684153-1	2001	Tacrine, a reversible cholinesterase (ChE) inhibitor, lowers body temperature by increasing cholinergic activity in the hypothalamus.	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	22-36
12207957-4	2002	In the present study the predictive value of the selective cholinergic immunolesioning model was tested by examining the ability of the cholinesterase inhibitor rivastigmine to restore prepulse inhibition in immunolesioned rats.	Rivastigmine	161-173	butyrylcholinesterase	Rattus norvegicus	136-150
11755136-0	2001	Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine.	Testosterone	0-12	butyrylcholinesterase	Rattus norvegicus	56-70
11755136-0	2001	Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine.	Rivastigmine	85-97	butyrylcholinesterase	Rattus norvegicus	56-70
11755136-1	2001	The fall in body temperature and inhibition of hypothalamic cholinesterase induced by rivastigmine (a pseudo-reversible carbamate inhibitor) were compared in male and female rats.	Rivastigmine	86-98	butyrylcholinesterase	Rattus norvegicus	60-74
11755136-5	2001	Testosterone (10 mg/rat) decreased the cholinesterase inhibition and the temperature reduction induced by rivastigmine in gonadectomised males and females, but that induced by pilocarpine in males only.	Testosterone	0-12	butyrylcholinesterase	Rattus norvegicus	39-53
11755136-6	2001	In conclusion, rivastigmine causes less inhibition of cholinesterase because testosterone may interfere with its entry into the brain.	Rivastigmine	15-27	butyrylcholinesterase	Rattus norvegicus	54-68
11755136-6	2001	In conclusion, rivastigmine causes less inhibition of cholinesterase because testosterone may interfere with its entry into the brain.	Testosterone	77-89	butyrylcholinesterase	Rattus norvegicus	54-68
11928722-0	2002	Effects of T-82, a new quinoline derivative, on cholinesterase activity and extracellular acetylcholine concentration in rat brain.	T-82	11-15	butyrylcholinesterase	Rattus norvegicus	48-62
11684153-1	2001	Tacrine, a reversible cholinesterase (ChE) inhibitor, lowers body temperature by increasing cholinergic activity in the hypothalamus.	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	38-41
11684153-7	2001	Plasma ChE can bind tacrine thereby lowering the amount available to the brain.	Tacrine	20-27	butyrylcholinesterase	Rattus norvegicus	7-10
11702010-1	2001	The effects of a single or repeated dermal administration of methyl parathion on motor function, learning and memory were investigated in adult female rats and correlated with blood cholinesterase activity.	Methyl Parathion	61-77	butyrylcholinesterase	Rattus norvegicus	182-196
11728425-7	2001	The effects observed with SCH 57790 in behavioral studies were qualitatively similar to the effects produced by the clinically used cholinesterase inhibitor donepezil, suggesting that blockade of muscarinic M(2) receptors is a viable approach to enhancing cognitive performance.	Donepezil	157-166	butyrylcholinesterase	Rattus norvegicus	132-146
11711044-3	2001	The cholinesterase inhibitor physostigmine at a dose of 3.2 microg/side and D-cycloserine (1.0 and 10 microg/side), which is a partial agonist acting at the glycine binding site of the NMDA receptor/channel complex, reduced the increase in working memory errors induced by 100 ng/side interleukin-1beta.	Physostigmine	29-42	butyrylcholinesterase	Rattus norvegicus	4-18
11711044-3	2001	The cholinesterase inhibitor physostigmine at a dose of 3.2 microg/side and D-cycloserine (1.0 and 10 microg/side), which is a partial agonist acting at the glycine binding site of the NMDA receptor/channel complex, reduced the increase in working memory errors induced by 100 ng/side interleukin-1beta.	Glycine	157-164	butyrylcholinesterase	Rattus norvegicus	4-18
11702010-2	2001	Exposure to a single dose of 50 mg/kg methyl parathion (75% of the dermal LD(50)) resulted in an 88% inhibition of blood cholinesterase activity and was associated with severe acute toxicity.	Methyl Parathion	38-54	butyrylcholinesterase	Rattus norvegicus	121-135
11702010-7	2001	Repeated treatment with 1 mg/kg/day methyl parathion resulted in a 50% inhibition of blood cholinesterase activity.	Methyl Parathion	36-52	butyrylcholinesterase	Rattus norvegicus	91-105
11702010-9	2001	Thus, a single dermal exposure of rats to doses of methyl parathion which are lower than those that elicit acute toxicity can cause decrements in both cholinesterase activity and motor function which are reversible.	Methyl Parathion	51-67	butyrylcholinesterase	Rattus norvegicus	151-165
11434979-0	2001	Acetyl- and butyrylcholinesterase molecular forms in normal and streptozotocin-diabetic rat retinal pigment epithelium.	Streptozocin	64-78	butyrylcholinesterase	Rattus norvegicus	0-33
11881970-5	2001	Acute chlorpyrifos administration produced a 85.01% inhibition of AChE and a 43.4% inhibition of BuChE but had no effect on MAO-A activity and 5-HT uptake.	Chlorpyrifos	6-18	butyrylcholinesterase	Rattus norvegicus	97-102
11881970-6	2001	In contrast, subacute chlorpyrifos exposure caused a 94.96% inhibition of AChE and a 85.8% inhibition of BuChE and, also, elicited a significant (35.02%) reduction in the platelet uptake of 5-HT.	Chlorpyrifos	22-34	butyrylcholinesterase	Rattus norvegicus	105-110
11881970-8	2001	Acute carbaryl administration produced a 56.38% AChE inhibition and a 55.95% BuChE inhibition and also caused a significant (26.36%) decrease in 5-HT uptake but no change in MAO-A.	Carbaryl	6-14	butyrylcholinesterase	Rattus norvegicus	77-82
11673119-4	2001	Chlorpyrifos oxon, the active metabolite that inhibits cholinesterase, also decreased DNA synthesis in PC12 and C6 cells with a preferential effect on the latter.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	0-17	butyrylcholinesterase	Rattus norvegicus	55-69
11673119-7	2001	Physostigmine, a non-organophosphate cholinesterase inhibitor, was less effective than either chlorpyrifos or diazinon, but still caused significant inhibition of DNA synthesis in C6 cells.	Physostigmine	0-13	butyrylcholinesterase	Rattus norvegicus	37-51
11481665-0	2001	Inhibition and recovery of maternal and fetal cholinesterase enzyme activity following a single cutaneous dose of methyl parathion and diazinon, alone and in combination, in pregnant rats.	Methyl Parathion	114-130	butyrylcholinesterase	Rattus norvegicus	46-60
11548114-1	2001	The purpose of the present study was to determine the effect of two different doses of the organophosphate insecticide O,O"-diethyl-O-3,5,6-trichloro-2-pyridylphosphorothionate [chlorpyrifos (CPF)], a cholinesterase (ChE) inhibitor, in the plus-maze test of anxiety in the rat, as well as on acetylcholinesterase (AChE) activity in the brain.	Organophosphates	91-106	butyrylcholinesterase	Rattus norvegicus	201-215
11548114-1	2001	The purpose of the present study was to determine the effect of two different doses of the organophosphate insecticide O,O"-diethyl-O-3,5,6-trichloro-2-pyridylphosphorothionate [chlorpyrifos (CPF)], a cholinesterase (ChE) inhibitor, in the plus-maze test of anxiety in the rat, as well as on acetylcholinesterase (AChE) activity in the brain.	Organophosphates	91-106	butyrylcholinesterase	Rattus norvegicus	217-220
11548114-1	2001	The purpose of the present study was to determine the effect of two different doses of the organophosphate insecticide O,O"-diethyl-O-3,5,6-trichloro-2-pyridylphosphorothionate [chlorpyrifos (CPF)], a cholinesterase (ChE) inhibitor, in the plus-maze test of anxiety in the rat, as well as on acetylcholinesterase (AChE) activity in the brain.	o,o"-diethyl-o-3,5,6-trichloro	119-149	butyrylcholinesterase	Rattus norvegicus	201-215
11548114-1	2001	The purpose of the present study was to determine the effect of two different doses of the organophosphate insecticide O,O"-diethyl-O-3,5,6-trichloro-2-pyridylphosphorothionate [chlorpyrifos (CPF)], a cholinesterase (ChE) inhibitor, in the plus-maze test of anxiety in the rat, as well as on acetylcholinesterase (AChE) activity in the brain.	o,o"-diethyl-o-3,5,6-trichloro	119-149	butyrylcholinesterase	Rattus norvegicus	217-220
11548114-1	2001	The purpose of the present study was to determine the effect of two different doses of the organophosphate insecticide O,O"-diethyl-O-3,5,6-trichloro-2-pyridylphosphorothionate [chlorpyrifos (CPF)], a cholinesterase (ChE) inhibitor, in the plus-maze test of anxiety in the rat, as well as on acetylcholinesterase (AChE) activity in the brain.	Chlorpyrifos	178-190	butyrylcholinesterase	Rattus norvegicus	201-215
11548114-1	2001	The purpose of the present study was to determine the effect of two different doses of the organophosphate insecticide O,O"-diethyl-O-3,5,6-trichloro-2-pyridylphosphorothionate [chlorpyrifos (CPF)], a cholinesterase (ChE) inhibitor, in the plus-maze test of anxiety in the rat, as well as on acetylcholinesterase (AChE) activity in the brain.	Chlorpyrifos	178-190	butyrylcholinesterase	Rattus norvegicus	217-220
11481665-7	2001	Although fetal plasma BuChE activity recovered to 100% of control within 96 h of application, maternal BuChE activity remained inhibited to 55% and 32% of control 96 h after application of methyl parathion and a mixture of methyl parathion and diazinon, respectively.	Methyl Parathion	189-205	butyrylcholinesterase	Rattus norvegicus	103-108
11481665-8	2001	Following a single dermal dose of methyl parathion, the activity of maternal liver BuChE was 63% of control 2 h after dosing, whereas inhibition of placental AChE or BuChE activity occurred 12 and 1 h following a single dose of methyl parathion, corresponding to activities of 63% and 54% of control, respectively.	Methyl Parathion	34-50	butyrylcholinesterase	Rattus norvegicus	83-88
11481665-8	2001	Following a single dermal dose of methyl parathion, the activity of maternal liver BuChE was 63% of control 2 h after dosing, whereas inhibition of placental AChE or BuChE activity occurred 12 and 1 h following a single dose of methyl parathion, corresponding to activities of 63% and 54% of control, respectively.	Methyl Parathion	34-50	butyrylcholinesterase	Rattus norvegicus	166-171
11481665-8	2001	Following a single dermal dose of methyl parathion, the activity of maternal liver BuChE was 63% of control 2 h after dosing, whereas inhibition of placental AChE or BuChE activity occurred 12 and 1 h following a single dose of methyl parathion, corresponding to activities of 63% and 54% of control, respectively.	Methyl Parathion	228-244	butyrylcholinesterase	Rattus norvegicus	166-171
11481665-10	2001	The results suggest that dermal application of a single dose of methyl parathion and diazinon, alone or in combination, has an easy access into maternal and fetal tissues, resulting in inhibition of cholinesterase enzymes.	Methyl Parathion	64-80	butyrylcholinesterase	Rattus norvegicus	199-213
11481665-10	2001	The results suggest that dermal application of a single dose of methyl parathion and diazinon, alone or in combination, has an easy access into maternal and fetal tissues, resulting in inhibition of cholinesterase enzymes.	Diazinon	85-93	butyrylcholinesterase	Rattus norvegicus	199-213
11481665-11	2001	The lower inhibitory effect of the combination of methyl parathion and diazinon might be due to competition of diazinon with methyl parathion for cytochrome P-450 enzymes, resulting in formation of the potent cholinesterase inhibitor methyl paraoxon.	Methyl Parathion	50-66	butyrylcholinesterase	Rattus norvegicus	209-223
11481665-11	2001	The lower inhibitory effect of the combination of methyl parathion and diazinon might be due to competition of diazinon with methyl parathion for cytochrome P-450 enzymes, resulting in formation of the potent cholinesterase inhibitor methyl paraoxon.	Diazinon	71-79	butyrylcholinesterase	Rattus norvegicus	209-223
11481665-0	2001	Inhibition and recovery of maternal and fetal cholinesterase enzyme activity following a single cutaneous dose of methyl parathion and diazinon, alone and in combination, in pregnant rats.	Diazinon	135-143	butyrylcholinesterase	Rattus norvegicus	46-60
11481665-11	2001	The lower inhibitory effect of the combination of methyl parathion and diazinon might be due to competition of diazinon with methyl parathion for cytochrome P-450 enzymes, resulting in formation of the potent cholinesterase inhibitor methyl paraoxon.	Diazinon	111-119	butyrylcholinesterase	Rattus norvegicus	209-223
11481665-11	2001	The lower inhibitory effect of the combination of methyl parathion and diazinon might be due to competition of diazinon with methyl parathion for cytochrome P-450 enzymes, resulting in formation of the potent cholinesterase inhibitor methyl paraoxon.	Methyl Parathion	125-141	butyrylcholinesterase	Rattus norvegicus	209-223
11481665-4	2001	Methyl parathion significantly inhibited maternal and fetal brain acetylcholinesterase (AChE) and plasma butyrylcholinesterase (BuChE) activity within 24 h after dosing.	Methyl Parathion	0-16	butyrylcholinesterase	Rattus norvegicus	105-126
11481665-11	2001	The lower inhibitory effect of the combination of methyl parathion and diazinon might be due to competition of diazinon with methyl parathion for cytochrome P-450 enzymes, resulting in formation of the potent cholinesterase inhibitor methyl paraoxon.	methylparaoxon	234-249	butyrylcholinesterase	Rattus norvegicus	209-223
11481665-4	2001	Methyl parathion significantly inhibited maternal and fetal brain acetylcholinesterase (AChE) and plasma butyrylcholinesterase (BuChE) activity within 24 h after dosing.	Methyl Parathion	0-16	butyrylcholinesterase	Rattus norvegicus	128-133
11405414-0	2001	Inhibition of cholinesterase enzymes following a single dermal dose of chlorpyrifos and methyl parathion, alone and in combination, in pregnant rats.	Chlorpyrifos	71-83	butyrylcholinesterase	Rattus norvegicus	14-28
11311445-12	2001	These data indicate that chronic metrifonate treatment may increase the extracellular acetylcholine level via cholinesterase inhibition, but it does not have any effects on the blood-brain barrier.	Trichlorfon	33-44	butyrylcholinesterase	Rattus norvegicus	110-124
11405414-0	2001	Inhibition of cholinesterase enzymes following a single dermal dose of chlorpyrifos and methyl parathion, alone and in combination, in pregnant rats.	Methyl Parathion	88-104	butyrylcholinesterase	Rattus norvegicus	14-28
11405414-10	2001	The results suggest that methyl parathion and chlorpyrifos, alone or in combination, were rapidly distributed in maternal and fetal tissues, resulting in rapid inhibition of cholinesterase enzyme activities.	Methyl Parathion	25-41	butyrylcholinesterase	Rattus norvegicus	174-188
11405414-10	2001	The results suggest that methyl parathion and chlorpyrifos, alone or in combination, were rapidly distributed in maternal and fetal tissues, resulting in rapid inhibition of cholinesterase enzyme activities.	Chlorpyrifos	46-58	butyrylcholinesterase	Rattus norvegicus	174-188
11405414-11	2001	The lower inhibitory effect of the combination could be due to competition between chlorpyrifos and methyl parathion for cytochrome P-450 enzymes, resulting in inhibition of the formation of the potent cholinesterase inhibitor oxon forms.	Chlorpyrifos	83-95	butyrylcholinesterase	Rattus norvegicus	202-216
11405414-11	2001	The lower inhibitory effect of the combination could be due to competition between chlorpyrifos and methyl parathion for cytochrome P-450 enzymes, resulting in inhibition of the formation of the potent cholinesterase inhibitor oxon forms.	Methyl Parathion	100-116	butyrylcholinesterase	Rattus norvegicus	202-216
11462767-0	2001	Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.	rasagiline	72-82	butyrylcholinesterase	Rattus norvegicus	33-47
11462767-1	2001	TV3326, (N-propargyl-(3R)-aminoindan-5-yl-ethyl,methyl carbamate) was prepared in order to combine the neuroprotective effects of rasagiline, a selective inhibitor of monoamine oxidase (MAO)-B with the cholinesterase (ChE) inhibitory activity of rivastigmine as a potential treatment for Alzheimer"s disease.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-6	butyrylcholinesterase	Rattus norvegicus	202-216
11462767-1	2001	TV3326, (N-propargyl-(3R)-aminoindan-5-yl-ethyl,methyl carbamate) was prepared in order to combine the neuroprotective effects of rasagiline, a selective inhibitor of monoamine oxidase (MAO)-B with the cholinesterase (ChE) inhibitory activity of rivastigmine as a potential treatment for Alzheimer"s disease.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-6	butyrylcholinesterase	Rattus norvegicus	218-221
11462767-1	2001	TV3326, (N-propargyl-(3R)-aminoindan-5-yl-ethyl,methyl carbamate) was prepared in order to combine the neuroprotective effects of rasagiline, a selective inhibitor of monoamine oxidase (MAO)-B with the cholinesterase (ChE) inhibitory activity of rivastigmine as a potential treatment for Alzheimer"s disease.	n-propargyl-(3r)-aminoindan-5-yl-ethyl	9-47	butyrylcholinesterase	Rattus norvegicus	202-216
11679020-2	2001	The reversible cholinesterase inhibitor, tacrine (THA) was examined against the contractions of rat duodenum to acetylcholine and carbachol (cholinesterase resistant).	Tacrine	41-48	butyrylcholinesterase	Rattus norvegicus	15-29
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	Donepezil	29-36	butyrylcholinesterase	Rattus norvegicus	4-18
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	Donepezil	29-36	butyrylcholinesterase	Rattus norvegicus	292-306
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	Acetylcholine	93-106	butyrylcholinesterase	Rattus norvegicus	4-18
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	3-ppb	187-192	butyrylcholinesterase	Rattus norvegicus	4-18
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	3-ppb	187-192	butyrylcholinesterase	Rattus norvegicus	292-306
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	Acetylcholine	267-280	butyrylcholinesterase	Rattus norvegicus	4-18
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	Acetylcholine	267-280	butyrylcholinesterase	Rattus norvegicus	292-306
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	3-(N-maleimidopropionyl)biocytin	335-340	butyrylcholinesterase	Rattus norvegicus	4-18
11304753-6	2001	The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected.	3-(N-maleimidopropionyl)biocytin	335-340	butyrylcholinesterase	Rattus norvegicus	292-306
11679020-2	2001	The reversible cholinesterase inhibitor, tacrine (THA) was examined against the contractions of rat duodenum to acetylcholine and carbachol (cholinesterase resistant).	Tacrine	41-48	butyrylcholinesterase	Rattus norvegicus	141-155
11679020-2	2001	The reversible cholinesterase inhibitor, tacrine (THA) was examined against the contractions of rat duodenum to acetylcholine and carbachol (cholinesterase resistant).	tha	50-53	butyrylcholinesterase	Rattus norvegicus	15-29
11679020-10	2001	Further evidence for muscarininc receptor antagonism by tacrine was a small rightward shift of the concentration-response curve for carbachol, an agonist immune to cholinesterase.	Tacrine	56-63	butyrylcholinesterase	Rattus norvegicus	164-178
11679020-10	2001	Further evidence for muscarininc receptor antagonism by tacrine was a small rightward shift of the concentration-response curve for carbachol, an agonist immune to cholinesterase.	Carbachol	132-141	butyrylcholinesterase	Rattus norvegicus	164-178
11679020-12	2001	This study has shown that tacrine acts both as a cholinesterase inhibitor and muscarinic antagonist on rat intestinal smooth muscle.	Tacrine	26-33	butyrylcholinesterase	Rattus norvegicus	49-63
11730559-0	2001	Cholinesterase inhibition by aluminium phosphide poisoning in rats and effects of atropine and pralidoxime chloride.	aluminum phosphide	29-48	butyrylcholinesterase	Rattus norvegicus	0-14
11274994-10	2001	Distigmine, a peripherally acting cholinesterase inhibitor, evoked fasciculations, but not yawning.	distigmine	0-10	butyrylcholinesterase	Rattus norvegicus	34-48
11274994-12	2001	These results indicated that E2030 and donepezil exhibited the most marked preferential central cholinergic activity, relative to peripheral activity, among cholinesterase inhibitors tested.	Donepezil	39-48	butyrylcholinesterase	Rattus norvegicus	157-171
11158719-13	2001	These data suggest that early postnatal chlorpyrifos exposures will depress locomotor activity in juvenile rats, with the effects most pronounced after brain ChE activity has substantially recovered.	Chlorpyrifos	40-52	butyrylcholinesterase	Rattus norvegicus	158-161
10996445-5	2000	The above-mentioned neuroprotective effects are also observed with tacrine (1 microM), donepezil (10 microM) and galanthamine (10 microM), suggesting that the neuroprotective effects of cholinesterase inhibitor might partly contribute to the clinical efficacy in AD treatment.	Tacrine	67-74	butyrylcholinesterase	Rattus norvegicus	186-200
11748873-1	2001	The aim of the study was to evaluate the neurotoxic effect of a dermally-applied mixture of chlorpyrifos and cypermethrin in rats based on cognitive function, activity of the blood cholinesterase and brain acetylcholinesterase, as well as histologic brain examination.	Chlorpyrifos	92-104	butyrylcholinesterase	Rattus norvegicus	181-195
11748873-11	2001	The results of the study showed that chlorpyrifos and cypermethrin applied in a mixture caused an inhibition of cholinesterase and acetylcholinesterase activity and elicited the pycnosis of brain neurocytes.	Chlorpyrifos	37-49	butyrylcholinesterase	Rattus norvegicus	112-126
11748873-11	2001	The results of the study showed that chlorpyrifos and cypermethrin applied in a mixture caused an inhibition of cholinesterase and acetylcholinesterase activity and elicited the pycnosis of brain neurocytes.	cypermethrin	54-66	butyrylcholinesterase	Rattus norvegicus	112-126
11113581-6	2000	Microinjection of the muscarinic receptor antagonist scopolamine and the cholinesterase inhibitor physostigmine into the RVLM inhibited and potentiated, respectively, the pressor response induced by PVN stimulation.	Physostigmine	98-111	butyrylcholinesterase	Rattus norvegicus	73-87
10987987-1	2000	Eptastigmine, a potent and long-lasting cholinesterase inhibitor on age-related memory deficits, was studied.	physostigmine heptyl	0-12	butyrylcholinesterase	Rattus norvegicus	40-54
10996445-5	2000	The above-mentioned neuroprotective effects are also observed with tacrine (1 microM), donepezil (10 microM) and galanthamine (10 microM), suggesting that the neuroprotective effects of cholinesterase inhibitor might partly contribute to the clinical efficacy in AD treatment.	Donepezil	87-96	butyrylcholinesterase	Rattus norvegicus	186-200
10996445-5	2000	The above-mentioned neuroprotective effects are also observed with tacrine (1 microM), donepezil (10 microM) and galanthamine (10 microM), suggesting that the neuroprotective effects of cholinesterase inhibitor might partly contribute to the clinical efficacy in AD treatment.	Galantamine	113-125	butyrylcholinesterase	Rattus norvegicus	186-200
10876030-7	2000	The gender-selective behavioral effects were associated with greater sensitivity of males to inhibition of cholinesterase in the first few hours after chlorpyrifos treatment.	Chlorpyrifos	151-163	butyrylcholinesterase	Rattus norvegicus	107-121
10936216-9	2000	BChE was inhibited by Triton X-100 in all species tested, except rat and chicken.	Octoxynol	22-34	butyrylcholinesterase	Rattus norvegicus	0-4
10936216-11	2000	The active site of rat BChE was unique, having an arginine in place of leucine at position 286 (human BChE numbering) in the acyl-binding pocket of the active site, thus explaining the lack of inhibition of rat BChE by Triton X-100.	Octoxynol	219-231	butyrylcholinesterase	Rattus norvegicus	23-27
10936216-11	2000	The active site of rat BChE was unique, having an arginine in place of leucine at position 286 (human BChE numbering) in the acyl-binding pocket of the active site, thus explaining the lack of inhibition of rat BChE by Triton X-100.	Octoxynol	219-231	butyrylcholinesterase	Rattus norvegicus	102-106
10925165-4	2000	Exposure of neuronal cells to glutamate leads to a decrease in the activities of cholinesterase, superoxide dismutase, and streptoavidin peroxidase, and an increase in lactate dehydrogenase release.	Glutamic Acid	30-39	butyrylcholinesterase	Rattus norvegicus	81-95
10941146-0	2000	Regulation of the rat oligodendroglia cell line OLN-93 by antisense transfection of butyrylcholinesterase.	oln-93	48-54	butyrylcholinesterase	Rattus norvegicus	84-105
11045897-0	2000	A post-ischaemic single administration of galanthamine, a cholinesterase inhibitor, improves learning ability in rats.	Galantamine	42-54	butyrylcholinesterase	Rattus norvegicus	58-72
11045897-2	2000	We have examined the effect of a single administration of the cholinesterase inhibitor galanthamine (2mg kg(-1) i.p.)	Galantamine	87-99	butyrylcholinesterase	Rattus norvegicus	62-76
11022862-1	2000	Pyridostigmine is a reversible cholinesterase (ChE) inhibitor that is associated with neurologic dysfunction involving both central and peripheral nervous systems.	Pyridostigmine Bromide	0-14	butyrylcholinesterase	Rattus norvegicus	31-45
11022862-1	2000	Pyridostigmine is a reversible cholinesterase (ChE) inhibitor that is associated with neurologic dysfunction involving both central and peripheral nervous systems.	Pyridostigmine Bromide	0-14	butyrylcholinesterase	Rattus norvegicus	47-50
11022862-3	2000	ChE inhibition was used as a biomarker of pyridostigmine activity.	Pyridostigmine Bromide	42-56	butyrylcholinesterase	Rattus norvegicus	0-3
10828206-0	2000	Acute effects of an insect repellent, N,N-diethyl-m-toluamide, on cholinesterase inhibition induced by pyridostigmine bromide in rats.	DEET	38-61	butyrylcholinesterase	Rattus norvegicus	66-80
10884065-0	2000	Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats.	Cannabinoids	0-11	butyrylcholinesterase	Rattus norvegicus	81-95
10884065-5	2000	20 min earlier, significantly reduced the memory deficit Pretreatment with eptastigmine, a second generation cholinesterase inhibitor, given orally 100 min before the cannabinoid agonist, relieved the memory impairment without affecting CP 55,940-induced behavioural alterations such as reduced spontaneous motor activity, analgesia and hind limb splaying.	physostigmine heptyl	75-87	butyrylcholinesterase	Rattus norvegicus	109-123
10828206-0	2000	Acute effects of an insect repellent, N,N-diethyl-m-toluamide, on cholinesterase inhibition induced by pyridostigmine bromide in rats.	Pyridostigmine Bromide	103-125	butyrylcholinesterase	Rattus norvegicus	66-80
10828206-1	2000	Acute lethal interactions have been previously described between a cholinesterase (ChE) inhibitor, pyridostigmine bromide (PB), and the insect repellent, N,N-diethyl-m-toluamide (DEET).	Pyridostigmine Bromide	99-121	butyrylcholinesterase	Rattus norvegicus	67-81
10828206-1	2000	Acute lethal interactions have been previously described between a cholinesterase (ChE) inhibitor, pyridostigmine bromide (PB), and the insect repellent, N,N-diethyl-m-toluamide (DEET).	Pyridostigmine Bromide	99-121	butyrylcholinesterase	Rattus norvegicus	83-86
10828206-1	2000	Acute lethal interactions have been previously described between a cholinesterase (ChE) inhibitor, pyridostigmine bromide (PB), and the insect repellent, N,N-diethyl-m-toluamide (DEET).	Pyridostigmine Bromide	123-125	butyrylcholinesterase	Rattus norvegicus	67-81
10828206-1	2000	Acute lethal interactions have been previously described between a cholinesterase (ChE) inhibitor, pyridostigmine bromide (PB), and the insect repellent, N,N-diethyl-m-toluamide (DEET).	Pyridostigmine Bromide	123-125	butyrylcholinesterase	Rattus norvegicus	83-86
10828206-1	2000	Acute lethal interactions have been previously described between a cholinesterase (ChE) inhibitor, pyridostigmine bromide (PB), and the insect repellent, N,N-diethyl-m-toluamide (DEET).	DEET	154-177	butyrylcholinesterase	Rattus norvegicus	67-81
10828206-1	2000	Acute lethal interactions have been previously described between a cholinesterase (ChE) inhibitor, pyridostigmine bromide (PB), and the insect repellent, N,N-diethyl-m-toluamide (DEET).	DEET	154-177	butyrylcholinesterase	Rattus norvegicus	83-86
10828206-1	2000	Acute lethal interactions have been previously described between a cholinesterase (ChE) inhibitor, pyridostigmine bromide (PB), and the insect repellent, N,N-diethyl-m-toluamide (DEET).	DEET	179-183	butyrylcholinesterase	Rattus norvegicus	67-81
10828206-1	2000	Acute lethal interactions have been previously described between a cholinesterase (ChE) inhibitor, pyridostigmine bromide (PB), and the insect repellent, N,N-diethyl-m-toluamide (DEET).	DEET	179-183	butyrylcholinesterase	Rattus norvegicus	83-86
10828206-4	2000	Studies were conducted to investigate PB-induced ChE inhibition in the presence of DEET.	Pyridostigmine Bromide	38-40	butyrylcholinesterase	Rattus norvegicus	49-52
10828206-9	2000	PB alone did not inhibit ChE in whole brain, but PB (3 mg/kg) + DEET (200 mg/kg) caused significant inhibition of whole brain ChE activity to approximately 60% of controls.	Pyridostigmine Bromide	49-51	butyrylcholinesterase	Rattus norvegicus	126-129
10828206-9	2000	PB alone did not inhibit ChE in whole brain, but PB (3 mg/kg) + DEET (200 mg/kg) caused significant inhibition of whole brain ChE activity to approximately 60% of controls.	DEET	64-68	butyrylcholinesterase	Rattus norvegicus	126-129
10828206-11	2000	PB (3 mg/kg) + DEET (200 mg/kg) reduced ChE activity to approximately 65-75% of controls in each brain area, but those results were not statistically significant.	Pyridostigmine Bromide	0-2	butyrylcholinesterase	Rattus norvegicus	40-43
10698015-5	2000	Rivastigmine (0.75 and 1.5 mg/kg) and physostigmine (0.05 mg/kg) caused significantly greater ChE inhibition in females than in males (P<0.01) in the cerebral cortex, hippocampus and striatum, but not in the periphery 30 and 60 min after injection.	Physostigmine	38-51	butyrylcholinesterase	Rattus norvegicus	94-97
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	butyrylcholinesterase	Rattus norvegicus	162-176
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	butyrylcholinesterase	Rattus norvegicus	178-181
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	Lithium	59-66	butyrylcholinesterase	Rattus norvegicus	162-176
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	Lithium	59-66	butyrylcholinesterase	Rattus norvegicus	178-181
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	Acetylcholine	94-97	butyrylcholinesterase	Rattus norvegicus	178-181
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	Physostigmine	145-158	butyrylcholinesterase	Rattus norvegicus	162-176
10841434-6	2000	The local application of 8-OH-DPAT into the hippocampus of lithium treated rats increased the ACh efflux in both the absence and the presence of physostigmine, a cholinesterase (ChE) inhibitor, in the perfusion fluid.	Physostigmine	145-158	butyrylcholinesterase	Rattus norvegicus	178-181
10841434-7	2000	The basal ACh efflux of lithium treated rats was not different from that of the control rats under normal conditions, but was significantly higher than that of the controls when ChE was inhibited.	Acetylcholine	10-13	butyrylcholinesterase	Rattus norvegicus	178-181
10841434-8	2000	These results demonstrate that chronic lithium treatment increases spontaneous ACh release in the hippocampus under conditions of ChE inhibition, but not under normal conditions, and enhances cholinergic neurotransmission through 5-HT1A receptor-mediated pathways, and suggest that activation of 5-HT1A receptor function by lithium is related to the enhancement of hippocampal cholinergic neurotransmission.	Lithium	39-46	butyrylcholinesterase	Rattus norvegicus	130-133
10841434-8	2000	These results demonstrate that chronic lithium treatment increases spontaneous ACh release in the hippocampus under conditions of ChE inhibition, but not under normal conditions, and enhances cholinergic neurotransmission through 5-HT1A receptor-mediated pathways, and suggest that activation of 5-HT1A receptor function by lithium is related to the enhancement of hippocampal cholinergic neurotransmission.	Acetylcholine	79-82	butyrylcholinesterase	Rattus norvegicus	130-133
10869589-0	2000	Effects of inescapable stress and treatment with pyridostigmine bromide on plasma butyrylcholinesterase and the acoustic startle response in rats.	Pyridostigmine Bromide	49-71	butyrylcholinesterase	Rattus norvegicus	82-103
10869589-8	2000	Further decreases in BuChE activity were not observed in rats exposed to supine restraint and PB treatment.	Pyridostigmine Bromide	94-96	butyrylcholinesterase	Rattus norvegicus	21-26
10700556-2	2000	Although chlorpyrifos exerts some effects through cholinesterase inhibition, recent studies suggest additional, direct actions on developing cells.	Chlorpyrifos	9-21	butyrylcholinesterase	Rattus norvegicus	50-64
10841434-7	2000	The basal ACh efflux of lithium treated rats was not different from that of the control rats under normal conditions, but was significantly higher than that of the controls when ChE was inhibited.	Lithium	24-31	butyrylcholinesterase	Rattus norvegicus	178-181
10688981-0	2000	Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer"s disease, on cholinesterase activity in rats.	Donepezil	41-64	butyrylcholinesterase	Rattus norvegicus	120-134
10688981-0	2000	Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer"s disease, on cholinesterase activity in rats.	Donepezil	66-71	butyrylcholinesterase	Rattus norvegicus	120-134
10688981-4	2000	Oral administration of donepezil, tacrine, ENA-713 or TAK-147, caused a dose-dependent inhibition of brain and plasma cholinesterase activities.	Donepezil	23-32	butyrylcholinesterase	Rattus norvegicus	118-132
10688981-4	2000	Oral administration of donepezil, tacrine, ENA-713 or TAK-147, caused a dose-dependent inhibition of brain and plasma cholinesterase activities.	Tacrine	34-41	butyrylcholinesterase	Rattus norvegicus	118-132
10688981-4	2000	Oral administration of donepezil, tacrine, ENA-713 or TAK-147, caused a dose-dependent inhibition of brain and plasma cholinesterase activities.	Rivastigmine	43-50	butyrylcholinesterase	Rattus norvegicus	118-132
10688981-4	2000	Oral administration of donepezil, tacrine, ENA-713 or TAK-147, caused a dose-dependent inhibition of brain and plasma cholinesterase activities.	TAK 147	54-61	butyrylcholinesterase	Rattus norvegicus	118-132
10688981-12	2000	These results suggest that orally administered donepezil satisfactorily penetrates into the brain and inhibits cholinesterase there, and that donepezil is a potent and selective inhibitor of brain cholinesterase in comparison with plasma cholinesterase in vivo.	Donepezil	47-56	butyrylcholinesterase	Rattus norvegicus	111-125
10688981-12	2000	These results suggest that orally administered donepezil satisfactorily penetrates into the brain and inhibits cholinesterase there, and that donepezil is a potent and selective inhibitor of brain cholinesterase in comparison with plasma cholinesterase in vivo.	Donepezil	47-56	butyrylcholinesterase	Rattus norvegicus	197-211
10688981-12	2000	These results suggest that orally administered donepezil satisfactorily penetrates into the brain and inhibits cholinesterase there, and that donepezil is a potent and selective inhibitor of brain cholinesterase in comparison with plasma cholinesterase in vivo.	Donepezil	47-56	butyrylcholinesterase	Rattus norvegicus	197-211
10688981-12	2000	These results suggest that orally administered donepezil satisfactorily penetrates into the brain and inhibits cholinesterase there, and that donepezil is a potent and selective inhibitor of brain cholinesterase in comparison with plasma cholinesterase in vivo.	Donepezil	142-151	butyrylcholinesterase	Rattus norvegicus	197-211
10688981-12	2000	These results suggest that orally administered donepezil satisfactorily penetrates into the brain and inhibits cholinesterase there, and that donepezil is a potent and selective inhibitor of brain cholinesterase in comparison with plasma cholinesterase in vivo.	Donepezil	142-151	butyrylcholinesterase	Rattus norvegicus	197-211
10698015-0	2000	Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats.	Rivastigmine	36-48	butyrylcholinesterase	Rattus norvegicus	58-72
10698015-1	2000	This study compared the effect of rivastigmine on cholinesterase (ChE) activity in different brain regions, heart, skeletal muscle and plasma and on the cognitive impairment induced by scopolamine (0.5 mg/kg) in male and female rats.	Rivastigmine	34-46	butyrylcholinesterase	Rattus norvegicus	50-64
10698015-1	2000	This study compared the effect of rivastigmine on cholinesterase (ChE) activity in different brain regions, heart, skeletal muscle and plasma and on the cognitive impairment induced by scopolamine (0.5 mg/kg) in male and female rats.	Rivastigmine	34-46	butyrylcholinesterase	Rattus norvegicus	66-69
10698015-5	2000	Rivastigmine (0.75 and 1.5 mg/kg) and physostigmine (0.05 mg/kg) caused significantly greater ChE inhibition in females than in males (P<0.01) in the cerebral cortex, hippocampus and striatum, but not in the periphery 30 and 60 min after injection.	Rivastigmine	0-12	butyrylcholinesterase	Rattus norvegicus	94-97
10698015-9	2000	It is concluded that a testicular hormone suppresses the effect of rivastigmine, by reducing the amount of drug reaching the brain or its interaction with ChE.	Rivastigmine	67-79	butyrylcholinesterase	Rattus norvegicus	155-158
10954048-3	2000	The cholinesterase inhibitor physostigmine ( 1.0 and 3.2 microg/side) and D-cycloserine (0.32 and 1.0 microg/side), the partial agonist at the glycine binding site on the NMDA receptor/channel complex, reduced the increase in working memory errors induced by intrahippocampal 32 microg/side pyrilamine.	Physostigmine	29-42	butyrylcholinesterase	Rattus norvegicus	4-18
11261809-1	2000	Phenserine, a phenylcarbamate of physostigmine, is a new potent and highly selective acetylcholinesterase (AChE) inhibitor, with a > 50-fold activity versus butyrylcholinesterase (BChE), in clinical trials for the treatment of Alzheimer"s disease (AD).	phenserine	0-10	butyrylcholinesterase	Rattus norvegicus	157-178
11261809-1	2000	Phenserine, a phenylcarbamate of physostigmine, is a new potent and highly selective acetylcholinesterase (AChE) inhibitor, with a > 50-fold activity versus butyrylcholinesterase (BChE), in clinical trials for the treatment of Alzheimer"s disease (AD).	phenserine	0-10	butyrylcholinesterase	Rattus norvegicus	180-184
11205137-1	2000	TV3326, [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate] is a novel aminoindan derivative of the selective irreversible monoamine oxidase (MAO)-B inhibitor, rasagiline (N-propargyl-(1R)-aminoindan), possessing both cholinesterase (ChE) and MAO-inhibitory activity.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-6	butyrylcholinesterase	Rattus norvegicus	226-240
11205137-1	2000	TV3326, [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate] is a novel aminoindan derivative of the selective irreversible monoamine oxidase (MAO)-B inhibitor, rasagiline (N-propargyl-(1R)-aminoindan), possessing both cholinesterase (ChE) and MAO-inhibitory activity.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-6	butyrylcholinesterase	Rattus norvegicus	242-245
11205137-1	2000	TV3326, [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate] is a novel aminoindan derivative of the selective irreversible monoamine oxidase (MAO)-B inhibitor, rasagiline (N-propargyl-(1R)-aminoindan), possessing both cholinesterase (ChE) and MAO-inhibitory activity.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	9-66	butyrylcholinesterase	Rattus norvegicus	226-240
11205137-1	2000	TV3326, [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate] is a novel aminoindan derivative of the selective irreversible monoamine oxidase (MAO)-B inhibitor, rasagiline (N-propargyl-(1R)-aminoindan), possessing both cholinesterase (ChE) and MAO-inhibitory activity.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	9-66	butyrylcholinesterase	Rattus norvegicus	242-245
11460797-4	2000	The results indicate that in rats treated with sodium bisulphite there is a significant increase (p < 0.05) in the activity of PHI, gamma-GT, arginase, AIP, GOT, GPT and 5"-N as well as an equally significant decrease (p < 0.05) in the activity of LDH, AM and CHE; these variations are proportional to the doses of the compound applied.	sodium bisulfite	47-64	butyrylcholinesterase	Rattus norvegicus	266-269
11205137-0	2000	TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer"s disease.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-6	butyrylcholinesterase	Rattus norvegicus	42-56
10924948-3	2000	Doses were determined that produced 60% cholinesterase inhibition by donepezil and galantamine for the old rats.	Donepezil	69-78	butyrylcholinesterase	Rattus norvegicus	40-54
10924948-3	2000	Doses were determined that produced 60% cholinesterase inhibition by donepezil and galantamine for the old rats.	Galantamine	83-94	butyrylcholinesterase	Rattus norvegicus	40-54
10876815-2	2000	Donepezil hydrochloride (DPZ), a novel class of cholinesterase (ChE) inhibitors, inhibits degradation of acetylcholine (ACh) and activates central cholinergic system.	Donepezil	0-23	butyrylcholinesterase	Rattus norvegicus	48-62
10876815-2	2000	Donepezil hydrochloride (DPZ), a novel class of cholinesterase (ChE) inhibitors, inhibits degradation of acetylcholine (ACh) and activates central cholinergic system.	Acetylcholine	120-123	butyrylcholinesterase	Rattus norvegicus	48-62
10876815-2	2000	Donepezil hydrochloride (DPZ), a novel class of cholinesterase (ChE) inhibitors, inhibits degradation of acetylcholine (ACh) and activates central cholinergic system.	Donepezil	0-23	butyrylcholinesterase	Rattus norvegicus	64-67
10876815-2	2000	Donepezil hydrochloride (DPZ), a novel class of cholinesterase (ChE) inhibitors, inhibits degradation of acetylcholine (ACh) and activates central cholinergic system.	Acetylcholine	120-123	butyrylcholinesterase	Rattus norvegicus	64-67
10876815-2	2000	Donepezil hydrochloride (DPZ), a novel class of cholinesterase (ChE) inhibitors, inhibits degradation of acetylcholine (ACh) and activates central cholinergic system.	Donepezil	25-28	butyrylcholinesterase	Rattus norvegicus	48-62
10876815-4	2000	After oral dosing, DPZ (ID50: 2.6 mg/kg) inhibited brain ChE dose-dependently without any remarkable effect on ChE in the heart and small intestine, whereas tacrine (ID50: 9.5 mg/kg) inhibited ChE equally in the brain and peripheral tissues.	Donepezil	19-22	butyrylcholinesterase	Rattus norvegicus	57-60
10876815-2	2000	Donepezil hydrochloride (DPZ), a novel class of cholinesterase (ChE) inhibitors, inhibits degradation of acetylcholine (ACh) and activates central cholinergic system.	Donepezil	25-28	butyrylcholinesterase	Rattus norvegicus	64-67
10876815-2	2000	Donepezil hydrochloride (DPZ), a novel class of cholinesterase (ChE) inhibitors, inhibits degradation of acetylcholine (ACh) and activates central cholinergic system.	Acetylcholine	105-118	butyrylcholinesterase	Rattus norvegicus	48-62
10876815-2	2000	Donepezil hydrochloride (DPZ), a novel class of cholinesterase (ChE) inhibitors, inhibits degradation of acetylcholine (ACh) and activates central cholinergic system.	Acetylcholine	105-118	butyrylcholinesterase	Rattus norvegicus	64-67
12016982-2	1999	After only one week treated with fluoride, a higher activity of NAG(N-acetyl-beta-D-glucosaminidase) in urine, ChE(cholinesterase) in blood and increased urinary excretion of fluoride (compared with the control, P < 0.01) were observed, and these changes were lasted to the end of the fourth week of the study, but hydroxyproline in serum and urine had not been changed in both groups.	Fluorides	33-41	butyrylcholinesterase	Rattus norvegicus	115-129
16787838-8	2000	Pretreatment of PC12 cells with cholinesterase inhibitors such as tacrine and donepezil in clinical relevant concentrations can attenuate Abeta (25-35) toxicity through mechanisms which may be mediated via nicotinic receptors.	Tacrine	66-73	butyrylcholinesterase	Rattus norvegicus	32-46
16787838-8	2000	Pretreatment of PC12 cells with cholinesterase inhibitors such as tacrine and donepezil in clinical relevant concentrations can attenuate Abeta (25-35) toxicity through mechanisms which may be mediated via nicotinic receptors.	Donepezil	78-87	butyrylcholinesterase	Rattus norvegicus	32-46
10611458-0	1999	Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats.	Donepezil	22-45	butyrylcholinesterase	Rattus norvegicus	57-71
10611458-2	1999	In the present study, its inhibitory effect on the activity of cholinesterase ex vivo was evaluated in the brain, plasma, erythrocytes, heart, small intestine, liver and pectoral muscle of young adult as well as aged rats, in comparison with that of tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride).	Tacrine	250-257	butyrylcholinesterase	Rattus norvegicus	63-77
10611458-2	1999	In the present study, its inhibitory effect on the activity of cholinesterase ex vivo was evaluated in the brain, plasma, erythrocytes, heart, small intestine, liver and pectoral muscle of young adult as well as aged rats, in comparison with that of tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride).	Tacrine hydrochloride	259-307	butyrylcholinesterase	Rattus norvegicus	63-77
10611458-5	1999	Donepezil, at doses of 1.25, 2.5 and 5 mg/kg, p.o., inhibited brain, plasma, erythrocyte, liver and pectoral muscle cholinesterase activity in young rats in a dose-dependent manner but had less effect on cholinesterase activity in heart and small intestine.	Donepezil	0-9	butyrylcholinesterase	Rattus norvegicus	116-130
10611458-5	1999	Donepezil, at doses of 1.25, 2.5 and 5 mg/kg, p.o., inhibited brain, plasma, erythrocyte, liver and pectoral muscle cholinesterase activity in young rats in a dose-dependent manner but had less effect on cholinesterase activity in heart and small intestine.	Donepezil	0-9	butyrylcholinesterase	Rattus norvegicus	204-218
10611458-6	1999	In aged animals, inhibition of cholinesterase activity in the brain, erythrocytes and pectoral muscle by donepezil was more potent than that in young animals.	Donepezil	105-114	butyrylcholinesterase	Rattus norvegicus	31-45
10611458-7	1999	Tacrine, at doses of 5, 10 and 20 mg/kg, p.o., dose-dependently inhibited cholinesterase activity in all tissues of both young and aged animals, but most potently in heart, small intestine and liver.	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	74-88
10611458-8	1999	The inhibition of cholinesterase activity by tacrine in the brain, plasma, erythrocytes, heart and liver was more potent in aged rats than in tissues of young rats.	Tacrine	45-52	butyrylcholinesterase	Rattus norvegicus	18-32
10611458-11	1999	It is concluded that the inhibitory effects of donepezil and tacrine on cholinesterase activity are greater in aged than in young rats, owing to differences in the tissue concentrations of these compounds between young and aged animals.	Donepezil	47-56	butyrylcholinesterase	Rattus norvegicus	72-86
10611458-11	1999	It is concluded that the inhibitory effects of donepezil and tacrine on cholinesterase activity are greater in aged than in young rats, owing to differences in the tissue concentrations of these compounds between young and aged animals.	Tacrine	61-68	butyrylcholinesterase	Rattus norvegicus	72-86
10611458-12	1999	It is also suggested that the effect of donepezil on cholinesterase activity is more tissue-selective than that of tacrine.	Donepezil	40-49	butyrylcholinesterase	Rattus norvegicus	53-67
10594314-2	1999	Rivastigmine, (0.5-2.5 mg/kg) inhibited cholinesterase in the cortex and hippocampus by 21-60% and antagonised the deficits in working and reference memory.	Rivastigmine	0-12	butyrylcholinesterase	Rattus norvegicus	40-54
10594314-3	1999	Tacrine (12.5 and 17.7 mg/kg) produced significantly less inhibition of cholinesterase in the hippocampus but more in the striatum than rivastigmine (0.75 and 1.5 mg/kg) and only antagonised the deficit in reference memory.	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	72-86
10594314-5	1999	The inability of higher doses of the cholinesterase inhibitors to antagonise memory deficits induced by scopolamine may be related to excessive cholinergic stimulation in the central nervous system.	Scopolamine	104-115	butyrylcholinesterase	Rattus norvegicus	37-51
10568702-0	1999	Gestational exposure to chlorpyrifos: dose response profiles for cholinesterase and carboxylesterase activity.	Chlorpyrifos	24-36	butyrylcholinesterase	Rattus norvegicus	65-79
10568702-1	1999	This study investigates the in vivo dose response profiles of the target enzyme cholinesterase (ChE) and the detoxifying enzymes carboxylesterase (CaE) in the fetal and maternal compartments of pregnant rats dosed with chlorpyrifos [(O,O"-diethyl O-3,5,6-trichloro-2-pyridyl) phosphorothionate], a commonly used organophosphorus insecticide.	Chlorpyrifos	219-231	butyrylcholinesterase	Rattus norvegicus	80-94
10568702-1	1999	This study investigates the in vivo dose response profiles of the target enzyme cholinesterase (ChE) and the detoxifying enzymes carboxylesterase (CaE) in the fetal and maternal compartments of pregnant rats dosed with chlorpyrifos [(O,O"-diethyl O-3,5,6-trichloro-2-pyridyl) phosphorothionate], a commonly used organophosphorus insecticide.	Chlorpyrifos	219-231	butyrylcholinesterase	Rattus norvegicus	96-99
10568702-1	1999	This study investigates the in vivo dose response profiles of the target enzyme cholinesterase (ChE) and the detoxifying enzymes carboxylesterase (CaE) in the fetal and maternal compartments of pregnant rats dosed with chlorpyrifos [(O,O"-diethyl O-3,5,6-trichloro-2-pyridyl) phosphorothionate], a commonly used organophosphorus insecticide.	Chlorpyrifos	233-293	butyrylcholinesterase	Rattus norvegicus	80-94
10568702-1	1999	This study investigates the in vivo dose response profiles of the target enzyme cholinesterase (ChE) and the detoxifying enzymes carboxylesterase (CaE) in the fetal and maternal compartments of pregnant rats dosed with chlorpyrifos [(O,O"-diethyl O-3,5,6-trichloro-2-pyridyl) phosphorothionate], a commonly used organophosphorus insecticide.	organophosphorus	312-328	butyrylcholinesterase	Rattus norvegicus	80-94
10568702-5	1999	In vivo exposure to 10 mg/kg chlorpyrifos from GD14-18 caused overt maternal toxicity, with dose-related decreases in ChE activity more notable in maternal brain than fetal brain.	Chlorpyrifos	29-41	butyrylcholinesterase	Rattus norvegicus	118-121
10568702-6	1999	Dose-related effects were also seen with chlorpyrifos-induced inhibition of fetal liver ChE and maternal brain CaE activities.	Chlorpyrifos	41-53	butyrylcholinesterase	Rattus norvegicus	88-91
10568702-8	1999	ChE activities in the maternal blood and liver, as well as fetal and maternal liver CaE, however, were maximally inhibited by even the lowest dosage of chlorpyrifos.	Chlorpyrifos	152-164	butyrylcholinesterase	Rattus norvegicus	0-3
10495004-3	1999	Rats were repeatedly administered with low doses of diisopropylfluorophosphate (DFP; 0.2 mg/kg/day, SC), an irreversible cholinesterase (ChE) inhibitor.	Isoflurophate	52-78	butyrylcholinesterase	Rattus norvegicus	121-135
10543028-0	1999	Changes in rat brain cholinesterase activity and muscarinic receptor density during and after repeated oral exposure to chlorpyrifos in early postnatal development.	Chlorpyrifos	120-132	butyrylcholinesterase	Rattus norvegicus	21-35
10543028-11	1999	In addition, repeated direct oral exposures of early postnatal rats to CPS will result in persistent brain ChE inhibition and will transiently reduce muscarinic receptor density.	Chlorpyrifos	71-74	butyrylcholinesterase	Rattus norvegicus	107-110
10507533-0	1999	Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex.	Dizocilpine Maleate	62-68	butyrylcholinesterase	Rattus norvegicus	29-43
10507533-2	1999	In the present study, the effects of six cholinesterase inhibitors, e.g. huperzine A, huperzine B, tacrine, donepezil (E2020), physostigmine and galanthamine on [3H]dizocilpine (MK-801) binding to synaptic membrane of rat cerebral cortex were compared.	Neurogard	161-176	butyrylcholinesterase	Rattus norvegicus	41-55
10495003-3	1999	Rats were repeatedly administered with a low dose of diisopropylfluorosphosphate (DFP; 0.2 mg/kg/day, SC, for 9 or 21 days), an irreversible cholinesterase (ChE) inhibitor.	diisopropylfluorosphosphate	53-80	butyrylcholinesterase	Rattus norvegicus	141-155
10495004-3	1999	Rats were repeatedly administered with low doses of diisopropylfluorophosphate (DFP; 0.2 mg/kg/day, SC), an irreversible cholinesterase (ChE) inhibitor.	Isoflurophate	52-78	butyrylcholinesterase	Rattus norvegicus	137-140
10495003-3	1999	Rats were repeatedly administered with a low dose of diisopropylfluorosphosphate (DFP; 0.2 mg/kg/day, SC, for 9 or 21 days), an irreversible cholinesterase (ChE) inhibitor.	diisopropylfluorosphosphate	53-80	butyrylcholinesterase	Rattus norvegicus	157-160
10411607-4	1999	5)decane-1,3-dione] hydrochloride (RS86) and the cholinesterase inhibitor physostigmine all decreased the percentage of avoidance responses at doses that produced less than approximately 30% response failures.	Physostigmine	74-87	butyrylcholinesterase	Rattus norvegicus	49-63
10225612-1	1999	The purpose of the present work was to verify the effect of pyridostigmine bromide, a reversible cholinesterase inhibitor, on the increases in cardiac work and myocardial oxygen demand produced by central sympathetic stimulation in pentobarbital-anesthetized Wistar rats.	Pyridostigmine Bromide	60-82	butyrylcholinesterase	Rattus norvegicus	97-111
10478948-0	1999	Kinetics of brain cholinesterase inhibition following metrifonate administration.	Trichlorfon	54-65	butyrylcholinesterase	Rattus norvegicus	18-32
10478948-2	1999	In the present study we investigated the kinetics of brain cholinesterase (ChE) inhibition following an acute administration of MTF (100 mg/kg) in various brain regions of young and old Fischer 344 rats.	Trichlorfon	128-131	butyrylcholinesterase	Rattus norvegicus	59-73
10478948-2	1999	In the present study we investigated the kinetics of brain cholinesterase (ChE) inhibition following an acute administration of MTF (100 mg/kg) in various brain regions of young and old Fischer 344 rats.	Trichlorfon	128-131	butyrylcholinesterase	Rattus norvegicus	75-78
10229647-4	1999	Hydrolysis of these esters was studied in different rat tissue homogenates, i.e., liver, intestine, plasma, skin, brain, and pure plasma cholinesterases, i.e., butyryl cholinesterase (EC 3.1.1.8) and acetyl cholinesterase (EC 3.1.1.7).	Esters	20-26	butyrylcholinesterase	Rattus norvegicus	160-182
10229647-4	1999	Hydrolysis of these esters was studied in different rat tissue homogenates, i.e., liver, intestine, plasma, skin, brain, and pure plasma cholinesterases, i.e., butyryl cholinesterase (EC 3.1.1.8) and acetyl cholinesterase (EC 3.1.1.7).	Esters	20-26	butyrylcholinesterase	Rattus norvegicus	137-151
10229647-7	1999	Hydrolysis of all four diastereomeric ester prodrugs was faster by acetyl cholinesterase than butyryl cholinesterase and is stereoselective.	Esters	38-43	butyrylcholinesterase	Rattus norvegicus	74-88
10229647-7	1999	Hydrolysis of all four diastereomeric ester prodrugs was faster by acetyl cholinesterase than butyryl cholinesterase and is stereoselective.	Esters	38-43	butyrylcholinesterase	Rattus norvegicus	94-116
10225612-1	1999	The purpose of the present work was to verify the effect of pyridostigmine bromide, a reversible cholinesterase inhibitor, on the increases in cardiac work and myocardial oxygen demand produced by central sympathetic stimulation in pentobarbital-anesthetized Wistar rats.	Oxygen	171-177	butyrylcholinesterase	Rattus norvegicus	97-111
10225612-1	1999	The purpose of the present work was to verify the effect of pyridostigmine bromide, a reversible cholinesterase inhibitor, on the increases in cardiac work and myocardial oxygen demand produced by central sympathetic stimulation in pentobarbital-anesthetized Wistar rats.	Pentobarbital	232-245	butyrylcholinesterase	Rattus norvegicus	97-111
10225612-4	1999	Our results also showed that the activity of plasmatic cholinesterase was effectively inhibited by pyridostigmine bromide.	Pyridostigmine Bromide	99-121	butyrylcholinesterase	Rattus norvegicus	55-69
10225612-5	1999	In conclusion, the increases in endogenous acetylcholine induced by cholinesterase inhibition blunted the centrally-evoked increases in myocardial oxygen demand in anesthetized rats.	Acetylcholine	43-56	butyrylcholinesterase	Rattus norvegicus	68-82
10225612-5	1999	In conclusion, the increases in endogenous acetylcholine induced by cholinesterase inhibition blunted the centrally-evoked increases in myocardial oxygen demand in anesthetized rats.	Oxygen	147-153	butyrylcholinesterase	Rattus norvegicus	68-82
10208549-2	1999	Based on IC50 ratios, the dimeric analog bis(7)-tacrine was, in a reversible manner, up to 150-fold more potent and 250-fold more selective than tacrine for acetylcholinesterase (AChE) over butyrylcholinesterase (BChE).	1,7-N-heptylene-bis-9,9'-amino-1,2,3,4-tetrahydroacridine	41-55	butyrylcholinesterase	Rattus norvegicus	190-211
10208549-2	1999	Based on IC50 ratios, the dimeric analog bis(7)-tacrine was, in a reversible manner, up to 150-fold more potent and 250-fold more selective than tacrine for acetylcholinesterase (AChE) over butyrylcholinesterase (BChE).	1,7-N-heptylene-bis-9,9'-amino-1,2,3,4-tetrahydroacridine	41-55	butyrylcholinesterase	Rattus norvegicus	213-217
10208549-2	1999	Based on IC50 ratios, the dimeric analog bis(7)-tacrine was, in a reversible manner, up to 150-fold more potent and 250-fold more selective than tacrine for acetylcholinesterase (AChE) over butyrylcholinesterase (BChE).	Tacrine	48-55	butyrylcholinesterase	Rattus norvegicus	190-211
10208549-2	1999	Based on IC50 ratios, the dimeric analog bis(7)-tacrine was, in a reversible manner, up to 150-fold more potent and 250-fold more selective than tacrine for acetylcholinesterase (AChE) over butyrylcholinesterase (BChE).	Tacrine	48-55	butyrylcholinesterase	Rattus norvegicus	213-217
10208549-3	1999	Following a single oral administration, both bis(7)-tacrine and tacrine produced dose-dependent inhibitions of AChE in rat brain, but bis(7)-tacrine exhibited higher efficacy and AChE/BChE selectivity than tacrine.	1,7-N-heptylene-bis-9,9'-amino-1,2,3,4-tetrahydroacridine	134-148	butyrylcholinesterase	Rattus norvegicus	184-188
10208549-3	1999	Following a single oral administration, both bis(7)-tacrine and tacrine produced dose-dependent inhibitions of AChE in rat brain, but bis(7)-tacrine exhibited higher efficacy and AChE/BChE selectivity than tacrine.	Tacrine	64-71	butyrylcholinesterase	Rattus norvegicus	184-188
10340119-0	1999	[The distant effects of acetylcholine--links in the pathogenesis of poisoning by cholinesterase inhibitors].	Acetylcholine	24-37	butyrylcholinesterase	Rattus norvegicus	81-95
9887183-0	1999	Role of cholinergic receptors and cholinesterase activity in hemodynamic responses to cocaine in conscious rats.	Cocaine	86-93	butyrylcholinesterase	Rattus norvegicus	34-48
9952157-9	1999	Pretreatment with intrathecal atropine but not mecamylamine yielded a complete antagonism of the effects of the cholinesterase inhibitors.	Atropine	30-38	butyrylcholinesterase	Rattus norvegicus	112-126
9952157-12	1999	CONCLUSIONS: These experiments suggest that intrathecal edrophonium or neostigmine produces an antagonism on touch-evoked allodynia at the spinal level in a rat model of neuropathic pain and that the antiallodynic action of cholinesterase inhibitors is probably mediated by a spinal muscarinic system, especially at the M1 receptor subtype.	Edrophonium	56-67	butyrylcholinesterase	Rattus norvegicus	224-238
9952157-12	1999	CONCLUSIONS: These experiments suggest that intrathecal edrophonium or neostigmine produces an antagonism on touch-evoked allodynia at the spinal level in a rat model of neuropathic pain and that the antiallodynic action of cholinesterase inhibitors is probably mediated by a spinal muscarinic system, especially at the M1 receptor subtype.	Neostigmine	71-82	butyrylcholinesterase	Rattus norvegicus	224-238
9972708-5	1999	Both acute and repeated pyridostigmine bromide administration decreased serum cholinesterase levels by approximately 50%, but neither treatment affected brain cholinesterase levels in our assay.	Pyridostigmine Bromide	24-46	butyrylcholinesterase	Rattus norvegicus	78-92
10229709-5	1999	Effects of cholinesterase inhibitors exhibit many similarities to those of nicotine.	Nicotine	75-83	butyrylcholinesterase	Rattus norvegicus	11-25
10229709-9	1999	We have tested this hypothesis in vitro with PC12 cells, which lack the enzymes necessary to produce chlorpyrifos oxon, the metabolite that inhibits cholinesterase.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	101-118	butyrylcholinesterase	Rattus norvegicus	149-163
9887183-5	1999	Pretreatment with the nonspecific cholinesterase inhibitors physostigmine (0.1-0.2 mg/kg) or neostigmine (0.1 mg/kg) reduced the pressor response by diminishing the increase in systemic vascular resistance.	Physostigmine	60-73	butyrylcholinesterase	Rattus norvegicus	34-48
10465900-19	1999	The above results show that some neurobehavioural effects of exposure to organophosphorous (OP) compounds may be detected after a time sufficient for recovery of ChE activity.	organophosphorous	73-90	butyrylcholinesterase	Rattus norvegicus	162-165
10202645-2	1999	Simultaneously we have define changes in cholinesterase-acetylcholine system and content of adrenaline and noradrenaline in liver and pancreas tissues, small intestines mucous and in blood.	Acetylcholine	56-69	butyrylcholinesterase	Rattus norvegicus	41-55
10082314-0	1999	Behavioral changes and cholinesterase activity of rats acutely treated with propoxur.	Propoxur	76-84	butyrylcholinesterase	Rattus norvegicus	23-37
10082314-2	1999	The time course of the effects of an oral dose of the anticholinesterase agent propoxur (8.3 mg/kg) was determined on behaviors displayed in the open-field and during an active avoidance task by rats and on blood and brain cholinesterase activity.	Propoxur	79-87	butyrylcholinesterase	Rattus norvegicus	58-72
10082314-3	1999	Maximum inhibition of blood cholinesterase was observed within 30 min after administration of propoxur.	Propoxur	94-102	butyrylcholinesterase	Rattus norvegicus	28-42
9891917-8	1998	Statistically significant inhibition of at least two of the three cholinesterase enzymes (PChe, RChe, or BChe) was observed on gestation day 16, 24 h following exposure, with all of the organophosphates tested.	Organophosphates	186-202	butyrylcholinesterase	Rattus norvegicus	66-80
10049139-2	1998	We investigated whether change in neuronal activity in cholinergic pathways mediates the anesthetic effect of the alpha2 agonist, dexmedetomidine, by determining whether physostigmine, a cholinesterase inhibitor, could antagonize the hypnotic response to dexmedetomidine in the rat and whether dexmedetomidine decreases the release of acetylcholine (ACh) in the thalamus in vivo.	Physostigmine	170-183	butyrylcholinesterase	Rattus norvegicus	187-201
10082314-8	1999	These data indicate that behavioral changes that occur during intoxication with low oral doses of propoxur may be dissociated from signs characteristic of cholinergic over-stimulation but accompany brain cholinesterase activity inhibition.	Propoxur	98-106	butyrylcholinesterase	Rattus norvegicus	204-218
10073483-2	1999	The present study determined whether systemically administered physostigmine, a cholinesterase inhibitor, alters the rat"s ability to discern among odorant mixtures.	Physostigmine	63-76	butyrylcholinesterase	Rattus norvegicus	80-94
9877077-1	1998	The effects of subchronic administration of metrifonate, a long-lasting cholinesterase inhibitor, on local cerebral glucose utilization were assessed in 3- and 27-month old Sprague-Dawley rats, using the autoradiographic [14C]2-deoxyglucose technique.	Trichlorfon	44-55	butyrylcholinesterase	Rattus norvegicus	72-86
9774528-2	1998	The present study examined the impact of the centrally active cholinesterase inhibitor physostigmine, which enhances memory and central cholinergic activity, on brief shock-induced hypoalgesia on the tail-flick test using Sprague-Dawley rats.	Physostigmine	87-100	butyrylcholinesterase	Rattus norvegicus	62-76
9891917-8	1998	Statistically significant inhibition of at least two of the three cholinesterase enzymes (PChe, RChe, or BChe) was observed on gestation day 16, 24 h following exposure, with all of the organophosphates tested.	Organophosphates	186-202	butyrylcholinesterase	Rattus norvegicus	105-109
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-59	butyrylcholinesterase	Rattus norvegicus	95-109
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-59	butyrylcholinesterase	Rattus norvegicus	198-212
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-59	butyrylcholinesterase	Rattus norvegicus	198-212
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-59	butyrylcholinesterase	Rattus norvegicus	339-343
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-59	butyrylcholinesterase	Rattus norvegicus	198-212
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-58	butyrylcholinesterase	Rattus norvegicus	95-109
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-58	butyrylcholinesterase	Rattus norvegicus	198-212
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-58	butyrylcholinesterase	Rattus norvegicus	198-212
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-58	butyrylcholinesterase	Rattus norvegicus	339-343
9891917-12	1998	These results demonstrate that for the six organophosphates tested: (1) inhibition of maternal cholinesterase activity was the most sensitive indicator of organophosphate exposure; (2) the level of cholinesterase inhibition associated with clinical findings was always greater than 20%; and (3) no effect on fetal cholinesterase activity (BChe) was observed, even at dose levels that continued to demonstrate significant inhibition of maternal cholinesterase activity.	Organophosphates	43-58	butyrylcholinesterase	Rattus norvegicus	198-212
9734325-0	1998	Correlation between whole blood cholinesterase activity and cerebral cortex cholinesterase activity in rats treated with parathion.	Parathion	121-130	butyrylcholinesterase	Rattus norvegicus	32-46
9778761-1	1998	Tacrine (1,2,3,4-tetrahydro-9-aminoacridine), a reversible cholinesterase inhibitor, was effective in the treatment of Alzheimer"s disease (AD).	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	59-73
9778761-1	1998	Tacrine (1,2,3,4-tetrahydro-9-aminoacridine), a reversible cholinesterase inhibitor, was effective in the treatment of Alzheimer"s disease (AD).	Tacrine	9-43	butyrylcholinesterase	Rattus norvegicus	59-73
9734325-0	1998	Correlation between whole blood cholinesterase activity and cerebral cortex cholinesterase activity in rats treated with parathion.	Parathion	121-130	butyrylcholinesterase	Rattus norvegicus	76-90
9845911-2	1998	Changes in cholinesterase activity and catecholamine content in histochemically active nerves following administration of cholinesterase (AChE) inhibiting agent phosphacol, seem to reflect compensatory responses to increasing dilatory cholinergic vasomotor effects under conditions of the AChE activity.	Catecholamines	39-52	butyrylcholinesterase	Rattus norvegicus	122-136
9845911-2	1998	Changes in cholinesterase activity and catecholamine content in histochemically active nerves following administration of cholinesterase (AChE) inhibiting agent phosphacol, seem to reflect compensatory responses to increasing dilatory cholinergic vasomotor effects under conditions of the AChE activity.	Paraoxon	161-171	butyrylcholinesterase	Rattus norvegicus	11-25
9845911-2	1998	Changes in cholinesterase activity and catecholamine content in histochemically active nerves following administration of cholinesterase (AChE) inhibiting agent phosphacol, seem to reflect compensatory responses to increasing dilatory cholinergic vasomotor effects under conditions of the AChE activity.	Paraoxon	161-171	butyrylcholinesterase	Rattus norvegicus	122-136
11498913-4	1998	The probe was perfused at a rate of 1 microL/min with Ringer"s solution which contained 10 mumol/L (for anesthetized rats) or 1 mumol/L (for freely moving rats) neostigmine, a reversible cholinesterase inhibitor, to elevate ACh level in microdialysate.	Neostigmine	161-172	butyrylcholinesterase	Rattus norvegicus	187-201
9632220-9	1998	Tacrine was more effective in inhibiting plasma butyrylcholinesterase (BuChE) than it was brain AChE.	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	48-69
9725111-0	1998	Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase.	Cocaine	15-22	butyrylcholinesterase	Rattus norvegicus	53-74
9725111-1	1998	A primary enzyme for the metabolism of cocaine is butyrylcholinesterase (BChE).	Cocaine	39-46	butyrylcholinesterase	Rattus norvegicus	50-71
9725111-1	1998	A primary enzyme for the metabolism of cocaine is butyrylcholinesterase (BChE).	Cocaine	39-46	butyrylcholinesterase	Rattus norvegicus	73-77
9725111-2	1998	To determine whether the systemic administration of BChE can increase the metabolism of cocaine sufficiently to alter a behavioral effect, rats were tested in a locomotor activity chamber after receiving 17 mg of cocaine per kg intraperitoneally.	Cocaine	88-95	butyrylcholinesterase	Rattus norvegicus	52-56
9725111-5	1998	When added to rat plasma, this amount of BChE reduced the cocaine half-life from over 5 hr to less than 5 min.	Cocaine	58-65	butyrylcholinesterase	Rattus norvegicus	41-45
9725111-6	1998	BChE altered the cocaine metabolic pattern such that the relatively nontoxic metabolite ecgonine methyl ester was produced, rather than benzoylecgonine.	Cocaine	17-24	butyrylcholinesterase	Rattus norvegicus	0-4
9725111-6	1998	BChE altered the cocaine metabolic pattern such that the relatively nontoxic metabolite ecgonine methyl ester was produced, rather than benzoylecgonine.	ecgonine methyl ester	88-109	butyrylcholinesterase	Rattus norvegicus	0-4
9725111-6	1998	BChE altered the cocaine metabolic pattern such that the relatively nontoxic metabolite ecgonine methyl ester was produced, rather than benzoylecgonine.	benzoylecgonine	136-151	butyrylcholinesterase	Rattus norvegicus	0-4
9725111-7	1998	These results suggest that systemic administration of BChE can increase the metabolism of cocaine sufficiently to alter a behavioral effect of cocaine and thus should be investigated as a potential treatment for cocaine abuse.	Cocaine	90-97	butyrylcholinesterase	Rattus norvegicus	54-58
9725111-7	1998	These results suggest that systemic administration of BChE can increase the metabolism of cocaine sufficiently to alter a behavioral effect of cocaine and thus should be investigated as a potential treatment for cocaine abuse.	Cocaine	143-150	butyrylcholinesterase	Rattus norvegicus	54-58
9632220-0	1998	Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities.	Tacrine	47-54	butyrylcholinesterase	Rattus norvegicus	71-85
9726626-9	1998	A 75% inhibition of cholinesterase activity was found 18 h after the last metrifonate administration, while only a 15% inhibition was detectable 18 h after the last tacrine administration.	Trichlorfon	74-85	butyrylcholinesterase	Rattus norvegicus	20-34
9726626-10	1998	The challenge with metrifonate or tacrine resulted in 90 and 80% cholinesterase inhibition, respectively.	Trichlorfon	19-30	butyrylcholinesterase	Rattus norvegicus	65-79
9726626-10	1998	The challenge with metrifonate or tacrine resulted in 90 and 80% cholinesterase inhibition, respectively.	Tacrine	34-41	butyrylcholinesterase	Rattus norvegicus	65-79
9726626-11	1998	These results demonstrate that in aging rats a subchronic treatment with metrifonate results in a long-lasting, cholinesterase inhibition, and a persistent increase in acetylcholine extracellular levels which compensate for the age-associated cholinergic hypofunction.	Trichlorfon	73-84	butyrylcholinesterase	Rattus norvegicus	112-126
9687000-9	1998	The results suggest that DMSO enhances the slow ventral root potential through mechanisms based on the inhibition of cholinesterase activity and other action(s) involved in increasing transmitter release from nerve endings in nociceptive transmission pathways in the isolated spinal cord of the newborn rat.	Dimethyl Sulfoxide	25-29	butyrylcholinesterase	Rattus norvegicus	117-131
9632220-9	1998	Tacrine was more effective in inhibiting plasma butyrylcholinesterase (BuChE) than it was brain AChE.	Tacrine	0-7	butyrylcholinesterase	Rattus norvegicus	71-76
9632220-10	1998	Conversely, the BuChE activity was less affected by huperzine A and E2020.	huperzine A	52-63	butyrylcholinesterase	Rattus norvegicus	16-21
9602037-4	1998	Microinjection of the muscarinic receptor antagonist scopolamine into the unilateral RVLM inhibited the pressor response to L-glutamate injected ipsilaterally into the lateral PBN, whereas microinjection of the cholinesterase inhibitor physostigmine into the RVLM enhanced it.	Scopolamine	53-64	butyrylcholinesterase	Rattus norvegicus	211-225
9631459-1	1998	The effect of the cholinesterase inhibitors tacrine and donepezil on A beta(25-35)-induced toxicity was investigated in rat pheochromocytoma PC12 cells by measuring the mitochondrial activity.	Tacrine	44-51	butyrylcholinesterase	Rattus norvegicus	18-32
9631459-4	1998	This study demonstrates that tacrine and donepezil can exert neuroprotective properties which might be of importance and contribute to the clinical efficacy of cholinesterase inhibitors in the treatment of Alzheimer"s disease.	Tacrine	29-36	butyrylcholinesterase	Rattus norvegicus	160-174
9631459-4	1998	This study demonstrates that tacrine and donepezil can exert neuroprotective properties which might be of importance and contribute to the clinical efficacy of cholinesterase inhibitors in the treatment of Alzheimer"s disease.	Donepezil	41-50	butyrylcholinesterase	Rattus norvegicus	160-174
9696463-7	1998	Attenuation of afferent nerve activity was not mimicked by the anticholinergic glycopyrrolate; the cholinesterase inhibitor neostigmine did not attenuate the effect of IMI on responses to noxious CRD.	Neostigmine	124-135	butyrylcholinesterase	Rattus norvegicus	99-113
9518577-1	1998	Effects of soman, an irreversible cholinesterase (ChE) inhibitor, on [3H]norepinephrine (NE) release evoked by N-methyl-d-aspartate (NMDA) were studied in rat brain cortical slices.	[3H]norepinephrine	69-87	butyrylcholinesterase	Rattus norvegicus	50-53
9554058-0	1998	Effect of combined fenthion and cimetidine use in rats on lethality, blood cholinesterase activities, and serum cholinesterase isoenzymes.	Cimetidine	32-42	butyrylcholinesterase	Rattus norvegicus	112-126
9554058-11	1998	Differences in suppression of ChE isoenzyme patterns were detectable between the FEN-dosed and FEN + CIM-dosed groups.	Fenthion	81-84	butyrylcholinesterase	Rattus norvegicus	30-33
9554058-11	1998	Differences in suppression of ChE isoenzyme patterns were detectable between the FEN-dosed and FEN + CIM-dosed groups.	Fenthion	95-98	butyrylcholinesterase	Rattus norvegicus	30-33
9554058-11	1998	Differences in suppression of ChE isoenzyme patterns were detectable between the FEN-dosed and FEN + CIM-dosed groups.	Cimetidine	101-104	butyrylcholinesterase	Rattus norvegicus	30-33
9518577-1	1998	Effects of soman, an irreversible cholinesterase (ChE) inhibitor, on [3H]norepinephrine (NE) release evoked by N-methyl-d-aspartate (NMDA) were studied in rat brain cortical slices.	N-Methylaspartate	111-131	butyrylcholinesterase	Rattus norvegicus	50-53
9608610-0	1998	Effect of exercise training and chronic ethanol ingestion on cholinesterase activity and lipid peroxidation in blood and brain regions of rat.	Ethanol	40-47	butyrylcholinesterase	Rattus norvegicus	61-75
9608610-2	1998	This study examines the effects of exercise training and chronic ethanol consumption on cholinesterase activity and its relationship to lipid peroxidation in blood and brain regions of rat.	Ethanol	65-72	butyrylcholinesterase	Rattus norvegicus	88-102
9443830-2	1998	In developing rat brain, chlorpyrifos doses that cause no discernible systemic toxicity and only a minor degree of cholinesterase inhibition, nevertheless evoke alterations in cell function and number that appear after several days" delay.	Chlorpyrifos	25-37	butyrylcholinesterase	Rattus norvegicus	115-129
9469652-1	1997	Effect of tacrine, a cholinesterase inhibitor, on spatial acquisition deficit caused by permanent occlusion of bilateral common carotid arteries (2VO) was examined by using the conventional 8-arm and the 4-arm baited radial maze tasks in rats.	Tacrine	10-17	butyrylcholinesterase	Rattus norvegicus	21-35
9475371-0	1997	Effect of tetrahydroaminoacridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury.	Tacrine	10-33	butyrylcholinesterase	Rattus norvegicus	37-51
9475371-3	1997	We examined the effects of repeated postinjury administration of a cholinesterase inhibitor, tetrahydroaminoacridine (THA), on cognitive performance following experimental TBI.	Tacrine	93-116	butyrylcholinesterase	Rattus norvegicus	67-81
9475371-3	1997	We examined the effects of repeated postinjury administration of a cholinesterase inhibitor, tetrahydroaminoacridine (THA), on cognitive performance following experimental TBI.	Tacrine	118-121	butyrylcholinesterase	Rattus norvegicus	67-81
10028411-1	1998	Recent data indicate that the neurotoxic effects of organophosphate compounds, including those of the nerve agents VX and sarin, are not solely due to irreversible cholinesterase inhibition.	Organophosphates	52-67	butyrylcholinesterase	Rattus norvegicus	164-178
9322468-8	1997	IMPLICATIONS: Spinal muscarinic agonists, such as carbachol and the cholinesterase inhibitor neostigmine, induce a potent analgesia in the rat.	Neostigmine	93-104	butyrylcholinesterase	Rattus norvegicus	68-82
9299188-0	1997	Tissue-specific effects of chlorpyrifos on carboxylesterase and cholinesterase activity in adult rats: an in vitro and in vivo comparison.	Chlorpyrifos	27-39	butyrylcholinesterase	Rattus norvegicus	64-78
9336338-1	1997	Chlorpyrifos (CPF) is a cholinesterase-inhibiting organophosphate pesticide used extensively to treat crops and domestic animals.	Chlorpyrifos	0-12	butyrylcholinesterase	Rattus norvegicus	24-38
9336338-1	1997	Chlorpyrifos (CPF) is a cholinesterase-inhibiting organophosphate pesticide used extensively to treat crops and domestic animals.	Chlorpyrifos	14-17	butyrylcholinesterase	Rattus norvegicus	24-38
9336338-1	1997	Chlorpyrifos (CPF) is a cholinesterase-inhibiting organophosphate pesticide used extensively to treat crops and domestic animals.	Organophosphates	50-65	butyrylcholinesterase	Rattus norvegicus	24-38
9266810-4	1997	Pretreatment of chloralose-urethane anesthetized rats with BChE, 0.1-7.8 mg/kg, decreased the hypertensive and arrhythmogenic effects produced by cocaine and increased the lethal dose of cocaine by three- to fourfold.	Chloralose	16-26	butyrylcholinesterase	Rattus norvegicus	59-63
9266810-4	1997	Pretreatment of chloralose-urethane anesthetized rats with BChE, 0.1-7.8 mg/kg, decreased the hypertensive and arrhythmogenic effects produced by cocaine and increased the lethal dose of cocaine by three- to fourfold.	Urethane	27-35	butyrylcholinesterase	Rattus norvegicus	59-63
9266810-4	1997	Pretreatment of chloralose-urethane anesthetized rats with BChE, 0.1-7.8 mg/kg, decreased the hypertensive and arrhythmogenic effects produced by cocaine and increased the lethal dose of cocaine by three- to fourfold.	Cocaine	146-153	butyrylcholinesterase	Rattus norvegicus	59-63
9266810-4	1997	Pretreatment of chloralose-urethane anesthetized rats with BChE, 0.1-7.8 mg/kg, decreased the hypertensive and arrhythmogenic effects produced by cocaine and increased the lethal dose of cocaine by three- to fourfold.	Cocaine	187-194	butyrylcholinesterase	Rattus norvegicus	59-63
9266810-5	1997	Treatment of conscious rats with 1 and 10 mg/kg BChE decreased the incidence of seizures and deaths produced by a prior dose of cocaine (80 mg/kg, i.p.).	Cocaine	128-135	butyrylcholinesterase	Rattus norvegicus	48-52
9266811-12	1997	Cocaine-associated effects upon the central nervous system were also shown to be reduced by administration of BChE to conscious rats.	Cocaine	0-7	butyrylcholinesterase	Rattus norvegicus	110-114
9253944-1	1997	To investigate the mutual dependence of calcitonin gene-related peptide (CGRP) and acetylcholine release, we examined the effect of a cholinesterase inhibitor neostigmine on the release of CGRP-like immunoreactivity in rat phrenic nerve-hemidiaphragm muscle preparation, and conversely, the effect of CGRP on [3H]acetylcholine release from motor nerve terminals loaded with [3H]choline in the same preparations of mice.	Neostigmine	159-170	butyrylcholinesterase	Rattus norvegicus	134-148
9253944-5	1997	These results suggest that CGRP, which is released by electrical nerve stimulation or a cholinesterase inhibitor in intact skeletal muscles, negatively modulates nerve-evoked acetylcholine release.	Acetylcholine	175-188	butyrylcholinesterase	Rattus norvegicus	88-102
9376763-1	1997	Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain.	dipiroxime	68-78	butyrylcholinesterase	Rattus norvegicus	34-48
9376763-1	1997	Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain.	dipiroxime	68-78	butyrylcholinesterase	Rattus norvegicus	50-53
9376763-1	1997	Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain.	benzyxime	83-92	butyrylcholinesterase	Rattus norvegicus	34-48
9376763-1	1997	Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain.	benzyxime	83-92	butyrylcholinesterase	Rattus norvegicus	50-53
9376763-1	1997	Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain.	tributam, pediphen	166-184	butyrylcholinesterase	Rattus norvegicus	34-48
9376763-1	1997	Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain.	tributam, pediphen	166-184	butyrylcholinesterase	Rattus norvegicus	50-53
9376763-1	1997	Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain.	aprofen	186-194	butyrylcholinesterase	Rattus norvegicus	34-48
9376763-1	1997	Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain.	aprofen	186-194	butyrylcholinesterase	Rattus norvegicus	50-53
9285539-10	1997	These findings are consistent with the notion that inhibition of ChE and elevation of ACh initiate the seizure process, resulting in secondary changes in DA turnover and release of NE, and later changes in excitatory (aspartate, glutamate) and inhibitory (GABA) amino acid transmitters.	Dopamine	154-156	butyrylcholinesterase	Rattus norvegicus	65-68
9285539-10	1997	These findings are consistent with the notion that inhibition of ChE and elevation of ACh initiate the seizure process, resulting in secondary changes in DA turnover and release of NE, and later changes in excitatory (aspartate, glutamate) and inhibitory (GABA) amino acid transmitters.	Aspartic Acid	218-227	butyrylcholinesterase	Rattus norvegicus	65-68
9285539-10	1997	These findings are consistent with the notion that inhibition of ChE and elevation of ACh initiate the seizure process, resulting in secondary changes in DA turnover and release of NE, and later changes in excitatory (aspartate, glutamate) and inhibitory (GABA) amino acid transmitters.	Glutamic Acid	229-238	butyrylcholinesterase	Rattus norvegicus	65-68
9190843-1	1997	Displacement of muscarinic radioligands by the cholinesterase inhibitors parathion, paraoxon, physostigmine and phenyl saligenin cyclic phosphate was examined in rat cortex and brain stem, human cortex and brain stem, and in Chinese hamster ovary (CHO) cells expressing human M2 or M4 muscarinic acetylcholine receptors.	Parathion	73-82	butyrylcholinesterase	Rattus norvegicus	47-61
9285539-10	1997	These findings are consistent with the notion that inhibition of ChE and elevation of ACh initiate the seizure process, resulting in secondary changes in DA turnover and release of NE, and later changes in excitatory (aspartate, glutamate) and inhibitory (GABA) amino acid transmitters.	gamma-Aminobutyric Acid	256-260	butyrylcholinesterase	Rattus norvegicus	65-68
9191090-8	1997	Phenserine, a novel, reversible acetyl-selective cholinesterase inhibitor, significantly decreased the levels of secreted beta-APP in the CSF of forebrain cholinergic system-lesioned rats whereas DFP, a relatively non-specific cholinesterase inhibitor, failed to affect CSF levels of secreted beta-APP.	phenserine	0-10	butyrylcholinesterase	Rattus norvegicus	49-63
9191090-8	1997	Phenserine, a novel, reversible acetyl-selective cholinesterase inhibitor, significantly decreased the levels of secreted beta-APP in the CSF of forebrain cholinergic system-lesioned rats whereas DFP, a relatively non-specific cholinesterase inhibitor, failed to affect CSF levels of secreted beta-APP.	phenserine	0-10	butyrylcholinesterase	Rattus norvegicus	227-241
9190843-1	1997	Displacement of muscarinic radioligands by the cholinesterase inhibitors parathion, paraoxon, physostigmine and phenyl saligenin cyclic phosphate was examined in rat cortex and brain stem, human cortex and brain stem, and in Chinese hamster ovary (CHO) cells expressing human M2 or M4 muscarinic acetylcholine receptors.	phenylsaligenin cyclic phosphate	112-145	butyrylcholinesterase	Rattus norvegicus	47-61
9324407-0	1997	[The presynaptic mechanism of interaction of cholinesterase reactivator and muscarinic antagonists in the animal"s defence in organophosphate intoxication].	Organophosphates	126-141	butyrylcholinesterase	Rattus norvegicus	45-59
9189894-4	1997	The increase in working memory errors induced by intrahippocampal administration of 0.32 microgram/side scopolamine to rats treated with 10 mg/kg propranolol was decreased by concurrent injection of the cholinesterase inhibitor physostigmine (3.2 micrograms/side).	Scopolamine	104-115	butyrylcholinesterase	Rattus norvegicus	203-217
9189894-4	1997	The increase in working memory errors induced by intrahippocampal administration of 0.32 microgram/side scopolamine to rats treated with 10 mg/kg propranolol was decreased by concurrent injection of the cholinesterase inhibitor physostigmine (3.2 micrograms/side).	Propranolol	146-157	butyrylcholinesterase	Rattus norvegicus	203-217
9189894-4	1997	The increase in working memory errors induced by intrahippocampal administration of 0.32 microgram/side scopolamine to rats treated with 10 mg/kg propranolol was decreased by concurrent injection of the cholinesterase inhibitor physostigmine (3.2 micrograms/side).	Physostigmine	228-241	butyrylcholinesterase	Rattus norvegicus	203-217
9175510-1	1997	The effects of both parathion and methyl parathion on the inhibition of plasma cholinesterase were elaborated in a rat model employing a modified isocratic reverse-phase HPLC method coupled with UV detection for the determination of the urinary metabolite p-nitrophenol (U-4NP).	Parathion	20-29	butyrylcholinesterase	Rattus norvegicus	79-93
9175510-1	1997	The effects of both parathion and methyl parathion on the inhibition of plasma cholinesterase were elaborated in a rat model employing a modified isocratic reverse-phase HPLC method coupled with UV detection for the determination of the urinary metabolite p-nitrophenol (U-4NP).	Methyl Parathion	34-50	butyrylcholinesterase	Rattus norvegicus	79-93
9175510-4	1997	A linear correlation was observed between the oral administration of parathion and methyl parathion for both the percent inhibiton of cholinesterase as well as the urinary elimination of 4NP.	Parathion	69-78	butyrylcholinesterase	Rattus norvegicus	134-148
9175510-4	1997	A linear correlation was observed between the oral administration of parathion and methyl parathion for both the percent inhibiton of cholinesterase as well as the urinary elimination of 4NP.	Methyl Parathion	83-99	butyrylcholinesterase	Rattus norvegicus	134-148
9163564-8	1997	The slight cholinesterase inhibition following metrifonate (30 mg/kg) in aged rats had no effect on cortical acetylcholine levels and object recognition.	Trichlorfon	47-58	butyrylcholinesterase	Rattus norvegicus	11-25
9324407-1	1997	The presynaptic and antidote activity of various combinations of cholinesterase reactivators and that of muscarinic antagonist were compare it was show that the mechanism of the antidote effect of some cholinesterase reactivators in poisoning with organophosphorous compounds, in addition to restoring the activity of the enzyme, includes the effect of counteraction to the effect of muscarinic antagonists in increased acetylcholine secretion into the synaptic cleft.	organophosphorous	248-265	butyrylcholinesterase	Rattus norvegicus	65-79
9324407-1	1997	The presynaptic and antidote activity of various combinations of cholinesterase reactivators and that of muscarinic antagonist were compare it was show that the mechanism of the antidote effect of some cholinesterase reactivators in poisoning with organophosphorous compounds, in addition to restoring the activity of the enzyme, includes the effect of counteraction to the effect of muscarinic antagonists in increased acetylcholine secretion into the synaptic cleft.	organophosphorous	248-265	butyrylcholinesterase	Rattus norvegicus	202-216
9163564-7	1997	In young rats, metrifonate caused 75% cholinesterase inhibition in the cerebral cortex and hippocampus, a 2-fold increase in cortical and hippocampal extracellular acetylcholine levels, and no effect on object recognition.	Trichlorfon	15-26	butyrylcholinesterase	Rattus norvegicus	38-52
9324407-1	1997	The presynaptic and antidote activity of various combinations of cholinesterase reactivators and that of muscarinic antagonist were compare it was show that the mechanism of the antidote effect of some cholinesterase reactivators in poisoning with organophosphorous compounds, in addition to restoring the activity of the enzyme, includes the effect of counteraction to the effect of muscarinic antagonists in increased acetylcholine secretion into the synaptic cleft.	Acetylcholine	420-433	butyrylcholinesterase	Rattus norvegicus	65-79
9324407-1	1997	The presynaptic and antidote activity of various combinations of cholinesterase reactivators and that of muscarinic antagonist were compare it was show that the mechanism of the antidote effect of some cholinesterase reactivators in poisoning with organophosphorous compounds, in addition to restoring the activity of the enzyme, includes the effect of counteraction to the effect of muscarinic antagonists in increased acetylcholine secretion into the synaptic cleft.	Acetylcholine	420-433	butyrylcholinesterase	Rattus norvegicus	202-216
9130298-2	1997	Cholinesterase inhibitors-tetrahydro-aminoacridine (THA: 1.0 and 3.0 mg/kg i.p.)	Tacrine	26-50	butyrylcholinesterase	Rattus norvegicus	0-14
9194147-0	1997	Influence of exercise and ethanol on cholinesterase activity and lipid peroxidation in blood and brain regions of rat.	Ethanol	26-33	butyrylcholinesterase	Rattus norvegicus	37-51
9130298-2	1997	Cholinesterase inhibitors-tetrahydro-aminoacridine (THA: 1.0 and 3.0 mg/kg i.p.)	Tacrine	52-55	butyrylcholinesterase	Rattus norvegicus	0-14
9067485-8	1997	Further, the cords treated with DFP (100 microM) showed significant decrease in the cholinesterase (ChE) activity (27% of control).	Isoflurophate	32-35	butyrylcholinesterase	Rattus norvegicus	84-98
9088864-6	1997	The basal forebrain lesion decreased the cholinesterase activity in the cerebral cortex, and metrifonate (100 mg/kg) further reduced the cholinesterase activity.	Trichlorfon	93-104	butyrylcholinesterase	Rattus norvegicus	137-151
9088864-8	1997	These results indicated that metrifonate ameliorated the impairment of learning in both scopolamine-treated and basal forebrain-lesioned rats by not only increasing extracellular acetylcholine levels by inhibiting cholinesterase, but also by undefined other mechanism(s).	Trichlorfon	29-40	butyrylcholinesterase	Rattus norvegicus	214-228
9067485-8	1997	Further, the cords treated with DFP (100 microM) showed significant decrease in the cholinesterase (ChE) activity (27% of control).	Isoflurophate	32-35	butyrylcholinesterase	Rattus norvegicus	100-103
8978935-5	1997	Heptyl-physostigmine (eptastigmine), a carbamate cholinesterase inhibitor with prolonged time of action improved cerebral blood flow in most regions, with the exception of the ischemic core.	physostigmine heptyl	0-20	butyrylcholinesterase	Rattus norvegicus	49-63
8978935-5	1997	Heptyl-physostigmine (eptastigmine), a carbamate cholinesterase inhibitor with prolonged time of action improved cerebral blood flow in most regions, with the exception of the ischemic core.	physostigmine heptyl	22-34	butyrylcholinesterase	Rattus norvegicus	49-63
9122369-3	1997	The threshold dose of metrifonate, a cholinesterase inhibitor, for suppression of HVSs was lower in nimodipine compared to placebo treated aged rats (30 mg/kg versus 60 mg/kg; p.o.).	Trichlorfon	22-33	butyrylcholinesterase	Rattus norvegicus	37-51
9291508-6	1997	Inhibition of cholinesterase activity by methamidophos was long lasting, which is consistent with the formation by the agent of a covalent bond with the enzyme"s active serine residue.	methamidophos	41-54	butyrylcholinesterase	Rattus norvegicus	14-28
9291508-6	1997	Inhibition of cholinesterase activity by methamidophos was long lasting, which is consistent with the formation by the agent of a covalent bond with the enzyme"s active serine residue.	Serine	169-175	butyrylcholinesterase	Rattus norvegicus	14-28
9291508-11	1997	Based on these data, methamidophos appears to have a selective effect on cholinesterase.	methamidophos	21-34	butyrylcholinesterase	Rattus norvegicus	73-87
8905730-2	1996	The increase in working memory errors induced by intrahippocampal 3.2 micrograms/side scopolamine was reduced by concurrent injection of the cholinesterase inhibitor physostigmine (1.0 and 3.2 micrograms/side.	Scopolamine	86-97	butyrylcholinesterase	Rattus norvegicus	141-155
8982984-7	1996	Comparison of the maximal rate of decrease in choline concentration following the injections of 1 mM choline and 1 mM acetylcholine was used to estimate the rate of acetylcholine clearance from extracellular fluid through cholinesterase activity at approx.	Choline	46-53	butyrylcholinesterase	Rattus norvegicus	222-236
8982984-7	1996	Comparison of the maximal rate of decrease in choline concentration following the injections of 1 mM choline and 1 mM acetylcholine was used to estimate the rate of acetylcholine clearance from extracellular fluid through cholinesterase activity at approx.	Choline	101-108	butyrylcholinesterase	Rattus norvegicus	222-236
8982984-7	1996	Comparison of the maximal rate of decrease in choline concentration following the injections of 1 mM choline and 1 mM acetylcholine was used to estimate the rate of acetylcholine clearance from extracellular fluid through cholinesterase activity at approx.	Acetylcholine	118-131	butyrylcholinesterase	Rattus norvegicus	222-236
8982984-7	1996	Comparison of the maximal rate of decrease in choline concentration following the injections of 1 mM choline and 1 mM acetylcholine was used to estimate the rate of acetylcholine clearance from extracellular fluid through cholinesterase activity at approx.	Acetylcholine	165-178	butyrylcholinesterase	Rattus norvegicus	222-236
9016911-1	1996	The present study investigated if short-term treatment with an L-type Ca2+-channel inhibitor, nimodipine, can stimulate cognitive functioning and cortical electroencephalograph (EEG) arousal, and potentiate the effect of a cholinesterase inhibitor, metrifonate.	Nimodipine	94-104	butyrylcholinesterase	Rattus norvegicus	223-237
8990522-3	1996	A clonal cell line derived from a rat pheochromocytoma (PC12) was used and cultures depolarized in the presence of cholinesterase inhibitor to maximize the recovery of acetylcholine from the culture medium and protect against its hydrolysis.	Acetylcholine	168-181	butyrylcholinesterase	Rattus norvegicus	115-129
8961166-4	1996	The opioids which inhibited horse serum BuChE were in order of potency: meptazinol, methadone, profadol, levallorphan and 1,2,3-trimethyl-3-(3-hydroxyphenyl)-piperidine.	Meptazinol	72-82	butyrylcholinesterase	Rattus norvegicus	40-45
8961166-4	1996	The opioids which inhibited horse serum BuChE were in order of potency: meptazinol, methadone, profadol, levallorphan and 1,2,3-trimethyl-3-(3-hydroxyphenyl)-piperidine.	Methadone	84-93	butyrylcholinesterase	Rattus norvegicus	40-45
8961166-4	1996	The opioids which inhibited horse serum BuChE were in order of potency: meptazinol, methadone, profadol, levallorphan and 1,2,3-trimethyl-3-(3-hydroxyphenyl)-piperidine.	profadol	95-103	butyrylcholinesterase	Rattus norvegicus	40-45
8961166-4	1996	The opioids which inhibited horse serum BuChE were in order of potency: meptazinol, methadone, profadol, levallorphan and 1,2,3-trimethyl-3-(3-hydroxyphenyl)-piperidine.	Levallorphan	105-117	butyrylcholinesterase	Rattus norvegicus	40-45
8961166-4	1996	The opioids which inhibited horse serum BuChE were in order of potency: meptazinol, methadone, profadol, levallorphan and 1,2,3-trimethyl-3-(3-hydroxyphenyl)-piperidine.	1,2,3-trimethyl-3-(3-hydroxyphenyl)-piperidine	122-168	butyrylcholinesterase	Rattus norvegicus	40-45
8905730-2	1996	The increase in working memory errors induced by intrahippocampal 3.2 micrograms/side scopolamine was reduced by concurrent injection of the cholinesterase inhibitor physostigmine (1.0 and 3.2 micrograms/side.	Physostigmine	166-179	butyrylcholinesterase	Rattus norvegicus	141-155
8819500-2	1996	The effects of organophosphorus compounds on peripheral synapses have been attributed to inhibition of cholinesterase and to direct actions on muscarinic and nicotinic receptors, but less is known about the actions of organophosphorus compounds, including paraoxon, in the central nervous system.	organophosphorus	15-31	butyrylcholinesterase	Rattus norvegicus	103-117
8768721-1	1996	Metrifonate is currently under development as a putative cholinergic Alzheimer therapeutic, because it is a prodrug of the long-acting organophosphate cholinesterase (ChE) inhibitor dichlorvos.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	151-165
8768721-1	1996	Metrifonate is currently under development as a putative cholinergic Alzheimer therapeutic, because it is a prodrug of the long-acting organophosphate cholinesterase (ChE) inhibitor dichlorvos.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	167-170
8768721-7	1996	Our results question whether the effect of metrifonate is mediated by inhibition of ChE alone and suggest the involvement of an additional, as yet unknown, mechanism of action.	Trichlorfon	43-54	butyrylcholinesterase	Rattus norvegicus	84-87
8727219-2	1996	The effects of organophosphates (fenthion, chlorpyrifos, diazinon, bromophos, propaphos, haloxon, and DFP) on serum ChE isoenzyme bands were studied in 32 male and 32 female 6-w-old Sprague-Dawley rats.	Isoflurophate	102-105	butyrylcholinesterase	Rattus norvegicus	116-119
9044164-5	1996	Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.	Edrophonium	121-132	butyrylcholinesterase	Rattus norvegicus	24-27
9044164-5	1996	Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.	Pyridostigmine Bromide	134-148	butyrylcholinesterase	Rattus norvegicus	24-27
9044164-5	1996	Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.	Neostigmine	150-161	butyrylcholinesterase	Rattus norvegicus	24-27
9044164-5	1996	Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.	Ambenonium Chloride	167-177	butyrylcholinesterase	Rattus norvegicus	24-27
9044164-12	1996	Other process such as desensitisization induced by endogenous ACh diffusion rate of drugs into the synaptic cleft, action of presynaptic receptors, etc., might contribute to the dose-effect relationship of ChE inhibitors.	Acetylcholine	62-65	butyrylcholinesterase	Rattus norvegicus	206-209
8836562-1	1996	Rat cortical synaptosomes preloaded with [3H]choline were superfused and stimulated with K+ in order to investigate the effect of the cholinesterase inhibitor tacrine on the in vitro release of acetylcholine (ACh).	Acetylcholine	194-207	butyrylcholinesterase	Rattus norvegicus	134-148
8737906-1	1996	Flinders Sensitive Line hypercholinergic rats, which exhibit augmented hypothermic responses to the cholinesterase inhibitor physostigmine and to the muscarinic agonist oxotremorine, have been proposed to represent a useful animal model for some aspects of human depression.	Physostigmine	125-138	butyrylcholinesterase	Rattus norvegicus	100-114
8727219-0	1996	Effects of selected organophosphate insecticides on serum cholinesterase isoenzyme patterns in the rat.	Organophosphates	20-35	butyrylcholinesterase	Rattus norvegicus	58-72
8727219-1	1996	The serum cholinesterase (ChE) isoenzyme in rats shows 6 bands after polyacrylamide gradient gel electrophoresis.	polyacrylamide	69-83	butyrylcholinesterase	Rattus norvegicus	10-24
8727219-1	1996	The serum cholinesterase (ChE) isoenzyme in rats shows 6 bands after polyacrylamide gradient gel electrophoresis.	polyacrylamide	69-83	butyrylcholinesterase	Rattus norvegicus	26-29
8727219-6	1996	Changes were observed in all 6 bands of the serum ChE isoenzymes after administration of fenthion, chlorpyrifos and propaphos.	Fenthion	89-97	butyrylcholinesterase	Rattus norvegicus	50-53
8727219-6	1996	Changes were observed in all 6 bands of the serum ChE isoenzymes after administration of fenthion, chlorpyrifos and propaphos.	Chlorpyrifos	99-111	butyrylcholinesterase	Rattus norvegicus	50-53
8727219-6	1996	Changes were observed in all 6 bands of the serum ChE isoenzymes after administration of fenthion, chlorpyrifos and propaphos.	propaphos	116-125	butyrylcholinesterase	Rattus norvegicus	50-53
8727219-9	1996	Serum ChE was most suppressed by fenthion, followed by DFP, bromophos, chlorpyrifos, propaphos and diazinon in that order of effect.	Fenthion	33-41	butyrylcholinesterase	Rattus norvegicus	6-9
8727219-11	1996	Erythrocyte ChE activity was suppressed by every organophosphate.	Organophosphates	49-64	butyrylcholinesterase	Rattus norvegicus	12-15
8727219-12	1996	This experiment demonstrated a correlation between the organophosphate suppression of serum ChE activity and the concentration of serum ChE isoenzyme band 6.	Organophosphates	55-70	butyrylcholinesterase	Rattus norvegicus	92-95
8727219-12	1996	This experiment demonstrated a correlation between the organophosphate suppression of serum ChE activity and the concentration of serum ChE isoenzyme band 6.	Organophosphates	55-70	butyrylcholinesterase	Rattus norvegicus	136-139
8624119-3	1996	These included physostigmine (PHY), heptyl-physostigmine (HEP) and 2,2-dichlorovinyldimethyl phosphate (DDVP), at the concentrations producing cholinesterase (ChE) inhibition ranging from 5% to 95%.	Dichlorvos	104-108	butyrylcholinesterase	Rattus norvegicus	143-157
8804059-0	1996	An indirect cholinesterase inhibitor, metrifonate, increases neocortical EEG arousal in rats.	Trichlorfon	38-49	butyrylcholinesterase	Rattus norvegicus	12-26
8804059-1	1996	We investigated the ability of a cholinesterase inhibitor, metrifonate, to desynchronize cortical EEG activity.	Trichlorfon	59-70	butyrylcholinesterase	Rattus norvegicus	33-47
8804059-5	1996	and partially alleviated by a reference cholinesterase inhibitor, THA (3 and 6 mg kg-1, i.p.).	Tacrine	66-69	butyrylcholinesterase	Rattus norvegicus	40-54
9139239-0	1996	Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	20-34
9139239-0	1996	Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos.	Dichlorvos	78-88	butyrylcholinesterase	Rattus norvegicus	20-34
9139239-1	1996	Metrifonate, a long-acting cholinesterase (ChE) inhibitor with very low toxicity in warm-blooded animals, inhibits rat brain and serum cholinesterase (ChE) in vitro through its hydrolytic degradation product, dichlorvos.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	27-41
9139239-1	1996	Metrifonate, a long-acting cholinesterase (ChE) inhibitor with very low toxicity in warm-blooded animals, inhibits rat brain and serum cholinesterase (ChE) in vitro through its hydrolytic degradation product, dichlorvos.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	43-46
9139239-1	1996	Metrifonate, a long-acting cholinesterase (ChE) inhibitor with very low toxicity in warm-blooded animals, inhibits rat brain and serum cholinesterase (ChE) in vitro through its hydrolytic degradation product, dichlorvos.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	135-149
9139239-1	1996	Metrifonate, a long-acting cholinesterase (ChE) inhibitor with very low toxicity in warm-blooded animals, inhibits rat brain and serum cholinesterase (ChE) in vitro through its hydrolytic degradation product, dichlorvos.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	151-154
9139239-2	1996	This conclusion is based on the finding that metrifonate-induced ChE inhibition showed the same pH dependence as its reported dehydrochlorination to dichlorvos.	Trichlorfon	45-56	butyrylcholinesterase	Rattus norvegicus	65-68
9139239-3	1996	The ChE inhibition induced by dichlorvos was not pH dependent.	Dichlorvos	30-40	butyrylcholinesterase	Rattus norvegicus	4-7
9139239-7	1996	However, the physostigmine-induced inhibition of ChE could be readily reversed by further substrate addition.	Physostigmine	13-26	butyrylcholinesterase	Rattus norvegicus	49-52
9139239-8	1996	Another reference compound, tetrahydroaminoacridine (THA), also induced a reversible inhibition of rat brain and serum cholinesterase, but with a mechanism of action different from that of both dichlorvos and physostigmine in that enzyme inhibition occurred rapidly upon drug addition at an allosteric site on the enzyme surface.	Tacrine	28-51	butyrylcholinesterase	Rattus norvegicus	119-133
9139239-8	1996	Another reference compound, tetrahydroaminoacridine (THA), also induced a reversible inhibition of rat brain and serum cholinesterase, but with a mechanism of action different from that of both dichlorvos and physostigmine in that enzyme inhibition occurred rapidly upon drug addition at an allosteric site on the enzyme surface.	Tacrine	53-56	butyrylcholinesterase	Rattus norvegicus	119-133
9139239-9	1996	It is suggested that the unique slow release plus the slow inhibition of ChE by dichlorvos is responsible for the lower toxicity of metrifonate compared to that of directly acting ChE inhibitors.	Trichlorfon	132-143	butyrylcholinesterase	Rattus norvegicus	73-76
9139240-0	1996	Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood.	Trichlorfon	0-11	butyrylcholinesterase	Rattus norvegicus	71-85
9139240-1	1996	Cholinesterase activities in rat forebrain, erythrocytes, and plasma were assessed after a single oral administration of metrifonate or dichlorvos.	Trichlorfon	121-132	butyrylcholinesterase	Rattus norvegicus	0-14
9139240-10	1996	The dose-dependence of drug-induced inhibition of cholinesterase in rat blood and brain was determined at the time of maximal inhibition, i.e., 30 min after dichlorvos treatment and 45 min after metrifonate treatment.	Trichlorfon	195-206	butyrylcholinesterase	Rattus norvegicus	50-64
9139240-11	1996	The oral ED(50) values obtained for dichlorvos were 8 mg/kg for brain and 6 mg/kg for both erythrocyte and plasma cholinesterase.	Dichlorvos	36-46	butyrylcholinesterase	Rattus norvegicus	114-128
9139240-13	1996	In rats deprived of food for 18 h before drug treatment, the corresponding ED(50) values for metrifonate were 60 and 45 mg/kg, respectively, indicating an about two-fold higher sensitivity of fasted rats to metrifonate-induced cholinesterase inhibition compared to non-fasted rats.	Trichlorfon	207-218	butyrylcholinesterase	Rattus norvegicus	227-241
9139240-16	1996	These results demonstrate that single oral administration of metrifonate and dichlorvos induces an inhibition of blood and brain cholinesterase in the conscious rat in a dose-dependent and apparently fully reversible manner.	Trichlorfon	61-72	butyrylcholinesterase	Rattus norvegicus	129-143
9139240-16	1996	These results demonstrate that single oral administration of metrifonate and dichlorvos induces an inhibition of blood and brain cholinesterase in the conscious rat in a dose-dependent and apparently fully reversible manner.	Dichlorvos	77-87	butyrylcholinesterase	Rattus norvegicus	129-143
8825739-3	1996	For this study, physostigmine was administered ip at doses of 0.05, 0.2 or 1.0 mg/kg, resulting in average cholinesterase inhibition in plasma (28, 38 and 70%), erythrocytes (19, 24 and 36%), and brain (2, 10 and 31%) which correlated well with increased total power and amplitude changes.	Physostigmine	16-29	butyrylcholinesterase	Rattus norvegicus	107-121
8551354-1	1996	Microinjections of the cholinergic receptor agonist nicotine and the cholinesterase inhibitor neostigmine were made into the ventral tegmental area (VTA) of urethane-anesthetized rats, and dopamine (DA) efflux in the nucleus accumbens was measured using in vivo chronoamperometry.	Neostigmine	94-105	butyrylcholinesterase	Rattus norvegicus	69-83
8697103-0	1996	Electrostatic interactions of the butyrylcholinesterase dimer of mucosal cells of rat intestine with glycosaminoglycans.	Glycosaminoglycans	101-119	butyrylcholinesterase	Rattus norvegicus	34-55
8697103-4	1996	Heparin-Sepharose chromatography, nondenaturing electrophoresis and sucrose gradient centrifugation were used to study heparin interaction with the G2 form BChE.	Heparin	119-126	butyrylcholinesterase	Rattus norvegicus	156-160
8697103-11	1996	In summary, these studies demonstrate that the ionic properties of the G2 form BChE are involved in the binding with heparin.	Heparin	117-124	butyrylcholinesterase	Rattus norvegicus	79-83
8790986-1	1996	The potential of heptylphysostigmine tartrate (pyrrolo [2,3b] indol-5-ol, 3,3a,8,8a-hexahydro-1,3a,8-trimethylheptylcarbamate [ester, (3aS-cis)]) (MF201), a new second-generation cholinesterase inhibitor, to antagonize scopolamine-induced amnesia in rats was assessed in an 8-arm radial maze.	heptylphysostigmine tartrate	17-45	butyrylcholinesterase	Rattus norvegicus	179-193
8604149-1	1996	Sarin (Agent GB, isopropyl methylphosphonofluoridate) is an organophosphate cholinesterase inhibitor.	Sarin	17-52	butyrylcholinesterase	Rattus norvegicus	76-90
8734490-5	1996	The maximal ChE inhibition at 30 min was 35.5% (2.0 mg/kg) and 15.6% (0.5 mg/kg) when measured as ACh hydrolysis in the diluted homogenate.	Acetylcholine	98-101	butyrylcholinesterase	Rattus norvegicus	12-15
9033122-2	1996	The cholinesterase inhibitor eserine (10 microM) decreased field responses by 20 +/- 2%.	Physostigmine	29-36	butyrylcholinesterase	Rattus norvegicus	4-18
8704639-1	1996	The results of application of cholinesterase inhibitors, aminostigmin and galantamin, for treatment of acute poisoning with cyclodol, dimedrol, and solutan of moderately grave condition are presented.	Trihexyphenidyl	124-132	butyrylcholinesterase	Rattus norvegicus	30-44
8603667-1	1996	The oxime HI-6 dichloride [1-(2 hydroxyiminomethyl -1-pyridino)-3-(4-carbamoyl-1-pyridino)-2-oxapropane dichloride monohydrate] has shown to be a potent reactivator of cholinesterase activity and may have efficacy for the treatment of organophosphate intoxication [SIPRI, 1976; Schenk et al.	Oximes	4-9	butyrylcholinesterase	Rattus norvegicus	168-182
8603667-1	1996	The oxime HI-6 dichloride [1-(2 hydroxyiminomethyl -1-pyridino)-3-(4-carbamoyl-1-pyridino)-2-oxapropane dichloride monohydrate] has shown to be a potent reactivator of cholinesterase activity and may have efficacy for the treatment of organophosphate intoxication [SIPRI, 1976; Schenk et al.	asoxime chloride	10-25	butyrylcholinesterase	Rattus norvegicus	168-182
8704639-1	1996	The results of application of cholinesterase inhibitors, aminostigmin and galantamin, for treatment of acute poisoning with cyclodol, dimedrol, and solutan of moderately grave condition are presented.	Diphenhydramine	134-142	butyrylcholinesterase	Rattus norvegicus	30-44
8704639-1	1996	The results of application of cholinesterase inhibitors, aminostigmin and galantamin, for treatment of acute poisoning with cyclodol, dimedrol, and solutan of moderately grave condition are presented.	Solutan	148-155	butyrylcholinesterase	Rattus norvegicus	30-44
8603667-1	1996	The oxime HI-6 dichloride [1-(2 hydroxyiminomethyl -1-pyridino)-3-(4-carbamoyl-1-pyridino)-2-oxapropane dichloride monohydrate] has shown to be a potent reactivator of cholinesterase activity and may have efficacy for the treatment of organophosphate intoxication [SIPRI, 1976; Schenk et al.	1-(2 hydroxyiminomethyl -1-pyridino)-3-(4-carbamoyl	27-78	butyrylcholinesterase	Rattus norvegicus	168-182
8603667-1	1996	The oxime HI-6 dichloride [1-(2 hydroxyiminomethyl -1-pyridino)-3-(4-carbamoyl-1-pyridino)-2-oxapropane dichloride monohydrate] has shown to be a potent reactivator of cholinesterase activity and may have efficacy for the treatment of organophosphate intoxication [SIPRI, 1976; Schenk et al.	-2-oxapropane dichloride monohydrate	90-126	butyrylcholinesterase	Rattus norvegicus	168-182
8817642-11	1996	Other drugs like the cholinesterase inhibitors, tacrine and eserine, also had a small inhibitory effect on L-C uptake, reducing it at 1 microM by 22 and 21% respectively, although higher concentrations were toxic (> 100 microM).	Carnitine	107-110	butyrylcholinesterase	Rattus norvegicus	21-35
8890920-2	1996	In conscious rats, the dose-response curves of muscarinic agonists arecoline and pilocarpine, cholinesterase inhibitors soman and physostigmine rather than GABA receptor antagonist pentylenetetrazol or glycine receptor antagonist strychnine for producing EEG seizures were shifted leftwards by acutely repeated injections of nicotine.	Physostigmine	130-143	butyrylcholinesterase	Rattus norvegicus	94-108
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	Physostigmine	88-101	butyrylcholinesterase	Rattus norvegicus	54-68
8588286-3	1995	For this study, physostigmine was administered ip at doses of 0.05, 0.2 or 1.0 mg/kg, resulting in average cholinesterase inhibition in plasma (28, 38 and 70%), erythrocytes (19, 24 and 36%), and brain (2, 10 and 31%) which correlated well with increased total power and amplitude changes.	Physostigmine	16-29	butyrylcholinesterase	Rattus norvegicus	107-121
8590272-2	1995	Using BW284C51 and iso-OMPA as selective inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively, it has been demonstrated that the rat retinal ChE is predominantly AChE.	Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide	6-14	butyrylcholinesterase	Rattus norvegicus	87-108
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	Physostigmine	103-106	butyrylcholinesterase	Rattus norvegicus	54-68
8590272-2	1995	Using BW284C51 and iso-OMPA as selective inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively, it has been demonstrated that the rat retinal ChE is predominantly AChE.	Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide	6-14	butyrylcholinesterase	Rattus norvegicus	110-114
8590272-2	1995	Using BW284C51 and iso-OMPA as selective inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively, it has been demonstrated that the rat retinal ChE is predominantly AChE.	Tetraisopropylpyrophosphamide	19-27	butyrylcholinesterase	Rattus norvegicus	87-108
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	physostigmine heptyl	112-131	butyrylcholinesterase	Rattus norvegicus	54-68
8590272-2	1995	Using BW284C51 and iso-OMPA as selective inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively, it has been demonstrated that the rat retinal ChE is predominantly AChE.	Tetraisopropylpyrophosphamide	19-27	butyrylcholinesterase	Rattus norvegicus	110-114
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	physostigmine heptyl	133-136	butyrylcholinesterase	Rattus norvegicus	54-68
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	Acetylcholine	188-201	butyrylcholinesterase	Rattus norvegicus	54-68
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	Acetylcholine	203-206	butyrylcholinesterase	Rattus norvegicus	54-68
7562554-1	1995	In previous investigations, we have demonstrated that cholinesterase inhibitors such as physostigmine (PHY) and heptylphysostigmine (HEP) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels in the rat cortex.	Norepinephrine	212-226	butyrylcholinesterase	Rattus norvegicus	54-68
7562554-3	1995	These data suggest that a combination of cholinergic and adrenergic drug may improve the pharmacological effect of the cholinesterase inhibitor on cortical neurotransmitters such as ACh-NE.	ach-ne	182-188	butyrylcholinesterase	Rattus norvegicus	119-133
8539321-2	1995	Specifically, we compared the activity of ondansetron to that of the cholinesterase inhibitor physostigmine in attenuating two distinct cognitive deficits in the Morris water maze.	Physostigmine	94-107	butyrylcholinesterase	Rattus norvegicus	69-83
7500384-1	1995	L-Huperzine-A (Hup-A), a natural cholinesterase inhibitor (ChEI) derived from the Chinese herb Huperzia serrata, was administered systemically (i.p.)	huperzine A	0-13	butyrylcholinesterase	Rattus norvegicus	33-47
7500384-11	1995	Our results show that Hup-A is a potent inhibitor of ChE which penetrates into the brain and produces a dose-dependent increase of ACh, NE, and DA in rat cortex.	Acetylcholine	131-134	butyrylcholinesterase	Rattus norvegicus	53-56
7500384-11	1995	Our results show that Hup-A is a potent inhibitor of ChE which penetrates into the brain and produces a dose-dependent increase of ACh, NE, and DA in rat cortex.	Dopamine	144-146	butyrylcholinesterase	Rattus norvegicus	53-56
8584510-3	1995	In the present investigation, we examined the possible involvement of a cholinergic component in the 2,5-hexanedione-induced antinociception, since literature data indicate that this hexacarbon compound may act as a competitive inhibitor of acetylcholinesterase and that cholinesterase inhibitors are analgesic to rodents.	2,5-hexanedione	101-116	butyrylcholinesterase	Rattus norvegicus	247-261
7473892-6	1995	It is suggested that atropine sulfate antagonizes benfuracarb poisoning by blocking acetylcholine (ACh) receptors, as many other carbamate insecticides, since benfuracarb was an in vivo cholinesterase (ChE) inhibitor and the toxic effect of benfuracarb was reduced by atropine sulfate.	Atropine	21-37	butyrylcholinesterase	Rattus norvegicus	186-200
7755051-10	1995	CONCLUSIONS: This biotransformation of cocaine to norcocaine may be a primary metabolic pathway induced in the cholinesterase-deficient placenta.	Cocaine	39-46	butyrylcholinesterase	Rattus norvegicus	111-125
7755051-10	1995	CONCLUSIONS: This biotransformation of cocaine to norcocaine may be a primary metabolic pathway induced in the cholinesterase-deficient placenta.	norcocaine	50-60	butyrylcholinesterase	Rattus norvegicus	111-125
7481530-1	1995	BACKGROUND: The hydrolysis of long-chain alkanoylcholines, presumably catalyzed by butyryl-cholinesterase (EC 3.1.1.8), in rat intestinal loops was studied.	long-chain alkanoylcholines	30-57	butyrylcholinesterase	Rattus norvegicus	83-105
7473892-6	1995	It is suggested that atropine sulfate antagonizes benfuracarb poisoning by blocking acetylcholine (ACh) receptors, as many other carbamate insecticides, since benfuracarb was an in vivo cholinesterase (ChE) inhibitor and the toxic effect of benfuracarb was reduced by atropine sulfate.	Atropine	21-37	butyrylcholinesterase	Rattus norvegicus	202-205
7473892-6	1995	It is suggested that atropine sulfate antagonizes benfuracarb poisoning by blocking acetylcholine (ACh) receptors, as many other carbamate insecticides, since benfuracarb was an in vivo cholinesterase (ChE) inhibitor and the toxic effect of benfuracarb was reduced by atropine sulfate.	benfuracarb	159-170	butyrylcholinesterase	Rattus norvegicus	186-200
7473892-6	1995	It is suggested that atropine sulfate antagonizes benfuracarb poisoning by blocking acetylcholine (ACh) receptors, as many other carbamate insecticides, since benfuracarb was an in vivo cholinesterase (ChE) inhibitor and the toxic effect of benfuracarb was reduced by atropine sulfate.	benfuracarb	159-170	butyrylcholinesterase	Rattus norvegicus	202-205
7473892-6	1995	It is suggested that atropine sulfate antagonizes benfuracarb poisoning by blocking acetylcholine (ACh) receptors, as many other carbamate insecticides, since benfuracarb was an in vivo cholinesterase (ChE) inhibitor and the toxic effect of benfuracarb was reduced by atropine sulfate.	benfuracarb	159-170	butyrylcholinesterase	Rattus norvegicus	186-200
7473892-6	1995	It is suggested that atropine sulfate antagonizes benfuracarb poisoning by blocking acetylcholine (ACh) receptors, as many other carbamate insecticides, since benfuracarb was an in vivo cholinesterase (ChE) inhibitor and the toxic effect of benfuracarb was reduced by atropine sulfate.	benfuracarb	159-170	butyrylcholinesterase	Rattus norvegicus	202-205
7781701-1	1995	We postulate that the effect of cholinesterase inhibitors to ameliorate the cholinergic deficit in Alzheimer"s disease is related to their ability to maintain long-lasting, non-toxic steady-state levels of acetylcholine in cortex.	Acetylcholine	206-219	butyrylcholinesterase	Rattus norvegicus	32-46
7602775-2	1995	Clinically, Juul separated ChE 12 bands by polyacrylamidegel electrophoresis.	polyacrylamide gels	43-60	butyrylcholinesterase	Rattus norvegicus	27-30
7602775-3	1995	We separated ChE as five bands using polyacrylamidegel electrophoresis, revealing fusion and deformity of the band.	polyacrylamide gels	37-54	butyrylcholinesterase	Rattus norvegicus	13-16
7714770-1	1995	Based on previous results indicating that cholinesterase inhibitors (ChEI) elicit a significant and simultaneous increase in acetylcholine (ACh) and norepinephrine (NE) levels, we studied whether the NE elevation could down-regulate ACh levels and possibly decrease the therapeutical effect of these drugs.	Acetylcholine	125-138	butyrylcholinesterase	Rattus norvegicus	42-56
7781701-2	1995	We investigated the effect of the cholinesterase inhibitor, MDL 73,745 (2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone), on the extracellular levels of acetylcholine, norepinephrine, dopamine and 5-hydroxytryptamine in the cerebral cortex of the rat by high-performance liquid chromatography coupled with electrochemical detection.	zifrosilone	60-70	butyrylcholinesterase	Rattus norvegicus	34-48
7781701-2	1995	We investigated the effect of the cholinesterase inhibitor, MDL 73,745 (2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone), on the extracellular levels of acetylcholine, norepinephrine, dopamine and 5-hydroxytryptamine in the cerebral cortex of the rat by high-performance liquid chromatography coupled with electrochemical detection.	zifrosilone	72-122	butyrylcholinesterase	Rattus norvegicus	34-48
7781701-2	1995	We investigated the effect of the cholinesterase inhibitor, MDL 73,745 (2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone), on the extracellular levels of acetylcholine, norepinephrine, dopamine and 5-hydroxytryptamine in the cerebral cortex of the rat by high-performance liquid chromatography coupled with electrochemical detection.	Acetylcholine	156-169	butyrylcholinesterase	Rattus norvegicus	34-48
7781701-2	1995	We investigated the effect of the cholinesterase inhibitor, MDL 73,745 (2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone), on the extracellular levels of acetylcholine, norepinephrine, dopamine and 5-hydroxytryptamine in the cerebral cortex of the rat by high-performance liquid chromatography coupled with electrochemical detection.	Norepinephrine	171-185	butyrylcholinesterase	Rattus norvegicus	34-48
7781701-2	1995	We investigated the effect of the cholinesterase inhibitor, MDL 73,745 (2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone), on the extracellular levels of acetylcholine, norepinephrine, dopamine and 5-hydroxytryptamine in the cerebral cortex of the rat by high-performance liquid chromatography coupled with electrochemical detection.	Dopamine	187-195	butyrylcholinesterase	Rattus norvegicus	34-48
7781701-2	1995	We investigated the effect of the cholinesterase inhibitor, MDL 73,745 (2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone), on the extracellular levels of acetylcholine, norepinephrine, dopamine and 5-hydroxytryptamine in the cerebral cortex of the rat by high-performance liquid chromatography coupled with electrochemical detection.	Serotonin	200-219	butyrylcholinesterase	Rattus norvegicus	34-48
7781701-4	1995	At both 2 and 10 mg/kg there was a good correlation between cholinesterase inhibition and acetylcholine increase in cortex.	Acetylcholine	90-103	butyrylcholinesterase	Rattus norvegicus	60-74
7605915-3	1995	These included: physostigmine (PHY), heptyl-physostigmine (HEP) and 2,2-dichloro-vinyldimethyl phosphate (DDVP), at concentrations producing cholinesterase (ChE) inhibition ranging from 5% to 95%.	Dichlorvos	106-110	butyrylcholinesterase	Rattus norvegicus	141-155
7856900-1	1995	BACKGROUND: The spinal delivery of the cholinesterase inhibitor neostigmine yields analgesia in rats and augments the analgesic effects of alpha 2 agonists in sheep.	Neostigmine	64-75	butyrylcholinesterase	Rattus norvegicus	39-53
7532610-4	1995	MOSs for potential chronic dietary exposure to chlorpyrifos residues were based on a NOEL for inhibition of brain cholinesterase activity in rats and dogs, and ranged from 2198 to 8065 for all population subgroups.	Chlorpyrifos	47-59	butyrylcholinesterase	Rattus norvegicus	114-128
7473067-8	1995	The administration of EuCl3.6H2O increased the serum iron concentration in males and the serum total iron binding capacity in each sex and decreased cholinesterase activity in females in the 1000 mg/kg dosed group.	eucl3.6h2o	22-32	butyrylcholinesterase	Rattus norvegicus	149-163
7870192-0	1994	Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats.	Acetylcholine	136-149	butyrylcholinesterase	Rattus norvegicus	32-46
7823770-0	1995	Differential effects of bromopride and domperidone on cholinesterase activity in rat tissues.	bromopride	24-34	butyrylcholinesterase	Rattus norvegicus	54-68
7823770-0	1995	Differential effects of bromopride and domperidone on cholinesterase activity in rat tissues.	Domperidone	39-50	butyrylcholinesterase	Rattus norvegicus	54-68
7823770-3	1995	BRO and DOMP effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM for BRO and from 0.006 to 125 microM for DOMP.	Domperidone	8-12	butyrylcholinesterase	Rattus norvegicus	24-38
7823770-4	1995	The results demonstrate that both BRO and DOMP can inhibit cholinesterase activity in all tissues studied, with DOMP being more potent than BRO in plasma and intestinal tissues.	bromopride	34-37	butyrylcholinesterase	Rattus norvegicus	59-73
7900273-0	1994	Tissue and erythrocyte cholinesterase inhibition and protection by clinoptilolite pretreatment.	clinoptilolite	67-81	butyrylcholinesterase	Rattus norvegicus	23-37
7875230-2	1994	We report here the characterization of the (-)-S isomer, YM796 ((-)-(S)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane L-tartrate monohydrate), and its (+)-R isomer in in vivo pharmacological studies in comparison with the cholinesterase inhibitors tacrine, amiridine and E-2020.	Sulfur	43-48	butyrylcholinesterase	Rattus norvegicus	229-243
7870192-9	1994	When ChE was inhibited locally by perfusion with physostigmine, THA (5 mg/kg) produced a transient and, at its maximum, a 1.42-fold increase in extracellular ACh concentration.	Physostigmine	49-62	butyrylcholinesterase	Rattus norvegicus	5-8
7870192-9	1994	When ChE was inhibited locally by perfusion with physostigmine, THA (5 mg/kg) produced a transient and, at its maximum, a 1.42-fold increase in extracellular ACh concentration.	Tacrine	64-67	butyrylcholinesterase	Rattus norvegicus	5-8
7870192-8	1994	produced significant, prolonged and dose-dependent increases (4 and 12 times the control value, respectively), the peak effect occurring within 1 h. Perfusion with 10 mumol/l physostigmine produced an about 30-fold increase of ACh output, suggesting that the basal extracellular ACh concentration is highly dependent on ChE activity.	Physostigmine	175-188	butyrylcholinesterase	Rattus norvegicus	320-323
7870192-9	1994	When ChE was inhibited locally by perfusion with physostigmine, THA (5 mg/kg) produced a transient and, at its maximum, a 1.42-fold increase in extracellular ACh concentration.	Acetylcholine	158-161	butyrylcholinesterase	Rattus norvegicus	5-8
7870192-8	1994	produced significant, prolonged and dose-dependent increases (4 and 12 times the control value, respectively), the peak effect occurring within 1 h. Perfusion with 10 mumol/l physostigmine produced an about 30-fold increase of ACh output, suggesting that the basal extracellular ACh concentration is highly dependent on ChE activity.	Acetylcholine	227-230	butyrylcholinesterase	Rattus norvegicus	320-323
7861669-2	1994	The Ch/ACh ratio in CSF perfused with Ringer"s solution (30 microliters/30 min) containing 10(-5) M physostigmine, a centrally active cholinesterase inhibitor, was significantly lower than that in unprocessed CSF due to significantly higher ACh levels in the former.	Physostigmine	100-113	butyrylcholinesterase	Rattus norvegicus	134-148
7875555-8	1994	Carbaryl significantly reduced blood cholinesterase activity and elevated blood glucose levels and SGOT and SGPT activities.	Carbaryl	0-8	butyrylcholinesterase	Rattus norvegicus	37-51
7854614-0	1994	Altered modulation by excitatory amino acids of cortical phosphatidylinositol system stimulated by carbachol in rats poisoned by an anti-cholinesterase compound, diisopropyl fluorophosphate.	Excitatory Amino Acids	22-44	butyrylcholinesterase	Rattus norvegicus	137-151
7854614-0	1994	Altered modulation by excitatory amino acids of cortical phosphatidylinositol system stimulated by carbachol in rats poisoned by an anti-cholinesterase compound, diisopropyl fluorophosphate.	Carbachol	99-108	butyrylcholinesterase	Rattus norvegicus	137-151
7854614-0	1994	Altered modulation by excitatory amino acids of cortical phosphatidylinositol system stimulated by carbachol in rats poisoned by an anti-cholinesterase compound, diisopropyl fluorophosphate.	Isoflurophate	162-189	butyrylcholinesterase	Rattus norvegicus	137-151
7816876-4	1994	Although tacrine (0.3 and 1 mg/kg, IP), a cholinesterase inhibitor, also did not affect the learning in young rats, it slightly augmented the aging-induced learning deficit in the present task.	Tacrine	9-16	butyrylcholinesterase	Rattus norvegicus	42-56
7975932-9	1994	The impairment of working and reference memories in OB lesioned rats, which was assessed using a 3-panel-runway apparatus, was reduced by cholinesterase inhibitor physostigmine and NIK-247.	Physostigmine	163-176	butyrylcholinesterase	Rattus norvegicus	138-152
7917744-1	1994	Cholinesterase inhibitors antagonize neuromuscular block produced by mivacurium, but some may also decrease its metabolism by inhibiting pseudocholinesterase.	Mivacurium	69-79	butyrylcholinesterase	Rattus norvegicus	0-14
7834577-4	1994	Systemically administered scopolamine greatly increased the PPT stimulation evoked cortical release of ACh when the cortical probe was perfused with the cholinesterase inhibitor neostigmine.	Scopolamine	26-37	butyrylcholinesterase	Rattus norvegicus	153-167
7834577-4	1994	Systemically administered scopolamine greatly increased the PPT stimulation evoked cortical release of ACh when the cortical probe was perfused with the cholinesterase inhibitor neostigmine.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	60-63	butyrylcholinesterase	Rattus norvegicus	153-167
7834577-4	1994	Systemically administered scopolamine greatly increased the PPT stimulation evoked cortical release of ACh when the cortical probe was perfused with the cholinesterase inhibitor neostigmine.	Acetylcholine	103-106	butyrylcholinesterase	Rattus norvegicus	153-167
7834577-4	1994	Systemically administered scopolamine greatly increased the PPT stimulation evoked cortical release of ACh when the cortical probe was perfused with the cholinesterase inhibitor neostigmine.	Neostigmine	178-189	butyrylcholinesterase	Rattus norvegicus	153-167
7990271-3	1994	On the other hand, in the presence of physostigmine (50 microM; under this condition, cholinesterase activity was inhibited), tacrine did not enhance the basal ACh release.	Physostigmine	38-51	butyrylcholinesterase	Rattus norvegicus	86-100
7990271-6	1994	These results indicate that a high-dose of tacrine increases cholinergic neurotransmission not only by inhibition of cholinesterase but also by increasing ACh release through an atropine-like effect, perhaps by blockade of part of the process of muscarinic autoinhibition.	Tacrine	43-50	butyrylcholinesterase	Rattus norvegicus	117-131
7518512-0	1994	Repeated inhibition of cholinesterase by chlorpyrifos in rats: behavioral, neurochemical and pharmacological indices of tolerance.	Chlorpyrifos	41-53	butyrylcholinesterase	Rattus norvegicus	23-37
7518512-1	1994	Previous work from this laboratory showed that daily s.c. injections of the organophosphate diisopropylfluorophosphate caused prolonged inhibition of cholinesterase (ChE) activity in whole blood and brain and downregulation of muscarinic receptors in the central nervous system; these changes were accompanied by progressive, persistent deterioration of working memory and motor function.	organophosphate diisopropylfluorophosphate	76-118	butyrylcholinesterase	Rattus norvegicus	150-164
7913496-5	1994	Systemic administration of two doses of cholinesterase inhibitor [PHY (30 and 300 micrograms/kg) and HEP (2 and 5 mg/kg)] produced a dose-dependent increase in ACh levels.	Physostigmine	66-69	butyrylcholinesterase	Rattus norvegicus	40-54
7913496-5	1994	Systemic administration of two doses of cholinesterase inhibitor [PHY (30 and 300 micrograms/kg) and HEP (2 and 5 mg/kg)] produced a dose-dependent increase in ACh levels.	physostigmine heptyl	101-104	butyrylcholinesterase	Rattus norvegicus	40-54
7913496-7	1994	HEP produced a longer lasting inhibition of cholinesterase and a more prolonged elevation of ACh in cerebral cortex than PHY.	physostigmine heptyl	0-3	butyrylcholinesterase	Rattus norvegicus	44-58
7518512-1	1994	Previous work from this laboratory showed that daily s.c. injections of the organophosphate diisopropylfluorophosphate caused prolonged inhibition of cholinesterase (ChE) activity in whole blood and brain and downregulation of muscarinic receptors in the central nervous system; these changes were accompanied by progressive, persistent deterioration of working memory and motor function.	organophosphate diisopropylfluorophosphate	76-118	butyrylcholinesterase	Rattus norvegicus	166-169
7518512-3	1994	In the present study, weekly injections of CPF (0, 15, 30 or 60 mg/kg s.c.) inhibited ChE activity in whole blood of rats by 60% to 90% after 5 weeks; the highest dose also induced tremor, working memory impairment and motor slowing in daily delayed matching-to-position/visual discrimination tests.	Chlorpyrifos	43-46	butyrylcholinesterase	Rattus norvegicus	86-89
8024582-0	1994	Butyrylcholinesterase amphiphilic forms of the mucosal cells of rat intestine bind heparin.	Heparin	83-90	butyrylcholinesterase	Rattus norvegicus	0-21
8024582-4	1994	Increasing concentrations of heparin resulted in higher sizes of heparin-BChE complex.	Heparin	29-36	butyrylcholinesterase	Rattus norvegicus	73-77
8024582-5	1994	These properties of intestinal BChE may be related to the possible occurrence of endogenous heparin in this tissue.	Heparin	92-99	butyrylcholinesterase	Rattus norvegicus	31-35
7935256-3	1994	This study measured the in vivo time-course of cholinesterase (ChE) inhibition and recovery in rat maternal serum, brain, and foetal brain after administration of a single acute oral dose of Bromophos (500 mg/kg b.w.)	bromophos	191-200	butyrylcholinesterase	Rattus norvegicus	47-61
7935256-3	1994	This study measured the in vivo time-course of cholinesterase (ChE) inhibition and recovery in rat maternal serum, brain, and foetal brain after administration of a single acute oral dose of Bromophos (500 mg/kg b.w.)	bromophos	191-200	butyrylcholinesterase	Rattus norvegicus	63-66
8207326-4	1994	Therefore, we have studied the inhibition of the rat retinal cholinesterase activity by BW284C51, a selective inhibitor of AChE, and iso-OMPA, a selective inhibitor of butyrylcholinesterase (BChE).	Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide	88-96	butyrylcholinesterase	Rattus norvegicus	61-75
8207326-6	1994	The cholinesterase activity in the sonicate was determined by a radiometric method using 14C-acetylcholine (ACh) as substrate (10(-2) M).	14c-acetylcholine	89-106	butyrylcholinesterase	Rattus norvegicus	4-18
8207326-6	1994	The cholinesterase activity in the sonicate was determined by a radiometric method using 14C-acetylcholine (ACh) as substrate (10(-2) M).	Acetylcholine	108-111	butyrylcholinesterase	Rattus norvegicus	4-18
8207326-9	1994	This study gave the following results: (a) Rat retinal sonicate gave total cholinesterase activity of 3.76 mumol of ACh hydrolyzed/mg protein/15 min; (b) This activity was inhibited by BW284C51 (IC50, 0.115 microM).	Acetylcholine	116-119	butyrylcholinesterase	Rattus norvegicus	75-89
8010100-0	1994	Effect of cholinesterase inhibition in vitro by huperzine analogs.	huperzine A	48-57	butyrylcholinesterase	Rattus norvegicus	10-24
8171435-5	1994	Fenthion produced 89% inhibition of ChE activity in both tissues at 4 days, and, although there was recovery, slight (15%) inhibition of the enzyme activity was still observed at 56 days in both tissues.	Fenthion	0-8	butyrylcholinesterase	Rattus norvegicus	36-39
8026702-13	1994	We concluded that the chronotropic sensitivity to acetylcholine of rat atria decreases post-natally during the period between 4 and 8 weeks after birth due to increase in cholinesterase activity.	Acetylcholine	50-63	butyrylcholinesterase	Rattus norvegicus	171-185
8110583-0	1994	Effects of cholinesterase inhibitors on the neuromuscular blocking action of suxamethonium.	Succinylcholine	77-90	butyrylcholinesterase	Rattus norvegicus	11-25
8307118-7	1994	The present study suggests that serotonergic dysfunction may decrease the efficacy of cholinesterase inhibitors to reverse the defect in WM and PA behavior occurring as a consequence of a decrease in activity of nicotinic-mediated functions.	Protactinium	144-146	butyrylcholinesterase	Rattus norvegicus	86-100
8309962-2	1993	Acute exercise equivalent to 80% VO2-max (maximal oxygen consumption) transiently increased the RBC ChE activity, whereas Phy decreased ChE activity in RBC and various tissues.	Oxygen	50-56	butyrylcholinesterase	Rattus norvegicus	100-103
7893376-4	1994	In this study, the biochemical effects of THA and one of these analogs, THB 013, on plasma cholinesterase activity, cholinergic receptors as well as the effect of these drugs on spatial learning in adult rats were examined.	tha	42-45	butyrylcholinesterase	Rattus norvegicus	91-105
7893376-4	1994	In this study, the biochemical effects of THA and one of these analogs, THB 013, on plasma cholinesterase activity, cholinergic receptors as well as the effect of these drugs on spatial learning in adult rats were examined.	THB 013	72-79	butyrylcholinesterase	Rattus norvegicus	91-105
7893376-5	1994	THB 013 was, at lower concentration, more efficacious in inhibiting plasma cholinesterase as well as blocking the scopolamine induced disruption of spatial learning when administered 10 min before the scopolamine injection.	THB 013	0-7	butyrylcholinesterase	Rattus norvegicus	75-89
8309962-1	1993	This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats.	Physostigmine	45-58	butyrylcholinesterase	Rattus norvegicus	117-131
8309962-1	1993	This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats.	Physostigmine	45-58	butyrylcholinesterase	Rattus norvegicus	133-136
8309962-1	1993	This study reports the modulatory effects of physostigmine (Phy) and concurrent acute exercise on the time course of cholinesterase (ChE) activity, the rate of decarbamylation (Kd), and half-time of recovery of ChE in red blood cells (RBC) and various tissues of rats.	Physostigmine	45-58	butyrylcholinesterase	Rattus norvegicus	211-214
8117420-7	1993	By contrast, in the DMTP test, although both the cholinesterase inhibitors and L-687,306 reversed the effects of scopolamine-induced deficit, L-689,660 and AF102B were without effects.	Scopolamine	113-124	butyrylcholinesterase	Rattus norvegicus	49-63
8117420-8	1993	These results suggest that cholinesterase inhibitors and low efficacy M1 selective muscarinic receptor agonists can reverse the effects of a scopolamine-induced deficit in animal tests of reference and working memory at doses that do not induce the side-effects usually associated with cholinomimetics.	Scopolamine	141-152	butyrylcholinesterase	Rattus norvegicus	27-41
8243558-5	1993	Similar results were obtained after administration of the reversible inhibitor of cholinesterase, eptastigmine.	physostigmine heptyl	98-110	butyrylcholinesterase	Rattus norvegicus	82-96
8297910-0	1993	Dietary cholesterol lowers the activity of butyrylcholinesterase (EC 3.1.1.8), but elevates that of esterase-1 (EC 3.1.1.1) in plasma of rats.	Cholesterol	8-19	butyrylcholinesterase	Rattus norvegicus	43-64
8297910-1	1993	The question addressed is whether an increased intake of cholesterol affects esterase-1 (EC 3.1.1.1; ES-1) and butyrylcholinesterase (EC 3.1.1.8) activity in plasma.	Cholesterol	57-68	butyrylcholinesterase	Rattus norvegicus	111-132
8297910-3	1993	Dietary cholesterol significantly decreased plasma butyrylcholinesterase activity, but raised plasma ES-1 activity.	Cholesterol	8-19	butyrylcholinesterase	Rattus norvegicus	51-72
8297910-4	1993	Evidence is discussed, suggesting that plasma butyrylcholinesterase is involved in plasma cholesterol metabolism, whereas esterase-1 is involved in intestinal cholesterol absorption.	Cholesterol	90-101	butyrylcholinesterase	Rattus norvegicus	46-67
8295230-6	1993	Intramedullary administration of 2-PAM to rats poisoned with fenitrothion or malathion enabled their survival and induced reactivation of brain cholinesterase.	Fenitrothion	61-73	butyrylcholinesterase	Rattus norvegicus	144-158
8295230-6	1993	Intramedullary administration of 2-PAM to rats poisoned with fenitrothion or malathion enabled their survival and induced reactivation of brain cholinesterase.	Malathion	77-86	butyrylcholinesterase	Rattus norvegicus	144-158
8045321-6	1993	It is supposed that influence of Na alpha-ketoglutarate on energy metabolism is realized by means of cholinesterase inhibition and of acetylcholine level increase.	na alpha-ketoglutarate	33-55	butyrylcholinesterase	Rattus norvegicus	101-115
8026770-1	1993	Inhalation exposure to kuscide changed the function of the CNS, microcirculation, blood cholinesterase activity.	kuscide	23-30	butyrylcholinesterase	Rattus norvegicus	88-102
7504821-3	1993	Repeated doses of CPF (40 mg/kg, SC, every 4 days, total of 4 doses) caused extensive inhibition of cortical, hippocampal, and striatal cholinesterase (ChE) activity in adult rats at 4 (90-92%) and 14 (71-78%) days after the last treatment.	Chlorpyrifos	18-21	butyrylcholinesterase	Rattus norvegicus	136-150
7504821-3	1993	Repeated doses of CPF (40 mg/kg, SC, every 4 days, total of 4 doses) caused extensive inhibition of cortical, hippocampal, and striatal cholinesterase (ChE) activity in adult rats at 4 (90-92%) and 14 (71-78%) days after the last treatment.	Chlorpyrifos	18-21	butyrylcholinesterase	Rattus norvegicus	152-155
7689099-0	1993	Behavioral and neurochemical effects of acute chlorpyrifos in rats: tolerance to prolonged inhibition of cholinesterase.	Chlorpyrifos	46-58	butyrylcholinesterase	Rattus norvegicus	105-119
8233096-0	1993	Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after cholinesterase inhibition.	Acetylcholine	58-71	butyrylcholinesterase	Rattus norvegicus	108-122
8233096-3	1993	However, it did potentiate the elevation of extracellular acetylcholine levels produced by a dose of systemic heptylphysostigmine which inhibited 25% of cortical and 40% of plasma cholinesterase activity.	Acetylcholine	58-71	butyrylcholinesterase	Rattus norvegicus	180-194
8233096-3	1993	However, it did potentiate the elevation of extracellular acetylcholine levels produced by a dose of systemic heptylphysostigmine which inhibited 25% of cortical and 40% of plasma cholinesterase activity.	physostigmine heptyl	110-129	butyrylcholinesterase	Rattus norvegicus	180-194
8405782-0	1993	A modified spectrophotometric method appropriate for measuring cholinesterase activity in tissue from carbaryl-treated animals.	Carbaryl	102-110	butyrylcholinesterase	Rattus norvegicus	63-77
8405782-1	1993	Inhibited cholinesterase in tissues of animals exposed to carbamate pesticides is known to reactivate readily, presenting considerable problems in the accurate assessment of cholinesterase activity in these tissues.	Carbamates	58-67	butyrylcholinesterase	Rattus norvegicus	10-24
8405782-1	1993	Inhibited cholinesterase in tissues of animals exposed to carbamate pesticides is known to reactivate readily, presenting considerable problems in the accurate assessment of cholinesterase activity in these tissues.	Carbamates	58-67	butyrylcholinesterase	Rattus norvegicus	174-188
8405782-10	1993	Use of this modified Ellman method will enable more accurate estimation of in vivo cholinesterase activity in animals treated with carbamates.	Carbamates	131-141	butyrylcholinesterase	Rattus norvegicus	83-97
8314923-0	1993	Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats.	physostigmine heptyl	52-64	butyrylcholinesterase	Rattus norvegicus	21-35
8413838-0	1993	Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex.	Acetylcholine	50-63	butyrylcholinesterase	Rattus norvegicus	0-14
8314923-1	1993	The cerebrovascular and metabolic effects of the novel cholinesterase inhibitor eptastigmine were tested in conscious rats.	physostigmine heptyl	80-92	butyrylcholinesterase	Rattus norvegicus	55-69
8357910-1	1993	Fenthion and diazinon, P = S type organothiophosphates which are precursors of cholinesterase inhibitors, cause remarkable atropine-insensitive hypotension in rats when administered intravenously in lethal doses.	Fenthion	0-8	butyrylcholinesterase	Rattus norvegicus	79-93
8388037-3	1993	The results obtained indicate that an unusual increase in the extracellular acetylcholine content, such as that induced by cholinesterase inhibition, is not essential for autoinhibition triggering.	Acetylcholine	76-89	butyrylcholinesterase	Rattus norvegicus	123-137
8357910-1	1993	Fenthion and diazinon, P = S type organothiophosphates which are precursors of cholinesterase inhibitors, cause remarkable atropine-insensitive hypotension in rats when administered intravenously in lethal doses.	Diazinon	13-21	butyrylcholinesterase	Rattus norvegicus	79-93
8357910-1	1993	Fenthion and diazinon, P = S type organothiophosphates which are precursors of cholinesterase inhibitors, cause remarkable atropine-insensitive hypotension in rats when administered intravenously in lethal doses.	Organothiophosphates	34-54	butyrylcholinesterase	Rattus norvegicus	79-93
8474626-0	1993	Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum.	Acetylcholine	50-63	butyrylcholinesterase	Rattus norvegicus	0-14
8049418-1	1993	Initial stages of animal poisoning with phosphacole and carbophos are accompanied by growth of erythrocytes in size and considerable changes of their surface shape, which disappear in 15 min--4 hrs regardless of the remaining cholinesterase activity inhibition.	phosphacole	40-51	butyrylcholinesterase	Rattus norvegicus	226-240
8049418-1	1993	Initial stages of animal poisoning with phosphacole and carbophos are accompanied by growth of erythrocytes in size and considerable changes of their surface shape, which disappear in 15 min--4 hrs regardless of the remaining cholinesterase activity inhibition.	Malathion	56-65	butyrylcholinesterase	Rattus norvegicus	226-240
8482867-2	1993	The changes in cholinesterase (ChE) activity was studied in different tissues of normal and 60 days T. spiralis infected albino rats following treatment with Mintezol (5 mg/rat/day, for 5 days) and 5-fluorouracil-Endoxan (500 mg/rat/day--100 mg/rat/day, for 5 days).	Thiabendazole	158-166	butyrylcholinesterase	Rattus norvegicus	31-34
8482867-3	1993	In normal rats, administration of either Mintezol or 5-fluorouracil-Endoxan provoked a general decrease in the ChE activity of the various rat tissues.	Thiabendazole	41-49	butyrylcholinesterase	Rattus norvegicus	111-114
8482867-3	1993	In normal rats, administration of either Mintezol or 5-fluorouracil-Endoxan provoked a general decrease in the ChE activity of the various rat tissues.	5-fluorouracil-endoxan	53-75	butyrylcholinesterase	Rattus norvegicus	111-114
8482867-4	1993	Treatment of 60 days T. spiralis infected rats with Mintezol increased markedly the ChE activity of the brain, liver, gastrocnemius muscle and serum.	Thiabendazole	52-60	butyrylcholinesterase	Rattus norvegicus	84-87
8482867-7	1993	This danger results from general inhibition of ChE activity which may cause accumulation of acetylcholine.	Acetylcholine	92-105	butyrylcholinesterase	Rattus norvegicus	47-50
8441002-3	1993	Enhancing extracellular concentrations of ACh in the substantia nigra by intranigral infusions of the cholinesterase inhibitor neostigmine also resulted in an increase in the chronoamperometric signal corresponding to DA overflow in the striatum.	Acetylcholine	42-45	butyrylcholinesterase	Rattus norvegicus	102-116
8441002-3	1993	Enhancing extracellular concentrations of ACh in the substantia nigra by intranigral infusions of the cholinesterase inhibitor neostigmine also resulted in an increase in the chronoamperometric signal corresponding to DA overflow in the striatum.	Neostigmine	127-138	butyrylcholinesterase	Rattus norvegicus	102-116
8496822-1	1993	1,2,3,4-Tetrahydro-9-aminoacridine (THA, tacrine) is a potent cholinesterase (ChE) inhibitor which is under consideration for the treatment of Alzheimer"s disease.	Tacrine	0-34	butyrylcholinesterase	Rattus norvegicus	62-76
8496822-1	1993	1,2,3,4-Tetrahydro-9-aminoacridine (THA, tacrine) is a potent cholinesterase (ChE) inhibitor which is under consideration for the treatment of Alzheimer"s disease.	Tacrine	0-34	butyrylcholinesterase	Rattus norvegicus	78-81
8496822-1	1993	1,2,3,4-Tetrahydro-9-aminoacridine (THA, tacrine) is a potent cholinesterase (ChE) inhibitor which is under consideration for the treatment of Alzheimer"s disease.	Tacrine	36-39	butyrylcholinesterase	Rattus norvegicus	62-76
8496822-1	1993	1,2,3,4-Tetrahydro-9-aminoacridine (THA, tacrine) is a potent cholinesterase (ChE) inhibitor which is under consideration for the treatment of Alzheimer"s disease.	Tacrine	36-39	butyrylcholinesterase	Rattus norvegicus	78-81
8496822-1	1993	1,2,3,4-Tetrahydro-9-aminoacridine (THA, tacrine) is a potent cholinesterase (ChE) inhibitor which is under consideration for the treatment of Alzheimer"s disease.	Tacrine	41-48	butyrylcholinesterase	Rattus norvegicus	62-76
8496822-1	1993	1,2,3,4-Tetrahydro-9-aminoacridine (THA, tacrine) is a potent cholinesterase (ChE) inhibitor which is under consideration for the treatment of Alzheimer"s disease.	Tacrine	41-48	butyrylcholinesterase	Rattus norvegicus	78-81
8496822-5	1993	In the presence of THA, atropine induced a smaller increase in extracellular ACh concentrations than it did in the presence of physostigmine, under experimental conditions in which THA (100 microM) and physostigmine (10 microM) produced an equivalent effect on ChE activity.	Atropine	24-32	butyrylcholinesterase	Rattus norvegicus	261-264
8496822-5	1993	In the presence of THA, atropine induced a smaller increase in extracellular ACh concentrations than it did in the presence of physostigmine, under experimental conditions in which THA (100 microM) and physostigmine (10 microM) produced an equivalent effect on ChE activity.	Physostigmine	202-215	butyrylcholinesterase	Rattus norvegicus	261-264
8496822-7	1993	THA (100 microM) and physostigmine (10 microM) produced an additive effect on the extracellular concentration of ACh, and the addition of THA (10 microM) to physostigmine (1 microM) produced further inhibition of in vitro ChE activity.	Tacrine	0-3	butyrylcholinesterase	Rattus norvegicus	222-225
8496822-7	1993	THA (100 microM) and physostigmine (10 microM) produced an additive effect on the extracellular concentration of ACh, and the addition of THA (10 microM) to physostigmine (1 microM) produced further inhibition of in vitro ChE activity.	Physostigmine	21-34	butyrylcholinesterase	Rattus norvegicus	222-225
8496822-7	1993	THA (100 microM) and physostigmine (10 microM) produced an additive effect on the extracellular concentration of ACh, and the addition of THA (10 microM) to physostigmine (1 microM) produced further inhibition of in vitro ChE activity.	Tacrine	138-141	butyrylcholinesterase	Rattus norvegicus	222-225
8474626-1	1993	The effects of inhibition of cholinesterase on levels of extracellular acetylcholine in the striatum of freely moving rats, were investigated with a microdialysis technique.	Acetylcholine	71-84	butyrylcholinesterase	Rattus norvegicus	29-43
8474626-3	1993	However, local administration of the cholinesterase inhibitors neostigmine, physostigmine or heptyl-physostigmine through the dialysis probe elevated acetylcholine above the detection limit.	Neostigmine	63-74	butyrylcholinesterase	Rattus norvegicus	37-51
8474626-3	1993	However, local administration of the cholinesterase inhibitors neostigmine, physostigmine or heptyl-physostigmine through the dialysis probe elevated acetylcholine above the detection limit.	Physostigmine	76-89	butyrylcholinesterase	Rattus norvegicus	37-51
8474626-3	1993	However, local administration of the cholinesterase inhibitors neostigmine, physostigmine or heptyl-physostigmine through the dialysis probe elevated acetylcholine above the detection limit.	physostigmine heptyl	93-113	butyrylcholinesterase	Rattus norvegicus	37-51
8474626-3	1993	However, local administration of the cholinesterase inhibitors neostigmine, physostigmine or heptyl-physostigmine through the dialysis probe elevated acetylcholine above the detection limit.	Acetylcholine	150-163	butyrylcholinesterase	Rattus norvegicus	37-51
8449387-1	1993	These experiments examined the relationship between behavioral alterations and neurochemical changes in rats exposed repeatedly to disulfoton, an organophosphate cholinesterase inhibitor.	Disulfoton	131-141	butyrylcholinesterase	Rattus norvegicus	162-176
8128831-5	1993	It is possible that some of these analogues with more potent cholinergic effect than THA might be the next generation of cholinesterase inhibitors which can be useful in the treatment of Alzheimer"s disease.	tha	85-88	butyrylcholinesterase	Rattus norvegicus	121-135
8446666-1	1993	Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman).	Carbamates	33-42	butyrylcholinesterase	Rattus norvegicus	92-106
8446666-1	1993	Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman).	Carbamates	33-42	butyrylcholinesterase	Rattus norvegicus	108-111
8446666-1	1993	Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman).	Physostigmine	43-56	butyrylcholinesterase	Rattus norvegicus	92-106
8446666-1	1993	Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman).	Physostigmine	43-56	butyrylcholinesterase	Rattus norvegicus	108-111
8446666-1	1993	Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman).	Soman	221-256	butyrylcholinesterase	Rattus norvegicus	92-106
8446666-1	1993	Continuous administration of the carbamate physostigmine, producing approximately 40% serum cholinesterase (ChE) inhibition, provides significant protection against the lethal effects of the organophosphorous nerve agent pinacolyl methylphosphonofluoridate (soman).	Soman	221-256	butyrylcholinesterase	Rattus norvegicus	108-111
8446666-3	1993	Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone.	Soman	0-5	butyrylcholinesterase	Rattus norvegicus	37-40
8446666-3	1993	Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone.	Physostigmine	10-23	butyrylcholinesterase	Rattus norvegicus	37-40
8446666-3	1993	Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone.	Physostigmine	70-83	butyrylcholinesterase	Rattus norvegicus	37-40
8446666-3	1993	Soman and physostigmine both inhibit ChE, yet animals pretreated with physostigmine exhibited less ChE inhibition in serum and brain than did animals exposed to soman alone.	Physostigmine	70-83	butyrylcholinesterase	Rattus norvegicus	99-102
8128832-0	1993	Effects of cholinesterase inhibitors on learning and memory in rats: a brief review with special reference to THA.	Tacrine	110-113	butyrylcholinesterase	Rattus norvegicus	11-25
8311691-1	1993	The ability of three oximes, HI-6, MMB-4 and ICD-467, to reactivate cholinesterase (ChE) inhibited by the organophosphorus compound soman was compared in blood (plasma and erythrocytes), brain regions (including spinal cord) and peripheral tissues of rats.	Oximes	21-27	butyrylcholinesterase	Rattus norvegicus	84-87
8154624-9	1993	It has been shown that chronic exposure to NH4F vapours causes a rise in the activity of studied aminotransferases and alkaline phosphatase, and a decreases in activity of cholinesterase.	ammonium fluoride	43-47	butyrylcholinesterase	Rattus norvegicus	172-186
8311691-1	1993	The ability of three oximes, HI-6, MMB-4 and ICD-467, to reactivate cholinesterase (ChE) inhibited by the organophosphorus compound soman was compared in blood (plasma and erythrocytes), brain regions (including spinal cord) and peripheral tissues of rats.	asoxime chloride	29-33	butyrylcholinesterase	Rattus norvegicus	68-82
8494501-5	1993	Pyridostigmine pretreatment also produced significant recovery of the total cholinesterase (ChE) activity in plasma, but not in trachea and lung.	Pyridostigmine Bromide	0-14	butyrylcholinesterase	Rattus norvegicus	76-90
8494501-5	1993	Pyridostigmine pretreatment also produced significant recovery of the total cholinesterase (ChE) activity in plasma, but not in trachea and lung.	Pyridostigmine Bromide	0-14	butyrylcholinesterase	Rattus norvegicus	92-95
8311691-1	1993	The ability of three oximes, HI-6, MMB-4 and ICD-467, to reactivate cholinesterase (ChE) inhibited by the organophosphorus compound soman was compared in blood (plasma and erythrocytes), brain regions (including spinal cord) and peripheral tissues of rats.	asoxime chloride	29-33	butyrylcholinesterase	Rattus norvegicus	84-87
8494501-11	1993	Combination of pyridostigmine pretreatment and oxime treatment enhanced the recovery of the tracheal contraction response and the ChE activity in the trachea compared to treatment with oximes alone.	Pyridostigmine Bromide	15-29	butyrylcholinesterase	Rattus norvegicus	130-133
8311691-1	1993	The ability of three oximes, HI-6, MMB-4 and ICD-467, to reactivate cholinesterase (ChE) inhibited by the organophosphorus compound soman was compared in blood (plasma and erythrocytes), brain regions (including spinal cord) and peripheral tissues of rats.	organophosphorus	106-122	butyrylcholinesterase	Rattus norvegicus	68-82
8494501-11	1993	Combination of pyridostigmine pretreatment and oxime treatment enhanced the recovery of the tracheal contraction response and the ChE activity in the trachea compared to treatment with oximes alone.	Oximes	47-52	butyrylcholinesterase	Rattus norvegicus	130-133
8311691-1	1993	The ability of three oximes, HI-6, MMB-4 and ICD-467, to reactivate cholinesterase (ChE) inhibited by the organophosphorus compound soman was compared in blood (plasma and erythrocytes), brain regions (including spinal cord) and peripheral tissues of rats.	organophosphorus	106-122	butyrylcholinesterase	Rattus norvegicus	84-87
8311691-5	1993	In blood, treatment with HI-6 or ICD-467 resulted in significant reactivation of soman-inhibited ChE.	asoxime chloride	25-29	butyrylcholinesterase	Rattus norvegicus	97-100
8311691-5	1993	In blood, treatment with HI-6 or ICD-467 resulted in significant reactivation of soman-inhibited ChE.	Soman	81-86	butyrylcholinesterase	Rattus norvegicus	97-100
8311691-8	1993	At the low dose ICD-467 treatment resulted in significantly higher plasma ChE than HI-6 treatment, whereas HI-6 treatment resulted in higher erythrocyte ChE than ICD-467 treatment.	asoxime chloride	107-111	butyrylcholinesterase	Rattus norvegicus	153-156
8311691-11	1993	HI-6 reactivated soman-inhibited ChE in all tissues except lung, heart, and skeletal muscle.	asoxime chloride	0-4	butyrylcholinesterase	Rattus norvegicus	33-36
8311691-11	1993	HI-6 reactivated soman-inhibited ChE in all tissues except lung, heart, and skeletal muscle.	Soman	17-22	butyrylcholinesterase	Rattus norvegicus	33-36
8311691-15	1993	These observations indicate that MMB-4 is completely ineffective in protecting and/or reactivating soman-inhibited ChE, HI-6 is an effective ChE reactivator as reported earlier in rats and other species, and the imidazolium oxime ICD-467 is a powerful reactivator of soman-inhibited ChE; however, its toxic interactions with soman may not be related to tissue ChE levels.	asoxime chloride	120-124	butyrylcholinesterase	Rattus norvegicus	141-144
8311691-15	1993	These observations indicate that MMB-4 is completely ineffective in protecting and/or reactivating soman-inhibited ChE, HI-6 is an effective ChE reactivator as reported earlier in rats and other species, and the imidazolium oxime ICD-467 is a powerful reactivator of soman-inhibited ChE; however, its toxic interactions with soman may not be related to tissue ChE levels.	asoxime chloride	120-124	butyrylcholinesterase	Rattus norvegicus	141-144
8311691-15	1993	These observations indicate that MMB-4 is completely ineffective in protecting and/or reactivating soman-inhibited ChE, HI-6 is an effective ChE reactivator as reported earlier in rats and other species, and the imidazolium oxime ICD-467 is a powerful reactivator of soman-inhibited ChE; however, its toxic interactions with soman may not be related to tissue ChE levels.	asoxime chloride	120-124	butyrylcholinesterase	Rattus norvegicus	141-144
8311691-15	1993	These observations indicate that MMB-4 is completely ineffective in protecting and/or reactivating soman-inhibited ChE, HI-6 is an effective ChE reactivator as reported earlier in rats and other species, and the imidazolium oxime ICD-467 is a powerful reactivator of soman-inhibited ChE; however, its toxic interactions with soman may not be related to tissue ChE levels.	imidazolium oxime icd-467	212-237	butyrylcholinesterase	Rattus norvegicus	141-144
8311691-15	1993	These observations indicate that MMB-4 is completely ineffective in protecting and/or reactivating soman-inhibited ChE, HI-6 is an effective ChE reactivator as reported earlier in rats and other species, and the imidazolium oxime ICD-467 is a powerful reactivator of soman-inhibited ChE; however, its toxic interactions with soman may not be related to tissue ChE levels.	imidazolium oxime icd-467	212-237	butyrylcholinesterase	Rattus norvegicus	141-144
8311691-15	1993	These observations indicate that MMB-4 is completely ineffective in protecting and/or reactivating soman-inhibited ChE, HI-6 is an effective ChE reactivator as reported earlier in rats and other species, and the imidazolium oxime ICD-467 is a powerful reactivator of soman-inhibited ChE; however, its toxic interactions with soman may not be related to tissue ChE levels.	imidazolium oxime icd-467	212-237	butyrylcholinesterase	Rattus norvegicus	141-144
8398050-1	1993	A choline amperometric biosensor was assembled and used to measure the anticholinesterase activity due to compounds (which have the property to inhibit cholinesterase enzymes) present in water samples.	Choline	2-9	butyrylcholinesterase	Rattus norvegicus	75-89
8440870-3	1993	Methyl isocyanate administration led to haemoconcentration, resulting in an increase in the plasma concentration of total proteins and a decrease in both the plasma concentration of albumin and the plasma cholinesterase activity.	methyl isocyanate	0-17	butyrylcholinesterase	Rattus norvegicus	205-219
8398050-3	1993	The organophosphorus insecticide Paraoxon, which has proved to be a strong inhibitor of cholinesterase enzymes, was chosen as the reference compound.	Paraoxon	33-41	butyrylcholinesterase	Rattus norvegicus	88-102
8459784-0	1993	Relationship between serum cholinesterase activity and the change in body temperature and motor activity in the rat: a dose-response study of diisopropyl fluorophosphate.	Isoflurophate	142-169	butyrylcholinesterase	Rattus norvegicus	27-41
8371630-1	1993	In rat brain microvessels, tetrahydroaminoacridine (THA) caused a significant inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities, in a dose-dependent manner.	Tacrine	52-55	butyrylcholinesterase	Rattus norvegicus	129-150
8371630-1	1993	In rat brain microvessels, tetrahydroaminoacridine (THA) caused a significant inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities, in a dose-dependent manner.	Tacrine	52-55	butyrylcholinesterase	Rattus norvegicus	152-157
8371630-4	1993	The results of the present study also established that the three molecular forms of BuChE (G1, G2 and G4), recently described to be present in brain microvessels, are inhibited after THA treatment.	Tacrine	183-186	butyrylcholinesterase	Rattus norvegicus	84-89
8371630-1	1993	In rat brain microvessels, tetrahydroaminoacridine (THA) caused a significant inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities, in a dose-dependent manner.	Tacrine	27-50	butyrylcholinesterase	Rattus norvegicus	129-150
8371630-1	1993	In rat brain microvessels, tetrahydroaminoacridine (THA) caused a significant inhibition of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities, in a dose-dependent manner.	Tacrine	27-50	butyrylcholinesterase	Rattus norvegicus	152-157
8459784-1	1993	Risk assessment of the neurotoxicology of organophosphate (OP) pesticides calls for a thorough understanding of the relationship between tissue cholinesterase (ChE) activity and changes in behavioral and autonomic responses to OP treatment.	Organophosphates	42-57	butyrylcholinesterase	Rattus norvegicus	144-158
8459784-1	1993	Risk assessment of the neurotoxicology of organophosphate (OP) pesticides calls for a thorough understanding of the relationship between tissue cholinesterase (ChE) activity and changes in behavioral and autonomic responses to OP treatment.	Organophosphates	42-57	butyrylcholinesterase	Rattus norvegicus	160-163
8459784-3	1993	DFP doses > or = 0.25 mg/kg led to significant decreases in serum ChE activity, whereas doses of > or = 0.5 mg/kg caused reductions in motor activity and body temperature.	Isoflurophate	0-3	butyrylcholinesterase	Rattus norvegicus	69-72
1301240-6	1992	(ii) The cholinesterase-resistant agonist carbachol (10(-9)-2.5 x 10(-6) M) elicited a 2- to 3-fold greater negative chronotropic response in the aged compared with adult hearts.	Carbachol	42-51	butyrylcholinesterase	Rattus norvegicus	9-23
8450938-1	1993	Cholinesterase inhibitors, such as physostigmine and tetrahydroaminoacridine, have been found to alleviate some of the memory deficits characteristic of senile dementia of the Alzheimer"s type (SDAT).	Physostigmine	35-48	butyrylcholinesterase	Rattus norvegicus	0-14
8450938-1	1993	Cholinesterase inhibitors, such as physostigmine and tetrahydroaminoacridine, have been found to alleviate some of the memory deficits characteristic of senile dementia of the Alzheimer"s type (SDAT).	Tacrine	53-76	butyrylcholinesterase	Rattus norvegicus	0-14
8450938-3	1993	Recently, a cholinesterase inhibitor, methanesulfonyl fluoride (MSF), was discovered to have low toxicity, central nervous system (CNS) selectivity, and a long therapeutic duration.	methanesulfonyl fluoride	38-62	butyrylcholinesterase	Rattus norvegicus	12-26
8450938-3	1993	Recently, a cholinesterase inhibitor, methanesulfonyl fluoride (MSF), was discovered to have low toxicity, central nervous system (CNS) selectivity, and a long therapeutic duration.	methanesulfonyl fluoride	64-67	butyrylcholinesterase	Rattus norvegicus	12-26
7871051-0	1993	Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.	phenserine	0-10	butyrylcholinesterase	Rattus norvegicus	74-88
7871051-1	1993	Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase.	phenserine	0-10	butyrylcholinesterase	Rattus norvegicus	119-133
7871051-1	1993	Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase.	phenserine	12-43	butyrylcholinesterase	Rattus norvegicus	119-133
7871051-1	1993	Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase.	Physostigmine	68-81	butyrylcholinesterase	Rattus norvegicus	119-133
7871051-1	1993	Phenserine ((-)-N-phenylcarbamoyl eseroline), a carbamate analog of physostigmine (Phy), is a long-acting inhibitor of cholinesterase.	Physostigmine	83-86	butyrylcholinesterase	Rattus norvegicus	119-133
7871053-8	1993	Administration of the cholinesterase inhibitor physostigmine (0.1-0.4 mg/kg) induced a dose related increase in the total number of purposeless chews, but primarily these were not associated with facial tremor.	Physostigmine	47-60	butyrylcholinesterase	Rattus norvegicus	22-36
1378635-1	1992	A single dose of the organophosphate insecticide O,O"-diethyl-O-3,5,6- trichloro-2-pyridylphosphorothioate [chlorpyrifos (CPF), 279 mg/kg, SC] caused extensive inhibition of cortical and striatal cholinesterase (ChE) activity in adult rats at 2 (94-96%), 4 (82-83%), and 6 (58-60%) weeks after treatment.	Chlorpyrifos	49-106	butyrylcholinesterase	Rattus norvegicus	196-210
1305879-1	1992	The new cholinesterase reactivator alloxime, 10 mg/kg, shows a marked therapeutical benefits in acute intoxication rats with carbamine pesticides such as carbofuran, pirimor, elocron.	alloxime	35-43	butyrylcholinesterase	Rattus norvegicus	8-22
1305879-1	1992	The new cholinesterase reactivator alloxime, 10 mg/kg, shows a marked therapeutical benefits in acute intoxication rats with carbamine pesticides such as carbofuran, pirimor, elocron.	Carbaryl	125-134	butyrylcholinesterase	Rattus norvegicus	8-22
1305879-1	1992	The new cholinesterase reactivator alloxime, 10 mg/kg, shows a marked therapeutical benefits in acute intoxication rats with carbamine pesticides such as carbofuran, pirimor, elocron.	Carbofuran	154-164	butyrylcholinesterase	Rattus norvegicus	8-22
1305879-1	1992	The new cholinesterase reactivator alloxime, 10 mg/kg, shows a marked therapeutical benefits in acute intoxication rats with carbamine pesticides such as carbofuran, pirimor, elocron.	pirimicarb	166-173	butyrylcholinesterase	Rattus norvegicus	8-22
1305879-1	1992	The new cholinesterase reactivator alloxime, 10 mg/kg, shows a marked therapeutical benefits in acute intoxication rats with carbamine pesticides such as carbofuran, pirimor, elocron.	dioxacarb	175-182	butyrylcholinesterase	Rattus norvegicus	8-22
1305879-3	1992	The mechanism of alloxime"s therapeutical action is due to its capacity to restore cholinesterase activity in the central nervous system, normalizing neuromuscular transmission and hepatic and renal cytochrome P-450 levels.	alloxime	17-25	butyrylcholinesterase	Rattus norvegicus	83-97
1436398-6	1992	The increase in working memory errors, induced by lesions of the basolateral amygdala was significantly reduced by intraperitoneal administration of the inhibitors of cholinesterase, tetrahydroaminoacridine (0.32-1.0 mg/kg) and physostigmine (0.032-0.1 mg/kg), and the muscarinic receptor agonist, oxotremorine (0.1 mg/kg), before the runway test.	Physostigmine	228-241	butyrylcholinesterase	Rattus norvegicus	167-181
1436398-6	1992	The increase in working memory errors, induced by lesions of the basolateral amygdala was significantly reduced by intraperitoneal administration of the inhibitors of cholinesterase, tetrahydroaminoacridine (0.32-1.0 mg/kg) and physostigmine (0.032-0.1 mg/kg), and the muscarinic receptor agonist, oxotremorine (0.1 mg/kg), before the runway test.	Oxotremorine	298-310	butyrylcholinesterase	Rattus norvegicus	167-181
1527361-8	1992	Also a significant reduction in blood cholinesterase activity was observed in both male and female rats fed on grain bound pirimiphos-methyl residues at two dose levels.	Pirimiphos	123-133	butyrylcholinesterase	Rattus norvegicus	38-52
1619216-7	1992	On the other hand, determination of cholinesterase activity showed that, phenamiphos inhibited the enzymes in both brain and plasma, where the depression of ChE activity was usually more marked in plasma than in brain.	fenamiphos	73-84	butyrylcholinesterase	Rattus norvegicus	36-50
1432252-9	1992	Plasma cholesterol concentration was negatively associated with butyryl cholinesterase activity, but was not related to ES-1 activity.	Cholesterol	7-18	butyrylcholinesterase	Rattus norvegicus	72-86
1432266-0	1992	Fat intake and clofibrate administration have interrelated effects on liver cholesterol concentration and serum butyryl cholinesterase activity in rats.	Clofibrate	15-25	butyrylcholinesterase	Rattus norvegicus	120-134
1432266-8	1992	Clofibrate elevated serum butyryl cholinesterase activity, with this effect being amplified by fat feeding.	Clofibrate	0-10	butyrylcholinesterase	Rattus norvegicus	34-48
1426013-0	1992	Suppression by cholinesterase inhibition of a Ca(2+)-independent efflux of [3H]acetylcholine from the neuromuscular junction of the isolated rat diaphragm.	Acetylcholine	75-92	butyrylcholinesterase	Rattus norvegicus	15-29
1426013-4	1992	Inhibitors of cholinesterase (physostigmine, diisopropylfluorophosphate) suppressed by 80% this Ca(2+)-independent efflux of [3H]acetylcholine.	Physostigmine	30-43	butyrylcholinesterase	Rattus norvegicus	14-28
1426013-4	1992	Inhibitors of cholinesterase (physostigmine, diisopropylfluorophosphate) suppressed by 80% this Ca(2+)-independent efflux of [3H]acetylcholine.	Isoflurophate	45-71	butyrylcholinesterase	Rattus norvegicus	14-28
1426013-4	1992	Inhibitors of cholinesterase (physostigmine, diisopropylfluorophosphate) suppressed by 80% this Ca(2+)-independent efflux of [3H]acetylcholine.	Acetylcholine	125-142	butyrylcholinesterase	Rattus norvegicus	14-28
1426013-7	1992	The present experiments showed cholinesterase inhibition to suppress a Ca(2+)-independent efflux of [3H]acetylcholine, probably by interference with a membrane-bound acetylcholine carrier.	Acetylcholine	100-117	butyrylcholinesterase	Rattus norvegicus	31-45
1426013-7	1992	The present experiments showed cholinesterase inhibition to suppress a Ca(2+)-independent efflux of [3H]acetylcholine, probably by interference with a membrane-bound acetylcholine carrier.	Acetylcholine	104-117	butyrylcholinesterase	Rattus norvegicus	31-45
1291487-0	1992	Acetylcholine and cholinesterase levels in the brain of methanol treated rats.	Methanol	56-64	butyrylcholinesterase	Rattus norvegicus	18-32
1378635-1	1992	A single dose of the organophosphate insecticide O,O"-diethyl-O-3,5,6- trichloro-2-pyridylphosphorothioate [chlorpyrifos (CPF), 279 mg/kg, SC] caused extensive inhibition of cortical and striatal cholinesterase (ChE) activity in adult rats at 2 (94-96%), 4 (82-83%), and 6 (58-60%) weeks after treatment.	Chlorpyrifos	49-106	butyrylcholinesterase	Rattus norvegicus	212-215
1501077-3	1992	4-[[(Dimethylamino)methylene]amino]-3-pyridyl N,N-dimethylcarbamate (7a), an intermediate in the synthesis of 2b, demonstrated surprisingly good cholinesterase inhibition (IC50 was 9.4 microM) but showed no activity as a release.	4-[[(dimethylamino)methylene]amino]-3-pyridyl n,n-dimethylcarbamate	0-67	butyrylcholinesterase	Rattus norvegicus	145-159
1617457-2	1992	Animals were treated either with a toxic dose of soman, an irreversible organophosphorus cholinesterase inhibitor, that produced convulsions or with saline as controls.	Soman	49-54	butyrylcholinesterase	Rattus norvegicus	89-103
1501077-3	1992	4-[[(Dimethylamino)methylene]amino]-3-pyridyl N,N-dimethylcarbamate (7a), an intermediate in the synthesis of 2b, demonstrated surprisingly good cholinesterase inhibition (IC50 was 9.4 microM) but showed no activity as a release.	AN 7 peptide complex	69-71	butyrylcholinesterase	Rattus norvegicus	145-159
1501077-2	1992	Although 4-amino-3-pyridyl N,N-dimethylcarbamate (2b) showed good cholinesterase inhibition [concentration that elicited a 50% reduction in the maximal enzyme response (IC50) was 13.4 microM], it had no effect on the stimulated release of [3H]acetylcholine from rat striatal slices.	4-amino-3-pyridyl n,n-dimethylcarbamate	9-48	butyrylcholinesterase	Rattus norvegicus	66-80
1640506-1	1992	This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF).	physostigmine heptyl	45-64	butyrylcholinesterase	Rattus norvegicus	87-101
1594645-1	1992	Whether the pharmacodynamics of physostigmine (Phy) [rate of decarbamylation of cholinesterase (ChE) enzyme] (Kd) is altered due to acute and/or trained exercise in brain and various tissues of rat has been addressed.	Physostigmine	32-45	butyrylcholinesterase	Rattus norvegicus	80-94
1594645-1	1992	Whether the pharmacodynamics of physostigmine (Phy) [rate of decarbamylation of cholinesterase (ChE) enzyme] (Kd) is altered due to acute and/or trained exercise in brain and various tissues of rat has been addressed.	Physostigmine	32-45	butyrylcholinesterase	Rattus norvegicus	96-99
1594645-5	1992	The Kd of heart ChE was significantly decreased (44% of control) by ET + Phy as compared to Phy alone.	et + phy	68-76	butyrylcholinesterase	Rattus norvegicus	16-19
1639235-2	1992	The effect of four hypolipidemic agents with different mechanisms of action (fenofibrate, probucol, colestipol and nicotinic acid) on plasma and liver cholinesterase has been studied.	Probucol	90-98	butyrylcholinesterase	Rattus norvegicus	151-165
1639235-2	1992	The effect of four hypolipidemic agents with different mechanisms of action (fenofibrate, probucol, colestipol and nicotinic acid) on plasma and liver cholinesterase has been studied.	Colestipol	100-110	butyrylcholinesterase	Rattus norvegicus	151-165
1639235-2	1992	The effect of four hypolipidemic agents with different mechanisms of action (fenofibrate, probucol, colestipol and nicotinic acid) on plasma and liver cholinesterase has been studied.	Niacin	115-129	butyrylcholinesterase	Rattus norvegicus	151-165
1639235-6	1992	Plasma and liver cholinesterase activity increased markedly after fenofibrate, a strong peroxisome proliferator, and slightly after nicotinic acid, a weak peroxisome proliferator.	Fenofibrate	66-77	butyrylcholinesterase	Rattus norvegicus	17-31
1639235-6	1992	Plasma and liver cholinesterase activity increased markedly after fenofibrate, a strong peroxisome proliferator, and slightly after nicotinic acid, a weak peroxisome proliferator.	Niacin	132-146	butyrylcholinesterase	Rattus norvegicus	17-31
1639235-8	1992	The data obtained suggest that increased cholinesterase activity is due to increased rate of fatty acid oxidation caused by peroxisome proliferators.	Fatty Acids	93-103	butyrylcholinesterase	Rattus norvegicus	41-55
1640506-1	1992	This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF).	physostigmine heptyl	45-64	butyrylcholinesterase	Rattus norvegicus	103-106
1640506-1	1992	This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF).	physostigmine heptyl	66-71	butyrylcholinesterase	Rattus norvegicus	103-106
1640506-1	1992	This study sought to determine the effect of heptylphysostigmine (H-PHY), a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer duration of action than physostigmine, on resting and basal forebrain (BF)-elicited increases in cortical cerebral blood flow (CBF).	Physostigmine	51-64	butyrylcholinesterase	Rattus norvegicus	103-106
1507523-7	1992	The increase in working errors in hippocampal-lesioned rats was significantly reduced by treatment with the cholinesterase inhibitor physostigmine at 0.1 mg/kg and the cholinergic activating drug minaprine at 10 mg/kg.	Physostigmine	133-146	butyrylcholinesterase	Rattus norvegicus	108-122
1564249-2	1992	The cholinesterase inhibitor was delivered via subcutaneously implanted osmotic minipumps (Alzet) at 9 micrograms h-1 (low dose) or 60 micrograms h-1 (high dose).	alzet	91-96	butyrylcholinesterase	Rattus norvegicus	4-18
1564249-9	1992	In the presence of atropine, subacutely administered pyridostigmine protected rats from two LD50 doses of the irreversible cholinesterase inhibitor, soman.	Atropine	19-27	butyrylcholinesterase	Rattus norvegicus	123-137
1564249-9	1992	In the presence of atropine, subacutely administered pyridostigmine protected rats from two LD50 doses of the irreversible cholinesterase inhibitor, soman.	Pyridostigmine Bromide	53-67	butyrylcholinesterase	Rattus norvegicus	123-137
1630594-3	1992	Application of the cholinesterase inhibitor, neostigmine, directly to the surface of the spinal cord elicited increases in heart rate selectively when neostigmine was applied to upper thoracic segments (Th1-Th4), whereas all thoracic segments participated in the generation of the associated hypertensive response.	Neostigmine	45-56	butyrylcholinesterase	Rattus norvegicus	19-33
1630594-3	1992	Application of the cholinesterase inhibitor, neostigmine, directly to the surface of the spinal cord elicited increases in heart rate selectively when neostigmine was applied to upper thoracic segments (Th1-Th4), whereas all thoracic segments participated in the generation of the associated hypertensive response.	Neostigmine	151-162	butyrylcholinesterase	Rattus norvegicus	19-33
1352646-1	1992	Previous studies in this laboratory have demonstrated that the centrally-acting alpha 2-adrenergic agonist clonidine can offer significant protection against both the acute and chronic toxicity following irreversible cholinesterase inactivation with soman.	Clonidine	107-116	butyrylcholinesterase	Rattus norvegicus	217-231
1635892-1	1992	Heptastigmine is a new long acting cholinesterase inhibitor that affects behaviour in a number of cognitive tests in animals.	physostigmine heptyl	0-13	butyrylcholinesterase	Rattus norvegicus	35-49
1539077-1	1992	Pyridostigmine bromide (Pyr), a reversible cholinesterase inhibitor, is currently suggested to be the most effective pretreatment drug against intoxication with potent organophosphates (OP).	Pyridostigmine Bromide	0-22	butyrylcholinesterase	Rattus norvegicus	43-57
1539077-1	1992	Pyridostigmine bromide (Pyr), a reversible cholinesterase inhibitor, is currently suggested to be the most effective pretreatment drug against intoxication with potent organophosphates (OP).	Pyridostigmine Bromide	0-3	butyrylcholinesterase	Rattus norvegicus	43-57
1539077-1	1992	Pyridostigmine bromide (Pyr), a reversible cholinesterase inhibitor, is currently suggested to be the most effective pretreatment drug against intoxication with potent organophosphates (OP).	Organophosphates	168-184	butyrylcholinesterase	Rattus norvegicus	43-57
1300633-1	1992	Simple method of continual monitoring of the rat blood cholinesterase activity in vivo was used to demonstrate its inhibition following i. m. administration of acridine and carbamate inhibitors.	Acridines	160-168	butyrylcholinesterase	Rattus norvegicus	55-69
1352646-3	1992	To investigate the central component of soman toxicity, animals were pretreated with the peripherally selective reversible cholinesterase inhibitor pyridostigmine, a standard protective agent.	Pyridostigmine Bromide	148-162	butyrylcholinesterase	Rattus norvegicus	123-137
1300633-1	1992	Simple method of continual monitoring of the rat blood cholinesterase activity in vivo was used to demonstrate its inhibition following i. m. administration of acridine and carbamate inhibitors.	Carbamates	173-182	butyrylcholinesterase	Rattus norvegicus	55-69
1300633-3	1992	Reactivation of the blood cholinesterase was also monitored following intoxication with VX and soman and treated with obidoxime and atropine.	Obidoxime Chloride	118-127	butyrylcholinesterase	Rattus norvegicus	26-40
1300633-3	1992	Reactivation of the blood cholinesterase was also monitored following intoxication with VX and soman and treated with obidoxime and atropine.	Atropine	132-140	butyrylcholinesterase	Rattus norvegicus	26-40
1755022-0	1991	Relationship between cholinesterase inhibition and thermoregulation following exposure to diisopropyl fluorophosphate in the rat.	Isoflurophate	90-117	butyrylcholinesterase	Rattus norvegicus	21-35
1375401-0	1992	Dose-related inhibition of brain and plasma cholinesterase in neonatal and adult rats following sublethal organophosphate exposures.	Organophosphates	106-121	butyrylcholinesterase	Rattus norvegicus	44-58
1375401-2	1992	The present study examined dose-related inhibition of both brain and plasma cholinesterase activity in neonatal and adult rats exposed to sublethal doses of one of three common OP pesticides, methyl parathion, parathion and chlorpyrifos.	Methyl Parathion	192-208	butyrylcholinesterase	Rattus norvegicus	76-90
1375401-2	1992	The present study examined dose-related inhibition of both brain and plasma cholinesterase activity in neonatal and adult rats exposed to sublethal doses of one of three common OP pesticides, methyl parathion, parathion and chlorpyrifos.	Chlorpyrifos	224-236	butyrylcholinesterase	Rattus norvegicus	76-90
1719070-4	1991	This avoids interference of the two histochemical reactions because Co++ binds unspecifically to the brown copper-ferroferricyanide complex representing CE activity, whereas Ni++ does not.	Cobalt(2+)	68-72	butyrylcholinesterase	Rattus norvegicus	153-155
1719070-4	1991	This avoids interference of the two histochemical reactions because Co++ binds unspecifically to the brown copper-ferroferricyanide complex representing CE activity, whereas Ni++ does not.	copper-ferroferricyanide	107-131	butyrylcholinesterase	Rattus norvegicus	153-155
1755022-1	1991	This study examined the relationship between inhibition of cholinesterase activity (CA) and thermoregulatory response in the rat following exposure to the organophosphate (OP), diisopropyl fluorophosphate (DFP).	Isoflurophate	206-209	butyrylcholinesterase	Rattus norvegicus	59-73
1755022-1	1991	This study examined the relationship between inhibition of cholinesterase activity (CA) and thermoregulatory response in the rat following exposure to the organophosphate (OP), diisopropyl fluorophosphate (DFP).	Organophosphates	155-170	butyrylcholinesterase	Rattus norvegicus	59-73
1755022-1	1991	This study examined the relationship between inhibition of cholinesterase activity (CA) and thermoregulatory response in the rat following exposure to the organophosphate (OP), diisopropyl fluorophosphate (DFP).	Isoflurophate	177-204	butyrylcholinesterase	Rattus norvegicus	59-73
1808835-0	1991	Effects of azamethiphos, an organophosphorus insecticide, on serum cholinesterase activity and isoenzymes in the rat.	azamethiphos	11-23	butyrylcholinesterase	Rattus norvegicus	67-81
1801966-0	1991	Pharmacokinetics of ambenonium, a reversible cholinesterase inhibitor, in rats.	Ambenonium Chloride	20-30	butyrylcholinesterase	Rattus norvegicus	45-59
1808835-1	1991	The inhibitory effect of azamethiphos (Az), an organophosphorus insecticide, was detected in both the serum cholinesterase (ChE) activity and the ChE isoenzyme concentration in male Wistar rats.	azamethiphos	25-37	butyrylcholinesterase	Rattus norvegicus	108-122
1808835-1	1991	The inhibitory effect of azamethiphos (Az), an organophosphorus insecticide, was detected in both the serum cholinesterase (ChE) activity and the ChE isoenzyme concentration in male Wistar rats.	azamethiphos	25-37	butyrylcholinesterase	Rattus norvegicus	124-127
1808835-1	1991	The inhibitory effect of azamethiphos (Az), an organophosphorus insecticide, was detected in both the serum cholinesterase (ChE) activity and the ChE isoenzyme concentration in male Wistar rats.	azamethiphos	25-37	butyrylcholinesterase	Rattus norvegicus	146-149
1808835-1	1991	The inhibitory effect of azamethiphos (Az), an organophosphorus insecticide, was detected in both the serum cholinesterase (ChE) activity and the ChE isoenzyme concentration in male Wistar rats.	azamethiphos	39-41	butyrylcholinesterase	Rattus norvegicus	108-122
1808835-1	1991	The inhibitory effect of azamethiphos (Az), an organophosphorus insecticide, was detected in both the serum cholinesterase (ChE) activity and the ChE isoenzyme concentration in male Wistar rats.	azamethiphos	39-41	butyrylcholinesterase	Rattus norvegicus	124-127
1808835-1	1991	The inhibitory effect of azamethiphos (Az), an organophosphorus insecticide, was detected in both the serum cholinesterase (ChE) activity and the ChE isoenzyme concentration in male Wistar rats.	azamethiphos	39-41	butyrylcholinesterase	Rattus norvegicus	146-149
1808835-2	1991	In our highest Az dosage group (270 mg/kg), following a single po administration, the serum ChE activity was significantly inhibited at 6 and 24 h post-Az administration.	azamethiphos	15-17	butyrylcholinesterase	Rattus norvegicus	92-95
1808835-2	1991	In our highest Az dosage group (270 mg/kg), following a single po administration, the serum ChE activity was significantly inhibited at 6 and 24 h post-Az administration.	azamethiphos	152-154	butyrylcholinesterase	Rattus norvegicus	92-95
1808835-3	1991	Five days after Az treatment, the ChE activity was still inhibited, but the observed difference was not statistically significant.	azamethiphos	16-18	butyrylcholinesterase	Rattus norvegicus	34-37
1808835-10	1991	For the highest Az dosage group (270 mg/kg), the ChE isoenzyme band ratio was band 5 greater than band 6 6 h after Az dosing.	azamethiphos	16-18	butyrylcholinesterase	Rattus norvegicus	49-52
1808835-10	1991	For the highest Az dosage group (270 mg/kg), the ChE isoenzyme band ratio was band 5 greater than band 6 6 h after Az dosing.	azamethiphos	115-117	butyrylcholinesterase	Rattus norvegicus	49-52
1801966-1	1991	The pharmacokinetics of ambenonium, a reversible cholinesterase inhibitor, in rats was investigated following intravenous administration of the drug.	Ambenonium Chloride	24-34	butyrylcholinesterase	Rattus norvegicus	49-63
1661000-5	1991	Intrathecal administration of the cholinesterase inhibitor physostigmine produced a rapid, reversible and significant increase in the mechanical withdrawal threshold; TF latency was increased slightly but not significantly.	Physostigmine	59-72	butyrylcholinesterase	Rattus norvegicus	34-48
1949011-2	1991	It is a water-soluble cholinesterase inhibitor whose estimated rat LD50 is 9.2 mg/kg, ip.	Water	8-13	butyrylcholinesterase	Rattus norvegicus	22-36
1763105-0	1991	The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents.	physostigmine heptyl	26-46	butyrylcholinesterase	Rattus norvegicus	54-68
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	49-60	butyrylcholinesterase	Rattus norvegicus	17-31
1933434-2	1991	Intrathecal (IT) injection of the cholinesterase inhibitor, neostigmine (NEO), produced marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	60-71	butyrylcholinesterase	Rattus norvegicus	34-48
1933434-2	1991	Intrathecal (IT) injection of the cholinesterase inhibitor, neostigmine (NEO), produced marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	73-76	butyrylcholinesterase	Rattus norvegicus	34-48
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	49-60	butyrylcholinesterase	Rattus norvegicus	33-36
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	49-60	butyrylcholinesterase	Rattus norvegicus	147-150
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	62-65	butyrylcholinesterase	Rattus norvegicus	17-31
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	62-65	butyrylcholinesterase	Rattus norvegicus	33-36
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	62-65	butyrylcholinesterase	Rattus norvegicus	147-150
1940017-8	1991	injection of NEO which inhibited both spinal and medullary ChE, produced characteristic respiratory changes--increased tidal volume and decreased respiratory rate and minute volume, as well as pressor and tachycardic responses.	Neostigmine	13-16	butyrylcholinesterase	Rattus norvegicus	59-62
1868356-1	1991	The effectiveness of diazepam alone or in the presence of atropine sulfate in reversing soman-induced convulsions, inhibition of blood and brain cholinesterase (ChE) activity, and elevation of brain acetylcholine (ACh) and choline (Ch) concentrations in rats was studied.	Diazepam	21-29	butyrylcholinesterase	Rattus norvegicus	161-164
1946590-1	1991	An in vitro comparison demonstrated that the concentration of NIK-247 that inhibited cholinesterase (ChE) activities to half the normal level (ID50) was 1.3 x 10(-6) M. This value was higher than those for both physostigmine (PHY; 1.2 x 10(-7) M) and tetrahydroaminoacridine (THA; 3.6 x 10(-7) M), which are used as cholinesterase inhibitors in the treatment of cholinergic deficits.	Physostigmine	211-224	butyrylcholinesterase	Rattus norvegicus	101-104
1946590-1	1991	An in vitro comparison demonstrated that the concentration of NIK-247 that inhibited cholinesterase (ChE) activities to half the normal level (ID50) was 1.3 x 10(-6) M. This value was higher than those for both physostigmine (PHY; 1.2 x 10(-7) M) and tetrahydroaminoacridine (THA; 3.6 x 10(-7) M), which are used as cholinesterase inhibitors in the treatment of cholinergic deficits.	Tacrine	276-279	butyrylcholinesterase	Rattus norvegicus	101-104
1946590-3	1991	These inhibitions of ChE by NIK-247 and PHY lasted for 2 h, while that by THA lasted for over 4 h. In the effects of NIK-247 and PHY, the concentrations of intrastriatal acetylcholine (ACh) were changed in relation to the inhibition of the ChE activity.	amiridine	28-35	butyrylcholinesterase	Rattus norvegicus	21-24
1946590-3	1991	These inhibitions of ChE by NIK-247 and PHY lasted for 2 h, while that by THA lasted for over 4 h. In the effects of NIK-247 and PHY, the concentrations of intrastriatal acetylcholine (ACh) were changed in relation to the inhibition of the ChE activity.	Acetylcholine	170-183	butyrylcholinesterase	Rattus norvegicus	21-24
1946590-3	1991	These inhibitions of ChE by NIK-247 and PHY lasted for 2 h, while that by THA lasted for over 4 h. In the effects of NIK-247 and PHY, the concentrations of intrastriatal acetylcholine (ACh) were changed in relation to the inhibition of the ChE activity.	Acetylcholine	170-183	butyrylcholinesterase	Rattus norvegicus	240-243
1999399-2	1991	In the first approach, comparison of the primary structure of rat pancreatic cholesterol esterase with that of acetylcholinesterase and cholinesterase revealed two conserved histidine residues located at positions 420 and 435.	Histidine	174-183	butyrylcholinesterase	Rattus norvegicus	117-131
1855619-5	1991	When P = O type insecticides were intravenously administered to anesthetized and conscious rats, animals exhibited typical anti-ChE poisoning signs in cardiorespiration: hypertension and apnea which were antagonized by atropine.	Atropine	219-227	butyrylcholinesterase	Rattus norvegicus	128-131
1884807-2	1991	The antenatal administration of carbophos was shown to produce combined disturbances of the postnatal development of the mongrel albino rats manifesting themselves in changes of the maturation of sensomotor reflexes, cholinesterase activity, increased addiction both to carbophos and ethanol.	Malathion	32-41	butyrylcholinesterase	Rattus norvegicus	217-231
1998202-6	1991	In soman-poisoned rats, the HI-6, but not the 2-PAM, group had significantly higher levels of ChE in blood and other peripheral tissues than did the group given soman alone.	asoxime chloride	28-32	butyrylcholinesterase	Rattus norvegicus	94-97
1900819-1	1991	Dichlorvos (dichlorovinyl dimethyl phosphoric acid ester) is a cholinesterase inhibitor used widely as a contact and stomach insecticide for control of internal and external parasites.	Dichlorvos	0-10	butyrylcholinesterase	Rattus norvegicus	63-77
1900819-1	1991	Dichlorvos (dichlorovinyl dimethyl phosphoric acid ester) is a cholinesterase inhibitor used widely as a contact and stomach insecticide for control of internal and external parasites.	dichlorovinyl dimethyl phosphoric acid ester	12-56	butyrylcholinesterase	Rattus norvegicus	63-77
2068191-1	1991	Pyridostigmine bromide (Pyr), the current drug of choice in the management of myasthenia gravis, has been suggested for use in Alzheimer"s dementia, and as a prophylactic treatment for intoxication with organophosphate cholinesterase inhibitors.	Pyridostigmine Bromide	0-22	butyrylcholinesterase	Rattus norvegicus	219-233
2068191-1	1991	Pyridostigmine bromide (Pyr), the current drug of choice in the management of myasthenia gravis, has been suggested for use in Alzheimer"s dementia, and as a prophylactic treatment for intoxication with organophosphate cholinesterase inhibitors.	Pyridostigmine Bromide	0-3	butyrylcholinesterase	Rattus norvegicus	219-233
1998202-12	1991	Maintenance by HI-6 of a certain amount of active ChE in the periphery appears to be important for survival after soman exposure.	asoxime chloride	15-19	butyrylcholinesterase	Rattus norvegicus	50-53
2029342-5	1991	Systemic co-administration of the cholinesterase inhibitor physostigmine (0, 0.1, 0.2 mg/kg; i.p.)	Physostigmine	59-72	butyrylcholinesterase	Rattus norvegicus	34-48
1781262-5	1991	This indicates that not only end-plate cholinesterase inhibition but also neural or neuronal factors might be responsible for acetylcholine overflow and muscle fiber degeneration.	Acetylcholine	126-139	butyrylcholinesterase	Rattus norvegicus	39-53
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	Oximes	84-89	butyrylcholinesterase	Rattus norvegicus	100-114
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	Oximes	84-89	butyrylcholinesterase	Rattus norvegicus	116-119
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	(bis)pyridinium oximes	229-251	butyrylcholinesterase	Rattus norvegicus	100-114
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	(bis)pyridinium oximes	229-251	butyrylcholinesterase	Rattus norvegicus	116-119
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	asoxime chloride	252-256	butyrylcholinesterase	Rattus norvegicus	100-114
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	asoxime chloride	252-256	butyrylcholinesterase	Rattus norvegicus	116-119
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	HGG 12	258-264	butyrylcholinesterase	Rattus norvegicus	100-114
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	HGG 12	258-264	butyrylcholinesterase	Rattus norvegicus	116-119
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	P-2	266-269	butyrylcholinesterase	Rattus norvegicus	100-114
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	P-2	266-269	butyrylcholinesterase	Rattus norvegicus	116-119
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	Obidoxime Chloride	274-283	butyrylcholinesterase	Rattus norvegicus	100-114
1664202-1	1991	Isolated rat diaphragm preparations treated with soman or with the irreversible and oxime resistant cholinesterase (ChE) inhibitor S27 showed a considerable recovery of neuromuscular transmission (NMT) during incubation with the (bis)pyridinium oximes HI-6, HGG-12, P2S and obidoxime.	Obidoxime Chloride	274-283	butyrylcholinesterase	Rattus norvegicus	116-119
1664202-3	1991	Atropinized rats were artificially ventilated after injection with 3 x LD50 soman for 3 h and then treated with HI-6, i.e. at a time when oxime reactivation of soman inhibited ChE is no longer possible.	Oximes	138-143	butyrylcholinesterase	Rattus norvegicus	176-179
1904531-5	1991	Activity of blood cholinesterase was reduced in young and mature rats at 30 and 60 min following carbaryl exposure.	Carbaryl	97-105	butyrylcholinesterase	Rattus norvegicus	18-32
1679020-8	1991	Only little changes of the investigated biochemical parameters were seen after metenolone administration to animals with intact liver function: increases in serum cholinesterase and tissue N-acetyl-beta-D-glucosaminidase activity; decreases in N-acetyl-beta-D-glucosaminidase in serum, liver hydroxyproline content and hepatic gamma-glutamyltranspeptidase activity.	Methenolone	79-89	butyrylcholinesterase	Rattus norvegicus	163-177
1676052-6	1991	The potential cholinesterase inhibiting properties of the carbamate prodrugs were assessed by a simple in-vitro incubation assay, which showed that only two carbamates were very weak cholinesterase inhibitors.	Carbamates	58-67	butyrylcholinesterase	Rattus norvegicus	14-28
1676052-6	1991	The potential cholinesterase inhibiting properties of the carbamate prodrugs were assessed by a simple in-vitro incubation assay, which showed that only two carbamates were very weak cholinesterase inhibitors.	Carbamates	58-67	butyrylcholinesterase	Rattus norvegicus	183-197
1676052-6	1991	The potential cholinesterase inhibiting properties of the carbamate prodrugs were assessed by a simple in-vitro incubation assay, which showed that only two carbamates were very weak cholinesterase inhibitors.	Carbamates	157-167	butyrylcholinesterase	Rattus norvegicus	14-28
1676052-6	1991	The potential cholinesterase inhibiting properties of the carbamate prodrugs were assessed by a simple in-vitro incubation assay, which showed that only two carbamates were very weak cholinesterase inhibitors.	Carbamates	157-167	butyrylcholinesterase	Rattus norvegicus	183-197
1904531-6	1991	These results indicate that carbaryl can induce an age-related impairment on some behavioral and autonomic functions in rats correlated to the inhibition of cholinesterase activity.	Carbaryl	28-36	butyrylcholinesterase	Rattus norvegicus	157-171
1987659-0	1991	The synergism of atropine and the cholinesterase reactivator HI-6 in counteracting lethality by organophosphate intoxication in the rat.	asoxime chloride	61-65	butyrylcholinesterase	Rattus norvegicus	34-48
1987659-0	1991	The synergism of atropine and the cholinesterase reactivator HI-6 in counteracting lethality by organophosphate intoxication in the rat.	Organophosphates	96-111	butyrylcholinesterase	Rattus norvegicus	34-48
2092650-5	1990	The cholinesterase activity in the brain was reduced by treatment with diazinon.	Diazinon	71-79	butyrylcholinesterase	Rattus norvegicus	4-18
1714639-0	1991	Comparison of in vivo cholinesterase inhibition in neonatal and adult rats by three organophosphorothioate insecticides.	organophosphorothioate	84-106	butyrylcholinesterase	Rattus norvegicus	22-36
1714639-1	1991	Developing mammals are more sensitive than adults to a variety of organophosphorothioate insecticides (OPs), compounds which act in vivo by inhibition of cholinesterase (ChE).	organophosphorothioate	66-88	butyrylcholinesterase	Rattus norvegicus	154-168
1714639-1	1991	Developing mammals are more sensitive than adults to a variety of organophosphorothioate insecticides (OPs), compounds which act in vivo by inhibition of cholinesterase (ChE).	organophosphorothioate	66-88	butyrylcholinesterase	Rattus norvegicus	170-173
1711162-2	1990	Acute tetrahydroaminoacridine (THA) dosing caused lower brain (68%) and higher plasma (90%) ChE inhibition than the other drugs studied and increased levels of brain dihydroxyphenylacetic acid (DOPAC) (236%), homovanillic acid (HVA) (197%) and 5-hydroxyindoleacetic acid (5-HIAA) (130%).	Tacrine	6-29	butyrylcholinesterase	Rattus norvegicus	92-95
1700067-6	1990	A cholinesterase inhibitor, physostigmine, at doses higher than 0.1 mg/kg, s.c., significantly inhibited the HA turnover.	Physostigmine	28-41	butyrylcholinesterase	Rattus norvegicus	2-16
1711162-4	1990	Despite high brain ChE inhibition induced by metrifonate (MTF), dichlorvos (DDVP) or naled no changes in brain noradrenaline (NA), dopamine (DA) or serotonin (5-HT) occurred due to treatment with the study drugs in the acute study.	Trichlorfon	58-61	butyrylcholinesterase	Rattus norvegicus	19-22
1711162-4	1990	Despite high brain ChE inhibition induced by metrifonate (MTF), dichlorvos (DDVP) or naled no changes in brain noradrenaline (NA), dopamine (DA) or serotonin (5-HT) occurred due to treatment with the study drugs in the acute study.	Dichlorvos	64-74	butyrylcholinesterase	Rattus norvegicus	19-22
1711162-5	1990	In the chronic 10-day study THA or PHY caused no substantial ChE inhibition in brain when measured 18 hours after the last dose, whereas MTF induced 74% ChE inhibition.	Trichlorfon	137-140	butyrylcholinesterase	Rattus norvegicus	153-156
2093139-5	1990	Dietary medium-chain triglycerides, when compared with corn oil, produced decreased and increased activities of butyrylcholinesterase and ES-1, respectively.	Triglycerides	21-34	butyrylcholinesterase	Rattus norvegicus	112-133
2093139-8	1990	For individual rats in 5 out of 6 experiments, weak, negative correlation coefficients of the order of 0.3 were found between the changes in plasma butyrylcholinesterase activities and in plasma triglyceride concentrations.	Triglycerides	195-207	butyrylcholinesterase	Rattus norvegicus	148-169
1711162-2	1990	Acute tetrahydroaminoacridine (THA) dosing caused lower brain (68%) and higher plasma (90%) ChE inhibition than the other drugs studied and increased levels of brain dihydroxyphenylacetic acid (DOPAC) (236%), homovanillic acid (HVA) (197%) and 5-hydroxyindoleacetic acid (5-HIAA) (130%).	Tacrine	31-34	butyrylcholinesterase	Rattus norvegicus	92-95
1711162-4	1990	Despite high brain ChE inhibition induced by metrifonate (MTF), dichlorvos (DDVP) or naled no changes in brain noradrenaline (NA), dopamine (DA) or serotonin (5-HT) occurred due to treatment with the study drugs in the acute study.	Trichlorfon	45-56	butyrylcholinesterase	Rattus norvegicus	19-22
2277866-1	1990	The present investigation reports the effect of chronic oral administration of mancozeb, a fungicide, on hepatic microsomal carboxylesterases/amidases or B-esterases responsible for hydrolytic metabolism of aspirin (acetylsalicylic acid or ASA) at pH 5.5 and 7.4, 2-acetylaminofluorene (AAF), acetanilide and p-nitrophenylacetate (NPA) and cholinesterase in rat.	mancozeb	79-87	butyrylcholinesterase	Rattus norvegicus	340-354
2277866-1	1990	The present investigation reports the effect of chronic oral administration of mancozeb, a fungicide, on hepatic microsomal carboxylesterases/amidases or B-esterases responsible for hydrolytic metabolism of aspirin (acetylsalicylic acid or ASA) at pH 5.5 and 7.4, 2-acetylaminofluorene (AAF), acetanilide and p-nitrophenylacetate (NPA) and cholinesterase in rat.	Aspirin	207-214	butyrylcholinesterase	Rattus norvegicus	340-354
2239207-6	1990	Results showed that TTS (Transdermal Therapeutic System)-scopolamine administration facilitated habituation to rotation, whereas physostigmine, a centrally acting cholinesterase inhibitor, suppressed it, and neostigmine, a peripherally active cholinesterase inhibitor, had no effect on habituation at all.	Disulfiram	20-23	butyrylcholinesterase	Rattus norvegicus	243-257
2274284-0	1990	Release of endogenous acetylcholine from rat brain slices with or without cholinesterase inhibition and its potentiation by hemicholinium-3.	Acetylcholine	22-35	butyrylcholinesterase	Rattus norvegicus	74-88
2174982-4	1990	The electrically evoked release of radioactivity was reduced by the muscarinic agonist oxotremorine and the delta selective opiate receptor agonist Metenkephalin, and was enhanced in the presence of the cholinesterase inhibitor physostigmine by the muscarinic antagonist atropine.	Oxotremorine	87-99	butyrylcholinesterase	Rattus norvegicus	203-217
2174982-4	1990	The electrically evoked release of radioactivity was reduced by the muscarinic agonist oxotremorine and the delta selective opiate receptor agonist Metenkephalin, and was enhanced in the presence of the cholinesterase inhibitor physostigmine by the muscarinic antagonist atropine.	Physostigmine	228-241	butyrylcholinesterase	Rattus norvegicus	203-217
2174982-4	1990	The electrically evoked release of radioactivity was reduced by the muscarinic agonist oxotremorine and the delta selective opiate receptor agonist Metenkephalin, and was enhanced in the presence of the cholinesterase inhibitor physostigmine by the muscarinic antagonist atropine.	Atropine	271-279	butyrylcholinesterase	Rattus norvegicus	203-217
2239207-6	1990	Results showed that TTS (Transdermal Therapeutic System)-scopolamine administration facilitated habituation to rotation, whereas physostigmine, a centrally acting cholinesterase inhibitor, suppressed it, and neostigmine, a peripherally active cholinesterase inhibitor, had no effect on habituation at all.	Physostigmine	129-142	butyrylcholinesterase	Rattus norvegicus	163-177
2353832-3	1990	When rats were administered methyl isocyanate (MIC) by inhalation or subcutaneous route it produced severe hyperglycemia, clinical lactic acidosis, highly elevated plasma urea, and reduced plasma cholinesterase activity with unaltered erythrocyte acetyl cholinesterase activity.	methyl isocyanate	28-45	butyrylcholinesterase	Rattus norvegicus	196-210
2095716-0	1990	Interactive effects of physostigmine and exercise on cholinesterase activity in red blood cells and tissues of rat.	Physostigmine	23-36	butyrylcholinesterase	Rattus norvegicus	53-67
2095716-5	1990	In unexercised rats given physostigmine, the cholinesterase activity ranges were 73-79, 66-68, 68-74, 67-81 and 57-61% of controls from 10-30 min in red blood cells, brain, heart, diaphragm and thigh muscle, respectively.	Physostigmine	26-39	butyrylcholinesterase	Rattus norvegicus	45-59
2095716-6	1990	In exercised rats exposed to physostigmine, the cholinesterase activity ranges were 54-51, 58-50, 77-73, 71-83 and 54-58% of controls from 10-30 min in red blood cells, brain, heart, diaphragm and thigh muscle, respectively.	Physostigmine	29-42	butyrylcholinesterase	Rattus norvegicus	48-62
2095716-8	1990	Acute exercise modifies the effect of physostigmine significantly (p less than 0.01) by increasing the cholinesterase inhibition in red blood cells and brain without affecting other tissues.	Physostigmine	38-51	butyrylcholinesterase	Rattus norvegicus	103-117
2095780-4	1990	In malathion treated adrenalectomized animals, changes in the activities of cerebral cholinesterase and succinic dehydrogenase were still present; other changes were, however, abolished by adrenalectomy.	Malathion	3-12	butyrylcholinesterase	Rattus norvegicus	85-126
2399538-0	1990	Association between rat serum cholinesterase and some phospholipid components of lipoproteins in thioacetamide-induced hepatic injury.	Phospholipids	54-66	butyrylcholinesterase	Rattus norvegicus	30-44
2399538-0	1990	Association between rat serum cholinesterase and some phospholipid components of lipoproteins in thioacetamide-induced hepatic injury.	Thioacetamide	97-110	butyrylcholinesterase	Rattus norvegicus	30-44
2399538-3	1990	Cholinesterase activity significantly increased with thioacetamide treatment.	Thioacetamide	53-66	butyrylcholinesterase	Rattus norvegicus	0-14
2399538-4	1990	Only two phospholipids: LDL-phosphatidylcholine and HDL-lysophosphatidylcholine appeared associated with cholinesterase activity.	Phospholipids	9-22	butyrylcholinesterase	Rattus norvegicus	105-119
2399538-4	1990	Only two phospholipids: LDL-phosphatidylcholine and HDL-lysophosphatidylcholine appeared associated with cholinesterase activity.	ldl-phosphatidylcholine	24-47	butyrylcholinesterase	Rattus norvegicus	105-119
2399538-4	1990	Only two phospholipids: LDL-phosphatidylcholine and HDL-lysophosphatidylcholine appeared associated with cholinesterase activity.	Lysophosphatidylcholines	56-79	butyrylcholinesterase	Rattus norvegicus	105-119
2399538-6	1990	Because of the high statistically significant association between changes in these lipoprotein phospholipids and in cholinesterase in this model of hepatic injury, we conclude that cholinesterase could be involved in the regulation of these phospholipid levels.	Phospholipids	95-107	butyrylcholinesterase	Rattus norvegicus	116-130
2399538-6	1990	Because of the high statistically significant association between changes in these lipoprotein phospholipids and in cholinesterase in this model of hepatic injury, we conclude that cholinesterase could be involved in the regulation of these phospholipid levels.	Phospholipids	95-107	butyrylcholinesterase	Rattus norvegicus	181-195
1700547-7	1990	Cholinesterase activity was lowered by 90% in blood within 11 weeks with the subsequent increase; but in the experimental group intoxicated with butyphos at 1/10 LD50 the enzymatic activity constituted only 60% of control values within 6 months.	butyl phosphorotrithioate	145-153	butyrylcholinesterase	Rattus norvegicus	0-14
2351210-1	1990	We administered tetrahydroaminoacridine (THA), a cholinesterase inhibitor, to rats with bilateral nucleus basalis magnocellularis lesions and measured their performance in a spatial learning task.	Tacrine	16-39	butyrylcholinesterase	Rattus norvegicus	49-63
2351210-1	1990	We administered tetrahydroaminoacridine (THA), a cholinesterase inhibitor, to rats with bilateral nucleus basalis magnocellularis lesions and measured their performance in a spatial learning task.	Tacrine	41-44	butyrylcholinesterase	Rattus norvegicus	49-63
2390670-10	1990	Cholinesterase inhibition with neostigmine potentiated the prejunctional effect induced by a low (20 microM) but not a high (50 microM) concentration of Phen.	Neostigmine	31-42	butyrylcholinesterase	Rattus norvegicus	0-14
2366261-7	1990	Structures with high cholinesterase activity (caudate-putamen, amygdala, hippocampus) showed greater retention of physostigmine over time.	Physostigmine	114-127	butyrylcholinesterase	Rattus norvegicus	21-35
2353832-3	1990	When rats were administered methyl isocyanate (MIC) by inhalation or subcutaneous route it produced severe hyperglycemia, clinical lactic acidosis, highly elevated plasma urea, and reduced plasma cholinesterase activity with unaltered erythrocyte acetyl cholinesterase activity.	methyl isocyanate	28-45	butyrylcholinesterase	Rattus norvegicus	254-268
1697627-5	1990	Notably, the reduction of ChE activities by fenthion, chlorpyrifos and dichlorvos were similar.	Fenthion	44-52	butyrylcholinesterase	Rattus norvegicus	26-29
1697627-5	1990	Notably, the reduction of ChE activities by fenthion, chlorpyrifos and dichlorvos were similar.	Chlorpyrifos	54-66	butyrylcholinesterase	Rattus norvegicus	26-29
1697627-5	1990	Notably, the reduction of ChE activities by fenthion, chlorpyrifos and dichlorvos were similar.	Dichlorvos	71-81	butyrylcholinesterase	Rattus norvegicus	26-29
2331495-8	1990	Short-term (14 days) and long-term (45 days) haloperidol treatment both resulted in altered levels of specific cholinesterase (ChE) isozymes.	Haloperidol	45-56	butyrylcholinesterase	Rattus norvegicus	127-130
2331495-14	1990	These findings indicate that, in the rat, chronic haloperidol treatment results in differential changes in the plasma levels of discrete ChE isozymes.	Haloperidol	50-61	butyrylcholinesterase	Rattus norvegicus	137-140
2331495-0	1990	Quantitative analyses of plasma cholinesterase isozymes in haloperidol-treated rats.	Haloperidol	59-70	butyrylcholinesterase	Rattus norvegicus	32-46
2339976-5	1990	Cholinesterase in carbamate-inhibited blood was not stable and had to be assayed soon after sampling.	Carbamates	18-27	butyrylcholinesterase	Rattus norvegicus	0-14
2331495-2	1990	Using this method, the effects of haloperidol treatment on plasma cholinesterase isozyme levels were examined in normal rats.	Haloperidol	34-45	butyrylcholinesterase	Rattus norvegicus	66-80
2331495-8	1990	Short-term (14 days) and long-term (45 days) haloperidol treatment both resulted in altered levels of specific cholinesterase (ChE) isozymes.	Haloperidol	45-56	butyrylcholinesterase	Rattus norvegicus	111-125
2333410-0	1990	In vivo and in vitro cholinesterase inhibitor property of the antitumor agent caracemide.	caracemide	78-88	butyrylcholinesterase	Rattus norvegicus	21-35
1971210-5	1990	Acetylcholine chloride (10(-5) M), as well as distigmine bromide (10(-6), 10(-5) M), both of which are cholinesterase inhibitors, stimulated insulin release, whereas atropine (5 x 10(-6), 5 x 10(-5) M) suppressed it.	distigmine	46-64	butyrylcholinesterase	Rattus norvegicus	103-117
2330075-0	1990	The cholinesterase inhibitor soman increases inositol trisphosphate in rat brain.	Soman	29-34	butyrylcholinesterase	Rattus norvegicus	4-18
2330075-0	1990	The cholinesterase inhibitor soman increases inositol trisphosphate in rat brain.	inositol 1,2,3-trisphosphate	45-67	butyrylcholinesterase	Rattus norvegicus	4-18
2330075-1	1990	Studies were conducted to determine the effect of the cholinesterase inhibitor soman on the amount of inositol trisphosphate in the neocortex, striatum, cerebellum, and medulla-pons regions of rat brain in vivo.	inositol 1,2,3-trisphosphate	102-124	butyrylcholinesterase	Rattus norvegicus	54-68
1690462-4	1990	The dose of paraoxon required to produce similar signs of toxicity and similar degrees of cholinesterase inhibition in rats and rabbits (0.5 and 2.0 mg/kg, respectively) differed by 4-fold.	Paraoxon	12-20	butyrylcholinesterase	Rattus norvegicus	90-104
1690462-9	1990	Rats pretreated with paraoxonase exhibited less inhibition of cholinesterase than vehicle-treated controls following identical doses of paraoxon, particularly when the organophosphate was given iv or dermally.	Paraoxon	21-29	butyrylcholinesterase	Rattus norvegicus	62-76
1690462-10	1990	A very high degree of protection, particularly toward brain and diaphragm cholinesterase, was provided by paraoxonase pretreatment in animals challenged with chlorpyrifos-oxon by all routes.	O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate	158-175	butyrylcholinesterase	Rattus norvegicus	74-88
2333410-2	1990	The present study was designed to further characterize the ability of caracemide to inhibit cholinesterase both in vivo and in vitro.	caracemide	70-80	butyrylcholinesterase	Rattus norvegicus	92-106
2333410-3	1990	Caracemide produced a time-dependent inhibition of purified acetylcholinesterase, pseudocholinesterase and rat brain homogenate cholinesterase with IC50 values of 0.60, 0.55 and 17.8 microM, respectively, at the maximal time point of inhibition.	caracemide	0-10	butyrylcholinesterase	Rattus norvegicus	66-80
2333410-5	1990	Intravenous administration of caracemide to rats resulted in a dose-dependent inhibition of brain cholinesterase activity, with the greatest inhibition occurring in the cortex.	caracemide	30-40	butyrylcholinesterase	Rattus norvegicus	98-112
2129284-2	1990	Administration of carbaryl (50 mg/kg) by gavage daily for 30 days resulted in a reduction of locomotor activity in the open-field and in an inhibition of cholinesterase activity within 30 min after the last treatment.	Carbaryl	18-26	butyrylcholinesterase	Rattus norvegicus	154-168
2350265-1	1990	The purpose of this study was to see if physostigmine, a reversible cholinesterase inhibitor, affects the secretion and composition of saliva of the major salivary glands of the rat.	Physostigmine	40-53	butyrylcholinesterase	Rattus norvegicus	68-82
2129284-5	1990	These findings suggest that repeated administration of carbaryl to aging rats can induce an impairment of motor function and a reduction of cholinesterase activity, while tolerance develops in some other parameters.	Carbaryl	55-63	butyrylcholinesterase	Rattus norvegicus	140-154
2165959-2	1990	The inhibition of cholinesterase and carboxylesterase activities in the diisopropyl fluorophosphate (DFP) intoxication, and the inducibility of organophosphate (OP) detoxicating enzymes was studied in rats.	Isoflurophate	72-99	butyrylcholinesterase	Rattus norvegicus	18-32
2323158-0	1990	Butyrylcholinesterase fluctuation in male albino rats with intracerebroventricular injection of gamma aminobutyric acid, muscimol, and picrotoxin.	gamma-Aminobutyric Acid	96-119	butyrylcholinesterase	Rattus norvegicus	0-21
2323158-0	1990	Butyrylcholinesterase fluctuation in male albino rats with intracerebroventricular injection of gamma aminobutyric acid, muscimol, and picrotoxin.	Muscimol	121-129	butyrylcholinesterase	Rattus norvegicus	0-21
2323158-0	1990	Butyrylcholinesterase fluctuation in male albino rats with intracerebroventricular injection of gamma aminobutyric acid, muscimol, and picrotoxin.	Picrotoxin	135-145	butyrylcholinesterase	Rattus norvegicus	0-21
2323158-1	1990	The effects of intracerebroventricular injection of gamma-Aminobutyric acid, muscimol, or picrotoxin have been studied on butyrylcholinesterase (BuChE) activities in the serum and several hypothalamic nuclei using biochemical, histochemical, and cytophotometric techniques, respectively.	gamma-Aminobutyric Acid	52-75	butyrylcholinesterase	Rattus norvegicus	122-143
2323158-1	1990	The effects of intracerebroventricular injection of gamma-Aminobutyric acid, muscimol, or picrotoxin have been studied on butyrylcholinesterase (BuChE) activities in the serum and several hypothalamic nuclei using biochemical, histochemical, and cytophotometric techniques, respectively.	gamma-Aminobutyric Acid	52-75	butyrylcholinesterase	Rattus norvegicus	145-150
2323158-1	1990	The effects of intracerebroventricular injection of gamma-Aminobutyric acid, muscimol, or picrotoxin have been studied on butyrylcholinesterase (BuChE) activities in the serum and several hypothalamic nuclei using biochemical, histochemical, and cytophotometric techniques, respectively.	Muscimol	77-85	butyrylcholinesterase	Rattus norvegicus	122-143
2323158-1	1990	The effects of intracerebroventricular injection of gamma-Aminobutyric acid, muscimol, or picrotoxin have been studied on butyrylcholinesterase (BuChE) activities in the serum and several hypothalamic nuclei using biochemical, histochemical, and cytophotometric techniques, respectively.	Muscimol	77-85	butyrylcholinesterase	Rattus norvegicus	145-150
2323158-1	1990	The effects of intracerebroventricular injection of gamma-Aminobutyric acid, muscimol, or picrotoxin have been studied on butyrylcholinesterase (BuChE) activities in the serum and several hypothalamic nuclei using biochemical, histochemical, and cytophotometric techniques, respectively.	Picrotoxin	90-100	butyrylcholinesterase	Rattus norvegicus	122-143
2323158-1	1990	The effects of intracerebroventricular injection of gamma-Aminobutyric acid, muscimol, or picrotoxin have been studied on butyrylcholinesterase (BuChE) activities in the serum and several hypothalamic nuclei using biochemical, histochemical, and cytophotometric techniques, respectively.	Picrotoxin	90-100	butyrylcholinesterase	Rattus norvegicus	145-150
2323158-3	1990	Biochemical estimations demonstrated a significant inhibition of BuChE after GABA and muscimol injections, whereas a pronounced stimulation of BuChE was observed after injection of picrotoxin.	gamma-Aminobutyric Acid	77-81	butyrylcholinesterase	Rattus norvegicus	65-70
2323158-3	1990	Biochemical estimations demonstrated a significant inhibition of BuChE after GABA and muscimol injections, whereas a pronounced stimulation of BuChE was observed after injection of picrotoxin.	Muscimol	86-94	butyrylcholinesterase	Rattus norvegicus	65-70
2323158-3	1990	Biochemical estimations demonstrated a significant inhibition of BuChE after GABA and muscimol injections, whereas a pronounced stimulation of BuChE was observed after injection of picrotoxin.	Picrotoxin	181-191	butyrylcholinesterase	Rattus norvegicus	143-148
2323158-6	1990	Only a marginal decrease was observed after injection of GABA in all nuclei, while muscimol induced a very conspicuous decrease of BuChE.	Muscimol	83-91	butyrylcholinesterase	Rattus norvegicus	131-136
2323158-7	1990	On the contrary, intracerebroventricularly administered picrotoxin markedly increased the levels of BuChE activity.	Picrotoxin	56-66	butyrylcholinesterase	Rattus norvegicus	100-105
2323158-8	1990	Thus it could be concluded that probably GABA and muscimol along with picrotoxin appear to alter BuChE.	gamma-Aminobutyric Acid	41-45	butyrylcholinesterase	Rattus norvegicus	97-102
2323158-8	1990	Thus it could be concluded that probably GABA and muscimol along with picrotoxin appear to alter BuChE.	Muscimol	50-58	butyrylcholinesterase	Rattus norvegicus	97-102
2323158-8	1990	Thus it could be concluded that probably GABA and muscimol along with picrotoxin appear to alter BuChE.	Picrotoxin	70-80	butyrylcholinesterase	Rattus norvegicus	97-102
2165959-2	1990	The inhibition of cholinesterase and carboxylesterase activities in the diisopropyl fluorophosphate (DFP) intoxication, and the inducibility of organophosphate (OP) detoxicating enzymes was studied in rats.	Isoflurophate	101-104	butyrylcholinesterase	Rattus norvegicus	18-32
34273065-3	2022	In this work, focusing on the efficient cholinesterase inhibitory activity of tacrine, design and synthesis of novel arylisoxazole-tacrine analogues was developed.	Tacrine	78-85	butyrylcholinesterase	Rattus norvegicus	40-54
20407407-4	2010	By inhibition of the cholinesterase, physostigmine increases acetylcholine and induces the cholinergic anti-inflammatory pathway.	Physostigmine	37-50	butyrylcholinesterase	Rattus norvegicus	21-35
20407407-4	2010	By inhibition of the cholinesterase, physostigmine increases acetylcholine and induces the cholinergic anti-inflammatory pathway.	Acetylcholine	61-74	butyrylcholinesterase	Rattus norvegicus	21-35
34534598-15	2022	CONCLUSION: Synergistic action of genistin, quercetin-3-D-galactoside, 9,12,15-octadecatrienoic-acid methyl-ester, phytol, retinal, stigmasterol, n-hexadecanoic acid, beta-sitosterol in GRHA restores memory-deficits via attenuation of cholinesterase, beta-secretase, MAPt level and inhibition of oxidative-stress imparts inflammation in AD.	gamma-sitosterol	167-182	butyrylcholinesterase	Rattus norvegicus	235-249
34453251-7	2021	Opioid type affects whether or not naloxone can reverse the changes of ChE.	Naloxone	35-43	butyrylcholinesterase	Rattus norvegicus	71-74
34453251-8	2021	Direct inhibitory action of morphine and the other opioid ligands believed responsible for the decrease in the ChE activity.	Morphine	28-36	butyrylcholinesterase	Rattus norvegicus	111-114
34491490-1	2022	A new series of quinolotacrine hybrids including cyclopenta- and cyclohexa-quinolotacrine derivatives were designed, synthesized, and assessed as anti-cholinesterase (ChE) agents.	quinolotacrine	16-30	butyrylcholinesterase	Rattus norvegicus	151-165
34491490-9	2022	A novel series of quinolotacrine hybrids were designed, synthesized, and evaluated against AChE and BChE enzymes as potential agents for the treatment of AD.	quinolotacrine	18-32	butyrylcholinesterase	Rattus norvegicus	100-104
2125863-1	1990	In order to investigate the correlation between the peripheral ACh and the primary input of acupuncture sensation, in the paper the cholinesterase inhibitor--Neostigmine and the ACh synthesis blocker--Hemicholine, which are unable to pass through blood brain barrier, and ACh were used as tools to increase or decrease the level of ACh in peripheral nerve system of rats.	Neostigmine	156-169	butyrylcholinesterase	Rattus norvegicus	132-146
34505519-2	2021	ACh is hydrolyzed by two cholinesterases (ChE), namely acetylcholin-esterase and butyrylcholinesterase (BChE).	Acetylcholine	0-3	butyrylcholinesterase	Rattus norvegicus	81-102
34505519-2	2021	ACh is hydrolyzed by two cholinesterases (ChE), namely acetylcholin-esterase and butyrylcholinesterase (BChE).	Acetylcholine	0-3	butyrylcholinesterase	Rattus norvegicus	104-108
34175450-6	2021	Next, we tested the effect of a cholinesterase inhibitor, donepezil, on the retrieval of memory after a long no-task period in extensively trained rats.	Donepezil	58-67	butyrylcholinesterase	Rattus norvegicus	32-46
35283111-8	2022	CSZ or CSZ plus caffeine reversed low glutamate gene expression, elevated cholinesterase level, and elevated caspase-3 activity in T2D rats.	Cilostazol	0-3	butyrylcholinesterase	Rattus norvegicus	74-88
34925565-13	2021	Acute cholinesterase inhibition may induce high levels of cortisol, free triiodothyronine, thyroxine and thyroid-stimulating hormone.	Hydrocortisone	58-66	butyrylcholinesterase	Rattus norvegicus	6-20
34925565-13	2021	Acute cholinesterase inhibition may induce high levels of cortisol, free triiodothyronine, thyroxine and thyroid-stimulating hormone.	Triiodothyronine	73-89	butyrylcholinesterase	Rattus norvegicus	6-20
34925565-13	2021	Acute cholinesterase inhibition may induce high levels of cortisol, free triiodothyronine, thyroxine and thyroid-stimulating hormone.	Thyroxine	91-100	butyrylcholinesterase	Rattus norvegicus	6-20
35358535-1	2022	Organophosphate (OP) chemicals include commonly used pesticides and chemical warfare agents, and mechanistically they are potent inhibitors of the cholinesterase (ChE) enzyme.	Organophosphates	0-15	butyrylcholinesterase	Rattus norvegicus	147-161
35358535-1	2022	Organophosphate (OP) chemicals include commonly used pesticides and chemical warfare agents, and mechanistically they are potent inhibitors of the cholinesterase (ChE) enzyme.	Organophosphates	0-15	butyrylcholinesterase	Rattus norvegicus	163-166
35283111-8	2022	CSZ or CSZ plus caffeine reversed low glutamate gene expression, elevated cholinesterase level, and elevated caspase-3 activity in T2D rats.	Cilostazol	7-10	butyrylcholinesterase	Rattus norvegicus	74-88
35283111-8	2022	CSZ or CSZ plus caffeine reversed low glutamate gene expression, elevated cholinesterase level, and elevated caspase-3 activity in T2D rats.	Caffeine	16-24	butyrylcholinesterase	Rattus norvegicus	74-88
32249606-9	2022	The ChE activity was inhibited significantly after 20 min of DZ treatment and continued till 24 h (p < 0.01).	Diazinon	61-63	butyrylcholinesterase	Rattus norvegicus	4-7
35127652-0	2021	Synthesis of New 3-Arylcoumarins Bearing N-Benzyl Triazole Moiety: Dual Lipoxygenase and Butyrylcholinesterase Inhibitors With Anti-Amyloid Aggregation and Neuroprotective Properties Against Alzheimer"s Disease.	3-arylcoumarins	17-32	butyrylcholinesterase	Rattus norvegicus	89-110
35023027-13	2022	Whole brain AChE, BChE, and MDA level were significantly raised and GSH, TP, SOD, CAT and Dopamine were significantly declined in Haloperidol treated group rats, especially V. negundo 400 mg/kg p.o.	Haloperidol	130-141	butyrylcholinesterase	Rattus norvegicus	18-22
35007992-2	2022	AIM: To compare the effects of ipidacrine, a reversible cholinesterase inhibitor, and sildenafil on DMED in a rat model of streptozotocin (STZ)-induced diabetes.	amiridine	31-41	butyrylcholinesterase	Rattus norvegicus	56-70
35007992-17	2022	CONCLUSION: This is the first study to show that administration of ipidacrine, the reversible cholinesterase inhibitor, improved erectile function in diabetic rats and these results may be beneficial in further studies using ipidacrine for treatment of DMED, particularly in non-responders to PDE5 inhibitors.	amiridine	67-77	butyrylcholinesterase	Rattus norvegicus	94-108